Rituximab Clinical Trials (2026): 2,053 Studies for Lymphoma & Chronic Lymphocytic Leukemia

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

2,053 Rituximab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 683 indications (including Lymphoma & Chronic Lymphocytic Leukemia) and 253,093 total planned enrollment. 367 Phase 3 Rituximab trials and 950 Phase 2, 77 Phase 4 are listed. 314 Rituximab clinical trials are actively recruiting at 1,419 U.S. sites across 50 states. Most recent activity: NCT04196413 (Jul 2043).

Where to Participate: All Rituximab Trial Sites in the U.S. (1,419 sites across 50 states)

Every actively recruiting Rituximabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ALChildren's Hospital of AlabamaBirmingham35233NCT05533775Map
ALUniversity Hospital (University Of Alabama Hospital)Birmingham35233NCT04884035Map
ALUniversity of Alabama at Birmingham Cancer CenterBirmingham35233NCT06337318Map
ALUniversity of Alabama at Birmingham School of Medicine: Division of NephrologyBirmingham35294NCT03949855Map
ALInfirmary Cancer CareMobile36607NCT06911502Map
ALInfirmary Cancer Care ( Site 0157)Mobile36607NCT06890884Map
AKAlaska Oncology and HematologyAnchorage99508NCT06911502Map
AZIronwood Cancer & Research Centers ( Site 0204)Chandler85224NCT06890884Map
AZBanner MD Anderson Cancer Center ( Site 0165)Gilbert85234NCT06717347Map
AZPalo Verde Cancer Specialists ( Site 0105)Glendale85304NCT06890884Map
AZPalo Verde Hematology/ Oncology Center, Ltd. ( Site 0175)Glendale85304NCT05139017Map
AZCity of Hope - Phoenix ( Site 0202)Goodyear85338NCT06890884Map
AZBanner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167)Phoenix85006NCT06717347Map
AZCity of Hope at PhoenixPhoenix85338NCT06918431Map
AZMayo Clinic Cancer CenterPhoenix85054NCT07104032Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT06337318Map
AZMayo Clinic in Arizona - PhoenixPhoenix85054NCT06090539Map
AZHonorHealth Cancer CenterScottsdale85251NCT07104032Map
AZMayo Clinic - ArizonaScottsdale85259NCT04884035Map
AZMayo Clinic in ArizonaScottsdale85259NCT06834373Map
AZBanner University Medical Center - TucsonTucson85719NCT04840602Map
AZBanner University Medical Center - TucsonTucson85719NCT06337318Map
AZThe University of Arizona Cancer Center - North Campus ( Site 0124)Tucson85719NCT06717347Map
AZUniversity of Arizona Cancer CenterTucson85724NCT06091254Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT04840602Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT06337318Map
ARHighlands Oncology Group - FayettevilleFayetteville72703NCT06337318Map
ARGenesis Cancer and Blood Institute ( Site 0193)Hot Springs71913NCT06890884Map
ARSt Bernards Medical CenterJonesboro72401NCT06846671Map
ARUniversity of ArkansasLittle Rock72205NCT03949855Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT05976763Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT06337318Map
ARHighlands Oncology Group - RogersRogers72758NCT06337318Map
ARHighlands Oncology GroupSpringdale72762NCT06337318Map
ARHighlands Oncology Group ( Site 5405)Springdale72762NCT05947851Map
CAKaiser Permanente-Deer Valley Medical CenterAntioch94531NCT03150693Map
CABeverly Hills Cancer Center ( Site 0184)Beverly Hills90211NCT05139017Map
CATower Cancer Research FoundationBeverly Hills90211NCT05976763Map
CATower Cancer Research FoundationBeverly Hills90211NCT06337318Map
CARoy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135)Burbank91505NCT06890884Map
CACommunity Cancer InstituteClovis93611NCT03150693Map
CAUC Irvine Health Cancer Center-NewportCosta Mesa92627NCT03150693Map
CACity of HopeDuarte91010NCT07226843Map
CACity of Hope Cancer CenterDuarte91010NCT06084936Map
CACity of Hope Comprehensive Cancer CenterDuarte91010NCT05886036Map
CACity of Hope Comprehensive Cancer CenterDuarte91010NCT06090539Map
CACity of Hope Comprehensive Cancer CenterDuarte91010NCT06337318Map
CACity of Hope Comprehensive Cancer CenterDuarte91010NCT06911502Map
CACity of Hope Comprehensive Cancer Center ( Site 0191)Duarte91010NCT06890884Map
CACity of Hope Medical centerDuarte91010NCT03523975Map
CACity of Hope Medical CenterDuarte91010NCT06572618Map
CACity of Hope Medical CenterDuarte91010NCT06918431Map
CACity of Hope Medical CenterDuarte91010NCT07365306Map
CACity Of Hope National Medical CenterDuarte91010NCT04884035Map
CAKaiser Permanente DublinDublin94568NCT03150693Map
CAKaiser Permanente-FremontFremont94538NCT03150693Map
CAKaiser Permanente Fresno Orchard PlazaFresno93720NCT03150693Map
CAKaiser Permanente-FresnoFresno93720NCT03150693Map
CAUCSF Fresno /ID# 264712Fresno93701-2302NCT06191744Map
CAProvidence Medical FoundationFullerton92835NCT07104032Map
CAProvidence Medical Foundation-Oncology ( Site 0168)Fullerton92835NCT06717347Map
CACity of Hope at Irvine LennarIrvine92618NCT06337318Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT03150693Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT06337318Map
CAUniversity of California, San DiegoLa Jolla92093NCT07222631Map
CAUci Health Laguna HillsLaguna Hills92653NCT06943872Map
CACity of Hope Antelope ValleyLancaster93534NCT06337318Map
CACity of Hope at Long Beach ElmLong Beach90813NCT06337318Map
CAMemorialCare Health System - Long Beach Medical Center ( Site 5421)Long Beach90806NCT05947851Map
CAMemorialCare Health System - Long Beach Medical Center ( Site 9559)Long Beach90806NCT06717347Map
CATibor Rubin VA Medical CenterLong Beach90822NCT06337318Map
CACancer Blood and Specialty Clinic ( Site 0109)Los Alamitos90720NCT06717347Map
CACedars-Sinai Medical CenterLos Angeles90048NCT04609046Map
CACedars-Sinai Medical CenterLos Angeles90048NCT05976763Map
CACedars-Sinai Medical CenterLos Angeles90048NCT06337318Map
CACedars-Sinai Medical Center ( Site 0115)Los Angeles90048NCT06717347Map
CADavid Geffen School of Medicine at UCLALos Angeles90095NCT06091254Map
CADavid Geffen School of Medicine at UCLALos Angeles90095NCT06091865Map
CADavid Geffen School of Medicine at UCLALos Angeles90095NCT06149286Map
CAUCLALos Angeles90095NCT06655896Map
CAUCLA Department of Medicine HematologyoncologyLos Angeles90095-3075NCT06846671Map
CAValkyrie Clinical TrialsLos Angeles90670NCT06119685Map
CAKaiser Permanente- Modesto MOB IIModesto95356NCT03150693Map
CAKaiser Permanente-ModestoModesto95356NCT03150693Map
CAHoag Memorial HospitalNewport Beach92663NCT05618925Map
CAKaiser Permanente Oakland Medical CenterOakland94611NCT05533775Map
CAKaiser Permanente-OaklandOakland94611NCT03150693Map
CAUCSF Benioff Children's Hospital OaklandOakland94609NCT05533775Map
CAChao Family Comprehensive Cancer CenterOrange92868-3201NCT06943872Map
CAResearch SiteOrange92868NCT05952024Map
CAUC Irvine HealthOrange92868NCT07104032Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT03150693Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT06337318Map
CAUniversity of California Irvine Medical CenterOrange92868NCT06091865Map
CALucile Packard Children's HospitalPalo Alto94305NCT05508009Map
CAStanford Cancer InstitutePalo Alto94304-2205NCT06943872Map
CAStanford Cancer Institute Palo AltoPalo Alto94304NCT03150693Map
CAKaiser Permanente-RichmondRichmond94801NCT03150693Map
CAKaiser Permanente - RosevilleRoseville95661NCT05533775Map
CAKaiser Permanente-RosevilleRoseville95661NCT03150693Map
CAKaiser Permanente Downtown CommonsSacramento95814NCT03150693Map
CAKaiser Permanente-South SacramentoSacramento95823NCT03150693Map
CAUniversity of California (UC) DavisSacramento95817NCT06091865Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT03150693Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT05600686Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT06905509Map
CAScripps Mercy Hospital /ID# 265393San Diego92103NCT06191744Map
CAScripps Prebys Cancer CenterSan Diego92103-2106NCT06943872Map
CAUC San Diego Moores Cancer CenterSan Diego92037NCT05600686Map
CAKaiser Permanente-San FranciscoSan Francisco94115NCT03150693Map
CAPacific Hematology Oncology Associates ( Site 0131)San Francisco94115NCT06717347Map
CAUCSFSan Francisco94115NCT06655896Map
CAUCSFSan Francisco94115NCT06655896Map
CAUCSF Helen Diller Medical Center at Parnassus HeightsSan Francisco94143NCT06911502Map
CAUCSF Medical Center-ParnassusSan Francisco94143NCT04609046Map
CAUniversity of California San FranciscoSan Francisco94146NCT03949855Map
CAKaiser Permanente-Santa Teresa-San JoseSan Jose95119NCT03150693Map
CAKaiser Permanente San LeandroSan Leandro94577NCT03150693Map
CASutter Health NetworkSan Pablo94806NCT06655896Map
CAKaiser San Rafael-GallinasSan Rafael94903NCT03150693Map
CASansum Clinic Research /ID# 261596Santa Barbara93105NCT06191744Map
CAKaiser Permanente - Santa ClaraSanta Clara95051NCT05533775Map
CAKaiser Permanente Medical Center - Santa ClaraSanta Clara95051NCT03150693Map
CAUniversity of California Los Angeles (UCLA) - Cancer Care - Santa MonicaSanta Monica90404-2023NCT06084936Map
CAKaiser Permanente-Santa RosaSanta Rosa95403NCT03150693Map
CACity of Hope South PasadenaSouth Pasadena91030NCT06337318Map
CAKaiser Permanente-South San FranciscoSouth San Francisco94080NCT03150693Map
CALucile Packard Children's Hospital (LPCH)Stanford94304NCT04196413Map
CAStanford UniversityStanford94305NCT04784052Map
CAStanford University School of Medicine: Division of NephrologyStanford94305NCT03949855Map
CAKaiser Permanente-StocktonStockton95210NCT03150693Map
CAThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:Division of Nephrology and HypertensionTorrance90502NCT03949855Map
CATorrance Memorial Physician Network - Cancer CareTorrance90505NCT06337318Map
CACity of Hope UplandUpland91786NCT06337318Map
CAKaiser Permanente Medical Center-VacavilleVacaville95688NCT03150693Map
CAKaiser Permanente-VallejoVallejo94589NCT03150693Map
CABass Medical Group ( Site 0123)Walnut Creek94598NCT06890884Map
CABass Medical Group ( Site 0166)Walnut Creek94598NCT05139017Map
CAKaiser Permanente-Walnut CreekWalnut Creek94596NCT03150693Map
CAPih Health Whittier HospitalWhittier90602NCT06846671Map
CORocky Mountain Cancer Centers (RMCC) ( Site 8001)Aurora80012NCT06890884Map
CORocky Mountain Cancer Centers (Williams) UsorAurora80012-5405NCT06846671Map
CORocky Mountain Cancer Centers (Williams) UsorAurora80012-5405NCT06943872Map
COUCHealth University of Colorado HospitalAurora80045NCT06337318Map
COUniversity of ColoradoAurora80045NCT03949855Map
COUniversity Of ColoradoAurora80045NCT07015242Map
COUniversity of Colorado Anschutz Medical CampusAurora80045NCT07335562Map
CORocky Mountain Cancer Centers - Boulder /ID# 261203Boulder80303NCT06191744Map
COColorado Blood Cancer InstituteDenver80218NCT07226843Map
COColorado Blood Cancer Institute (CBCI)Denver80218NCT06561347Map
COCancer Care and Hematology-Fort CollinsFort Collins80528NCT06337318Map
COPoudre Valley HospitalFort Collins80524NCT06337318Map
COLutheran Hospital - Cancer Centers of Colorado ( Site 0180)Golden80401NCT06717347Map
COColorado West Healthcare System-Grand Valley Oncology ( Site 0165)Grand Junction81505NCT06890884Map
COUCHealth Greeley HospitalGreeley80631NCT06337318Map
COMedical Center of the RockiesLoveland80538NCT06337318Map
CTSmilow Cancer Hospital-Derby Care CenterDerby06418NCT05976763Map
CTSmilow Cancer Hospital Care Center-FairfieldFairfield06824NCT05976763Map
CTSmilow Cancer Hospital Care Center at GlastonburyGlastonbury06033NCT05976763Map
CTSmilow Cancer Hospital Care Center at GreenwichGreenwich06830NCT05976763Map
CTSmilow Cancer Hospital Care Center - GuilfordGuilford06437NCT05976763Map
CTSmilow Cancer Hospital Care Center at Saint FrancisHartford06105NCT05976763Map
CTYale Cancer CenterNew Haven06520NCT06084936Map
CTYale Cancer CenterNew Haven06520NCT07104032Map
CTYale UniversityNew Haven06520NCT03150693Map
CTYale UniversityNew Haven06520NCT05976763Map
CTYale University School of Medicine /ID# 242089New Haven06510NCT05283720Map
CTYale University Yale Cancer CenterNew Haven06520-8028NCT06943872Map
CTYale-New Haven Hospital North Haven Medical CenterNorth Haven06473NCT05976763Map
CTEastern Connecticut Hematology and OncologyNorwich06360-2700NCT06943872Map
CTSmilow Cancer Hospital Care Center at Long RidgeStamford06902NCT05976763Map
CTSmilow Cancer Hospital-Torrington Care CenterTorrington06790NCT05976763Map
CTSmilow Cancer Hospital Care Center-TrumbullTrumbull06611NCT05976763Map
CTSmilow Cancer Hospital-Waterbury Care CenterWaterbury06708NCT05976763Map
CTSmilow Cancer Hospital Care Center - WaterfordWaterford06385NCT05976763Map
DEChristiana Care Health Service /ID# 242301Newark19713NCT05283720Map
DEChristiana Care Health Service /ID# 261207Newark19713NCT06191744Map
DEHelen F Graham Cancer CenterNewark19713NCT05976763Map
DEHelen F Graham Cancer CenterNewark19713NCT06337318Map
DEMedical Oncology Hematology Consultants (MOHC) ( Site 8007)Newark19713NCT06890884Map
DEMedical Oncology Hematology Consultants PANewark19713NCT05976763Map
DEMedical Oncology Hematology Consultants PANewark19713NCT06337318Map
DCGeorgetown UniversityWashington D.C.20007NCT06084936Map
DCGeorgetown University Medical Center ( Site 0117)Washington D.C.20007NCT06890884Map
DCMedStar Georgetown University HospitalWashington D.C.20007NCT06337318Map
DCSibley Memorial HospitalWashington D.C.20016NCT06337318Map
FLUM Sylvester Comprehensive Cancer Center at AventuraAventura33180NCT05886036Map
FLUM Sylvester Comprehensive Cancer Center at AventuraAventura33180NCT06337318Map
FLBoca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163)Boca Raton33486NCT05139017Map
FLBoca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130)Boca Raton33486NCT06890884Map
FLClermont Oncology Center ( Site 0174)Clermont34711NCT05139017Map
FLClermont Oncology Center ( Site 0182)Clermont34711NCT06717347Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT04609046Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT05886036Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT06337318Map
FLUniversity of MiamiCoral Gables33146NCT06084936Map
FLUM Sylvester Comprehensive Cancer Center at Coral SpringsCoral Springs33065NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at Coral SpringsCoral Springs33065NCT05886036Map
FLUM Sylvester Comprehensive Cancer Center at Coral SpringsCoral Springs33065NCT06337318Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT04609046Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT05886036Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT06337318Map
FLUM Sylvester Comprehensive Cancer Center at DoralDoral33166NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at DoralDoral33166NCT05886036Map
FLUM Sylvester Comprehensive Cancer Center at DoralDoral33166NCT06337318Map
FLFlorida Oncology and HematologyFort Myers33912NCT06846671Map
FLBioresearch Partner ( Site 0157)Hialeah33013NCT06717347Map
FLBRP-Hialeah Hospital ( Site 0182)Hialeah33013NCT05139017Map
FLMemorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood33021NCT03150693Map
FLUM Sylvester Comprehensive Cancer Center at HollywoodHollywood33021NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at HollywoodHollywood33021NCT05886036Map
FLUM Sylvester Comprehensive Cancer Center at HollywoodHollywood33021NCT06337318Map
FLBaptist Md Anderson Cancer CenterJacksonville32207-8432NCT06846671Map
FLBaptist MD Anderson Cancer Center ( Site 0176)Jacksonville32207NCT06890884Map
FLCancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 262445Jacksonville32256NCT06191744Map
FLMayo Clinic Cancer CenterJacksonville32224NCT07104032Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT04840602Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT06337318Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT06834373Map
FLMayo Clinic Jacksonville - PPDSJacksonville32224NCT04884035Map
FLMayo Clinic Jacksonville: Department of Nephrology and HypertensionJacksonville32224NCT03949855Map
FLUM Sylvester Comprehensive Cancer Center at KendallMiami33176NCT04609046Map
FLUM Sylvester Comprehensive Cancer Center at KendallMiami33176NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at KendallMiami33176NCT05886036Map
FLUM Sylvester Comprehensive Cancer Center at KendallMiami33176NCT06337318Map
FLUniversity of MiamiMiami33136NCT04998669Map
FLUniversity of MiamiMiami33136NCT06730542Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT04609046Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT04840602Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT05886036Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT06337318Map
FLUniversity of Miami Miller School of Medicine, Div of NephrologyMiami33136NCT03949855Map
FLUniversity of Miami Sylvester Cancer CenterMiami33136NCT05800366Map
FLMount Sinai Braman Comprehensive Cancer Center ( Site 0140)Miami Beach33140NCT06890884Map
FLMount Sinai Medical CenterMiami Beach33140NCT06337318Map
FLUniversity of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami33181NCT04609046Map
FLUniversity of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami33181NCT04840602Map
FLUniversity of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami33181NCT06337318Map
FLOrlando Health Cancer Institute ( Site 0169)Ocoee34761NCT06717347Map
FLMid Florida Hematology and Oncology Center ( Site 0152)Orange City32763NCT06890884Map
FLMid Florida Hematology and Oncology Center ( Site 0172)Orange City32763NCT06717347Map
FLAdvent Health /ID# 261578Orlando32803NCT06191744Map
FLOrlando Health Cancer InstituteOrlando32806NCT03150693Map
FLOrlando Health Cancer Institute /ID# 260983Orlando32806NCT06191744Map
FLMemorial Hospital WestPembroke Pines33028NCT06337318Map
FLMemorial Hospital West ( Site 5410)Pembroke Pines33028NCT05947851Map
FLBoca Raton Clinical Research (BRCR) GlobalPlantation33322NCT06149286Map
FLBRCR Medical CenterPlantation33322NCT06351527Map
FLIRIS Research and Development, LLCPlantation33324NCT06581562Map
FLUM Sylvester Comprehensive Cancer Center at PlantationPlantation33324NCT04609046Map
FLUM Sylvester Comprehensive Cancer Center at PlantationPlantation33324NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at PlantationPlantation33324NCT05886036Map
FLUM Sylvester Comprehensive Cancer Center at PlantationPlantation33324NCT06337318Map
FLFlorida Cancer Specialists - SarasotaSarasota34236NCT07226843Map
FLMoffitt Cancer CenterTampa33612NCT05581030Map
FLMoffitt Cancer CenterTampa33612NCT06090539Map
FLMoffitt Cancer CenterTampa33612NCT06350318Map
FLMoffitt Cancer CenterTampa33612-9416NCT07015242Map
FLMoffitt Cancer Center /ID# 259487Tampa33612-9416NCT06191744Map
FLTampa General Hospital /ID# 246748Tampa33606NCT05283720Map
FLCleveland Clinic FloridaWeston33331-3609NCT06846671Map
FLCleveland Clinic FloridaWeston33331-3609NCT06943872Map
FLFL Medical Clinic Orlando HealthZephyrhills33542NCT06655896Map
GAPhoebe Putney Memorial HospitalAlbany31701NCT05976763Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT05976763Map
GAEmory Saint Joseph's HospitalAtlanta30342NCT06337318Map
GAEmory University HospitalAtlanta30322NCT06119685Map
GAEmory University HospitalAtlanta30322NCT07226843Map
GAEmory University Hospital MidtownAtlanta30308NCT05976763Map
GAEmory University Hospital MidtownAtlanta30308NCT06337318Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT03150693Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT05886036Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT05976763Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT06337318Map
GAEmory University School of MedicineAtlanta30322NCT07335562Map
GAEmory University Winship Cancer InstituteAtlanta30322-1013NCT06846671Map
GAGrady Health SystemAtlanta30303NCT05976763Map
GANorthside Cancer CenterAtlanta30342NCT06846671Map
GANorthside HospitalAtlanta30342NCT06046248Map
GAAugusta University Medical CenterAugusta30912NCT03150693Map
GAAugusta University Medical CenterAugusta30912NCT05976763Map
GAAugusta University Medical CenterAugusta30912NCT06337318Map
GAEmory Johns Creek HospitalJohns Creek30097NCT05976763Map
GANorthwest Georgia Oncology Centers PCMarietta30060NCT04884035Map
GANorthwest Georgia Oncology Centers, a Service of Wellstar Cobb HospitalMarietta30060NCT06911502Map
GASoutheastern Regional Medical CenterNewnan30265NCT06911502Map
HIKapiolani Medical Center for Women and ChildrenHonolulu96826NCT03150693Map
HIStraub Clinic and HospitalHonolulu96813NCT03150693Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT03150693Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT05976763Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT06337318Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT03150693Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05976763Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT03150693Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT05976763Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT06337318Map
IDBeacon Cancer Care - Coeur d'Alene /ID# 260670Coeur d'Alene83814NCT06191744Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT03150693Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT05976763Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT06337318Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT03150693Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05976763Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT03150693Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05976763Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT04840602Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT03150693Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05976763Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT06337318Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT03150693Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05976763Map
IDBeacon Cancer Care ( Site 0142)Post Falls83854NCT06890884Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT03150693Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT05976763Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT06337318Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT03150693Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT05976763Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT06337318Map
IDSaint Luke's Cancer Institute - Twin FallsTwin Falls83301NCT03150693Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT05976763Map
ILIllinois CancerCare-CantonCanton61520NCT05976763Map
ILIllinois CancerCare-CarthageCarthage62321NCT05976763Map
ILCentralia Oncology ClinicCentralia62801NCT04840602Map
ILAlliance for Clinical Trials in OncologyChicago60606NCT05976763Map
ILNorthwestern Medicine - Northwestern Memorial Hospital /ID# 259814Chicago60611NCT06191744Map
ILNorthwestern UniversityChicago60611NCT03150693Map
ILNorthwestern UniversityChicago60611NCT06655896Map
ILNorthwestern UniversityChicago60611NCT06943872Map
ILRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityChicago60611NCT07015242Map
ILRush MD Anderson Cancer CenterChicago60612NCT03150693Map
ILSwedish Covenant HospitalChicago60625NCT06337318Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT03150693Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT06337318Map
ILUniversity of Chicago Medical CenterChicago60637NCT03571321Map
ILUniversity of Chicago Medical Center ( Site 0126)Chicago60637NCT06890884Map
ILUniversity of Chicago Medicine Comprehensive Cancer CenterChicago60637NCT07294677Map
ILUniversity of IllinoisChicago60612NCT03150693Map
ILUniversity of IllinoisChicago60612NCT05976763Map
ILCarle at The RiverfrontDanville61832NCT04840602Map
ILCarle at The RiverfrontDanville61832NCT05976763Map
ILCarle at The RiverfrontDanville61832NCT06337318Map
ILCancer Care Specialists Of Central Illinois /ID# 272464Decatur62526NCT06191744Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT04840602Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT05976763Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT06337318Map
ILDecatur Memorial HospitalDecatur62526NCT05976763Map
ILDecatur Memorial HospitalDecatur62526NCT06337318Map
ILIllinois CancerCare-DixonDixon61021NCT05976763Map
ILCarle Physician Group-EffinghamEffingham62401NCT04840602Map
ILCarle Physician Group-EffinghamEffingham62401NCT05976763Map
ILCarle Physician Group-EffinghamEffingham62401NCT06337318Map
ILCrossroads Cancer CenterEffingham62401NCT04840602Map
ILCrossroads Cancer CenterEffingham62401NCT05976763Map
ILCrossroads Cancer CenterEffingham62401NCT06337318Map
ILElmhurst Memorial HospitalElmhurst60126NCT06337318Map
ILIllinois CancerCare-EurekaEureka61530NCT05976763Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT03150693Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT06337318Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT05976763Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT03150693Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT06337318Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT03150693Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT06337318Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT05976763Map
ILIllinois CancerCare-MacombMacomb61455NCT05976763Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT04840602Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05976763Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT06337318Map
ILLoyola University Medical CenterMaywood60153NCT03150693Map
ILEdward Hospital/Cancer CenterNaperville60540NCT06337318Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT03150693Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT06337318Map
ILIllinois Cancer Specialists ( Site 8000)Niles60714NCT05139017Map
ILIllinois Cancer Specialists (Niles) UsorNiles60714-5905NCT06943872Map
ILCancer Care Center of O'FallonO'Fallon62269NCT04840602Map
ILCancer Care Center of O'FallonO'Fallon62269NCT05976763Map
ILCancer Care Center of O'FallonO'Fallon62269NCT06337318Map
ILCancer Care Specialists of Illinois ( Site 0152)O'Fallon62269NCT06717347Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT03150693Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT06337318Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT05976763Map
ILIllinois CancerCare-PekinPekin61554NCT05976763Map
ILIllinois Cancer Care ( Site 7005)Peoria61615NCT06890884Map
ILIllinois Cancer Care, PC /ID# 261526Peoria61615NCT06191744Map
ILIllinois CancerCare-PeoriaPeoria61615NCT05976763Map
ILIllinois CancerCare-PeruPeru61354NCT05976763Map
ILEdward Hospital/Cancer Center?PlainfieldPlainfield60585NCT06337318Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT05976763Map
ILMemorial Hospital EastShiloh62269NCT05976763Map
ILMemorial Hospital EastShiloh62269NCT06337318Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT04840602Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05976763Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT06337318Map
ILSpringfield ClinicSpringfield62702NCT04840602Map
ILSpringfield ClinicSpringfield62702NCT05976763Map
ILSpringfield ClinicSpringfield62702NCT06337318Map
ILSpringfield Memorial HospitalSpringfield62781NCT04840602Map
ILSpringfield Memorial HospitalSpringfield62781NCT05976763Map
ILSpringfield Memorial HospitalSpringfield62781NCT06337318Map
ILCarle Cancer CenterUrbana61801NCT04840602Map
ILCarle Cancer CenterUrbana61801NCT05976763Map
ILCarle Cancer CenterUrbana61801NCT06337318Map
ILIllinois CancerCare - WashingtonWashington61571NCT05976763Map
INNorthwest Cancer Center - Crown PointCrown Point46307NCT06337318Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT06337318Map
INNorthwest Oncology LLCDyer46311NCT06337318Map
INFort Wayne Medical Oncology and Hematology ( Site 0149)Fort Wayne46804NCT06717347Map
INFort Wayne Medical Oncology and Hematology- South Office /ID# 259583Fort Wayne46804NCT06191744Map
INNorthwest Cancer Center - HobartHobart46342NCT05976763Map
INNorthwest Cancer Center - HobartHobart46342NCT06337318Map
INSaint Mary Medical CenterHobart46342NCT06337318Map
INIndiana University and Comprehensive Cancer CenterIndianapolis46202NCT06149286Map
INIndiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis46202NCT06091865Map
INIndiana University/Melvin and Bren Simon Cancer CenterIndianapolis46202NCT06337318Map
INSaint Catherine HospitalIndianapolis46312NCT06337318Map
INSt Vincent Ascension at Peyton Manning Childrens HospitalIndianapolis46260NCT06091865Map
INThe Community HospitalMunster46321NCT06337318Map
INWomen's Diagnostic Center - MunsterMunster46321NCT06337318Map
INInvestigative Clinical Research of IndianaNoblesville46062NCT06091254Map
INInvestigative Clinical Research of IndianaNoblesville46062NCT06091865Map
INNorthwest Cancer Center - ValparaisoValparaiso46383NCT06337318Map
IAMary Greeley Medical CenterAmes50010NCT04840602Map
IAMary Greeley Medical CenterAmes50010NCT05976763Map
IAMary Greeley Medical CenterAmes50010NCT06337318Map
IAMcFarland Clinic - AmesAmes50010NCT04840602Map
IAMcFarland Clinic - AmesAmes50010NCT05976763Map
IAMcFarland Clinic - AmesAmes50010NCT06337318Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT04609046Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT05976763Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT06337318Map
IAUniversity of Iowa Healthcare Cancer Services Quad CitiesBettendorf52722NCT06337318Map
IASaint Anthony Regional HospitalCarroll51401NCT04609046Map
IASaint Anthony Regional HospitalCarroll51401NCT05976763Map
IAMercy HospitalCedar Rapids52403NCT06337318Map
IAOncology Associates at Mercy Medical CenterCedar Rapids52403NCT06337318Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT04609046Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT05976763Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT06337318Map
IABroadlawns Medical CenterDes Moines50314NCT04609046Map
IABroadlawns Medical CenterDes Moines50314NCT05976763Map
IAIowa Methodist Medical CenterDes Moines50309NCT04609046Map
IAIowa Methodist Medical CenterDes Moines50309NCT05976763Map
IAIowa Methodist Medical CenterDes Moines50309NCT06337318Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT04609046Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT05976763Map
IAResearch SiteDes Moines50309NCT05952024Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT04609046Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT05976763Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT06337318Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT04609046Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT05976763Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT06337318Map
IAUniversity of Iowa Health Care /ID# 262132Des Moines50314-3017NCT06191744Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT04840602Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT05976763Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT06337318Map
IAUI Healthcare Mission Cancer and Blood - Fort DodgeFort Dodge50501NCT05976763Map
IAUniversity Of IowaIowa City52242NCT06655896Map
IAUniversity of Iowa-Holden Comprehensive Cancer Center ( Site 0139)Iowa City52242NCT06890884Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT03150693Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT05976763Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT06337318Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT04840602Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT05976763Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT06337318Map
IAMission Blood & Cancer Care ( Site 0114)Waukee50263NCT06890884Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT04609046Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT05976763Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT06337318Map
KSHaysMedHays67601NCT05976763Map
KSHaysMedHays67601NCT06337318Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT03150693Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT05886036Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT05976763Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT06337318Map
KSUniversity Of Kansas Medical CenterKansas City66160NCT04884035Map
KSLawrence Memorial HospitalLawrence66044NCT05976763Map
KSLawrence Memorial HospitalLawrence66044NCT06337318Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT05976763Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT06337318Map
KSUniversity of Kansas Cancer Center-Overland ParkOverland Park66210NCT05886036Map
KSUniversity of Kansas Cancer Center-Overland ParkOverland Park66210NCT05976763Map
KSUniversity of Kansas Cancer Center-Overland ParkOverland Park66210NCT06337318Map
KSFreeman Physician Group of PittsburgPittsburg66762NCT05976763Map
KSSalina Regional Health CenterSalina67401NCT05976763Map
KSSalina Regional Health CenterSalina67401NCT06337318Map
KSCotton O'Neil Cancer Center ( Site 0108)Topeka66606NCT06717347Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT05976763Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT06337318Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT03150693Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT05886036Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT05976763Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT06337318Map
KSCancer Center of Kansas - WichitaWichita67214NCT03150693Map
KSCancer Center Of Kansas-WichitaWichita67214NCT04884035Map
KYSaint Elizabeth Medical Center Edgewood ( Site 0141)Edgewood41017NCT06890884Map
KYSaint Elizabeth Medical Center Edgewood ( Site 0165)Edgewood41017NCT05139017Map
KYBaptist Health Hardin ( Site 0154)Elizabethtown42701NCT06890884Map
KYBaptist Health Lexington ( Site 0127)Lexington40503NCT06890884Map
KYUniversity of KentuckyLexington40536NCT06091865Map
KYUniversity of Kentucky ( Site 0106)Lexington40536NCT06717347Map
KYUniversity of Kentucky Chandler Medical Center ( Site 0158)Lexington40536NCT05139017Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT03150693Map
KYNorton Cancer Institute - St. Matthews /ID# 261076Louisville40207NCT06191744Map
KYNorton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405Louisville40207NCT03571568Map
KYNorton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133)Louisville40207NCT05139017Map
KYNorton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163)Louisville40207NCT06717347Map
KYNorton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0185)Louisville40207NCT06890884Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT05976763Map
KYUniversity of Louisville Hospital /ID# 260544Louisville40202NCT06191744Map
KYUniversity of Louisville, Brown Cancer CenterLouisville40202NCT06943872Map
KYUofL Health Medical Center NortheastLouisville40245NCT05976763Map
KYOwensboro Medical Health System ( Site 0195)Owensboro42303NCT06717347Map
LACHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184)Alexandria71301NCT06717347Map
LALSU Health Baton Rouge-North ClinicBaton Rouge70805NCT06337318Map
LAMary Bird Perkins Cancer CenterBaton Rouge70809-3738NCT06943872Map
LAOur Lady of the Lake HospitalBaton Rouge70808-4365NCT06846671Map
LAOur Lady of the Lake Physician GroupBaton Rouge70808NCT06337318Map
LAOur Lady of the Lake Physician Group-Medical Oncology ( Site 0180)Baton Rouge70808NCT06890884Map
LAOchsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209)Monroe71202NCT06890884Map
LAOchsner Clinic Foundation ( Site 0189)New Orleans70121NCT06890884Map
LALouisiana State University Health Sciences Shreveport ( Site 0195)Shreveport71103NCT06890884Map
MEMaineHealth Maine Medical Center - PortlandPortland04102NCT04609046Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT04609046Map
MEMaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland04106NCT04609046Map
MENew England Cancer Specialists - Westbrook /ID# 260672Westbrook04092NCT06191744Map
MDJohns HopkinsBaltimore21287NCT03949855Map
MDJohns Hopkins UniversityBaltimore21231NCT05533775Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT06337318Map
MDUniversity of Maryland ( Site 0123)Baltimore21201NCT05139017Map
MDUniversity of Maryland Greenebaum Comprehensive Cancer CenterBaltimore21201NCT06091865Map
MDUniversity of Maryland Greenebaum Comprehensive Cancer CenterBaltimore21201-1544NCT06943872Map
MDUniversity of Maryland, Baltimore /ID# 242218Baltimore21201NCT05283720Map
MDUniversity of Maryland, Baltimore /ID# 259538Baltimore21201NCT06191744Map
MDUniversity of Maryland/Greenebaum Cancer CenterBaltimore21201NCT03150693Map
MDAmerican Oncology Partners of Maryland PaBethesda20817-7847NCT06846671Map
MDAmerican Oncology Partners, P.A. ( Site 0185)Bethesda20817NCT06717347Map
MDCenter for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 259476Bethesda20817NCT06191744Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT03949855Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT03952637Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT04002947Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT01419561Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT00977977Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT05389423Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT06364423Map
MDNational Naval Medical CenterBethesda20889NCT00977977Map
MDNCI - Center for Cancer ResearchBethesda20892NCT06965114Map
MDWalter Reed National Military Medical CenterBethesda20889-5600NCT06337318Map
MDGreater Baltimore Medical CenterTowson21204NCT06911502Map
MABeth Israel Deaconess Medical CenterBoston02215NCT04421560Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06561347Map
MABeth Israel Deaconess Medical CenterBoston02215NCT05783609Map
MABeth Israel Deaconess Medical CenterBoston02215NCT05800366Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06091254Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06091865Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06510309Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06854003Map
MABeth Israel Deaconess Medical CenterBoston02115NCT07104032Map
MABeth Israel Deaconess Medical Center (Data Collection Only)Boston02215NCT07231952Map
MABoston Medical CenterBoston02118NCT06655896Map
MABrigham and Women's HospitalBoston02115NCT06475235Map
MADana Farber Cancer InstituteBoston02215NCT04669171Map
MADana Farber Cancer InstituteBoston02115NCT04421560Map
MADana Farber Cancer InstituteBoston02215NCT06561347Map
MADana Farber Cancer InstituteBoston02215NCT05800366Map
MADana Farber Cancer InstituteBoston02215NCT06475235Map
MADana Farber Cancer InstituteBoston02215-5418NCT06943872Map
MADana Farber Cancer Institute ( Site 0111)Boston02215NCT06890884Map
MADana Farber Cancer Institute (Data Collection and Specimen Analysis)Boston02115NCT07231952Map
MADana-Farber Cancer InstituteBoston02215NCT03150693Map
MADana-Farber Cancer InstituteBoston02215NCT06563596Map
MADana-Farber Cancer InstituteBoston02215NCT05533775Map
MADana-Farber Cancer InstituteBoston02215NCT05783609Map
MADana-Farber Cancer InstituteBoston02215NCT06090539Map
MADana-Farber Cancer InstituteBoston02115NCT06644183Map
MADana-Farber Cancer InstituteBoston02215NCT06854003Map
MADana-Farber Cancer InstituteBoston02215NCT07015242Map
MADana-Farber Cancer InstituteBoston02115NCT07104032Map
MADana-Farber Cancer InstituteBoston02215NCT07226843Map
MADana-Farber Cancer Institute-Lymphoma ( Site 0111)Boston02215NCT05139017Map
MAMassachusetts General HospitalBoston02114NCT06561347Map
MAMassachusetts General HospitalBoston02114NCT07104032Map
MAMassachusetts General HospitalBoston02114NCT07226843Map
MAMassachusetts General Hospital Cancer CenterBoston02114NCT03150693Map
MAResearch SiteBoston02215NCT06564038Map
MAUniversity of Massachusetts Medical School ( Site 0119)Worcester01655NCT05139017Map
MIMichigan Med University of MichiganAnn Arbor48109 5271NCT06655896Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT04840602Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT03150693Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT05976763Map
MIUniversity of MichiganAnn Arbor48109NCT03523975Map
MIUniversity of MichiganAnn Arbor48104NCT03949855Map
MIUniversity of MichiganAnn Arbor48109NCT04998669Map
MIUniversity of Michigan Health SystemAnn Arbor48109NCT06084936Map
MIUniversity of Michigan Rogel Cancer CenterAnn Arbor48109NCT06337318Map
MIBronson Battle CreekBattle Creek49017NCT06337318Map
MIMcLaren Cancer Institute-Bay CityBay City48706NCT05976763Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT04840602Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT03150693Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05976763Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT06337318Map
MITrinity Health Medical Center - BrightonBrighton48114NCT04840602Map
MITrinity Health Medical Center - BrightonBrighton48114NCT03150693Map
MITrinity Health Medical Center - BrightonBrighton48114NCT05976763Map
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT06337318
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT04840602Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT03150693Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05976763Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT06337318Map
MITrinity Health Medical Center - CantonCanton48188NCT04840602Map
MITrinity Health Medical Center - CantonCanton48188NCT03150693Map
MITrinity Health Medical Center - CantonCanton48188NCT05976763Map
MIChelsea HospitalChelsea48118NCT04840602Map
MIChelsea HospitalChelsea48118NCT03150693Map
MIChelsea HospitalChelsea48118NCT05976763Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT04840602Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT03150693Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05976763Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT06337318Map
MIHematology Oncology Consultants-ClarkstonClarkston48346NCT04840602Map
MIMcLaren Cancer Institute-ClarkstonClarkston48346NCT05976763Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT04840602Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT06337318Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT06337318Map
MIHenry Ford Health SystemDetroit48202NCT06091865Map
MIHenry Ford HospitalDetroit48202NCT04840602Map
MIHenry Ford HospitalDetroit48202NCT06337318Map
MIKarmanos Cancer InstituteDetroit48201NCT06091254Map
MIKarmanos Cancer Institute ( Site 0174)Detroit48201NCT06717347Map
MIWayne State University/Karmanos Cancer InstituteDetroit48201NCT03150693Map
MIWayne State University/Karmanos Cancer InstituteDetroit48201NCT05976763Map
MIWayne State University/Karmanos Cancer InstituteDetroit48201NCT06337318Map
MICorewell Health Farmington Hills HospitalFarmington Hills48336NCT05976763Map
MIWeisberg Cancer Treatment CenterFarmington Hills48334NCT03150693Map
MIWeisberg Cancer Treatment CenterFarmington Hills48334NCT05976763Map
MIWeisberg Cancer Treatment CenterFarmington Hills48334NCT06337318Map
MICancer Hematology Centers - FlintFlint48503NCT04840602Map
MICancer Hematology Centers - FlintFlint48503NCT03150693Map
MICancer Hematology Centers - FlintFlint48503NCT05976763Map
MICancer Hematology Centers - FlintFlint48503NCT06337318Map
MIGenesys Hurley Cancer InstituteFlint48503NCT04840602Map
MIGenesys Hurley Cancer InstituteFlint48503NCT03150693Map
MIGenesys Hurley Cancer InstituteFlint48503NCT05976763Map
MIGenesys Hurley Cancer InstituteFlint48503NCT06337318Map
MIHurley Medical CenterFlint48503NCT04840602Map
MIHurley Medical CenterFlint48503NCT03150693Map
MIHurley Medical CenterFlint48503NCT05976763Map
MIMcLaren Cancer Institute-FlintFlint48532NCT05976763Map
MICancer and Hematology Centers of Western MichiganGrand Rapids49503NCT06091865Map
MICorewell Health ( Site 0130)Grand Rapids49503NCT06717347Map
MICorewell Health ( Site 0162)Grand Rapids49503NCT05139017Map
MICorewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids49503NCT03150693Map
MICorewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids49503NCT06337318Map
MIThe Cancer and Hematology CentersGrand Rapids49503-2563NCT06943872Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT03150693Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT06337318Map
MIAllegiance HealthJackson49201NCT06337318Map
MIBeacon Kalamazoo Cancer CenterKalamazoo49009NCT03150693Map
MIBronson Methodist HospitalKalamazoo49007NCT03150693Map
MIBronson Methodist HospitalKalamazoo49007NCT06337318Map
MIWest Michigan Cancer CenterKalamazoo49007NCT03150693Map
MIWest Michigan Cancer CenterKalamazoo49007NCT06337318Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT04840602Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT05976763Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT06337318Map
MIMcLaren Cancer Institute-Lapeer RegionLapeer48446NCT05976763Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT04840602Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT03150693Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05976763Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT06337318Map
MIHenry Ford Saint John Hospital - Macomb MedicalMacomb48044NCT03150693Map
MIHenry Ford Saint John Hospital - Macomb MedicalMacomb48044NCT05976763Map
MIMcLaren Cancer Institute-Central MichiganMount Pleasant48858NCT05976763Map
MITrinity Health Muskegon HospitalMuskegon49444NCT03150693Map
MITrinity Health Muskegon HospitalMuskegon49444NCT06337318Map
MICorewell Health Lakeland Hospitals - Niles HospitalNiles49120NCT03150693Map
MICorewell Health Lakeland Hospitals - Niles HospitalNiles49120NCT06337318Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT03150693Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT06337318Map
MIHenry Ford Health Providence Novi HospitalNovi48374NCT06337318Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT04840602Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT06337318Map
MIMcLaren Cancer Institute-Northern MichiganPetoskey49770NCT05976763Map
MIHope Cancer CenterPontiac48341NCT06337318Map
MIMichigan Healthcare Professionals PontiacPontiac48341NCT04840602Map
MINewland Medical Associates-PontiacPontiac48341NCT04840602Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT04840602Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT03150693Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT05976763Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT06337318Map
MICorewell Health Reed City HospitalReed City49677NCT03150693Map
MICorewell Health Reed City HospitalReed City49677NCT06337318Map
MICorewell Health William Beaumont University HospitalRoyal Oak48073NCT05976763Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT04840602Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT05976763Map
MICorewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph49085NCT03150693Map
MICorewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph49085NCT06337318Map
MICorewell Health Lakeland Hospitals - Saint Joseph HospitalSaint Joseph49085NCT06337318Map
MIHenry Ford Health Providence Southfield HospitalSouthfield48075NCT06337318Map
MIMyMichigan Medical Center TawasTawas City48764NCT04840602Map
MIMyMichigan Medical Center TawasTawas City48764NCT05976763Map
MIMunson Medical CenterTraverse City49684NCT03150693Map
MIMunson Medical CenterTraverse City49684NCT06337318Map
MICorewell Health Beaumont Troy HospitalTroy48085NCT05976763Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT04840602Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT06337318Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT06337318Map
MIUniversity of Michigan Health - WestWyoming49519NCT03150693Map
MIUniversity of Michigan Health - WestWyoming49519NCT06337318Map
MIHuron Gastroenterology PCYpsilanti48106NCT04840602Map
MIHuron Gastroenterology PCYpsilanti48106NCT03150693Map
MIHuron Gastroenterology PCYpsilanti48106NCT05976763Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT04840602Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT03150693Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05976763Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT06337318Map
MNMayo Clinic Health System in Albert LeaAlbert Lea56007NCT06834373Map
MNSanford Joe Lueken Cancer CenterBemidji56601NCT05976763Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT05976763Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT06337318Map
MNMinnesota Oncology - BurnsvilleBurnsville55337NCT06337318Map
MNMinnesota Oncology Hematology (MNO) ( Site 8004)Burnsville55337NCT06890884Map
MNMercy HospitalCoon Rapids55433NCT05976763Map
MNMercy HospitalCoon Rapids55433NCT06337318Map
MNEssentia Health - Deer River ClinicDeer River56636NCT05976763Map
MNEssentia Health - Deer River ClinicDeer River56636NCT06337318Map
MNEssentia Health Cancer CenterDuluth55805NCT03150693Map
MNEssentia Health Cancer CenterDuluth55805NCT05976763Map
MNEssentia Health Cancer CenterDuluth55805NCT06337318Map
MNFairview Southdale HospitalEdina55435NCT06337318Map
MNEssentia Health Hibbing ClinicHibbing55746NCT05976763Map
MNEssentia Health Hibbing ClinicHibbing55746NCT06337318Map
MNMayo Clinic Health Systems-MankatoMankato56001NCT06834373Map
MNSaint John's Hospital - HealtheastMaplewood55109NCT05976763Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT04840602Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT03150693Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05976763Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT06337318Map
MNHennepin County Medical CenterMinneapolis55415NCT04840602Map
MNHennepin County Medical CenterMinneapolis55415NCT05976763Map
MNMasonic Cancer CenterMinneapolis55455NCT06792825Map
MNMasonic Cancer Center at University of MinnesotaMinneapolis55455NCT03579875Map
MNUniversity of MinnesotaMinneapolis55455NCT06119685Map
MNUniversity of MinnesotaMinneapolis55455NCT06655896Map
MNUniversity of Minnesota Health Clinical Research UnitMinneapolis55455NCT03949855Map
MNUniversity of Minnesota Masonic Cancer CenterMinneapolis55455NCT05735717Map
MNUniversity of Minnesota Masonic Cancer CenterMinneapolis55455NCT06412497Map
MNMayo ClinicRochester55905NCT04669171Map
MNMayo Clinic - RochesterRochester55905-0001NCT04884035Map
MNMayo Clinic Cancer CenterRochester55905NCT07104032Map
MNMayo Clinic in RochesterRochester55905NCT03418038Map
MNMayo Clinic in RochesterRochester55905NCT04840602Map
MNMayo Clinic in RochesterRochester55905NCT03150693Map
MNMayo Clinic in RochesterRochester55905NCT06337318Map
MNMayo Clinic in RochesterRochester55905NCT06834373Map
MNMayo Clinic in Rochester, MinnesotaRochester55905NCT06090539Map
MNMayo Clinic RochesterRochester55905-0001NCT06943872Map
MNCoborn Cancer Center at Saint Cloud HospitalSaint Cloud56303NCT05976763Map
MNHealthPartners Cancer Research CenterSaint Louis Park55426NCT04884035Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT04840602Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05976763Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT06337318Map
MNRegions HospitalSaint Paul55101NCT04840602Map
MNRegions HospitalSaint Paul55101NCT05976763Map
MNRegions HospitalSaint Paul55101NCT06337318Map
MNUnited HospitalSaint Paul55102NCT04840602Map
MNUnited HospitalSaint Paul55102NCT05976763Map
MNUnited HospitalSaint Paul55102NCT06337318Map
MNEssentia Health SandstoneSandstone55072NCT05976763Map
MNEssentia Health SandstoneSandstone55072NCT06337318Map
MNSaint Francis Regional Medical CenterShakopee55379NCT06337318Map
MNEssentia Health Virginia ClinicVirginia55792NCT05976763Map
MNEssentia Health Virginia ClinicVirginia55792NCT06337318Map
MNMinnesota Oncology Hematology PA-WoodburyWoodbury55125NCT05976763Map
MSHattiesburg ClinicHattiesburg39401NCT06149286Map
MSHattiesburg Clinic Hematology/OncologyHattiesburg39401-7233NCT06911502Map
MSThe University of Mississippi Medical Center ( Site 0161)Jackson39216NCT06717347Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT06337318Map
MOCircuit Clinical - SSM Health Cancer Care DePaul ( Site 0166)Bridgeton63044NCT06717347Map
MOSaint Francis Medical CenterCape Girardeau63703NCT04840602Map
MOSaint Francis Medical CenterCape Girardeau63703NCT05976763Map
MOSaint Francis Medical CenterCape Girardeau63703NCT06337318Map
MOSaint Luke's HospitalChesterfield63017NCT05976763Map
MOSaint Luke's HospitalChesterfield63017NCT06337318Map
MOSt. Luke's HospitalChesterfield63017NCT06084936Map
MOSt. Luke's Hospital - Chesterfield /ID# 260489Chesterfield63017NCT06191744Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT04609046Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT03150693Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT05976763Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT06337318Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT04609046Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT03150693Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT05976763Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT06337318Map
MOParkland Health Center - FarmingtonFarmington63640NCT06337318Map
MOChildrens Mercy Hosp & ClinicsKansas City64108NCT05533775Map
MOKansas City Veterans Affairs Medical CenterKansas City64128NCT05976763Map
MOKansas City Veterans Affairs Medical CenterKansas City64128NCT06337318Map
MOTruman Medical Center ( Site 0122)Kansas City64108NCT06717347Map
MOUniversity Health Truman Medical CenterKansas City64108NCT05976763Map
MOUniversity Health Truman Medical CenterKansas City64108NCT06337318Map
MOUniversity of Kansas Cancer Center - BriarcliffKansas City64116NCT05886036Map
MOUniversity of Kansas Cancer Center - BriarcliffKansas City64116NCT05976763Map
MOUniversity of Kansas Cancer Center - BriarcliffKansas City64116NCT06337318Map
MOUniversity of Kansas Cancer Center - NorthKansas City64154NCT05886036Map
MOUniversity of Kansas Cancer Center - NorthKansas City64154NCT05976763Map
MOUniversity of Kansas Cancer Center - NorthKansas City64154NCT06337318Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT05886036Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT05976763Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT06337318Map
MOHeartland Regional Medical CenterSaint Joseph64506NCT04840602Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT06337318Map
MOCoxHealth South HospitalSpringfield65807NCT05976763Map
MOMercy Hospital SpringfieldSpringfield65804NCT05976763Map
MOOncology Hematology AssociatesSpringfield65807-5288NCT06846671Map
MOMercy Hospital Saint LouisSt Louis63141NCT03150693Map
MOMercy Hospital SouthSt Louis63128NCT04840602Map
MOMercy Hospital SouthSt Louis63128NCT03150693Map
MOMercy Hospital SouthSt Louis63128NCT05976763Map
MOMissouri Baptist Medical CenterSt Louis63131NCT06337318Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT04609046Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT05976763Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT06337318Map
MOSiteman Cancer Center-South CountySt Louis63129NCT04609046Map
MOSiteman Cancer Center-South CountySt Louis63129NCT03150693Map
MOSiteman Cancer Center-South CountySt Louis63129NCT05976763Map
MOSiteman Cancer Center-South CountySt Louis63129NCT06337318Map
MOWashington UniversitySt Louis63130NCT06390956Map
MOWashington UniversitySt Louis63110NCT06854003Map
MOWashington University in St. LouisSt Louis63110NCT03949855Map
MOWashington University School of MedicineSt Louis63110NCT04609046Map
MOWashington University School of MedicineSt Louis63110NCT03150693Map
MOWashington University School of MedicineSt Louis63110NCT05976763Map
MOWashington University School of MedicineSt Louis63110NCT06040320Map
MOWashington University School of MedicineSt Louis63110NCT06337318Map
MOWashington University School of Medicine in St. LouisSt Louis63110-1010NCT07015242Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT06337318Map
MOBJC Outpatient Center at Sunset HillsSunset Hills63127NCT06337318Map
MTCommunity Hospital of AnacondaAnaconda59711NCT03150693Map
MTCommunity Hospital of AnacondaAnaconda59711NCT05976763Map
MTCommunity Hospital of AnacondaAnaconda59711NCT06337318Map
MTBillings Clinic Cancer CenterBillings59101NCT03150693Map
MTBillings Clinic Cancer CenterBillings59101NCT05976763Map
MTBillings Clinic Cancer CenterBillings59101NCT06337318Map
MTIntermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178)Billings59102NCT06717347Map
MTIntermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 260006Billings59102NCT06191744Map
MTSaint Vincent Frontier Cancer CenterBillings59102NCT04840602Map
MTSt. Vincent Frontier Cancer Center-Research ( Site 0108)Billings59102NCT05139017Map
MTBozeman Health Deaconess HospitalBozeman59715NCT03150693Map
MTBozeman Health Deaconess HospitalBozeman59715NCT05976763Map
MTBozeman Health Deaconess HospitalBozeman59715NCT06337318Map
MTBozeman Health Deaconess Hospital ( Site 0183)Bozeman59715NCT06890884Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT03150693Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT05976763Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT06337318Map
MTLogan Health Medical CenterKalispell59901NCT03150693Map
MTLogan Health Medical CenterKalispell59901NCT05976763Map
MTLogan Health Medical CenterKalispell59901NCT06337318Map
MTCommunity Medical CenterMissoula59804NCT03150693Map
MTCommunity Medical CenterMissoula59804NCT05976763Map
MTCommunity Medical CenterMissoula59804NCT06337318Map
NENebraska Medicine-BellevueBellevue68123NCT03150693Map
NENebraska Medicine-BellevueBellevue68123NCT05976763Map
NENebraska Cancer Specialists (NCS) - Regional Cancer Center - St Francis Location /ID# 262506Grand Island68803NCT06191744Map
NEOncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0188)Grand Island68803NCT05139017Map
NEFred and Pamela Buffett Cancer Center - KearneyKearney68845NCT05976763Map
NENHO - Nebraska Hematology-Oncology /ID# 269692Lincoln68506NCT06191744Map
NENHO Revive Research Institute, LLC ( Site 0121)Lincoln68506NCT06890884Map
NENebraska Cancer Specialists - Omaha - Wright Street /ID# 262505Omaha68130NCT06191744Map
NENebraska Medicine-Village PointeOmaha68118NCT03150693Map
NENebraska Medicine-Village PointeOmaha68118NCT05976763Map
NEOncology Hematology West, Pc Dba Nebraska Cancer SpecialistsOmaha68130-2042NCT06846671Map
NEOncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0177)Omaha68130NCT05139017Map
NEUniversity of NebraskaOmaha68198NCT03949855Map
NEUniversity of Nebraska - Fred and Pamela Buffet CenterOmaha68198NCT04884035Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT03414502Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT03150693Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT05976763Map
NEUniversity Of Nebraska Medical Center ( Site 0110)Omaha68198NCT06890884Map
NEUniversity of Nebraska Medical Center /ID# 261996Omaha68198NCT06191744Map
NVComprehensive Cancer Centers of Nevada ( Site 0113)Las Vegas89169NCT06717347Map
NVComprehensive Cancer Centers of Nevada ( Site 0168)Las Vegas89169NCT05139017Map
NVOptumCare Cancer Care ( Site 0121)Las Vegas89102NCT06717347Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT03150693Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT06337318Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT03150693Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT06337318Map
NVRenown Regional Medical CenterReno89502NCT06084936Map
NHDartmouth Cancer CenterLebanon03756NCT06149286Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT05976763Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT06337318Map
NJMemorial Sloan Kettering at Basking Ridge (All Protocol Activities)Basking Ridge07920NCT06561360Map
NJMemorial Sloan Kettering at Basking Ridge (Consent only)Basking Ridge07920NCT05736419Map
NJMemorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)Basking Ridge07920NCT06756308Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT04840602Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT05886036Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT07231952Map
NJMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge07920NCT06765317Map
NJMemorial Sloan Kettering Cancer Center (Limited Protocol Activities)Basking Ridge07920NCT06756308Map
NJHackensack Meridian Health (Data collection only)Hackensack07601NCT06765317Map
NJResearch SiteHackensack07601NCT06564038Map
NJSaint Barnabas Medical CenterLivingston07039NCT06337318Map
NJMonmouth Medical CenterLong Branch07740NCT06337318Map
NJMemoral Sloan Kettering MonmouthMiddletown07748NCT07231952Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT04840602Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT05886036Map
NJMemorial Sloan Kettering Monmouth (Consent only)Middletown07748NCT05736419Map
NJMemorial Sloan Kettering Monmouth (Limited protocol activities)Middletown07748NCT06756308Map
NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown07748NCT06561360Map
NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown07748NCT06765317Map
NJMemorial Sloan Kettering BergenMontvale07645NCT04840602Map
NJMemorial Sloan Kettering BergenMontvale07645NCT05886036Map
NJMemorial Sloan Kettering BergenMontvale07645NCT07231952Map
NJMemorial Sloan Kettering Bergen (Consent only)Montvale07645NCT05736419Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT06561360Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT06756308Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT06765317Map
NJAtlantic Health Morristown Medical Center ( Site 0163)Morristown07960NCT06890884Map
NJResearch SiteNew Brunswick08901NCT06564038Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08901NCT04998669Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT05786040Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08901NCT06084936Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08901NCT06091865Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT06337318Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08901NCT07015242Map
NJValley Health Systems - Ridgewood Campus ( Site 0125)Paramus07652NCT06890884Map
NJSidney Kimmel Comprehensive Cancer Center Washington TwpSewell08080NCT06943872Map
NJAtlantic Health Overlook Medical CenterSummit07901NCT07104032Map
NMPresbyterian Kaseman Hospital /ID# 262451Albuquerque87110NCT06191744Map
NMUniversity of New Mexico /ID# 261083Albuquerque87102-4517NCT06191744Map
NMPresbyterian Rust Jorgensen Cancer ( Site 9506)Rio Rancho87124NCT05139017Map
NMPresbyterian Rust Medical Center /ID# 262447Rio Rancho87124NCT06191744Map
NMChristus St Vincent Regional Cancer CenterSanta Fe87505NCT06943872Map
NYNew York Oncology Hematology, P.C. ( Site 0129)Albany12206NCT06717347Map
NYErie County Medical Center ( Site 0175)Buffalo14215NCT06890884Map
NYRoswell Park Cancer InstituteBuffalo14263NCT03150693Map
NYRoswell Park Cancer InstituteBuffalo14263NCT05976763Map
NYRoswell Park Cancer Institute ( Site 0192)Buffalo14263NCT06890884Map
NYRoswell Park Comprehensive Cancer CenterBuffalo14263NCT07015242Map
NYHematology Oncology Associates of CNY at CamillusCamillus13031NCT05976763Map
NYMemorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)Commack11725NCT06765317Map
NYMemorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)Commack11725NCT06561360Map
NYMemorial Sloan Kettering CommackCommack11725NCT04840602Map
NYMemorial Sloan Kettering CommackCommack11725NCT05886036Map
NYMemorial Sloan Kettering Suffolk - CommackCommack11725NCT07231952Map
NYMemorial Sloan Kettering Suffolk - Commack (Consent only)Commack11725NCT05736419Map
NYMemorial Sloan Kettering Suffolk-Commack (Limited protocol activity)Commack11725NCT06756308Map
NYNorth Shore Hematology Oncology AssociatesEast Setauket11733NCT05279300Map
NYHematology Oncology Associates of Central New York-East SyracuseEast Syracuse13057NCT05976763Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT04840602Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT05886036Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT07231952Map
NYMemorial Sloan Kettering Westchester (All protocol activities)Harrison10604NCT06756308Map
NYMemorial Sloan Kettering Westchester (All Protocol Activities)Harrison10604NCT06561360Map
NYMemorial Sloan Kettering Westchester (All Protocol Activities)Harrison10604NCT06765317Map
NYMemorial Sloan Kettering Westchester (Consent only)Harrison10604NCT05736419Map
NYNorthwell Health - Monter Cancer Center /ID# 245435Lake Success11042NCT05283720Map
NYNorthwell Health/Center for Advanced MedicineLake Success11042NCT04609046Map
NYNorthwell Health/Center for Advanced MedicineLake Success11042NCT03150693Map
NYNorth Shore University HospitalManhasset11030NCT04609046Map
NYNorth Shore University HospitalManhasset11030NCT03150693Map
NYNYU Langone Hospital - Long IslandMineola11501NCT05976763Map
NYNYU Langone Hospital - Long Island /ID# 265531Mineola11501NCT06191744Map
NYPerlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0208)Mineola11501NCT06890884Map
NYLong Island Jewish Medical CenterNew Hyde Park11040NCT03150693Map
NYColumbia U. - Herbert Irving Comprehensive Cancer CenterNew York10032NCT05279300Map
NYColumbia UniversityNew York10032NCT07226843Map
NYColumbia University Irving Medical CenterNew York10032NCT06954805Map
NYColumbia University Irving Medical CenterNew York10032NCT07104032Map
NYColumbia University Medical CenterNew York10032NCT04679012Map
NYColumbia University Medical Center: Division of NephrologyNew York10032NCT03949855Map
NYHospital for Special SurgeryNew York10021NCT03844061Map
NYIcahn School of Medicine at Mount Sinai ( Site 0164)New York10029NCT06717347Map
NYIcahn School of Medicine at Mount Sinai /ID# 242123New York10029NCT05283720Map
NYIcahn School of Medicine at Mount Sinai /ID# 259595New York10029NCT06191744Map
NYIcahn School of Medicine at Mount Sinai HospitalNew York10029NCT05783609Map
NYIcahn School of Medicine at Mt SinaiNew York10029NCT06091254Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT05976763Map
NYLaura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108)New York10016NCT06890884Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT04840602Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT04421560Map
NYMemorial Sloan Kettering Cancer CenterNew York10021NCT06563596Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05886036Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06090539Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06854003Map
NYMemorial Sloan Kettering Cancer CenterNew York10021NCT07015242Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT07104032Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT07231952Map
NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)New York10065NCT06561360Map
NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)New York10065NCT06765317Map
NYMemorial Sloan Kettering Cancer Center MskccNew York10065-6800NCT06846671Map
NYMemorial Sloan Kettering Cancer Center MskccNew York10065-6800NCT06943872Map
NYMount Sinai HospitalNew York10029NCT03150693Map
NYMount Sinai- Icahn School of MedicineNew York10029NCT04679012Map
NYMSKCCNew York10065NCT05533775Map
NYNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York10032NCT04609046Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT04609046Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT03150693Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT05976763Map
NYNYU Langone HealthNew York10016NCT07104032Map
NYNYU Langone Medical Center /ID# 264518New York10016-6402NCT06191744Map
NYResearch SiteNew York10029NCT06564038Map
NYWeill Cornell MedicineNew York10065NCT04679012Map
NYUniversity of RochesterRochester14642NCT03758989Map
NYUniversity of RochesterRochester14642NCT04840602Map
NYUniversity of RochesterRochester14642NCT03150693Map
NYUniversity of RochesterRochester14642NCT05976763Map
NYUniversity of RochesterRochester14642NCT06084936Map
NYUniversity of RochesterRochester14642NCT06337318Map
NYUniversity of RochesterRochester14618NCT07226843Map
NYUniversity of Rochester Medical CenterRochester14642NCT05783609Map
NYUniversity of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)Rochester14642NCT04669171Map
NYMemorial Sloan Kettering Nassau (All protocol activities)Rockville Centre11553NCT05736419Map
NYMemorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville Centre11553NCT06765317Map
NYStony Brook University HospitalStony Brook11794NCT06091254Map
NYStony Brook University HospitalStony Brook11794NCT06091865Map
NYStony Brook University HospitalStony Brook11794NCT06149286Map
NYSUNY Upstate Cancer Center ( Site 0178)Syracuse13210NCT06890884Map
NYNew York Oncology Hematology /ID# 270208Troy12180NCT06191744Map
NYMemorial Sloan Kettering NassauUniondale11553NCT04840602Map
NYMemorial Sloan Kettering NassauUniondale11553NCT05886036Map
NYMemorial Sloan Kettering NassauUniondale11553NCT07231952Map
NYMemorial Sloan Kettering Nassau (Limited protocol activities)Uniondale11553NCT06756308Map
NYMemorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale11553NCT06561360Map
NYNew York Medical College ( Site 0113)Valhalla10595NCT05139017Map
NYWilmot Cancer Institute at WebsterWebster14580NCT05976763Map
NYWilmot Cancer Institute at WebsterWebster14580NCT06337318Map
NYClinical Research AllianceWestbury11590NCT06351527Map
NYClinical Research Alliance - Westbury /ID# 261078Westbury11590NCT06191744Map
NYClinical Research Alliance ( Site 0122)Westbury11590NCT06890884Map
NYClinical Research Alliance, IncWestbury11590-5119NCT06846671Map
NYClinical Research Alliance, IncWestbury11590-5119NCT06943872Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT04609046Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT05976763Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT06337318Map
NCUniversity of North CarolinaChapel Hill27514NCT06091254Map
NCUniversity of North Carolina At Chapel HillChapel Hill27514-4220NCT06943872Map
NCUniversity of North Carolina Medical Center ( Site 0136)Chapel Hill27514NCT06890884Map
NCUniversity of North Carolina School of Medicine: Division of Nephrology and Hypertension, Kidney CenterChapel Hill27599-NCT03949855Map
NCAtrium Health Pineville/LCI-PinevilleCharlotte28210NCT06337318Map
NCAtrium Health University City/LCI-UniversityCharlotte28262NCT06337318Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT04626791Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT04840602Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT06337318Map
NCLevine Cancer CenterCharlotte28204-2990NCT06943872Map
NCLevine Cancer InstituteCharlotte28204NCT04884035Map
NCLevine Cancer InstituteCharlotte28207NCT06091254Map
NCLevine Cancer Institute-SouthParkCharlotte28211NCT06337318Map
NCNovant Health Presbyterian Medical CenterCharlotte28204NCT06337318Map
NCNovant Health Presbyterian Medical Center ( Site 0177)Charlotte28204NCT06890884Map
NCNovant Health Presbyterian Medical Center /ID# 259740Charlotte28204NCT06191744Map
NCResearch SiteCharlotte28204NCT06564038Map
NCWake Forest University at ClemmonsClemmons27012NCT06337318Map
NCSoutheastern Medical Oncology Center-ClintonClinton28328NCT04840602Map
NCSoutheastern Medical Oncology Center-ClintonClinton28328NCT06337318Map
NCAtrium Health Cabarrus/LCI-ConcordConcord28025NCT06337318Map
NCDuke University Medical CenterDurham27710NCT06091865Map
NCDuke University Medical CenterDurham27710NCT06337318Map
NCDuke University Medical CenterDurham27710NCT07104032Map
NCLevine Cancer Institute-GastonGastonia28054NCT04840602Map
NCSoutheastern Medical Oncology Center-GoldsboroGoldsboro27534NCT04840602Map
NCSoutheastern Medical Oncology Center-GoldsboroGoldsboro27534NCT06337318Map
NCEast Carolina UniversityGreenville27834NCT03150693Map
NCEast Carolina UniversityGreenville27834NCT06091865Map
NCEast Carolina University - Brody School of Medicine /ID# 242506Greenville27834NCT05283720Map
NCUniversity of North Carolina-Hillsborough CampusHillsborough27278NCT05786040Map
NCSoutheastern Medical Oncology Center-JacksonvilleJacksonville28546NCT04840602Map
NCSoutheastern Medical Oncology Center-JacksonvilleJacksonville28546NCT06337318Map
NCAtrium Health Union/LCI-UnionMonroe28112NCT04840602Map
NCAtrium Health Union/LCI-UnionMonroe28112NCT06337318Map
NCNovant Health Cancer Institute - MooresvilleMooresville28117NCT06337318Map
NCAtrium Health Wake Forest BaptistWinston-Salem27157NCT04884035Map
NCAtrium Health Wake Forest BaptistWinston-Salem27157NCT06119685Map
NCAtrium Health Wake Forest BaptistWinston-Salem27157NCT06943872Map
NCNovant Health Forsyth Medical CenterWinston-Salem27103NCT06337318Map
NCNovant Health Forsyth Medical Center ( Site 0206)Winston-Salem27103NCT06890884Map
NCNovant Health Forsyth Medical Center /ID# 259741Winston-Salem27103NCT06191744Map
NCWake Forest University Health SciencesWinston-Salem27157NCT03150693Map
NCWake Forest University Health SciencesWinston-Salem27157NCT05886036Map
NCWake Forest University Health SciencesWinston-Salem27157NCT06337318Map
NDSanford Bismarck Medical CenterBismarck58501NCT05976763Map
NDEssentia Health Cancer Center-South University ClinicFargo58103NCT05976763Map
NDEssentia Health Cancer Center-South University ClinicFargo58103NCT06337318Map
NDSanford Broadway Medical CenterFargo58122NCT05976763Map
NDSanford Health Roger Maris Cancer Center ( Site 0189)Fargo58102NCT06717347Map
NDSanford Roger Maris Cancer CenterFargo58122NCT05976763Map
OHCincinnati Children's Hospital Medical CenterCincinnati45229NCT05533775Map
OHOncology Hematology Care Clinical Trials, LlcCincinnati45245-1995NCT06943872Map
OHOncology Hematology Care, Inc - Blue Ash /ID# 261204Cincinnati45252NCT06191744Map
OHUniversity of Cincinnati Cancer Center-UC Medical CenterCincinnati45219NCT03150693Map
OHUniversity of Cincinnati Cancer Center-UC Medical CenterCincinnati45219NCT05886036Map
OHUniversity of Cincinnati Medical Center ( Site 0156)Cincinnati45219NCT06890884Map
OHCase Western Reserve UniversityCleveland44106NCT03150693Map
OHCleveland ClinicCleveland44195NCT03949855Map
OHCleveland ClinicCleveland44195NCT07015242Map
OHCleveland Clinic FoundationCleveland44195NCT03150693Map
OHCleveland Clinic Main ( Site 0101)Cleveland44195NCT06890884Map
OHFairview Hospital-Moll Cancer Center ( Site 0198)Cleveland44111NCT06890884Map
OHUniversity HospitalsCleveland44106-1716NCT06846671Map
OHUniversity Hospitals ClevelandCleveland44106NCT06119685Map
OHUniversity Hospitals Cleveland Medical CenterCleveland44106NCT06091254Map
OHUniversity Hospitals Cleveland Medical CenterCleveland44106NCT06091865Map
OHUniversity Hospitals of Cleveland ( Site 0155)Cleveland44106NCT06890884Map
OHJames Cancer HospitalColumbus43210NCT06655896Map
OHOhio state UniversityColumbus43210NCT04679012Map
OHOhio State UniversityColumbus43210NCT06561360Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT04609046Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT03150693Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05786040Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05886036Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05976763Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT06209619Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT06337318Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT06965114Map
OHOhio State University Wexner Medical Center: Division of NephrologyColumbus43210NCT03949855Map
OHResearch SiteColumbus43210NCT06564038Map
OHThe Ohio State University (OSU)Columbus43210NCT07226843Map
OHThe Ohio State University Comprehensive Cancer CenterColumbus43202-2224NCT07015242Map
OHThe Ohio State University Wexner Medical CenterColumbus43210NCT06563596Map
OHThe Ohio State University Wexner Medical CenterColumbus43210NCT05783609Map
OHDayton Physician NetworkDayton45415NCT06846671Map
OHCleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0199)Mayfield Heights44124NCT06890884Map
OHLicking Memorial HospitalNewark43055NCT04840602Map
OHUniversity of Cincinnati Cancer Center-West ChesterWest Chester45069NCT03150693Map
OHUniversity of Cincinnati Cancer Center-West ChesterWest Chester45069NCT05886036Map
OKCancer Centers of Southwest Oklahoma ResearchLawton73505NCT05976763Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT04609046Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT03150693Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05886036Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05976763Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT06337318Map
OKOklahoma Cancer Specialists and Research Institute-TulsaTulsa74146NCT05976763Map
OROncology Associates of Oregon Willamette Valley Cancer CenterEugene97401NCT06846671Map
OROncology Associates of Oregon Willamette Valley Cancer CenterEugene97401NCT06943872Map
OROncology Associates of Oregon, P.C. /ID# 261816Eugene97401NCT06191744Map
ORProvidence Newberg Medical CenterNewberg97132NCT04840602Map
ORProvidence Newberg Medical CenterNewberg97132NCT03150693Map
ORProvidence Newberg Medical CenterNewberg97132NCT05976763Map
ORProvidence Newberg Medical CenterNewberg97132NCT06337318Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT03150693Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT05976763Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT06337318Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT04840602Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT05976763Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT06337318Map
ORKaiser Permanente NorthwestPortland97227NCT06337318Map
OROregon Health and Science UniversityPortland97239NCT03150693Map
OROregon Health and Science UniversityPortland97239NCT06337318Map
OROregon Health and Science University ( Site 5425)Portland97239-3011NCT05947851Map
OROregon Health Sciences UniversityPortland97239NCT06655896Map
ORProvidence Neurological Specialties WestPortland97225NCT07104032Map
ORProvidence Oncology and Hematology Clinic Westside ( Site 0179)Portland97225NCT06890884Map
ORProvidence Portland Medical CenterPortland97213NCT04840602Map
ORProvidence Portland Medical CenterPortland97213NCT03150693Map
ORProvidence Portland Medical CenterPortland97213NCT05976763Map
ORProvidence Portland Medical CenterPortland97213NCT06337318Map
ORProvidence Portland Medical Center ( Site 0120)Portland97213NCT06890884Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT04840602Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT03150693Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05976763Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT06337318Map
ORResearch SitePortland97239NCT06564038Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT03150693Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT03150693Map
PAPenn State Milton S Hershey Medical CenterHershey17033NCT06943872Map
PAAlliance Cancer Specialists (ACS) ( Site 8001)Horsham19044NCT05139017Map
PAFox Chase Cancer CenterPhiladelphia19111NCT06337318Map
PAResearch SitePhiladelphia19104NCT06564038Map
PATemple University Hospital ( Site 0133)Philadelphia19140NCT06890884Map
PAThomas Jefferson UniversityPhiladelphia19107-4216NCT06943872Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT03150693Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT06337318Map
PAUniversity of PennsylvaniaPhiladelphia19104NCT06973096Map
PAUniversity of PennsylvaniaPhiladelphia19104NCT07015242Map
PAUniversity of Pennsylvania: Department of Medicine: Renal-Electrolyte and Hypertension DivisionPhiladelphia19104NCT03949855Map
PAUniversity of Pennsylvania/Abramson Cancer CenterPhiladelphia19104NCT03150693Map
PAChildren's Hospital of Pittsburgh of UPMCPittsburgh15224NCT03500731Map
PAChildren's Hospital of Pittsburgh of UPMCPittsburgh15213NCT03630211Map
PAChildren's Hospital of Pittsburgh of UPMCPittsburgh15224NCT03653338Map
PAChildren's Hospital of Pittsburgh of UPMC-Bone Marrow TeamPittsburgh15224NCT00692939Map
PAResearch SitePittsburgh15232NCT06564038Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT06965114Map
PAUniversity of Pittsburgh Medical CenterPittsburgh15261NCT03630211Map
PAUniversity of Pittsburgh Medical CenterPittsburgh15261NCT03630211Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT07104032Map
PAUpmc Hillman Cancer Center(Univ of Pittsburgh)Pittsburgh15232-1309NCT06943872Map
PAUPMC Prebyterian- Adult GastroenterologyPittsburgh15213NCT00692939Map
PAUPMC PresbyterianPittsburgh15214NCT03500731Map
PAWest Penn HospitalPittsburgh15224NCT06846671Map
PAAlliance Cancer Specialists (ACS) ( Site 8010)Sellersville18960NCT06890884Map
PAAsplundh Cancer PavilionWillow Grove19090NCT06337318Map
PACancer Care Associates of YorkYork17403-5049NCT06846671Map
PACancer Care Associates Of York ( Site 0174)York17403NCT06890884Map
RIResearch SiteProvidence02903NCT06564038Map
RIRhode Island HospitalProvidence02903NCT04609046Map
RIRhode Island HospitalProvidence02903NCT03150693Map
RIRhode Island HospitalProvidence02903NCT05976763Map
RIRhode Island HospitalProvidence02903NCT06119685Map
RIRhode Island HospitalProvidence02903NCT06337318Map
RIRhode Island HospitalProvidence02903NCT07104032Map
RISmilow Cancer Hospital Care Center - WesterlyWesterly02891NCT05976763Map
SCPrisma Health Cancer Institute - SpartanburgBoiling Springs29316NCT03150693Map
SCPrisma Health Cancer Institute - SpartanburgBoiling Springs29316NCT05976763Map
SCMedical University of South CarolinaCharleston29425NCT04609046Map
SCMedical University of South CarolinaCharleston29425NCT05976763Map
SCMedical University of South CarolinaCharleston29425NCT06337318Map
SCMedical University of South Carolina ( Site 0153)Charleston29425NCT06890884Map
SCMUSC Hollings Cancer Center /ID# 259604Charleston29425NCT06191744Map
SCPrisma Health Richland HospitalColumbia29203NCT03150693Map
SCPrisma Health Cancer Institute - EasleyEasley29640NCT03150693Map
SCPrisma Health Cancer Institute - EasleyEasley29640NCT05976763Map
SCPrisma Health - Upstate ( Site 0158)Greenville29605NCT06717347Map
SCPrisma Health /ID# 259602Greenville29605NCT06191744Map
SCPrisma Health Cancer Institute - ButternutGreenville29605NCT03150693Map
SCPrisma Health Cancer Institute - ButternutGreenville29605NCT05976763Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT03150693Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT05976763Map
SCPrisma Health Cancer Institute - FarisGreenville29605NCT03150693Map
SCPrisma Health Cancer Institute - FarisGreenville29605NCT05976763Map
SCPrisma Health Greenville Memorial HospitalGreenville29605NCT03150693Map
SCSaint Francis Cancer CenterGreenville29607NCT03150693Map
SCSaint Francis HospitalGreenville29601NCT03150693Map
SCPrisma Health Cancer Institute - GreerGreer29650NCT03150693Map
SCPrisma Health Cancer Institute - GreerGreer29650NCT05976763Map
SCPrisma Health Cancer Institute - SenecaSeneca29672NCT03150693Map
SCPrisma Health Cancer Institute - SenecaSeneca29672NCT05976763Map
SDAvera CancerSioux Falls57105NCT06655896Map
SDSanford Cancer Center ( Site 0143)Sioux Falls57104NCT06717347Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT05976763Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT05976763Map
TNTennessee Oncology Greco Hainsworth Centers For Research ChattanoogaChattanooga37404NCT06943872Map
TNTennessee Cancer Specialists ( Site 7000)Knoxville37909NCT05139017Map
TNTennessee Cancer Specialists ( Site 7004)Knoxville37909NCT06890884Map
TNThe University of Tennessee Medical Center ( Site 0142)Knoxville37920NCT06717347Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT06337318Map
TNSt Jude Children's Research HospitalMemphis38105NCT04318678Map
TNSt. Jude Children's Research HospitalMemphis38105NCT04318678Map
TNSarah Cannon Research InstituteNashville37203NCT07226843Map
TNSarah Cannon Research Institute - Tristar Centennial Medical Center /ID# 274985Nashville37203NCT06191744Map
TNSarah Cannon Research Institute Oncology PartnersNashville37203NCT07015242Map
TNSCRI Oncology PartnersNashville37203NCT06119685Map
TNSCRI Oncology Partners ( Site 7002)Nashville37203NCT06890884Map
TNTennessee OncologyNashville37205NCT06943872Map
TNVanderbilt University Medical CenterNashville37232NCT06091254Map
TNVanderbilt University Medical CenterNashville37212NCT07226843Map
TXTexas Oncology - West Texas ( Site 8008)Amarillo79124NCT06890884Map
TXTexas Oncology - Austin Midtown /ID# 261208Austin78705NCT06191744Map
TXTexas Oncology - Central/South TexasAustin78705NCT06911502Map
TXTexas Oncology - Central/South Texas ( Site 8006)Austin78705NCT06890884Map
TXBUMC - Mary Crowley Cancer Research Centers (MCCRC)Dallas75201-7307NCT05279300Map
TXTexas Oncology Baylorcharles A Sammons Cancer CenterDallas75246-2003NCT06943872Map
TXTexas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 261206Dallas75246-2003NCT06191744Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT06561347Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT04609046Map
TXRenovatio Clinical - El PasoEl Paso79915NCT06084936Map
TXCenter for Oncology and Blood DisordersHouston77030NCT06091254Map
TXCenter for Oncology and Blood Disorders ( Site 0153)Houston77030NCT06717347Map
TXHouston Methodist Cancer Center ( Site 0154)Houston77030NCT06717347Map
TXHouston Methodist HospitalHouston77030NCT03150693Map
TXM D Anderson Cancer CenterHouston77030NCT04745949Map
TXM D Anderson Cancer CenterHouston77030NCT04022239Map
TXM D Anderson Cancer CenterHouston77030NCT02727803Map
TXM D Anderson Cancer CenterHouston77030NCT02877303Map
TXM D Anderson Cancer CenterHouston77030NCT00412594Map
TXM D Anderson Cancer CenterHouston77030NCT03136146Map
TXM D Anderson Cancer CenterHouston77030NCT01371630Map
TXM D Anderson Cancer CenterHouston77030NCT04216524Map
TXM D Anderson Cancer CenterHouston77030NCT05645718Map
TXM D Anderson Cancer CenterHouston77030NCT05683171Map
TXM D Anderson Cancer CenterHouston77030NCT06045247Map
TXMD Anderson Cancer CenterHouston77003NCT04884035Map
TXMD Anderson Cancer CenterHouston77030NCT06263491Map
TXMD Anderson Cancer CenterHouston77030NCT07015242Map
TXMD Anderson Cancer CenterHouston77030NCT07257055Map
TXMD Anderson Cancer Center /ID# 260984Houston77030-4000NCT06191744Map
TXOncology Consultants /ID# 268390Houston77030NCT06191744Map
TXUniversity of Texas MD Anderson Cancer CenterHouston77030NCT06119685Map
TXUT MD Anderson Cancer CenterHouston77030NCT05886036Map
TXUT MD Anderson Cancer CenterHouston77030NCT06337318Map
TXJoe Arrington Cancer Research /ID# 260382Lubbock79410NCT06191744Map
TXTexas Oncology - Northeast Texas ( Site 8002)Palestine75801NCT06890884Map
TXTexas Oncology - San Antonio ( Site 8009)San Antonio78240NCT06890884Map
TXTexas Oncology San Antonio Medical Center UsorSan Antonio78240-5251NCT06943872Map
TXUniversity Hospital SystemSan Antonio78228NCT06977711Map
TXUniversity of Texas Health Science Center at San AntonioSan Antonio78229NCT06337318Map
TXUniversity of Texas Health Science Center San Antonio at the Cancer Therapy and Research CenterSan Antonio78229NCT06977711Map
TXRenovatio ClinicalThe Woodlands77380NCT06084936Map
TXTexas OncologyTyler75702NCT05618925Map
TXTexas Oncology - Northeast TexasTyler75702NCT06911502Map
TXTexas Oncology TylerTyler75702-7522NCT06846671Map
TXTexas Oncology TylerTyler75702-7522NCT06943872Map
UTIntermountain Medical Center ( Site 0182)Murray84107NCT06890884Map
UTIntermountain Medical OncologyMurray84107NCT04884035Map
UTCommunity Cancer Trials of UtahOgden84405NCT06091865Map
UTHuntsman Cancer InstituteSalt Lake City84112NCT05786040Map
UTHuntsman Cancer Institute - Oncology DivisionSalt Lake City84112NCT06091254Map
UTHuntsman Cancer Institute at University of UtahSalt Lake City84112NCT06390956Map
UTHuntsman Cancer Institute at University of UtahSalt Lake City84112NCT06607549Map
UTHuntsman Cancer Institute at University of UtahSalt Lake City84112NCT06788964Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT03150693Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05886036Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05976763Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT06337318Map
UTIntermountain Healthcare LDS Hospital /ID# 259759Salt Lake City84143NCT06191744Map
UTLDS HospitalSalt Lake City84143NCT06655896Map
UTIntermountain Cancer Center - St GeorgeSt. George84790NCT04884035Map
UTIntermountain Healthcare - St. George ( Site 0203)St. George84790NCT06890884Map
VTDartmouth Cancer Center - NorthSaint Johnsbury05819NCT05976763Map
VAUniversity of VirginiaCharlottesville22906NCT06084936Map
VAUniversity of VirginiaCharlottesville22908NCT06091254Map
VAUniversity of Virginia Cancer CenterCharlottesville22903NCT03523975Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT05886036Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT06337318Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT06965114Map
VAUniversity of Virginia Cancer Center ( Site 0138)Charlottesville22903NCT06717347Map
VANEXT Oncology VirginiaFairfax22031NCT06119685Map
VAVirginia Cancer Specialists - Fairfax /ID# 261205Fairfax22031NCT06191744Map
VAHematology Oncology Associates of FredericksburgFredericksburg22408NCT06911502Map
VAVirginia Cancer Specialists, PC ( Site 8003)Manassas20110NCT06890884Map
VAVCU Health Adult Outpatient Pavillion ( Site 0138)Richmond23219NCT06890884Map
VAVCU Massey Cancer Center at Stony PointRichmond23235NCT05976763Map
VAVCU Massey Cancer Center at Stony PointRichmond23235NCT06337318Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT04840602Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT03150693Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT05886036Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT05976763Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT06337318Map
VAVirginia Cancer Institute ( Site 0148)Richmond23229NCT06717347Map
VABlue Ridge Cancer CareRoanoke24014NCT06911502Map
VABlue Ridge Cancer Care ( Site 0132)Roanoke24014NCT06717347Map
VABlue Ridge Cancer Care ( Site 0169)Roanoke24014NCT05139017Map
VAOncology and Hematology Associates of Southwest Virginia /ID# 261592Roanoke98684NCT06191744Map
WASwedish Cancer Institute - Edmonds /ID# 266356Edmonds98026NCT06191744Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT04840602Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT05976763Map
WASwedish Cancer Institute - Issaquah /ID# 266358Issaquah98029NCT06191744Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT04840602Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT05976763Map
WAVista Oncology - East Olympia /ID# 261360Olympia98506-5028NCT06191744Map
WAVista Oncology ( Site 4201)Olympia98506NCT06717347Map
WAFred Hutch/University of Washington Cancer ConsortiumSeattle98109NCT04231877Map
WAFred Hutch/University of Washington Cancer ConsortiumSeattle98109NCT05455697Map
WAFred Hutch/University of Washington Cancer ConsortiumSeattle98109NCT06738368Map
WAFred Hutch/University of Washington Cancer ConsortiumSeattle98109NCT06839053Map
WAFred Hutch/University of Washington Cancer ConsortiumSeattle98109NCT07097363Map
WAFred Hutch/University of Washington Cancer ConsortiumSeattle98109NCT07224100Map
WAFred Hutchinson Cancer CenterSeattle98109NCT07015242Map
WASwedish Medical Center - Seattle /ID# 242269Seattle98104NCT05283720Map
WASwedish Medical Center - Seattle /ID# 260370Seattle98104NCT06191744Map
WASwedish Medical Center-First HillSeattle98122NCT04840602Map
WASwedish Medical Center-First HillSeattle98122NCT05976763Map
WAUniversity of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)Seattle98195NCT07226843Map
WAUniversity of Washington Medical Center - MontlakeSeattle98195NCT04626791Map
WAUniversity of Washington-Seattle Cancer Care AllianceSeattle98109NCT04669171Map
WAVirginia Mason Hospital & Medical Center /ID# 260549Seattle98101NCT06191744Map
WAMedical Oncology Associates, PS ( Site 5406)Spokane99208NCT05947851Map
WAProvidence Medical Research Center, Providence Health Care: NephrologySpokane99204NCT03949855Map
WANorthwest Medical Specialties - Tacoma /ID# 262133Tacoma98405NCT06191744Map
WAResearch SiteTacoma98405NCT05952024Map
WANorthwest Cancer Specialist, Pc(Us Oncology Research)Vancouver98684-6930NCT06943872Map
WANorthwest Cancer Specialists (Compass Oncology) ( Site 8000)Vancouver98684NCT06890884Map
WVWest Virginia University Charleston DivisionCharleston25304NCT06337318Map
WVWest Virginia UniversityMorgantown26506NCT06084936Map
WVWest Virginia University HealthcareMorgantown26506NCT04609046Map
WIThedaCare Regional Cancer CenterAppleton54911NCT04840602Map
WIThedaCare Regional Cancer CenterAppleton54911NCT05976763Map
WIThedaCare Regional Cancer CenterAppleton54911NCT06337318Map
WIThedaCare Regional Medical Center - AppletonAppleton54911NCT05976763Map
WIThedaCare Regional Medical Center - AppletonAppleton54911NCT06337318Map
WIDuluth Clinic AshlandAshland54806NCT05976763Map
WIDuluth Clinic AshlandAshland54806NCT06337318Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT04609046Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT05976763Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT06337318Map
WIMayo Clinic Health System-Eau Claire ClinicEau Claire54701NCT06834373Map
WIUniversity of Wisconsin Carbone Cancer Center - Johnson CreekJohnson Creek53038NCT05976763Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT04609046Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT04840602Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT05976763Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT06337318Map
WIMayo Clinic Health System-Franciscan HealthcareLa Crosse54601NCT06834373Map
WISSM Health Dean Medical Group ( Site 0106)Madison53715NCT06890884Map
WISSM Health Dean Medical Group ( Site 0140)Madison53715NCT06717347Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT03150693Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT05976763Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT03150693Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT05976763Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT04609046Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT03150693Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05976763Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT06337318Map
WIFroedtert Menomonee Falls HospitalMenomonee Falls53051NCT06337318Map
WIMedical College of WisconsinMilwaukee53226NCT03150693Map
WIMedical College of WisconsinMilwaukee53226NCT05783609Map
WIMedical College of WisconsinMilwaukee53226NCT05976763Map
WIMedical College of WisconsinMilwaukee53226NCT06337318Map
WIMedical College of Wisconsin ( Site 0103)Milwaukee53226NCT06890884Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT04609046Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT05976763Map
WIProHealth D N Greenwald CenterMukwonago53149NCT05976763Map
WIProHealth D N Greenwald CenterMukwonago53149NCT06337318Map
WIFroedtert and MCW Moorland Reserve Health CenterNew Berlin53151NCT05976763Map
WIFroedtert and MCW Moorland Reserve Health CenterNew Berlin53151NCT06337318Map
WIDrexel Town Square Health CenterOak Creek53154NCT06337318Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT05976763Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT06337318Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT05976763Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT04609046Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05976763Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT06337318Map
WIProhealth Care IncWaukesha53188NCT06149286Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT06337318Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT05976763Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT06337318Map
WIFroedtert West Bend Hospital/Kraemer Cancer CenterWest Bend53095NCT06337318Map
WIMarshfield Medical Center - WestonWeston54476NCT04609046Map
WIMarshfield Medical Center - WestonWeston54476NCT05976763Map
WIMarshfield Medical Center - WestonWeston54476NCT06337318Map

Rituximab clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingenrolling by invitationcompletedterminatedwithdrawnsuspendednot yet recruitingunknownapproved for marketingTotal
Early P13932118
P1232612345112511246
P1/P23220102381211016231
P212669245113442220104950
P2/P34428221546
P3524317042151836367
P412406221577
N/A102164666221118

Recruiting Rituximab clinical trials (314)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT04196413DIPGGD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)P1Glioma of Spinal Cord97Jun 2020
NCT06973096CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial RadiotherapyP1Glioblastoma9Jul 2025
NCT06986382Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn DiseaseP1/P2Crohn Disease14Jul 2025
NCT06854003BRAZANBRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaP2Mantle Cell Lymphoma60Apr 2025
NCT05976763Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaP3Mantle Cell Lymphoma421Oct 2023
NCT06191744EPCORE™FL-2Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaP3Follicular Lymphoma (FL)1,095Feb 2024
NCT07220187Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID TrialP3Richter Syndrome102Aug 2026
NCT06412497MT2023-20MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.P2Severe Aplastic Anemia60Jun 2024
NCT05947851VRA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).P3Leukemia, Lymphocytic, Chronic, B-Cell735Aug 2023
NCT05508009Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same DonorP1/P2SIOD12Jan 2023
NCT04669171SIDNEYA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin LymphomaP1/P2Follicular Lymphoma80Jul 2021
NCT06284122MorningLyteStudy of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5P3Follicular Lymphoma790Jun 2024
NCT03418038Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaP2Clonal Cytopenia of Undetermined Significance80Mar 2018
NCT07520006Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesP1/P2B-cell Lymphoma150May 2026
NCT05991388Glo-BNHLA Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaP2/P3B-cell Non Hodgkin Lymphoma210May 2024
NCT05099471VIWA-1Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaP2Waldenstrom Macroglobulinemia80Mar 2025
NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasP1/P2Non Hodgkin Lymphoma48Feb 2026
NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaP2Mantle Cell Lymphoma (MCL)50Apr 2025
NCT07285590IMCL-2023Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell LymphomaP2Mantle Cell Lymphoma (MCL)50Sep 2025
NCT06688331PreTregTreatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 AntibodyP2Presymptomatic Diabetes Type 1 (Stage 1)150Mar 2025
NCT06390956PIONEER-MZLPirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)P2Marginal Zone Lymphoma23Feb 2025
NCT06890884MK-2140A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)P2Lymphoma, Large B-Cell, Diffuse594Apr 2025
NCT05533775iMATRIX GLOA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaP1/P2Mature B-Cell Non-Hodgkin Lymphoma65Nov 2022
NCT05283720SCA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaP2Non-Hodgkin Lymphoma496Jun 2022
NCT06644183IOA-244Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)P1/P2Leukemia64Mar 2025
NCT06006117Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaP3Marginal Zone Lymphoma260Sep 2023
NCT06655896Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisP2Scleroderma, Diffuse96Oct 2024
NCT07137481Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological MalignanciesP2Hematological Malignancies70Feb 2027
NCT06839053Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell LymphomaP2Chronic Lymphocytic Leukemia30Jun 2025
NCT07259122ZBR in WMA Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström MacroglobulinemiaP2Waldenström Macroglobulinemia (WM)43Dec 2025
NCT06363994A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLP3Mantle Cell Lymphoma476May 2024
NCT05389423Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasP1Diffuse Large Cell Lymphoma25Jun 2023
NCT06040320RPolatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)P1/P2Post-transplant Lymphoproliferative Disorder12Oct 2023
NCT05898308RITUX4Comparison of a Personalized Maintenance Therapy With the Standard Treatment in PemphigusP4Pemphigus133Dec 2024
NCT07294677CAVALRYCApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLP1/P2Leukemia104Mar 2026
NCT06337318Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaP3Classic Follicular Lymphoma600Oct 2024
NCT06717347MK-2140A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)P3Diffuse Large B-Cell Lymphoma1,046Jan 2025
NCT07509840REFINEImmunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian InsufficiencyP3Autoimmune Prematur Ovarian Insuffience40Feb 2026
NCT06943872CELESTIAL-RRCLLA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)P3Chronic Lymphocytic Leukemia630Jun 2025
NCT04231877Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell LymphomaP1Aggressive Non-Hodgkin Lymphoma56Oct 2020
NCT05848765REFRACTRelapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyP2Relapsed Follicular Lymphoma284Sep 2023
NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaP2Lymphoma33Feb 2026
NCT06341205iRITUXPersonalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)P3Membranous Nephropathy120Feb 2025
NCT06792825HM2023-43HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLP2Follicular Lymphoma65Aug 2025
NCT07573436PLUTOLoncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)P1/P2Post-transplant Lymphoproliferative Disorder23Jun 2026
NCT07208981Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLP2Marginal Zone Lymphoma(MZL)169Aug 2025
NCT07299331Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone LymphomaN/AMarginal Zone Lymphoma(MZL)50Jan 2026
NCT07415980Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCLP1/P2Double Expressor DLBCL68Apr 2026
NCT04002947Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaP2Non-Hodgkin's Lymphoma132Aug 2019
NCT07517185HiHatThe HIt HArd and hiT Early in Multiple Sclerosis TrialP2Relapsing-remitting Multiple Sclerosis60Apr 2026
NCT06682169Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host DiseaseP3Graft-versus-host Disease182Nov 2024
NCT06664411Pola-ZR2P in Previously Untreated DLBCLP2Diffuse Large B-cell Lymphoma80Sep 2024
NCT06607549SOLARLoncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)P1Central Nervous System Lymphoma12Mar 2025
NCT05735717MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesP2Hematologic Malignancy70May 2023
NCT07257055Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 StudyP2Phase 2 Study30Apr 2026
NCT07335562Breakfree-SScA Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisP3Systemic Sclerosis92Aug 2026
NCT07255963Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCLP2DLBCL - Diffuse Large B Cell Lymphoma29Nov 2025
NCT07189325DESIRE MSA Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple SclerosisP3Relapsing-Remitting Multiple Sclerosis (RRMS)250Sep 2025
NCT04518475ITPEltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in AdultsP4Primary Immune Thrombocytopenia (ITP)224Aug 2020
NCT06905509Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell LymphomaP2Recurrent Diffuse Large B-Cell Lymphoma25Jul 2025
NCT04998669Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular LymphomaP2Follicular Lymphoma100Feb 2022
NCT06911502GOLSEEK-4A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)P3Follicular Lymphoma400Jul 2025
NCT06045247Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell LymphomaP2Large B-cell Lymphoma40Jan 2024
NCT04318678CATCHAMLCD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)P1AML/MDS108Jul 2020
NCT06364423Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for LeukemiasP1/P2Leukemia, Lymphocytic, Chronic, B-Cell132Sep 2024
NCT07233720Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone LymphomaMarginal Zone Lymphoma30Nov 2025
NCT05100862MAHOGANYA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaP3Relapsed/Refractory Follicular Lymphoma780Mar 2022
NCT07010302BEST-NMOSDRituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDP4NMOSD540May 2026
NCT07097363EPOCH-REpcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaP2B-Cell Non-Hodgkin Lymphoma18Dec 2025
NCT05758831TRIORItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.P3Multiple Sclerosis386Jun 2023
NCT05545384IDARImmediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical TrialP3Acute Demyelinating Syndrome86Apr 2025
NCT06730542Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS LymphomaP1CNS Lymphoma20Apr 2025
NCT06835530FIL_RICCOA Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)P2Diffuse Large B Cell Non-Hodgkin Lymphoma47Apr 2025
NCT07578077Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaP1/P2Recurrent Mantle Cell Lymphoma58Dec 2026
NCT06788964CORALLoncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)P2Relapsed or Refractory Large B-cell Lymphoma29Aug 2025
NCT06336395Ma-Spore ALL 2020 StudyP2B Lymphoblastic Leukemia500Mar 2020
NCT04061512RAINBOWRituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaP2/P3Waldenstrom Macroglobulinemia148Feb 2020
NCT06965114Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaP1/P2Hairy Cell Leukemia84May 2026
NCT06563596Epco, Zanu, Ritux for R/R FL or MZLP2Follicular Lymphoma45Jan 2025
NCT03949855REBOOTBelimumab With Rituximab for Primary Membranous NephropathyP2Membranous Nephropathy58Mar 2020
NCT07226843A Study of LY4584180 in Adult Participants With Previously Treated Blood CancersP1Lymphoma, Non-Hodgkin's460Apr 2026
NCT07451847PREP-ANCAComparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.P4ANCA Associated Vasculitis (AAV)70Feb 2026
NCT05783609Epcoritamab and Rituximab for First-line Follicular LymphomaP2Follicular Lymphoma100Jun 2023
NCT06082102Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaP3Relapsed/Refractory Marginal Zone Lymphoma324Dec 2023
NCT06846671CaDAnCe-302A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsP3CLL250Apr 2025
NCT07448324Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLP2Marginal Zone Lymphoma(MZL)50Apr 2025
NCT07104032IGNITEIGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)P3Relapsed/Refractory Primary Central Nervous System Lymphoma132Jun 2026
NCT07594899GUIDANCE-10AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLP2Large B-Cell Lymphoma (LBCL)178May 2026
NCT07410520PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.P2Primary Central Nervous System Lymphoma (PCNSL)50Feb 2026
NCT07418190Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaP2Relapsed/Refractory Follicular Lymphoma33Feb 2026
NCT07051915The Holistic StudyP3Thrombocytopenia Purpura220Sep 2025
NCT07139873TAI-SHAN6A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)P3Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma250Sep 2025
NCT06521255Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaP3DLBCL244May 2024
NCT06251180Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaP1B-cell Non-Hodgkin Lymphoma112Apr 2024
NCT06190301RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT LymphomaN/APrimary Ocular Adnexal MALT Lymphoma108Dec 2023
NCT06119685IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersP1/P2NHL128Oct 2023
NCT05645718Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaP2Leukemia27Jul 2023
NCT06134284Clinical Study of OR for Second-line Treatment of Refractory MZLP4OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma39Jan 2023
NCT04745728Different Immunosuppressive Treatment in iMNP3Idiopathic Membranous Nephropathy200Apr 2021
NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLP2Diffuse Large B-Cell Lymphoma (DLBCL)50Apr 2026
NCT07389356Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCLN/ADLBCL - Diffuse Large B Cell Lymphoma70Feb 2026
NCT06742502Si-RiSintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBLP2Primary Mediastinal Diffuse Large B-cell Lymphoma30Nov 2024
NCT07034508A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1P2DLBCL - Diffuse Large B Cell Lymphoma134Jun 2025
NCT06946407Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System LymphomaN/APrimary Central Nervous System Lymphoma (PCNSL)41Dec 2022
NCT04989491REPLYEvaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney AllograftP4Epstein-Barr Virus Infections120Dec 2021
NCT06970743CaDAnCe-303A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsP3Chronic Lymphocytic Leukemia150May 2025
NCT06091254OLYMPIA-1A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaP3Follicular Lymphoma (FL)822Dec 2023
NCT06973811ZR-MTXZR-MTX for PIOL Phase II TrialP2Primary Intraocular Lymphoma47May 2025
NCT07124936A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell LymphomaP1/P2Diffuse Large B Cell Lymphoma (DLBCL)97Jul 2025
NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaP2Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified43Apr 2026
NCT07550855FLOURISHSonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular LymphomaP2Follicular Lymphoma (FL)52Sep 2026
NCT07608731Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS LymphomasP1Large B-cell Lymphoma18Jun 2026
NCT05800366A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaP2Lymphoma41Apr 2023
NCT06091865OLYMPIA-3A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaP3Diffuse Large B-cell Lymphoma (DLBCL)904Dec 2023
NCT07022223Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone LymphomaP2Marginal Zone Lymphoma(MZL)51Mar 2025
NCT06554561A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System LymphomaP1/P2PCNSL43Aug 2024
NCT06522555The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaP3Diffuse Large B-Cell Lymphoma100Jul 2024
NCT07588698Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin LymphomaP2Non-Hodgkin's B-cell Lymphoma20Jul 2026
NCT07185373Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSLP2/P3Primary Central Nervous System Lymphoma215Oct 2025
NCT06504940MZLOptimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)P2Marginal Zone Lymphoma69Jun 2024
NCT07562022A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaP3Follicular Lymphoma (FL)93May 2026
NCT07350850PRIME-PCNSLA Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSLP2PCNSL77Dec 2025
NCT06342544IMCOMGImmediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.P3Ocular Myasthenia Gravis128Apr 2025
NCT06792253Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaP3Relapsed/Refractory Diffuse Large B-Cell Lymphoma416Jan 2025
NCT06564038Soundtrack-EA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesP1/P2Chronic Lymphocytic Leukaemia408Jan 2025
NCT06942507BRZ-WMZanubrutinib Combined With BR in the First-line Treatment of Waldenström's MacroglobulinemiaN/AWaldenström's Macroglobulinemia (WM)104May 2025
NCT05952024ACRUEStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLP2Diffuse Large B-Cell Lymphoma80Jul 2024
NCT06516978A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLP2Diffuse Large B Cell Lymphoma528Oct 2024
NCT06188676Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBLP3Primary Mediastinal Lymphoma100Apr 2022
NCT04871191SATELITEStudy of Salvage Therapy to Treat Patients With Granulomatosis With PolyangiitisP3Granulomatosis With Polyangiitis42Jun 2025
NCT06350318Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasP2Follicular Lymphoma43Apr 2024
NCT05249959FIL_COLUMNConsolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.P2Relapsed Mantle Cell Lymphoma49Mar 2022
NCT03414502Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseP3Rheumatoid Arthritis400Dec 2007
NCT06918431Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaP2B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative53Oct 2025
NCT07029139A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous NephropathyP2Primary Membranous Nephropathy156Jun 2025
NCT07187960Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular LymphomaP3Follicular Lymphoma228Nov 2025
NCT06983821SAFE-LOWSafe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)P3Granulomatosis With Polyangiitis36Nov 2025
NCT06149286OLYMPIA-5A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaP3Relapsed/Refractory Follicular Lymphoma470Dec 2023
NCT06549231EVER-ILD 3Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic SclerosisP3Interstitial Lung Disease With Systemic Sclerosis102Jan 2025
NCT03579875Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersP2Fanconi Anemia48Nov 2018
NCT07477366Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaP2Relapsed B-Cell Non-Hodgkin Lymphoma20Apr 2026
NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaP2Diffuse Large B-Cell Lymphoma (DLBCL)150Nov 2025
NCT07002099Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II StudyP2Lymphomas26Jun 2025
NCT06803693Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLP2Diffuse Large B-Cell Lymphoma152Apr 2025
NCT06581562IRIS-RD-01Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.P1Rheumatoid Arthritis30May 2024
NCT05998642Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaP2Non-hodgkin Lymphoma30Feb 2024
NCT06031233MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieP4Oncology776Sep 2023
NCT05136976THERAMAGRituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good RespondersP3Anti-MAG Neuropathy90Jun 2023
NCT05207358GLUREDLUPMinimizing Glucocorticoid Administration in Patients With Proliferative Lupus NephritisP4Lupus Nephritis30Mar 2022
NCT04784052Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing BriquilimabP1/P2Fanconi Anemia18Dec 2021
NCT04856137DLBLA Phase I/II Study of Diffuse Large B-cell LymphomaP1/P2Refractory Diffuse Large B-cell Lymphoma74May 2021
NCT03500731Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureP1/P2Idiopathic Pulmonary Fibrosis8Apr 2018
NCT01419561KICSNatural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)P2KSHV Inflammatory Cytokine Syndrome (KICS)140Sep 2011
NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLP2Diffuse Large B-Cell Lymphoma (DLBCL)58Jan 2026
NCT07405255ZillionZillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS LymphomaP2Central Nervous System Lymphoma19Jan 2026
NCT07029737SOUND-MCLA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainP2Mantle-cell Lymphoma55Sep 2025
NCT06220032HO170DLBCLPrevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaP3DLBCL - Diffuse Large B Cell Lymphoma324Aug 2024
NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaP2Lymphoma65Nov 2025
NCT05004064CARAMELAcalabrutinib and Rituximab in Previously Untreated Mantle Cell LymphomaP2Mantle Cell Lymphoma48Nov 2023
NCT04323566Ra-P-OCDRituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System InvolvementP2Obsessive-Compulsive Disorder40May 2022
NCT04884035CC-220Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaP1Lymphoma, B-Cell224Sep 2021
NCT07601607Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaP1/P2Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)51May 2026
NCT07234019ITPRituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)P2Immune Thrombocytopenia160Jan 2026
NCT04627753Lemon-CStudy of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.P2Primary CNS Lymphoma30Nov 2020
NCT06714838ReCIXRituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating PolyneuropathyP3CIDP100Oct 2024
NCT05635162ZEBRAZanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell LymphomaP2Mantle Cell Lymphoma50May 2024
NCT06090539A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasP1/P2Relapsed/Refractory Non-Hodgkin Lymphoma308Dec 2023
NCT06611696ARRIAAvacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisP4ANCA Associated Vasculitis (AAV)160Nov 2024
NCT06647732MALTZanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)P2Mucosa-associated Lymphoid Tissue Lymphoma (MALT)42Oct 2024
NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseP2Mantle Cell Lymphoma (MCL)25Sep 2025
NCT07269639Go-Pro-DLBCLGolcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell LymphomaP1/P2Large B-Cell Lymphoma (LBCL)20Jan 2026
NCT07169565Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström MacroglobulinemiaP1Waldenström Macroglobulinemia (WM)21Sep 2025
NCT06554600A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaP2Refractory or Relapsed Diffuse Large B Cell Lymphoma36Aug 2024
NCT06319456APG-2575A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.P3CLL/SLL344Apr 2024
NCT04989621RR FLOrelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)P2Follicular Lymphoma32Aug 2021
NCT04496037MOT-AMRMechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney TransplantTransplant; Complication, Rejection170Sep 2020
NCT04626791Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell LymphomaP2Mantle Cell Lymphoma45Aug 2021
NCT07614282Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemiaP1PTLD28Jul 2026
NCT07224100Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaP2B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL133Mar 2026
NCT06738368DA-EPOCHEtoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaP2B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative30May 2026
NCT07073833The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin LymphomaP1Relapsed/Refractory B-cell Non-Hodgkin Lymphoma40Jul 2025
NCT07199296Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentP2Mantle Cell Lymphoma (MCL)45Jul 2025
NCT07432022A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin LymphomaP1/P2Combination Therapy115Mar 2026
NCT05018520The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low RiskP3Diffuse Large B Cell Lymphoma640Sep 2021
NCT06414148EpLCARTMRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell LymphomaP2Relapsed/Refractory Large B-cell Lymphoma40May 2024
NCT07583810Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone LymphomaP2Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma35Dec 2026
NCT06468943Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLP2Effects of Chemotherapy20Jul 2023
NCT06954805PTLDDefining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)P2Lymphoma30Apr 2025
NCT07231952WMA Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)P2Waldenstrom Macroglobulinemia40Nov 2025
NCT07362238ITPDaratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)P2Immune Thrombocytopenia122Mar 2026
NCT07041268Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of RituximabP2Diabetes Mellitus, Type 1116Apr 2024
NCT06084936GLOBRYTEA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaP3Lymphoma182Oct 2023
NCT04840602Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaP2Lymphoplasmacytic Lymphoma92Jan 2022
NCT06557330MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin LymphomaP2Lymphoma24Jun 2025
NCT06530004Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in ChildrenNephrotic Syndrome50Mar 2020
NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisP3ANCA Associated Vasculitis (AAV)300Nov 2025
NCT06832267RMTTRituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCLN/APrimary Central Nervous System Lymphoma44Feb 2025
NCT05600686Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaP2Double-Expressor Lymphoma24May 2023
NCT06929624A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaP3Diffuse Large B-cell Lymphoma280Apr 2025
NCT06765317A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell LymphomaP2Diffuse Large B Cell Lymphoma (DLBCL)42Jan 2025
NCT05615974A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant TumorsP1/P2Malignant Tumors139Jan 2023
NCT03952637A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisP1/P2Lysosomal Diseases54Aug 2019
NCT07225439NHLRituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)P1Non Hodgkin Lymphoma15Dec 2025
NCT06676631NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus NephritisP1Refractory Systemic Lupus Erythematosus18Feb 2025
NCT06441097Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLP2Diffuse Large B-Cell Lymphoma152Dec 2024
NCT06756308A Study of Enasidenib in People With T-Cell LymphomaP2T-cell Lymphoma25Dec 2024
NCT06046248Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-DiseaseP2Chronic Graft Versus Host Disease25Jan 2024
NCT06003283RITUXERATapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid ArthritisP4Rheumatoid Arthritis134Jan 2024
NCT05786768OBIRINSEfficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic SyndromeP2/P3Steroid-Dependent Nephrotic Syndrome88Oct 2023
NCT05914155PRIMEClinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic SyndromeP3Glomerulonephritis, Membranous88Jun 2023
NCT05786040Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderP2Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder28Mar 2023
NCT05600660Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System LymphomaP2Primary Central Nervous System Lymphoma28Aug 2022
NCT05279300A Study of CS5001 in Patients With Advanced Solid Tumors and LymphomasP1Advanced Solid Tumor480Mar 2022
NCT00692939Autologous Stem Cell Transplantation for Crohn's DiseaseP1/P2Crohn's Disease20Jun 2012
NCT00977977Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyP2Nephrotic Syndrome30Dec 2010
NCT06704555Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular LymphomaP2Follicular Lymphoma20Dec 2024
NCT06254560Rituximab for Serious Aplastic Anemia With Platelet Transfusion RefractorinessP2Severe Aplastic Anemia20Feb 2023
NCT04758975VALUABLEVenetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)P2Chronic Lymphocytic Leukemia (CLL)55Sep 2022
NCT01371630Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic LeukemiaP1/P2B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1276Aug 2011
NCT06700798Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II TrialP2Marginal Zone Lymphoma(MZL)90Dec 2024
NCT06561347ZEBRAZanubrutinib, Bendamustine, Rituximab Prev. Untreated WMP2Waldenstrom Macroglobulinemia56Dec 2024
NCT07297563ITPAnti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)P2Immune Thrombocytopenia160Jan 2026
NCT07001540DLBCLEvaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous TransplantationP2Diffuse Large B-Cell Lymphoma130May 2025
NCT05338190RITUX-PLUS 2Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune ThrombocytopeniaP3Primary Immune Thrombocytopenia (ITP)132Nov 2022
NCT06136351A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell LymphomaP2Lymphoma, Mantle-Cell23Nov 2023
NCT06952413Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)P2Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)30Apr 2025
NCT06351527Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell MalignanciesP1Mature B-cell Malignancies78Apr 2024
NCT06176729Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL PatientsP2Diffuse Large B Cell Lymphoma30Oct 2023
NCT06064344RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT LymphomaN/APrimary Ocular Adnexal MALT Lymphoma108Oct 2023
NCT07138898Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyP2Rheumatic Disease80Sep 2025
NCT05683171A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaP1/P2Lymphoma60May 2023
NCT04679012Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's TransformationP2Richter Syndrome20Sep 2021
NCT05139017MK-2140A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)P2/P3DLBCL290Jan 2022
NCT06561360HCLA Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)P2Hairy Cell Leukemia86Sep 2024
NCT03571321Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic LeukemiaP1Acute Lymphoblastic Leukemia15May 2019
NCT07444710Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaP1Ann Arbor Stage II Mantle Cell Lymphoma16Aug 2026
NCT07270835Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaP4Hemophagocytic Lymphohistiocytosis40Nov 2025
NCT04913103CLSGMCLPOLAStudy of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCLP2Lymphoma, Mantle-Cell21Sep 2021
NCT03150693Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaP3B Acute Lymphoblastic Leukemia310Sep 2017
NCT04745949PACIFICPACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyP2Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma31May 2021
NCT03653338SCDT-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasP1/P2Sickle Cell Anemia5Aug 2018
NCT03136146Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaP2Recurrent Acute Lymphoblastic Leukemia42Aug 2017
NCT07206823Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune ThrombocytopeniaN/APrimacy Immune Thrombocytopenia30Sep 2025
NCT04022239Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell TransplantP1/P2Hematopoietic and Lymphoid System Neoplasm25Mar 2020
NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaP1/P2Diffuse Large B-cell Lymphoma108May 2024
NCT06573645A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCLP3Lymphoma, Large B-Cell, Diffuse428Aug 2024
NCT06496308Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentP3Mantle Cell Lymphoma (MCL)78Jul 2024
NCT05455697Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaP1/P2Diffuse Large B-Cell Lymphoma35Jan 2023
NCT07057778Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITPP2Immune Thrombocytopenia (ITP)120Jul 2025
NCT06475235Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLP1Lymphoma15Oct 2024
NCT06362967The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCTP2High Titers of Anti-HLA Antibody (MFI ≥5000)30May 2024
NCT06047171RENAL-F02Rescue of Nephrons With ALE.F02 (RENAL-F02)P2Glomerulonephritis Rapidly Progressive80Sep 2023
NCT00412594Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaP2Hairy Cell Leukemia150Jun 2004
NCT03523975Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaP1/P2Mantle Cell Lymphoma28Dec 2018
NCT06478472ORProspective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local TherapyN/AMarginal Zone Lymphoma36Jun 2024
NCT06471738Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaP2Ann Arbor Stage II Follicular Lymphoma30Jul 2024
NCT03758989A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell LymphomaP2DLBCL40May 2019
NCT06489808Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCLP2Relapsed/Refractory Large B-Cell Lymphoma89May 2024
NCT05834855Noisy RebelsNon-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MSP3Multiple Sclerosis200Apr 2023
NCT03899337STELLARA Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeP2Richter Syndrome105Jul 2019
NCT02727803Personalized NK Cell Therapy in CBTP2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive100May 2016
NCT05868395Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell LymphomaP2Mantle-cell Lymphoma16Jan 2024
NCT05583071MTR²Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLP2Non-Hodgkin Lymphoma20Aug 2024
NCT07081022JS203 Combination Regimens in B-Cell Non-Hodgkin's LymphomaP2B-cell Non-Hodgkin's Lymphoma180Aug 2025
NCT04609046Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaP1Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System47May 2021
NCT07362199ITPAnti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)P2Immune Thrombocytopenia20Mar 2026
NCT05618925Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaP1Non Hodgkin's Lymphoma Refractory/Relapsed20Aug 2025
NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyP2Large B-Cell Lymphoma With IRF4 Rearrangement41Apr 2025
NCT06921044A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCLP2Diffuse Large B-Cell Lymphoma33Apr 2025
NCT06263491PRPhase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsP2Mantle Cell Lymphoma50May 2024
NCT06981988YY-20394A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHLP1/P2Relapsed/Refractory Indolent NHL80Jun 2025
NCT05736419HCTA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)P2Sickle Cell Disease24Feb 2023
NCT06572618Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell LymphomaP2Mantle Cell Lymphoma27Jan 2025
NCT04421560Pembrolizumab, Ibrutinib and Rituximab in PCNSLP1/P2Primary Central Nervous System Lymphoma37Aug 2020
NCT05514015Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous NephropathyP4Primary Membranous Nephropathy78Mar 2024
NCT06301399Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety StudyP2Advanced Hepatocellular Carcinoma20Mar 2024
NCT06410833BRRPJSBelimumab After Rituximab in Resistant Primary Juvenile SSP4Sjogren's Syndrome15Mar 2024
NCT06209619CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaP1B-Cell Non-Hodgkin Lymphoma-Recurrent18Jan 2024
NCT05698147Selinexor in Combination With MTX+Ritu to Treat R/R CNSLP1/P2Central Nervous System Lymphoma30Aug 2023
NCT05280626First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOPP2Diffuse Large B-Cell Lymphoma100Mar 2022
NCT04432714Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC RearrangementP1/P2DLBCL81Jun 2020
NCT04216524Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmP2Blastic Plasmacytoid Dendritic Cell Neoplasm40May 2020
NCT05506410A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell LymphomaNewly Diagnosed Mantle Cell Lymphoma100Aug 2022
NCT05850546Rituximab in the First Episode of Paediatric Nephrotic SyndromeP3Steroid-Sensitive Nephrotic Syndrome138Mar 2025
NCT05946486TIM-DePisTEvaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.P3Mental Disorder174Oct 2023
NCT05057468Second-line Treatment of Primary Autoimmune Hemolytic AnemiaP3Primary Autoimmune Hemolytic Anemia30Oct 2021
NCT02877303Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaP2B Acute Lymphoblastic Leukemia80Nov 2016
NCT05886036Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialP2Nodular Lymphocyte Predominant B-Cell Lymphoma70Jan 2024
NCT06086197A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLP2Diffuse Large B-cell Lymphoma Recurrent41Oct 2023
NCT05581030ALLCalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)P1Acute Lymphoblastic Leukemia7May 2023
NCT05728658The Study of ICP-248 in Patients With Mature B-cell MalignanciesP1Hematological Malignancies191Mar 2023
NCT06599307The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple SclerosisP2Secondary Progressive Multiple Sclerosis (SPMS)46Aug 2024
NCT03571568A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLP1/P2Indolent B-Cell Non-Hodgkin Lymphoma140May 2018
NCT06832228Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody (PPR) in Third or Later Line Therapy of DLBCLN/ADiffuse Large B-cell Lymphoma (DLBCL)30Sep 2024
NCT06530511PROPolatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCLP2Diffuse Large B Cell Lymphoma30Aug 2024
NCT05990985The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.N/ADiffuse Large B-cell Lymphoma20Sep 2023
NCT05690191Chidamide in Patients With Recurrent and Refractory Diffuse Large bDiffuse Large B-cell Lymphoma169Jun 2021
NCT03630211SScAutologous Stem Cell Transplantation in Patients With Systemic SclerosisP2Systemic Sclerosis8Jul 2018
NCT06906549RADAREvaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid ArthritisP4Rheumatoid Arthritis (RA)260Jul 2025
NCT06977711DLBCLLoncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)P1Diffuse Large B-cell Lymphoma10Jun 2025
NCT05734794STORMStudy of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled TrialP3Nephrotic Syndrome in Children80Feb 2023
NCT05596786EvER-ILD2Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized TrialP3Lung Diseases126Jan 2023
NCT05809180Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsN/ADiffuse Large B Cell Lymphoma35Jan 2023
NCT05843968Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic SyndromeP2Nephrotic Syndrome in Children46Jan 2023
NCT03274375IANMDARImmunoadsorption Therapy in Managing NMDAR Antibodies EncephalitisP2Anti-NMDAR Encephalitis20Jun 2021
NCT03844061Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic SclerosisP2Systemic Sclerosis30Jul 2019
NCT03697356BallondorR-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's MacroglobulinemiaP2Waldenström's Macroglobulinemia54Mar 2019
NCT06683885A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell LymphomaP1/P2Newly Diagnosed Diffuse Large B-cell Lymphoma80Nov 2024
NCT04737889Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System LymphomaP2Primary Central Nervous System Lymphoma30Jan 2021
NCT05422066Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell LymphomaP2DLBCL Germinal Center B-Cell Type50Jul 2022
NCT04920968OVERALLObinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"P2CD20-positive Acute Lymphoblastic Leukemia124Oct 2021
NCT04494503Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLP1/P2Chronic Lymphocytic Leukemia123Aug 2020
NCT05914662ZBRZanubrutinib Plus BR in Newly Diagnosed Symptomatic WMP2Waldenstrom Macroglobulinemia42Feb 2023
NCT05868837REFINERituximab EfFicacy IN MyasthEnia Gravis (REFINE)P3Myasthenia Gravis, Generalized40Feb 2022

Rituximab clinical trials by indication

Lymphoma (224)

NCTAcronymPhaseStatusTitle
NCT06510309P2recruitingRituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
NCT01415752P2active not recruitingRituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT05800366P2recruitingA Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
NCT07015242P2recruitingA Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT06954805PTLDP2recruitingDefining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
NCT06084936GLOBRYTEP3recruitingA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06557330P2not yet recruitingMRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
NCT05683171P1/P2recruitingA Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
+ 216 more, see All trials below.

Chronic Lymphocytic Leukemia (81)

NCTAcronymPhaseStatusTitle
NCT06839053P2recruitingSonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
NCT06943872CELESTIAL-RRCLLP3recruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT05624554P3active not recruitingA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
NCT02339922P2active not recruitingIxazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
NCT04843904SAVEP1active not recruitingSafe Accelerated Venetoclax Escalation in CLL
NCT06970743CaDAnCe-303P3recruitingA Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
NCT05023980BRUIN CLL-313P3active not recruitingA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04965493BRUIN CLL-322P3active not recruitingA Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
+ 73 more, see All trials below.

Leukemia (69)

NCTAcronymPhaseStatusTitle
NCT06644183IOA-244P1/P2recruitingRoginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT07294677CAVALRYP1/P2recruitingCApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
NCT05645718P2recruitingStudy of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
NCT01446133CLL-SLLP2active not recruitingCombination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
NCT01085617UKALL14N/AcompletedStandard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01027000P2completedDonor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01319981P2completedHyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
NCT02423915GVHDP1completedFucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
+ 61 more, see All trials below.

Rheumatoid Arthritis (68)

NCTAcronymPhaseStatusTitle
NCT03414502P3recruitingTreatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT06581562IRIS-RD-01P1recruitingOpen-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
NCT06003283RITUXERAP4recruitingTapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis
NCT06475495COMPAREP1/P2active not recruitingComparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis
NCT06175338P1active not recruitingStudy, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis
NCT04680962MABRIDGEP3withdrawnMabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis
NCT02304354LYRITUXP3completedRelationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)
NCT02468791P3completedMabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
+ 60 more, see All trials below.

Non-Hodgkin's Lymphoma (64)

NCTAcronymPhaseStatusTitle
NCT04002947P2recruitingAcalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
NCT05191225P4unknownUltrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study
NCT02611323FLP1/P2completedA Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01332968RO5072759P3completedA Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
NCT00712582P2completedTherapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
NCT01594229BRP1completedA Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT02453087P1completedA Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
NCT02624986FLP1/P2terminatedA Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
+ 56 more, see All trials below.

Follicular Lymphoma (59)

NCTAcronymPhaseStatusTitle
NCT04669171SIDNEYP1/P2recruitingA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
NCT06284122MorningLyteP3recruitingStudy of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT03361852P1active not recruitingPersonalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
NCT05867030P1withdrawnParsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
NCT06792825HM2023-43P2recruitingHM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
NCT04998669P2recruitingLoncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
NCT06911502GOLSEEK-4P3recruitingA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT05058404P3active not recruitingShortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
+ 51 more, see All trials below.

Diffuse Large B-Cell Lymphoma (56)

NCTAcronymPhaseStatusTitle
NCT06717347MK-2140P3recruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT05578976EPCORE DLBCL-2P3active not recruitingA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT06522555P3recruitingThe Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
NCT05952024ACRUEP2recruitingStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
NCT06803693P2recruitingEfficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
NCT03984448P2/P3active not recruitingTesting the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT06508658EPCORE DLBCL-4P3active not recruitingA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06441097P2not yet recruitingEfficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
+ 48 more, see All trials below.

Mantle Cell Lymphoma (47)

NCTAcronymPhaseStatusTitle
NCT06854003BRAZANP2recruitingBRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
NCT05976763P3recruitingTesting Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT04849715CITADEL-310P3withdrawnA Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT06363994P3recruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
NCT01661881P2active not recruitingRituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
NCT02682641P2active not recruitingIbrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
NCT06522386GATE1P2active not recruitingGATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
NCT05004064CARAMELP2recruitingAcalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
+ 39 more, see All trials below.

Diffuse Large B Cell Lymphoma (42)

NCTAcronymPhaseStatusTitle
NCT05934097P1withdrawnFT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
NCT06516978P2not yet recruitingA Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
NCT05018520P3recruitingThe Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
NCT06176729P2recruitingPola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
NCT04542824EPCORE™ NHL-3P1/P2active not recruitingTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT03943901P2active not recruitingSplit-Dose R-CHOP for Older Adults With DLBCL
NCT05221645P+R-ICEP2active not recruitingPembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT06530511PROP2recruitingPolatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
+ 34 more, see All trials below.

Diffuse Large B-cell Lymphoma (33)

NCTAcronymPhaseStatusTitle
NCT06664411P2recruitingPola-ZR2P in Previously Untreated DLBCL
NCT06929624P3recruitingA Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
NCT04824092frontMINDP3active not recruitingTafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT06594640P1/P2recruitingR-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT04404283ECHELON-3P3active not recruitingBrentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT05990985N/Anot yet recruitingThe Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
NCT05690191N/Aenrolling by invitationChidamide in Patients With Recurrent and Refractory Diffuse Large b
NCT06977711DLBCLP1recruitingLoncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
+ 25 more, see All trials below.

Lymphoma, Non-Hodgkin (30)

NCTAcronymPhaseStatusTitle
NCT03930953P1/P2active not recruitingA Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
NCT03366272NIVEAUP2/P3completedNivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
NCT01996865MAGNIFYP3completedLenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
NCT02626455CHRONOS-4P3terminatedStudy of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
NCT04074330P1/P2terminatedA Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
NCT01938001AUGMENTP3completedRituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
NCT00324467LYTPETP2unknownTailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
NCT02703272P3terminatedA Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
+ 22 more, see All trials below.

Lymphoma, Large B-Cell, Diffuse (19)

NCTAcronymPhaseStatusTitle
NCT06890884MK-2140P2recruitingA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT05798156R-Pola-GloP2active not recruitingRituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
NCT06573645P3not yet recruitingA Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
NCT05186558P2unknownPenpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
NCT05923879N/AunknownMechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
NCT04790903RP1terminatedA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04021992P2unknownGVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
NCT02031419P1terminatedNovel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
+ 11 more, see All trials below.

Primary Central Nervous System Lymphoma (17)

NCTAcronymPhaseStatusTitle
NCT07185373P2/P3not yet recruitingOrelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
NCT04931368OptiMATeP3active not recruitingOptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma
NCT06541665P1active not recruitingPhase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
NCT06832267RMTTN/ArecruitingRituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
NCT05600660P2recruitingOrelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT02203526TEDDI-RP1active not recruitingPhase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
NCT04421560P1/P2recruitingPembrolizumab, Ibrutinib and Rituximab in PCNSL
NCT05549284RMOP2unknownOrelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)
+ 9 more, see All trials below.

Lymphocytic Leukemia, Chronic (17)

NCTAcronymPhaseStatusTitle
NCT01292603P1completedA Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia
NCT02053610CLL11P3completedCLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
NCT01998880CLL11P3completedCLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
NCT01010061CLL11P3completedCLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
NCT01263704P2completedA Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
NCT01271010P4terminatedA Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
NCT01283386P4terminatedA Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
NCT01609023CaLLypsoN/AcompletedA Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia
+ 9 more, see All trials below.

Marginal Zone Lymphoma (14)

NCTAcronymPhaseStatusTitle
NCT06390956PIONEER-MZLP2recruitingPirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
NCT06006117P3recruitingMosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
NCT07233720N/ArecruitingZanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
NCT06504940MZLP2recruitingOptimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
NCT03474744P2active not recruitingCopanlisib and Rituximab in Marginal Zone Lymphoma Patients
NCT06478472ORN/ArecruitingProspective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
NCT03697512MALIBUP2active not recruitingMALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
NCT04212013P3active not recruitingA Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
+ 6 more, see All trials below.

Lymphoma, B-Cell (14)

NCTAcronymPhaseStatusTitle
NCT04882163CC-220P1/P2withdrawnStudy to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
NCT04884035CC-220P1recruitingStudy of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
NCT04161248Early P1active not recruitingPhase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT04245722P1terminatedFT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
NCT04246359RIPPLEP2unknownRituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
NCT00577629P2completedChemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
NCT00634179P1/P2completedA Phase I/II Trial of VR-CHOP in Lymphoma Patients
NCT01421667P2completedA Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
+ 6 more, see All trials below.

Lymphoma, Follicular (13)

NCTAcronymPhaseStatusTitle
NCT06425302GOLSEEK-2P2active not recruitingA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT00317096P3unknownFCM Versus R-FCM Followed by R-Maintenance or Observation Only
NCT01234766Fol-BRITeP2completedBendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
NCT02472756REFLECT 2N/AcompletedA Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma
NCT00510887P2terminatedBortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
NCT02569996P3completedA Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
NCT00930514P1completedA Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
NCT00193492P2completedA Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
+ 5 more, see All trials below.

Acute Lymphoblastic Leukemia (13)

NCTAcronymPhaseStatusTitle
NCT03571321P1recruitingRuxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT02003222P3active not recruitingCombination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT05581030ALLP1recruitingCalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
NCT05457556P3active not recruitingMismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
NCT03856216P2terminatedInotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
NCT02881086P3completedOptimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
NCT02960646P1completedEngineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT03023046P2completedEtoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
+ 5 more, see All trials below.

Immune Thrombocytopenia (12)

NCTAcronymPhaseStatusTitle
NCT07234019ITPP2recruitingRituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07362238ITPP2recruitingDaratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT07297563ITPP2recruitingAnti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07362199ITPP2recruitingAnti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT04588194P2unknownRomiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
NCT03443570P3unknownRituximab Combining Bortezomib Versus Rituximab in Management of ITP
NCT03304288P2unknownThe Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
NCT03154385RITUX PLUSN/AcompletedEfficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia
+ 4 more, see All trials below.

Waldenstrom's Macroglobulinemia (12)

NCTAcronymPhaseStatusTitle
NCT00492050P2active not recruitingBortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
NCT02371148FIL_BRBP2completedFase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
NCT02400437P2completedTrial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
NCT01470196CaRDP2completedCarfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
NCT01078974P1terminatedPomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
NCT01046006P2completedBortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
NCT00422799WMP2completedCombination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
NCT01125293P1/P2terminatedEverolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
+ 4 more, see All trials below.

Non Hodgkin Lymphoma (11)

NCTAcronymPhaseStatusTitle
NCT07222631P1/P2recruitingSB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
NCT02180711P1/P2active not recruitingStudy of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
NCT07225439NHLP1not yet recruitingRituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
NCT04673617P1/P2completedAB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT05200312ZR2-CHOPP2unknownA Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
NCT03688451P2active not recruitingIntrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
NCT02953509P1/P2terminatedTrial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT03169790NHLP1/P2withdrawnQUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
+ 3 more, see All trials below.

Waldenstrom Macroglobulinemia (11)

NCTAcronymPhaseStatusTitle
NCT05099471VIWA-1P2recruitingEfficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
NCT04624906BRAWMP2active not recruitingBendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
NCT04061512RAINBOWP2/P3recruitingRituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
NCT07231952WMP2recruitingA Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
NCT06561347ZEBRAP2recruitingZanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
NCT03620903P2active not recruitingEfficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
NCT05914662ZBRP2recruitingZanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
NCT03630042PembroWMP2completedInvestigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
+ 3 more, see All trials below.

Non-Hodgkin Lymphoma (11)

NCTAcronymPhaseStatusTitle
NCT05283720SCP2recruitingA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05583071MTR²P2recruitingMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
NCT05171647SUNMOP3active not recruitingA Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT01796171LYMRIT-37-01P1/P2completedA Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02406092SCP3completedSafety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
NCT01939327R2P2completedSafety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
NCT01097057G-CSFP2completedRituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
NCT01181258NKP2completedPenostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
+ 3 more, see All trials below.

Multiple Sclerosis (11)

NCTAcronymPhaseStatusTitle
NCT05758831TRIOP3recruitingRItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
NCT05834855Noisy RebelsP3recruitingNon-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
NCT05078177P1unknownSafety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis
NCT04640818N/AunknownSafety and Efficacy of Cladribine Therapy After Anti CD20 Therapy
NCT05762003CPEN/AcompletedCzech Pharmaco-epidemiological Study on Disease Modifying Drugs
NCT02980042P3completedSafety of Switching From Rituximab to Ocrelizumab in MS Patients
NCT01212094P1/P2terminatedDouble Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
NCT01569451GATEWAYIIP2completedComparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
+ 3 more, see All trials below.

DLBCL (10)

NCTAcronymPhaseStatusTitle
NCT06521255P3recruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT05139017MK-2140P2/P3recruitingA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT04974216P2active not recruitingStudy of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
NCT03758989P2recruitingA Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
NCT04432714P1/P2recruitingLenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
NCT04594798P2active not recruitingA Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
NCT04994626P2unknownIbrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
NCT04842487P2unknownR2-CHOP in Untreated DEL-DLBCL:An Open-lable,Multicenter,Phase II Study
+ 2 more, see All trials below.

Central Nervous System Lymphoma (9)

NCTAcronymPhaseStatusTitle
NCT06607549SOLARP1recruitingLoncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
NCT07405255ZillionP2not yet recruitingZillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma
NCT03684980Early P1active not recruitingLTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
NCT05698147P1/P2recruitingSelinexor in Combination With MTX+Ritu to Treat R/R CNSL
NCT04938297P2unknownRituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
NCT01011920CNSP2completedTrial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
NCT04516655C-R-HDMTXP2unknownA Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients
NCT00293475P1/P2unknownMethotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
+ 1 more, see All trials below.

Lymphoma, Mantle-Cell (9)

NCTAcronymPhaseStatusTitle
NCT06136351P2recruitingA Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT04913103CLSGMCLPOLAP2not yet recruitingStudy of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
NCT05564052VEGAP2completedA Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT00209209MCLelderlyP3unknownInduction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
NCT00490529P2completedPhase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
NCT00209222P3unknownEfficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
NCT00992134R-BACP2completedImmunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma
NCT00038623P2completedStudy Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
+ 1 more, see All trials below.

Chronic Lymphocytic Leukemia (CLL) (9)

NCTAcronymPhaseStatusTitle
NCT04758975VALUABLEP2recruitingVenetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
NCT04285567CRISTALLOP3completedA Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
NCT03788291P2completedAcalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
NCT02914938P1terminatedA Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
NCT01723839FCRP2completedPhase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide
NCT01203930P2terminatedA Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
NCT01466153CLLP2completedA Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT01754870CLLP2withdrawnPhase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
+ 1 more, see All trials below.

Non-Hodgkins Lymphoma (9)

NCTAcronymPhaseStatusTitle
NCT00856245P2completedEvaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
NCT01290549P1completedA Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
NCT00807196P1/P2unknownZevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
NCT00574730N/AcompletedCHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
NCT00193479P2completedCombination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
NCT00193440P2completedRituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
NCT00193466P2completedRituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00301301GEM-PN/AcompletedA Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
+ 1 more, see All trials below.

Follicular Lymphoma (FL) (8)

NCTAcronymPhaseStatusTitle
NCT06191744EPCORE™FL-2P3recruitingStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT05888493LEDAP3active not recruitingA Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
NCT05409066EPCORE FL-1P3active not recruitingStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT06091254OLYMPIA-1P3recruitingA Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT07550855FLOURISHP2not yet recruitingSonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
NCT06097364OLYMPIA-2P3active not recruitingA Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT07562022P3not yet recruitingA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
NCT04745832ME-401P3terminatedPhase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

B-cell Lymphoma (8)

NCTAcronymPhaseStatusTitle
NCT07520006P1/P2not yet recruitingStudy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NCT05270057LONCAP1active not recruitingLoncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
NCT05379647NKP1unknownNatural Killer (NK) Cell Therapy for B-Cell Malignancies
NCT03424122CITADEL-112P1completedINCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
NCT02741388SELINDAP1completedA Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
NCT02933320P1/P2completedBI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
NCT00895661P2completedHigh Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
NCT00486759P3terminatedA Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma (8)

NCTAcronymPhaseStatusTitle
NCT06905509P2recruitingEpcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
NCT03321643P1active not recruitingTesting the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
NCT02446457P2active not recruitingRituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
NCT05052528P1unknownFludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT03259503P1completedOlaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
NCT03401853P2terminatedPembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
NCT03440567P1completedAvelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
NCT02366663SPINOZAP3terminatedBEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Idiopathic Membranous Nephropathy (8)

NCTAcronymPhaseStatusTitle
NCT04745728P3recruitingDifferent Immunosuppressive Treatment in iMN
NCT04743739P3terminatedRituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
NCT03804359PMMNP2completedPersonalized Medicine for Membranous Nephropathy
NCT05667909N/AunknownPrognostic Model of Rituximab in the Treatment of MN
NCT05782933N/AunknownEfficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy
NCT04154787P2terminatedEfficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
NCT01180036MENTORP2/P3completedMEmbranous Nephropathy Trial Of Rituximab
NCT01508468GEMRITUXP3completedEvaluate Rituximab Treatment for Idiopathic Membranous Nephropathy

Nephrotic Syndrome (8)

NCTAcronymPhaseStatusTitle
NCT06530004N/ArecruitingClinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
NCT00977977P2recruitingRituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
NCT03501459P3unknownLymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome
NCT05704400P2unknownEfficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome
NCT02382575P4unknownEfficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome
NCT02394119P2completedOfatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome
NCT02438982P3completedEfficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome
NCT00981838NEMOP3completedRituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)

Hairy Cell Leukemia (7)

NCTAcronymPhaseStatusTitle
NCT06965114P1/P2recruitingTesting the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
NCT00923013P2active not recruitingCladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
NCT01059786P2active not recruitingRandomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
NCT06561360HCLP2recruitingA Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
NCT00412594P2recruitingCladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
NCT03805932TMP1active not recruitingMoxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
NCT05388123P2completedLow Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

Granulomatosis With Polyangiitis (7)

NCTAcronymPhaseStatusTitle
NCT04871191SATELITEP3recruitingStudy of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
NCT06983821SAFE-LOWP3recruitingSafe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
NCT05376319P2terminatedPR3-AAV Resilient Remission or PRRR
NCT01750697P2completedA Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
NCT02169219SCOUTP4completedPilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
NCT01613599N/AcompletedAn Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
NCT01731561MAINRITSAN 2P3completedComparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis

Pemphigus (7)

NCTAcronymPhaseStatusTitle
NCT05898308RITUX4P4recruitingComparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
NCT04400994P2active not recruitingIVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
NCT01974518P3unknownComparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
NCT01299857SuivirituxP3completedLong-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
NCT01338103N/AunknownTreatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
NCT00960713RITAIN/AcompletedThe RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
NCT00656656P2completedImmunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus

Leukemia, Lymphocytic, Chronic, B-Cell (7)

NCTAcronymPhaseStatusTitle
NCT05947851VRP3recruitingA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
NCT06205290P3withdrawnA Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
NCT06364423P1/P2recruitingAnti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
NCT00545714CLLP2completedA Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
NCT01373229CLLP1completedLenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
NCT00738829P1/P2completedLenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
NCT01005979CR2P1terminatedA Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Lupus Nephritis (7)

NCTAcronymPhaseStatusTitle
NCT05207358GLUREDLUPP4recruitingMinimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
NCT03791827N/AunknownMulticenter Registry of Pediatric Lupus Nephritis in China
NCT02260934CALIBRATEP2completedRituximab and Belimumab for Lupus Nephritis
NCT01765842RITULUPP3terminatedComparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy
NCT00282347LUNARP3completedA Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
NCT00908986N/AwithdrawnOpen Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
NCT00404157P3withdrawnA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g

Contiguous Stage II Adult Diffuse Large Cell Lymphoma (7)

NCTAcronymPhaseStatusTitle
NCT02073097P1/P2completedCarfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
NCT00736450Early P1terminatedOblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
NCT01539174P2withdrawnRituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
NCT00088881P2terminatedRituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
NCT00121199P2completedCombination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
NCT00080847P2terminatedS0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00017381Early P1completedMonoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue (7)

NCTAcronymPhaseStatusTitle
NCT01479842P1active not recruitingRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
NCT02049541P1completedStudy of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
NCT01812005P2terminatedAlisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01238146P1/P2withdrawnObatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT00012298P1/P2terminatedRadiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00068315P1completedBortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00026182P2completedRituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

B-cell Chronic Lymphocytic Leukemia (7)

NCTAcronymPhaseStatusTitle
NCT00119392P2completedYttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT01269385P1/P2completedImprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
NCT00098670P2completedFludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
NCT00845104P2withdrawnFludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment
NCT00612612P1terminatedObatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
NCT00098488P1terminated17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
NCT00058227P1completedAlvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL) (6)

NCTAcronymPhaseStatusTitle
NCT07493148P2recruitingChidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
NCT07189065P2recruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07397832P2recruitingCRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
NCT05364424P1completedA Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
NCT00001337P2completedDose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
NCT00400478P3completedA Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Mantle Cell Lymphoma (MCL) (6)

NCTAcronymPhaseStatusTitle
NCT06846489P2recruitingAcalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
NCT07285590IMCL-2023P2recruitingClinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
NCT05951959TrAVeRseP2active not recruitingA Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
NCT07272499P2recruitingOrelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
NCT07199296P2recruitingOrelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
NCT06496308P3recruitingBendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

Diffuse Large Cell Lymphoma (6)

NCTAcronymPhaseStatusTitle
NCT05389423P1recruitingPomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
NCT01859819REBOOTP2completedTreatment for Advanced B-Cell Lymphoma
NCT00591630P2completedZevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
NCT00169195R-GEMOXP2completedRituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma
NCT00144807P2completedACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
NCT00140660P3terminatedACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

Systemic Lupus Erythematosus (6)

NCTAcronymPhaseStatusTitle
NCT05828147P4unknownAnti-CD20 Antibodies for Treatment of SLE-PAH
NCT05659407PREDICTN/AunknownBAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis
NCT03312907SLEP3completedA Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
NCT00556192P2completedCan Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
NCT00230035LISTP2withdrawnLupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)
NCT00293072SLEP2completedPilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis

Burkitt Lymphoma (6)

NCTAcronymPhaseStatusTitle
NCT04933617P1terminatedCopanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
NCT03864419P1terminatedRituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
NCT01290120B-ALLP2completedChemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
NCT00126191P2terminatedIntensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
NCT00180882P3unknownLMBA02 Protocol for Patients With a Burkitt Lymphoma
NCT00180895P2terminatedRituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Diffuse, Large B-Cell, Lymphoma (6)

NCTAcronymPhaseStatusTitle
NCT04236141P3terminatedA Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
NCT02871869P2/P3unknownCinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
NCT00599170P2completedRituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
NCT02867566P3completedA Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
NCT01848132P2completedEfficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
NCT02855359SGN-CD19AP2terminatedDenintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Thrombotic Thrombocytopenic Purpura (6)

NCTAcronymPhaseStatusTitle
NCT04074187P2/P3completedA Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
NCT01554514P2completedLow Dose Rituximab in Thrombotic Thrombocytopenic Purpura
NCT00907751PTTrituxP2completedRituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
NCT00531089P2unknownRituximab in Patients With Relapsed or Refractory TTP-HUS
NCT00799773STARP3terminatedEvaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
NCT00251277P1/P2withdrawnUse of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

B-Cell Lymphoma (6)

NCTAcronymPhaseStatusTitle
NCT03467373CHOPP1completedA Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
NCT02945215IBI301P1completedA Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
NCT03003039P1completedA Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
NCT00299494NHLP1/P2completedStudy Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
NCT00965289P2completedHigh-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
NCT00085696P2completedVELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Lupus Erythematosus, Systemic (6)

NCTAcronymPhaseStatusTitle
NCT02284984SYNBIoSeP2completedSynergetic B-cell Immodulation in SLE
NCT00076752P2completedLymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
NCT00381810VOYAGERP3terminatedA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT01702038P2withdrawnDetermining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT00137969EXPLORERP2/P3completedA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT00036491P1/P2completedAnti-CD20 in Systemic Lupus Erythematosus

Kidney Transplantation (6)

NCTAcronymPhaseStatusTitle
NCT01136395P2completedImpact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
NCT00476164RituxiCAN-C4P4completedStudy of Rituximab to Treat Chronic Renal Transplant Rejection
NCT00565331P2/P3completedRituximab for Prevention of Rejection After Renal Transplantation
NCT00801632P2completedCombined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
NCT00371904RAPTUREP2unknownTrial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients
NCT00697996P2/P3completedRituximab for Pediatric Renal Transplant Rejection

Systemic Sclerosis (5)

NCTAcronymPhaseStatusTitle
NCT07335562Breakfree-SScP3recruitingA Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT03630211SScP2recruitingAutologous Stem Cell Transplantation in Patients With Systemic Sclerosis
NCT03844061P2recruitingBelimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
NCT03593902CASTP2/P3terminatedCardiac Safe Transplants for Systemic Sclerosis
NCT01748084RECOVERP2/P3completedRituximab in Systemic Sclerosis

Lymphoma, Non-Hodgkin's (5)

NCTAcronymPhaseStatusTitle
NCT07226843P1recruitingA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT00363636NHLP3terminatedA Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
NCT00384150NHLP3terminatedRetreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
NCT00143871P2completedStudy of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
NCT00141700P2terminatedStudy of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Relapsed/Refractory Follicular Lymphoma (5)

NCTAcronymPhaseStatusTitle
NCT05371093ZUMA-22P3active not recruitingStudy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05100862MAHOGANYP3recruitingA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT07418190P2recruitingEfficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
NCT04224493SYMPHONY-1P3active not recruitingA Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT06149286OLYMPIA-5P3recruitingA Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Marginal Zone Lymphoma(MZL) (5)

NCTAcronymPhaseStatusTitle
NCT07208981P2recruitingOrelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
NCT07299331N/Anot yet recruitingZanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
NCT07448324P2recruitingOrelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
NCT07022223P2recruitingOrelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
NCT06700798P2recruitingOrelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial

Hematologic Malignancies (5)

NCTAcronymPhaseStatusTitle
NCT01810588P2active not recruitingTargeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
NCT07200583PAIA-HaploN/AcompletedProtein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
NCT02663518TTI-621P1terminatedA Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
NCT00824135P1completedHaploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
NCT00496340Pento & tBUP2completedPhase II Trial of Pentostatin and Targeted Busulfan

Diffuse Large B-cell Lymphoma (DLBCL) (5)

NCTAcronymPhaseStatusTitle
NCT06091865OLYMPIA-3P3recruitingA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06832228N/ArecruitingStudy of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody (PPR) in Third or Later Line Therapy of DLBCL
NCT02957019DLBCLP1/P2terminatedA Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02983097R²-DHAPP1/P2terminatedTherapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
NCT01054781DLBCLP2completedIntensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)

B Acute Lymphoblastic Leukemia (5)

NCTAcronymPhaseStatusTitle
NCT05303792P2active not recruitingTesting the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
NCT04872790P1active not recruitingVenetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
NCT03150693P3recruitingInotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT02877303P2recruitingBlinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
NCT02538926P2withdrawnEtoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma (5)

NCTAcronymPhaseStatusTitle
NCT04447716P1active not recruitingAn Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
NCT01695941P1active not recruitingAlisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
NCT02628405P1/P2active not recruitingR-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
NCT04659044P2terminatedPolatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
NCT00764517P2completedVorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Multiple Myeloma (5)

NCTAcronymPhaseStatusTitle
NCT03524235P1completedHaploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
NCT04136756P1completedNKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
NCT04045028PKP1terminatedA Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT00505895P2completedFM 140 vs FM100 Study in Patients With Multiple Myeloma
NCT00427557P2completedCellular Therapy With Cord Blood Cells

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (5)

NCTAcronymPhaseStatusTitle
NCT01424982P2active not recruitingCombination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
NCT02727803P2recruitingPersonalized NK Cell Therapy in CBT
NCT03147612P2active not recruitingLow-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
NCT03096782P2completedUmbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
NCT01619761P1unknownNK Cells in Cord Blood Transplantation

B-cell Adult Acute Lymphoblastic Leukemia (5)

NCTAcronymPhaseStatusTitle
NCT01670084P2withdrawnNilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT02281279P1/P2withdrawnRituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
NCT00867529P2completedRituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
NCT02168907CPI-613P1terminatedCPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT00010192P1completedRituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

CD20 Positive (5)

NCTAcronymPhaseStatusTitle
NCT01959698P1active not recruitingCarfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
NCT00880815P1completedFludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
NCT00439556P2completedBortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
NCT01729806P1completedIpilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
NCT02219737P1completedIbrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Graft Versus Host Disease (5)

NCTAcronymPhaseStatusTitle
NCT00577278P2completedA Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
NCT01810926P2unknownT&B Depletion Non Malignant
NCT01309997P2completedImatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
NCT01135641R-GVHDP2completedStudy of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)
NCT01066598P2terminatedA Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)

Post-transplant Lymphoproliferative Disorder (4)

NCTAcronymPhaseStatusTitle
NCT06040320RP1/P2recruitingPolatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
NCT07573436PLUTOP1/P2not yet recruitingLoncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)
NCT04337827P2terminatedRituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
NCT00064246P1/P2completedYttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Large B-cell Lymphoma (4)

NCTAcronymPhaseStatusTitle
NCT06045247P2recruitingPhase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT06356129GOLSEEK-1P3active not recruitingStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT07608731P1not yet recruitingGolcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
NCT05929716P2withdrawnAn Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

DLBCL - Diffuse Large B Cell Lymphoma (4)

NCTAcronymPhaseStatusTitle
NCT07255963P2recruitingPirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
NCT07389356N/Anot yet recruitingModified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
NCT07034508P2not yet recruitingA Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
NCT06220032HO170DLBCLP3recruitingPrevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Primary Central Nervous System Lymphoma (PCNSL) (4)

NCTAcronymPhaseStatusTitle
NCT07410520P2recruitingPD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
NCT06946407N/ArecruitingRituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma
NCT03703167P1completedIbrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
NCT04688151RADP1active not recruitingRituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

PCNSL (4)

NCTAcronymPhaseStatusTitle
NCT06554561P1/P2recruitingA Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
NCT07350850PRIME-PCNSLP2recruitingA Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
NCT05896007P2unknownZanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
NCT04481815P2unknownRituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Membranous Nephropathy (4)

NCTAcronymPhaseStatusTitle
NCT06341205iRITUXP3recruitingPersonalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
NCT03949855REBOOTP2recruitingBelimumab With Rituximab for Primary Membranous Nephropathy
NCT00405340Early P1completedRituximab in the Treatment of Idiopathic Membranous Nephropathy
NCT00425217P2/P3completedRituximab in Membranous Nephropathy

Chronic Lymphocytic Leukaemia (4)

NCTAcronymPhaseStatusTitle
NCT06564038Soundtrack-EP1/P2recruitingA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT03582098RETRO-idelN/AcompletedClinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
NCT01446900P2terminatedR-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
NCT00504491R-CHOPP2withdrawnR-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia

Sjogren's Syndrome (4)

NCTAcronymPhaseStatusTitle
NCT06410833BRRPJSP4recruitingBelimumab After Rituximab in Resistant Primary Juvenile SS
NCT02631538P2completedSafety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
NCT00101829P1completedAnti-CD20 Antibody Therapy for Sjogren's Syndrome
NCT00363350P1/P2completedRituximab Treatment in Sjogren's Syndrome

Waldenström's Macroglobulinemia (4)

NCTAcronymPhaseStatusTitle
NCT03697356BallondorP2recruitingR-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia
NCT05979948CZ-WM01P2unknownA Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia
NCT01788020P3completedEfficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
NCT02165397P3completedIbrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Hodgkin Lymphoma (4)

NCTAcronymPhaseStatusTitle
NCT06201507P2unknownBV-AVD-R Treatment Children Hodgkin's Lymphoma
NCT02398240P2completedBrentuximab for Newly Diagnosed Hodgkin Disease
NCT01030900DA-EPOCH-RP2completedPhase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
NCT00992030P3terminatedR-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma

Aggressive Non-Hodgkin Lymphoma (4)

NCTAcronymPhaseStatusTitle
NCT04231877P1recruitingPolatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
NCT03749018P2active not recruitingNivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT03704714P1/P2suspendedNivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
NCT03161054P2completedMetronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

B Cell Lymphoma (4)

NCTAcronymPhaseStatusTitle
NCT02898259P1/P2terminatedLenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
NCT03670888P1terminatedA Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
NCT00841945P3terminatedTreatment of Aggressive Localized Lymphoma
NCT00169468P2completedAssociation of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

Purpura, Thrombocytopenic, Idiopathic (4)

NCTAcronymPhaseStatusTitle
NCT03010202P3unknownThe PROLONG Trial - Rituximab Maintenance Therapy in ITP
NCT03258866P4completedThe Study of Different Dose Rituximab in the Treatment of ITP
NCT00372892ITPP2completedPilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)
NCT00005652P2completedPhase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

Lymphoma, Large-Cell, Diffuse (4)

NCTAcronymPhaseStatusTitle
NCT01014208ORCHARRDP3completedOfatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT00561379N/AcompletedDiffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab
NCT00135499P3terminatedR-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
NCT00137995P3completedR-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Graft vs Host Disease (4)

NCTAcronymPhaseStatusTitle
NCT00350545N/AcompletedA Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
NCT01042509LowARN/AcompletedCombination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
NCT00136396P1/P2completedRituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
NCT00578591Rituximab GVHDP2withdrawnRituximab for GVHD

Brain and Central Nervous System Tumors (4)

NCTAcronymPhaseStatusTitle
NCT00068250P1/P2completedCombination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00416819N/AcompletedCombination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
NCT00734773Early P1withdrawnPilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
NCT00416923P1completedIntrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

Idiopathic Thrombocytopenic Purpura (4)

NCTAcronymPhaseStatusTitle
NCT00909077ITPP3completedThe Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)
NCT00475423P2completedA Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
NCT00749112P2/P3completedAlemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
NCT00770562ITPP3completedA Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Multiple Myeloma and Plasma Cell Neoplasm (4)

NCTAcronymPhaseStatusTitle
NCT00477815P1completedRituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
NCT00567229P2terminatedLenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
NCT00258206P2completedRituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
NCT00003554P2completedRituximab in Treating Patients With Multiple Myeloma

Hematological Malignancies (3)

NCTAcronymPhaseStatusTitle
NCT07137481P2not yet recruitingPhase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
NCT05728658P1recruitingThe Study of ICP-248 in Patients With Mature B-cell Malignancies
NCT00379587P1/P2completedRituximab for Prevention of Chronic GVHD

Recurrent Mantle Cell Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT07578077P1/P2not yet recruitingGolcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT04047797P2terminatedIxazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT00109967P2completedCCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PTLD (3)

NCTAcronymPhaseStatusTitle
NCT07614282P1not yet recruitingRituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
NCT04138875P2withdrawnA Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
NCT00590447PTLD-1/3P2completedRisk Stratified Sequential Treatment for CD20-positive PTLD

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (3)

NCTAcronymPhaseStatusTitle
NCT05453500P2active not recruitingChemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
NCT06918431P2recruitingAsparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT06738368DA-EPOCHP2recruitingEtoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Richter Syndrome (3)

NCTAcronymPhaseStatusTitle
NCT07220187P3not yet recruitingAdding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
NCT04679012P2recruitingPolatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
NCT03899337STELLARP2recruitingA Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

ANCA Associated Vasculitis (AAV) (3)

NCTAcronymPhaseStatusTitle
NCT07451847PREP-ANCAP4not yet recruitingComparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
NCT06611696ARRIAP4recruitingAvacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
NCT07168161P3recruitingBDB-001 Phase III Trial in ANCA-Associated Vasculitis

B-Cell Non-Hodgkin Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT07097363EPOCH-RP2recruitingEpcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
NCT03505762P2active not recruitingTailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
NCT05201248SCP1/P2active not recruitingA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

Mantle-cell Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT07029737SOUND-MCLP2recruitingA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
NCT05868395P2recruitingEfficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
NCT02267915MAN2P2unknownPhase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT

Primary Membranous Nephropathy (3)

NCTAcronymPhaseStatusTitle
NCT07029139P2not yet recruitingA Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy
NCT05514015P4recruitingClinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy
NCT05696613P3unknownA Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

Type 1 Diabetes Mellitus (3)

NCTAcronymPhaseStatusTitle
NCT03929601TN25P2active not recruitingRituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
NCT00468442P2terminatedB-Lymphocyte Immunotherapy in Islet Transplantation
NCT00279305TN05P2completedRituximab in New Onset Type 1 Diabetes

NHL (3)

NCTAcronymPhaseStatusTitle
NCT06119685P1/P2recruitingIDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT04555811P1completedFT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
NCT03527147PRISMP1completedPlatform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

Nephrotic Syndrome in Children (3)

NCTAcronymPhaseStatusTitle
NCT05734794STORMP3recruitingStudy of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial
NCT05843968P2recruitingEfficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome
NCT07049172N/AcompletedRituximab and Targeted Nursing for Pediatric Nephrotic Syndrome

Multiple Sclerosis, Relapsing-Remitting (3)

NCTAcronymPhaseStatusTitle
NCT05482542N/AwithdrawnOptimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis
NCT03979456RIDOSE-MSP3unknownRItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS
NCT02746744RIFUND-MSP3completedRItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

Primary CNS Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT04627753Lemon-CP2recruitingStudy of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
NCT05425654P2unknownRL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL
NCT03569995P2unknown[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma

Relapsed Diffuse Large B-Cell Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT04384484LOTIS 5P3active not recruitingStudy to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02077166P1/P2completedIbrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT03136497P1terminatedA Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Autoimmune Diseases (3)

NCTAcronymPhaseStatusTitle
NCT05586737P2completedImmunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency
NCT04127747P4unknownEfficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus
NCT03790293LTFURITUX3P3completedClinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial

IgA Nephropathy (3)

NCTAcronymPhaseStatusTitle
NCT04525729RITAP4completedRituximab and RASi in Patients with IgAN
NCT05824390P4unknownA Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
NCT00498368P4completedRituximab in Progressive Immunoglobulin A (IgA) Nephropathy

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3)

NCTAcronymPhaseStatusTitle
NCT02749292MAINTANCAVASP4terminatedMaintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
NCT02198248LoVASP4unknownLow-dose Glucocorticoid Vasculitis Induction Study
NCT01697267RITAZAREMP3completedRituximab Vasculitis Maintenance Study

Indolent Non-Hodgkin's Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT02576275BRAVURAP3withdrawnA Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
NCT01889797PrE0401P2terminatedPhase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
NCT01088048P1completedStudy to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

B-cell Non Hodgkin's Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT02787239P3completedClinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
NCT02456207P2unknownA Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
NCT02584920P1/P2completedA Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

Lymphoma, B-cell (3)

NCTAcronymPhaseStatusTitle
NCT02592876SGN-CD19AP2terminatedTreatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
NCT01925612DLBCLP2terminatedStudy of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
NCT00482053P2terminatedPhase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Pompe Disease (3)

NCTAcronymPhaseStatusTitle
NCT02525172P4unknownImmune Modulation Therapy for Pompe Disease
NCT01451879N/AcompletedObservational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies
NCT00701129P4completedAn Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease

B-Cell Chronic Lymphocytic Leukemia (3)

NCTAcronymPhaseStatusTitle
NCT01576588P2completedRituximab in Pretreated Elderly or Unfit B-CLL Patients
NCT02315118P1/P2unknownPilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
NCT00254163P3completedFludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients

Immune Thrombocytopenic Purpura (3)

NCTAcronymPhaseStatusTitle
NCT01719692ITPN/AcompletedLow-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
NCT01107951P2completedLow-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP
NCT00774202P2/P3completedHigher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

Purpura (3)

NCTAcronymPhaseStatusTitle
NCT01525836P3completedrhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
NCT01506414ITPP3completedRecombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
NCT01734057ITPP3withdrawnRecombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Adult Nasal Type Extranodal NK/T-cell Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT00072514P2completedGemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
NCT01419795P2terminatedLenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
NCT00601718P1/P2completedVorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT01318317P1/P2active not recruitingGenetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
NCT00096460BMT CTN 0202P2/P3terminatedAutologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
NCT00079443P2terminatedFR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Chronic Fatigue Syndrome (3)

NCTAcronymPhaseStatusTitle
NCT01156922P2terminatedB-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
NCT01156909P2completedB-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
NCT00848692KTS-1-2008P2/P3completedDrug Intervention in Chronic Fatigue Syndrome

Chronic Myeloproliferative Disorders (3)

NCTAcronymPhaseStatusTitle
NCT00691015P2completedSirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
NCT01116232P2terminatedSirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
NCT00080925P1completedT-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Lymphoproliferative Disorder (3)

NCTAcronymPhaseStatusTitle
NCT00092222P2active not recruitingVirotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
NCT00869323P2terminatedBortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
NCT00066469P2completedCyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Large B-Cell Lymphoma (LBCL) (2)

NCTAcronymPhaseStatusTitle
NCT07594899GUIDANCE-10P2not yet recruitingAI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
NCT07269639Go-Pro-DLBCLP1/P2not yet recruitingGolcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Relapsing-remitting Multiple Sclerosis (2)

NCTAcronymPhaseStatusTitle
NCT07517185HiHatP2not yet recruitingThe HIt HArd and hiT Early in Multiple Sclerosis Trial
NCT03193866COMBAT-MSN/AcompletedCOMparison Between All immunoTherapies for Multiple Sclerosis.

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (2)

NCTAcronymPhaseStatusTitle
NCT07224100P2recruitingDose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
NCT01371630P1/P2recruitingInotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Waldenström Macroglobulinemia (WM) (2)

NCTAcronymPhaseStatusTitle
NCT07259122ZBR in WMP2not yet recruitingA Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia
NCT07169565P1not yet recruitingIbrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT07139873TAI-SHAN6P3recruitingA Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
NCT04458610P2active not recruitingZanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Diffuse Large B Cell Lymphoma (DLBCL) (2)

NCTAcronymPhaseStatusTitle
NCT07124936P1/P2recruitingA Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
NCT06765317P2recruitingA Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Immune Thrombocytopenia (ITP) (2)

NCTAcronymPhaseStatusTitle
NCT07057778P2not yet recruitingIguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
NCT00344149P3completedRituximab as Second Line Treatment for ITP

Lymphomas (2)

NCTAcronymPhaseStatusTitle
NCT07002099P2recruitingSelinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
NCT00980304P2unknownR Retreatment in 1st Relapsed DLBCL

Primary Intraocular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT06973811ZR-MTXP2not yet recruitingZR-MTX for PIOL Phase II Trial
NCT03746223P2unknownIntravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

CNS Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT06730542P1recruitingZanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
NCT05926427P2unknownOrelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

CLL (2)

NCTAcronymPhaseStatusTitle
NCT06846671CaDAnCe-302P3recruitingA Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT05209308CORALP2withdrawnRituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Diffuse Large B Cell Non-Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT06835530FIL_RICCOP2recruitingA Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
NCT02141451P1/P2completedADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL

Steroid-Sensitive Nephrotic Syndrome (2)

NCTAcronymPhaseStatusTitle
NCT05850546P3not yet recruitingRituximab in the First Episode of Paediatric Nephrotic Syndrome
NCT04783675RTXFIRPedINSP2completedEfficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT06792253P3recruitingStudy Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06164327P1unknownStudy of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ann Arbor Stage II Follicular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT06471738P2recruitingCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
NCT02532257P2completedIbrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Severe Aplastic Anemia (2)

NCTAcronymPhaseStatusTitle
NCT06412497MT2023-20P2recruitingMT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
NCT06254560P2recruitingRituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

B-cell Non Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT05991388Glo-BNHLP2/P3recruitingA Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
NCT01516580P3completedIntergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

Diabetes Mellitus, Type 1 (2)

NCTAcronymPhaseStatusTitle
NCT07041268P2recruitingImmunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab
NCT00798785P1/P2unknownLong-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients

B-cell Non-Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT06251180P1recruitingPhase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
NCT03671018BTCT4465AP1/P2active not recruitingA Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Relapsed or Refractory Follicular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT06313996P3withdrawnA Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
NCT04712097CelestimoP3active not recruitingA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Non-hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT05998642P2recruitingIbrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
NCT04502706P1terminatedStudy of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Primary Ocular Adnexal MALT Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT06190301N/ArecruitingRCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
NCT06064344N/Anot yet recruitingRCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma

Steroid-Dependent Nephrotic Syndrome (2)

NCTAcronymPhaseStatusTitle
NCT05786768OBIRINSP2/P3recruitingEfficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome
NCT03899103RITURNS IIP3completedCompare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome

Kidney Failure (2)

NCTAcronymPhaseStatusTitle
NCT05900401P1/P2active not recruitingDelayed Tolerance Through Mixed Chimerism
NCT00986947P2terminatedDesensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates

Diffuse Large B-cell Lymphoma Recurrent (2)

NCTAcronymPhaseStatusTitle
NCT06086197P2recruitingA-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
NCT03795571R2-GODP1unknownLenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

Relapsed Follicular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT05848765REFRACTP2recruitingRelapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
NCT00715208P2completedPhase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Glomerulonephritis, Membranous (2)

NCTAcronymPhaseStatusTitle
NCT05914155PRIMEP3recruitingClinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome
NCT03018535RI-CYCLOP3unknownRituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy

Schizophrenia Spectrum and Other Psychotic Disorders (2)

NCTAcronymPhaseStatusTitle
NCT05622201RCT-RITSP2active not recruitingA Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults
NCT03983018RITS-PS-2019P2completedRituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)

Polymyalgia Rheumatica (2)

NCTAcronymPhaseStatusTitle
NCT05533164REDUCE-PMR-2P3active not recruitingRituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
NCT05533125REDUCE-PMR-1P3completedRituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed

Sickle Cell Disease (2)

NCTAcronymPhaseStatusTitle
NCT05736419HCTP2recruitingA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT01279616SCTP2terminatedA Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

Primary Immune Thrombocytopenia (ITP) (2)

NCTAcronymPhaseStatusTitle
NCT04518475ITPP4recruitingEltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
NCT05338190RITUX-PLUS 2P3recruitingEfficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

Antiphospholipid Syndrome (2)

NCTAcronymPhaseStatusTitle
NCT05644210N/AunknownTelitacicept Followed With Rituximab Therapy on APS Secondary to SLE
NCT00537290RITAPSP2completedA Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome

Treatment (2)

NCTAcronymPhaseStatusTitle
NCT07071246N/Aactive not recruitingRituximab for the Treatment of New-onset AChR-Myasthenia Gravis
NCT02971982P1/P2unknownPCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

Obsessive-Compulsive Disorder (2)

NCTAcronymPhaseStatusTitle
NCT04323566Ra-P-OCDP2enrolling by invitationRituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
NCT03983031RITS-PO-2019P1completedRituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)

Stem Cell Transplantation (2)

NCTAcronymPhaseStatusTitle
NCT05293509PTISP2withdrawnPharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
NCT00972101P1withdrawnInfusion of Expanded Cord Blood T Cells

Fanconi Anemia (2)

NCTAcronymPhaseStatusTitle
NCT03579875P2recruitingAlpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT04784052P1/P2recruitingDepleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Interstitial Lung Disease (2)

NCTAcronymPhaseStatusTitle
NCT05963048P2/P3completedRituxmab Versus IL-6 in Treating ILD
NCT01862926RECITALP2/P3completedRituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD

Epstein-Barr Virus Infections (2)

NCTAcronymPhaseStatusTitle
NCT04989491REPLYP4recruitingEvaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft
NCT04507477P1/P2unknownEx-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial

Recurrent Aggressive Non-Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03003546P1completedNab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial
NCT04220008P2withdrawnVorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Relapsing Remitting Multiple Sclerosis (2)

NCTAcronymPhaseStatusTitle
NCT04688788DanNORMSP3active not recruitingNon-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
NCT04578639OVERLORD-MSP3active not recruitingOcrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Hematopoietic and Lymphoid Cell Neoplasm (2)

NCTAcronymPhaseStatusTitle
NCT04752163P1/P2terminatedDS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
NCT01664910P1/P2completedCMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Diffuse Large B-Cell Lymphoma Unclassifiable (2)

NCTAcronymPhaseStatusTitle
NCT04665765P2active not recruitingPolatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT02636322P2completedSmart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Nephrotic Syndrome Steroid-Dependent (2)

NCTAcronymPhaseStatusTitle
NCT04585152RTXvsMMFP2unknownRituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.
NCT04402580P2terminatedEfficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

Refractory Myasthenia Gravis (2)

NCTAcronymPhaseStatusTitle
NCT05332587P3unknownEfficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
NCT00619671P1/P2completedA Pilot Trial of Rituxan in Refractory Myasthenia Gravis

Untreated Mantle Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT05504603ZRP2unknownZanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma
NCT00401817P2completedBevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT04404088P2active not recruitingAcalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
NCT00695786P2completedLenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

Indolent Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT04431635P1terminatedDose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
NCT00954005R-GOP1/P2terminatedStudy With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT04323956P1active not recruitingParsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
NCT01856192P2active not recruitingRituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Lymphoid Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT01754857P2completedBendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
NCT04155840P2terminatedBendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Neuromyelitis Optica (2)

NCTAcronymPhaseStatusTitle
NCT03829566ATTENDP2/P3withdrawnAutologous Transplant To End NMO Spectrum Disorder
NCT00501748P1completedSafety and Tolerability of Rituximab in Neuromyelitis Optica

CCND1 Positive (2)

NCTAcronymPhaseStatusTitle
NCT01880567P2active not recruitingIbrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT03232307P2withdrawnIbrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2)

NCTAcronymPhaseStatusTitle
NCT06325943CIDPRITP3completedRituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT05877040P2unknownA Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy

ANCA Associated Vasculitis (2)

NCTAcronymPhaseStatusTitle
NCT03942887ENDURRANCE-1P3unknownExploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
NCT03967925COMBIVASP2unknownRituximab and Belimumab Combination Therapy in PR3 Vasculitis

Recurrent B Acute Lymphoblastic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT03808610P1/P2terminatedLow-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
NCT02420717P2terminatedRuxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Renal Transplant (2)

NCTAcronymPhaseStatusTitle
NCT04033276P4completedIVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies
NCT00820469PK-rituximabP4completedStudy of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab

Relapsed Non Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03892421P1/P2completedOutpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT03778619P1/P2unknownMG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Acquired Hemophilia A (2)

NCTAcronymPhaseStatusTitle
NCT03384277P4completedTrial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
NCT03700229P2unknownStudy to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

Idiopathic Nephrotic Syndrome (2)

NCTAcronymPhaseStatusTitle
NCT03298698P3unknownEfficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
NCT04494438P3completedRituximab for Idiopathic Nephrotic Syndrome

Sickle Cell Anemia (2)

NCTAcronymPhaseStatusTitle
NCT03653338SCDP1/P2recruitingT-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
NCT01350232N/AterminatedTreatment of Sickle Cell Anemia With Stem Cell Transplant

Idiopathic Pulmonary Fibrosis (2)

NCTAcronymPhaseStatusTitle
NCT03500731P1/P2recruitingLung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
NCT01524068P2withdrawnA MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations

Mature B-cell Non-Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT02405676BNHL-2015P2/P3active not recruitingBNHL-2015 for Children or Adolescents in China
NCT03206671B-NHL 2013P3active not recruitingTreatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Lymphoma, Mantle Cell (2)

NCTAcronymPhaseStatusTitle
NCT02972840P3active not recruitingA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT00114738P2completedEPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Bullous Pemphigoid (2)

NCTAcronymPhaseStatusTitle
NCT04128176P3withdrawnEfficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
NCT00286325P1/P2completedRituximab in the Treatment of Patients With Bullous Pemphigoid

B-Cell Malignancies (2)

NCTAcronymPhaseStatusTitle
NCT02018861CITADEL-101P1/P2completedA Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
NCT01775631P1completedCombination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Acute Lymphoblastic Leukemia (ALL) (2)

NCTAcronymPhaseStatusTitle
NCT02790515P2active not recruitingProvision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
NCT02259348P2terminatedRepeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Large B Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT00118209P3completedRituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT03188198P2unknownRisk Adapted Therapy in Diffuse Large B Cell Lymphoma

AIDS-Related Burkitt Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT02337985P1active not recruitingGene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
NCT02199184P2completedDose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Neuromyelitis Optica Spectrum Disorder (2)

NCTAcronymPhaseStatusTitle
NCT04256252RESCUEP4completedRituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)
NCT03002038P2/P3completedComparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients

Renal Transplant Rejection (2)

NCTAcronymPhaseStatusTitle
NCT02500251P1/P2completedBelimumab Impacting Transplant Eligibility
NCT00695097N/AcompletedThe Effect of Rituximab on the Development of Anti-Donor Antibodies

Marginal Zone B-cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT02853370P2completedBendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
NCT02433795BRP2completedBendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Kidney Failure, Chronic (2)

NCTAcronymPhaseStatusTitle
NCT02314403P1completedRenal Allograft Tolerance Through Mixed Chimerism (Belatacept)
NCT00446251MMFP2completedEffects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant

Ann Arbor Stage I Grade 1 Follicular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT01473628P1/P2active not recruitingRadiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma
NCT02320292P3terminatedRituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Adult Grade III Lymphomatoid Granulomatosis (2)

NCTAcronymPhaseStatusTitle
NCT02213913DA-EPOCH-RP1/P2completedLenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
NCT01805037P1/P2terminatedBrentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Stage I Chronic Lymphocytic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT01886872P3active not recruitingRituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT00602459P2completedFludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Prolymphocytic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT02007044P2active not recruitingIbrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
NCT00281931P2terminatedFludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia

Lymphoma, Non Hodgkin (2)

NCTAcronymPhaseStatusTitle
NCT01992653P1/P2completedA Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
NCT01987505P3completedMabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT01829568P1active not recruitingRituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
NCT01145495P2completedLenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

End Stage Renal Disease (2)

NCTAcronymPhaseStatusTitle
NCT01780454P1/P2completedRenal Allograft Tolerance Through Mixed Chimerism
NCT00167791N/AwithdrawnRituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant

Cold Agglutinin Disease (2)

NCTAcronymPhaseStatusTitle
NCT02689986CAD5P2completedBendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
NCT00373594P2completedTherapy for Chronic Cold Agglutinin Disease

Indolent Non-Hodgkin's Lymphomas (2)

NCTAcronymPhaseStatusTitle
NCT01732913YosemiteP3terminatedEfficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
NCT01732926BridalveilP3terminatedEfficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Anaplastic Large Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT01686165P2completedBelinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
NCT00720135P1completedFusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Aggressive Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT01686321B-R-ENDAP2completedRituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma
NCT01562977RGemOxP2completedStudy to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

Acquired Haemophilia (2)

NCTAcronymPhaseStatusTitle
NCT01808911CREHAP3completedOutcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
NCT01403740EHEMN/AunknownTurkish Acquired Haemophilia Registry

Acute Rejection (2)

NCTAcronymPhaseStatusTitle
NCT01117662RIACTP3terminatedEfficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients
NCT00579592N/AterminatedCampath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

Mantle-Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT00878254P2completedRituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
NCT01497275P2terminatedZevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Contiguous Stage II Mantle Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT01267812P2completedBortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
NCT00433537P2completedCombination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT01165112TRECP1/P2completedBendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
NCT00086944P1/P2completedOblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Adult Non-Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT00438880P1/P2completedAgatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
NCT01045928P1terminatedLenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Primary Non Hodgkin Lymphoma of the Central Nervous System (2)

NCTAcronymPhaseStatusTitle
NCT00647049P2unknownFreiburg ZNS-NHL Study
NCT00989352PRIMAINP2unknownMethotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma

Hodgkin's Disease (2)

NCTAcronymPhaseStatusTitle
NCT00667615DLBCLP1/P2completedTrial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT00648037EBVN/AcompletedRituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT

Lymphoma, Small Lymphocytic (2)

NCTAcronymPhaseStatusTitle
NCT00636155P2terminatedEL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00143065P2completedFludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Myositis (2)

NCTAcronymPhaseStatusTitle
NCT00774462FORCEP2completedRituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis
NCT00106184DMP2completedRituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

Myelodysplastic Syndrome (2)

NCTAcronymPhaseStatusTitle
NCT00520130P1/P2completedChemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
NCT00498316P1completedCord Blood Expansion on Mesenchymal Stem Cells

Lymphoma, Large Cell, Diffuse (2)

NCTAcronymPhaseStatusTitle
NCT00689169ZBEAM2P2completedTargeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma
NCT00436280P2completedChemotherapy for Participants With Lymphoma

Contiguous Stage II Grade 1 Follicular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT01682044P2completedPegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
NCT00244855P2completedRituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma

Stage III Grade 1 Follicular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT00301795P2terminatedRituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00003204P3completedCombination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

Kidney Transplant (2)

NCTAcronymPhaseStatusTitle
NCT00307125P2completedRituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
NCT00642655IVIGP1/P2completedRituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation

Lymphoma, Low-Grade (2)

NCTAcronymPhaseStatusTitle
NCT00311129P2completedEfficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL
NCT00060684P1completedDose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Renal Transplantation (2)

NCTAcronymPhaseStatusTitle
NCT00255593P1completedSafety and Efficacy Study of Rituximab in Renal Transplantation
NCT00214266P2completedA Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation

Neuroblastoma (2)

NCTAcronymPhaseStatusTitle
NCT00790413Early P1unknownHaploidentical Stem Cell Transplantation in Neuroblastoma
NCT00202930P2terminatedUse of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

Wegener's Granulomatosis (2)

NCTAcronymPhaseStatusTitle
NCT00307593RATTRAPN/AcompletedRATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
NCT00072592P1completedAn Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies

Adult Acute Lymphocytic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT00198978P4completedGerman Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00199004P4completedTrial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Idiopathic Thrombocytopenic Purpura (ITP) (2)

NCTAcronymPhaseStatusTitle
NCT01713738ITPP1/P2completedClinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT00161564P2withdrawnA Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Burkitt's Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT00669877P2completedRituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
NCT00199082P4completedNewly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults

Lymphoma, B Cell (2)

NCTAcronymPhaseStatusTitle
NCT00210379P2completedPhase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma
NCT00210340P1withdrawnA Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis

AIDS Related Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT00001563P2completedEPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
NCT00126243CHOPP2terminatedEfficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma

Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT07583810P2not yet recruitingNon-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

Ann Arbor Stage II Mantle Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT07444710P1not yet recruitingTesting the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

Hypophosphatasia (1)

NCTAcronymPhaseStatusTitle
NCT06015750RESTOREP4withdrawnMitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Non-Hodgkin's B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT07588698P2not yet recruitingEpcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

Relapsed/Refractory Primary Central Nervous System Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT07104032IGNITEP3recruitingIGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

NMOSD (1)

NCTAcronymPhaseStatusTitle
NCT07010302BEST-NMOSDP4not yet recruitingRituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (1)

NCTAcronymPhaseStatusTitle
NCT07601607P1/P2not yet recruitingLisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Relapsed B-Cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT07477366P2not yet recruitingStudy of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (1)

NCTAcronymPhaseStatusTitle
NCT07365306P2recruitingEpcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Study (1)

NCTAcronymPhaseStatusTitle
NCT07257055P2recruitingPhase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

Double Expressor DLBCL (1)

NCTAcronymPhaseStatusTitle
NCT07415980P1/P2not yet recruitingPhase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

Combination Therapy (1)

NCTAcronymPhaseStatusTitle
NCT07432022P1/P2not yet recruitingA Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Autoimmune Prematur Ovarian Insuffience (1)

NCTAcronymPhaseStatusTitle
NCT07509840REFINEP3recruitingImmunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency

Hemophagocytic Lymphohistiocytosis (1)

NCTAcronymPhaseStatusTitle
NCT07270835P4recruitingZanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

Rheumatic Disease (1)

NCTAcronymPhaseStatusTitle
NCT07138898P2not yet recruitingImmunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Relapsing-Remitting Multiple Sclerosis (RRMS) (1)

NCTAcronymPhaseStatusTitle
NCT07189325DESIRE MSP3not yet recruitingA Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Marginal Zone Lymphoma of Ocular Adnexal (1)

NCTAcronymPhaseStatusTitle
NCT07247383P2active not recruitingOrelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

Thrombocytopenia Purpura (1)

NCTAcronymPhaseStatusTitle
NCT07051915P3not yet recruitingThe Holistic Study

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06824701TARZANP1suspendedTazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Primacy Immune Thrombocytopenia (1)

NCTAcronymPhaseStatusTitle
NCT07206823N/ArecruitingEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia

Relapsed or Refractory Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06788964CORALP2recruitingLoncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

Non Hodgkin's Lymphoma Refractory/Relapsed (1)

NCTAcronymPhaseStatusTitle
NCT05618925P1recruitingStudy for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

B-cell Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT07081022P2recruitingJS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Crohn Disease (1)

NCTAcronymPhaseStatusTitle
NCT06986382P1/P2not yet recruitingPhase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

Chronic Inflammatory Demyelinating Polyneuropathy (1)

NCTAcronymPhaseStatusTitle
NCT04480450P2withdrawnRituximab in Chronic Inflammatory Demyelinating Polyneuropathy

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT07073833P1recruitingThe Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

Glioblastoma (1)

NCTAcronymPhaseStatusTitle
NCT06973096P1recruitingCART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

Rheumatoid Arthritis (RA) (1)

NCTAcronymPhaseStatusTitle
NCT06906549RADARP4recruitingEvaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis

Relapsed/Refractory Indolent NHL (1)

NCTAcronymPhaseStatusTitle
NCT06981988YY-20394P1/P2not yet recruitingA Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL

Waldenström's Macroglobulinemia (WM) (1)

NCTAcronymPhaseStatusTitle
NCT06942507BRZ-WMN/Anot yet recruitingZanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

Acute Demyelinating Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT05545384IDARP3recruitingImmediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial

Ocular Myasthenia Gravis (1)

NCTAcronymPhaseStatusTitle
NCT06342544IMCOMGP3recruitingImmediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.

Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (1)

NCTAcronymPhaseStatusTitle
NCT06952413P2recruitingStudy of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Large B-Cell Lymphoma With IRF4 Rearrangement (1)

NCTAcronymPhaseStatusTitle
NCT06834373P2recruitingGolcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Presymptomatic Diabetes Type 1 (Stage 1) (1)

NCTAcronymPhaseStatusTitle
NCT06688331PreTregP2recruitingTreatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody

Refractory Systemic Lupus Erythematosus (1)

NCTAcronymPhaseStatusTitle
NCT06676631P1recruitingNK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

T-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06756308P2recruitingA Study of Enasidenib in People With T-Cell Lymphoma

Graft-versus-host Disease (1)

NCTAcronymPhaseStatusTitle
NCT06682169P3recruitingEvaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Newly Diagnosed Diffuse Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06683885P1/P2recruitingA Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

Interstitial Lung Disease With Systemic Sclerosis (1)

NCTAcronymPhaseStatusTitle
NCT06549231EVER-ILD 3P3recruitingEvaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis

Primary Mediastinal Diffuse Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06742502Si-RiP2recruitingSintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL

Mucosa-associated Lymphoid Tissue Lymphoma (MALT) (1)

NCTAcronymPhaseStatusTitle
NCT06647732MALTP2recruitingZanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

Scleroderma, Diffuse (1)

NCTAcronymPhaseStatusTitle
NCT06655896P2recruitingPhase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Classic Follicular Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06337318P3recruitingComparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

CIDP (1)

NCTAcronymPhaseStatusTitle
NCT06714838ReCIXP3recruitingRituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Refractory or Relapsed Diffuse Large B Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06554600P2recruitingA Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis (1)

NCTAcronymPhaseStatusTitle
NCT06388941P2active not recruitingIptacopan in Patients With ANCA Associated Vasculitis

Secondary Progressive Multiple Sclerosis (SPMS) (1)

NCTAcronymPhaseStatusTitle
NCT06599307P2recruitingThe Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis

Relapsed/Refractory Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06489808P2recruitingLinperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Splenic Marginal Zone Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05735834RITZP3active not recruitingComparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Relapsed/Refractory Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06414148EpLCARTP2recruitingMRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

High Titers of Anti-HLA Antibody (MFI ≥5000) (1)

NCTAcronymPhaseStatusTitle
NCT06362967P2recruitingThe Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

Mature B-cell Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT06351527P1recruitingEvaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Tophaceous Gout (1)

NCTAcronymPhaseStatusTitle
NCT06186219P1completedRecapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout

CLL/SLL (1)

NCTAcronymPhaseStatusTitle
NCT06319456APG-2575P3recruitingA Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Lupus Nephritis - WHO Class III (1)

NCTAcronymPhaseStatusTitle
NCT06265220P1active not recruitingAB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Recurrent Transformed Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06247540P2withdrawnVenetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Advanced Hepatocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06301399P2recruitingRituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

B-Cell Non-Hodgkin Lymphoma (B-NHL) (1)

NCTAcronymPhaseStatusTitle
NCT06230224OLYMPIA-4P3active not recruitingA Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Chronic Graft Versus Host Disease (1)

NCTAcronymPhaseStatusTitle
NCT06046248P2recruitingBelumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

B-Cell Non-Hodgkin Lymphoma-Recurrent (1)

NCTAcronymPhaseStatusTitle
NCT06209619P1recruitingCC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05886036P2recruitingComparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Relapsed/Refractory Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06090539P1/P2recruitingA Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed/Refractory Marginal Zone Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06082102P3recruitingEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Relapsed/Refractory B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05950334FT522-101P1completedFT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Neuromyelitis Optica Spectrum Disorders (1)

NCTAcronymPhaseStatusTitle
NCT06068829N/AunknownInebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

Mental Disorder (1)

NCTAcronymPhaseStatusTitle
NCT05946486TIM-DePisTP3not yet recruitingEvaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.

Mild Cognitive Impairment (1)

NCTAcronymPhaseStatusTitle
NCT06245707N/Aunknownthe Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy

Anemia, Sickle Cell (1)

NCTAcronymPhaseStatusTitle
NCT06078696CD2 SCDP1/P2terminatedSiplizumab for Sickle Cell Disease Transplant

Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06047080P3active not recruitingAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Glomerulonephritis Rapidly Progressive (1)

NCTAcronymPhaseStatusTitle
NCT06047171RENAL-F02P2recruitingRescue of Nephrons With ALE.F02 (RENAL-F02)

Mantle Cell Lymphoma Refractory (1)

NCTAcronymPhaseStatusTitle
NCT05864742P2active not recruitingGenetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Oncology (1)

NCTAcronymPhaseStatusTitle
NCT06031233MINUTEP4recruitingEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Follicular Lymphoma Stage II (1)

NCTAcronymPhaseStatusTitle
NCT05788081TOP-FLORP2active not recruitingTreatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Effects of Chemotherapy (1)

NCTAcronymPhaseStatusTitle
NCT06468943P2enrolling by invitationPolatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Anti-MAG Neuropathy (1)

NCTAcronymPhaseStatusTitle
NCT05136976THERAMAGP3recruitingRituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

Hypersenstivity Pneumonitis (1)

NCTAcronymPhaseStatusTitle
NCT07035561P2completedRituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis

Double-Expressor Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05600686P2recruitingLoncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Hematologic Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT05735717P2recruitingMT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder (1)

NCTAcronymPhaseStatusTitle
NCT05786040P2recruitingTafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Peripheral T-Cell Lymphoma, Not Otherwise Specified (1)

NCTAcronymPhaseStatusTitle
NCT05821192N/AunknownChemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Mucopolysaccharidosis (MPS) (1)

NCTAcronymPhaseStatusTitle
NCT05494593P4withdrawnA Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Double Express Diffuse Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05527912P2unknownA Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

High-risk Large B-cell Lymphoma (LBCL) (1)

NCTAcronymPhaseStatusTitle
NCT05605899ZUMA-23P3active not recruitingStudy to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Lung Diseases (1)

NCTAcronymPhaseStatusTitle
NCT05596786EvER-ILD2P3recruitingEvaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial

Malignant Tumors (1)

NCTAcronymPhaseStatusTitle
NCT05615974P1/P2recruitingA Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

SIOD (1)

NCTAcronymPhaseStatusTitle
NCT05508009P1/P2recruitingEarly Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Rheumatic Heart Disease in Children (1)

NCTAcronymPhaseStatusTitle
NCT05682196AGRAF-2P2suspendedRituximab in Patients With Acute Rheumatic Fever

OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06134284P4recruitingClinical Study of OR for Second-line Treatment of Refractory MZL

Follicular Lymphoma ( FL) (1)

NCTAcronymPhaseStatusTitle
NCT04796922FLP3withdrawnTo Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Mature B-Cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05533775iMATRIX GLOP1/P2recruitingA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Pharmacological Action (1)

NCTAcronymPhaseStatusTitle
NCT05553496P2/P3unknownAssessment of Rituximab Therapeutic Response Versus Conventional Treatment

Efficacy and Safety (1)

NCTAcronymPhaseStatusTitle
NCT05532111N/AunknownEfficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial

Newly Diagnosed Mantle Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05506410N/ArecruitingA Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

DLBCL Germinal Center B-Cell Type (1)

NCTAcronymPhaseStatusTitle
NCT05422066P2recruitingSelinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse (DLBCL) (1)

NCTAcronymPhaseStatusTitle
NCT05406401waveLINE-007P2active not recruitingA Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Transplant Rejection (1)

NCTAcronymPhaseStatusTitle
NCT05156710SAR445088P2active not recruitingBIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Relapsed or Refractory DLBCL (1)

NCTAcronymPhaseStatusTitle
NCT05115409PCRP2unknownAnti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

Overall Survival (1)

NCTAcronymPhaseStatusTitle
NCT05392257P2unknownEfficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Relapsed Diffuse Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05267054BGB-A1217P1/P2completedTreatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Advanced Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT05245916P1withdrawnIBI397 or Combination Therapies in Patients With Advanced Malignancies

Rituximab (1)

NCTAcronymPhaseStatusTitle
NCT05324917N/AunknownPopulation Pharmacokinetic-pharmacodynamic Study of Rituximab in Children With Blood Diseases

Primary Mediastinal Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06188676P3recruitingMulticenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Advanced Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT05279300P1recruitingA Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Relapsed Mantle Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05249959FIL_COLUMNP2recruitingConsolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

IgA Vasculitis (1)

NCTAcronymPhaseStatusTitle
NCT05329090RIGAP3completedEvaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis

Myasthenia Gravis, Generalized (1)

NCTAcronymPhaseStatusTitle
NCT05868837REFINEP3recruitingRituximab EfFicacy IN MyasthEnia Gravis (REFINE)

Recurrent Adult Lymphoblastic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05032183P1/P2terminatedTagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Secondary Hemophagocytic Lymphohistiocytosis (1)

NCTAcronymPhaseStatusTitle
NCT05384743P3unknownRituximab Monotherapy for EBV-HLH and CAEBV

Lymphoplasmacytic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04840602P2recruitingTesting the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Inert Non Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05073250P2unknownIBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

MCL (1)

NCTAcronymPhaseStatusTitle
NCT05214183ALTAMIRAP2active not recruitingAcalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

IgM MGUS (1)

NCTAcronymPhaseStatusTitle
NCT05065554P2active not recruitingACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Primary Autoimmune Hemolytic Anemia (1)

NCTAcronymPhaseStatusTitle
NCT05057468P3recruitingSecond-line Treatment of Primary Autoimmune Hemolytic Anemia

Aggressive B-Cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05025800ALX148P1/P2active not recruitingALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Primary Mediastinal Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04759586P3active not recruitingNivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

CD20-positive Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT04920968OVERALLP2recruitingObinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

Autoimmune Hemolytic Anemia (1)

NCTAcronymPhaseStatusTitle
NCT05057481P3unknownReappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04981912P1active not recruitingRituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

Renal Failure (1)

NCTAcronymPhaseStatusTitle
NCT04540380P1active not recruitingRenal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

Chemotherapy (1)

NCTAcronymPhaseStatusTitle
NCT04113226RelyageP2completedAssessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma

Giant Cell Arteritis (1)

NCTAcronymPhaseStatusTitle
NCT05168475BIOVASP2terminatedBiologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis

Anti-NMDAR Encephalitis (1)

NCTAcronymPhaseStatusTitle
NCT03274375IANMDARP2recruitingImmunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis

Multicentric Castleman Disease (1)

NCTAcronymPhaseStatusTitle
NCT04585893P2active not recruitingSafety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System (1)

NCTAcronymPhaseStatusTitle
NCT04609046P1recruitingTesting the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Ann Arbor Stage III Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04799275P2/P3active not recruitingTesting CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04745949PACIFICP2recruitingPACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Refractory Diffuse Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04856137DLBLP1/P2not yet recruitingA Phase I/II Study of Diffuse Large B-cell Lymphoma

Non-GCB/ABC Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04835870P2unknownZanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Intravascular Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04899570P2unknownZanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Secondary Central Nervous System Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT05398224P2unknownR-MTX-zanbrutinib in Secondary CNS Lymphoma

Heart Failure With Reduced Ejection Fraction (1)

NCTAcronymPhaseStatusTitle
NCT03332888ICFEr-RITU2P2unknownSafety of HMA-CD20 in Patients With HFrEF

Frequently Relapsing Nephrotic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT04531865P3withdrawnRandomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment

Beta Thalassemia Major (1)

NCTAcronymPhaseStatusTitle
NCT04776850Early P1withdrawnPre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Relapsed/Refractory Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT04623541EPCORE™ CLL-1P1/P2active not recruitingSafety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04607772RRP1/P2withdrawnStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Microscopic Polyangiitis (MPA) (1)

NCTAcronymPhaseStatusTitle
NCT03920722RITUXGOPROP3completedEfficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis

Inflammatory Disease (1)

NCTAcronymPhaseStatusTitle
NCT03651518PIMOCP2completedPersonalized Therapies in Inflammatory Complex Disease

Refractory Epilepsy (1)

NCTAcronymPhaseStatusTitle
NCT04542629P4unknownComparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children

Immune-related Adverse Events (1)

NCTAcronymPhaseStatusTitle
NCT04375228P2active not recruitingStudy of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

HBV (1)

NCTAcronymPhaseStatusTitle
NCT04519710HepB20N/AcompletedSpecific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies

Interstitial Lymphocytic Lung Disease (1)

NCTAcronymPhaseStatusTitle
NCT04572620N/AunknownRituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.

Relapsed/Refractory Diffuse Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04442022R-GDPP2/P3active not recruitingA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Transplant; Complication, Rejection (1)

NCTAcronymPhaseStatusTitle
NCT04496037MOT-AMRN/Anot yet recruitingMechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant

Primary Vitreoretinal Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04899453P2unknownIntravitreal MTX and ZR Regimen in Newly Diagnosed PVRL

AML/MDS (1)

NCTAcronymPhaseStatusTitle
NCT04318678CATCHAMLP1recruitingCD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Minimal Change Nephrotic Syndrome (MCNS) (1)

NCTAcronymPhaseStatusTitle
NCT03970577RIFIREINSP2unknownRItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome

Large-B-cell Diffuse Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03804372CLL1818P2terminatedThe Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Glioma of Spinal Cord (1)

NCTAcronymPhaseStatusTitle
NCT04196413DIPGP1recruitingGD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

Blastic Plasmacytoid Dendritic Cell Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT04216524P2recruitingVenetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

High Grade B-Cell Lymphoma, Not Otherwise Specified (1)

NCTAcronymPhaseStatusTitle
NCT04285268P2withdrawnRituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Immune Thrombocytopenia Purpura (1)

NCTAcronymPhaseStatusTitle
NCT05861297P4unknownImmune Thrombocytopenia Management in Adults

Grade 3b Follicular Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04156828P1terminatedCopanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Oncology Patients Receiving Chemotherapy (1)

NCTAcronymPhaseStatusTitle
NCT04189588versusP2completedPhase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

Angioimmunoblastic T-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04319601AITLN/AunknownRituximab Combined With Chidamide and Lenalidomide for r/r AITL

Hematopoietic and Lymphoid System Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT04022239P1/P2recruitingBendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

B Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06336395P2recruitingMa-Spore ALL 2020 Study

Untreated Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT04075292P3active not recruitingStudy of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL) (1)

NCTAcronymPhaseStatusTitle
NCT04129710PCNSLP2unknownA Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Graft Vs Host Disease (1)

NCTAcronymPhaseStatusTitle
NCT04235036P2terminatedIbrutinib and Rituxan for Chronic GVHD

Liver Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04115631P2active not recruitingA Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Refractory Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04002401ZUMA-14P2completedSafety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Relapsing Multiple Sclerosis (1)

NCTAcronymPhaseStatusTitle
NCT04121403NOR-MSP3completedNorwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)

Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT03997968P1/P2completedA Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Acute Myelogenous Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT04023071P1terminatedFT516 in Subjects With Advanced Hematologic Malignancies

CD19 Positive (1)

NCTAcronymPhaseStatusTitle
NCT03579927P1/P2withdrawnCAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04002297MANGROVEP3active not recruitingA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Lysosomal Diseases (1)

NCTAcronymPhaseStatusTitle
NCT03952637P1/P2recruitingA Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

HTLV-1-associated Myelopathy (1)

NCTAcronymPhaseStatusTitle
NCT04004819P2unknownRituximab for HTLV-1-associated Myelopathy

Kidney Transplant Rejection (1)

NCTAcronymPhaseStatusTitle
NCT03994783TAR:GET-1P3terminatedTransplant Antibody-Mediated Rejection: Guiding Effective Treatments

Severe Forms of Mucous Membrane Pemphigoid (1)

NCTAcronymPhaseStatusTitle
NCT03295383RITUX-MMPP3active not recruitingRandomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid

Focal Segmental Glomerulosclerosis (1)

NCTAcronymPhaseStatusTitle
NCT03763643PRI-VENT FSGSEarly P1completedPRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Cutaneous Melanoma, Stage III (1)

NCTAcronymPhaseStatusTitle
NCT03719131P2active not recruitingRituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT03934814P1completedStudy of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Chronic Graft-versus-host-disease (1)

NCTAcronymPhaseStatusTitle
NCT03689894P1/P2terminatedIbrutinib Plus Rituximab for cGVHD Following Allo-SCT

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (1)

NCTAcronymPhaseStatusTitle
NCT03864185RECIPEP2completedThe Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT03783403P1terminatedA Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

EBV-Positive DLBCL, Nos (1)

NCTAcronymPhaseStatusTitle
NCT04181489P2unknownSintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

CD20 Positive B Cell NHL (1)

NCTAcronymPhaseStatusTitle
NCT03980379P1unknownPharmacokinetics, Efficacy and Safety of the 304 Injection

CD20-positive Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03578198MG4101P2terminatedRituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)

Chronic Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT03455517VeRitAsP2completedActivity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia

Relapsed or Refractory Diffuse Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04279938P1withdrawnA Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Acute Lymphoblastic Leukemia, in Relapse (1)

NCTAcronymPhaseStatusTitle
NCT04224571P2completedCCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Acute Lymphoid Leukemia (ALL) (1)

NCTAcronymPhaseStatusTitle
NCT03615105P2terminatedDonor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

End-stage Renal Disease (1)

NCTAcronymPhaseStatusTitle
NCT03507348N/AterminatedEvaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCTAcronymPhaseStatusTitle
NCT03576547P1/P2terminatedVenetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Recurrent Central Nervous System Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03558750P1terminatedRituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03571568P1/P2recruitingA Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Membranous Nephropathy - PLA2R Induced (1)

NCTAcronymPhaseStatusTitle
NCT05679336N/AunknownRituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy

Philadelphia Chromosome Negative (1)

NCTAcronymPhaseStatusTitle
NCT03518112P2terminatedLow-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia in Remission (1)

NCTAcronymPhaseStatusTitle
NCT03488225P2terminatedCombination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

Breast Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT03432741P1terminatedDirect Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Clonal Cytopenia of Undetermined Significance (1)

NCTAcronymPhaseStatusTitle
NCT03418038P2recruitingAscorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

AIDS-Related Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03220022P1active not recruitingIbrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Eosinophilic Granulomatosis With Polyangiitis (1)

NCTAcronymPhaseStatusTitle
NCT03164473MAINRITSEGP3completedMaintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.

Invasive Pneumococcal Infection (1)

NCTAcronymPhaseStatusTitle
NCT03069703PNEUMOVASP2completedInnovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL (1)

NCTAcronymPhaseStatusTitle
NCT03372837P3completedPhase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Scleroderma, Systemic (1)

NCTAcronymPhaseStatusTitle
NCT04274257DesiReSP2/P3completedA Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis

Secondary Progressive Multiple Sclerosis (1)

NCTAcronymPhaseStatusTitle
NCT03315923P2/P3completedComparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients

Psychosis (1)

NCTAcronymPhaseStatusTitle
NCT03194815SINAPPS2P2active not recruitingIVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

Diffuse B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03283202CC-122P1completedStudy of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Systemic Lupus Erythematosus Arthritis (1)

NCTAcronymPhaseStatusTitle
NCT03054259ROOTSP2unknownRituximab Objective Outcome Measures Trial in SLE

Recurrent Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT03136146P2recruitingCombination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Primary Effusion Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02911142EPOCH-R2P1/P2active not recruitingLenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Membranoproliferative Glomerulonephritis (1)

NCTAcronymPhaseStatusTitle
NCT03180723P3unknownEffect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis

Graft-versus-host Disease (GVHD) (1)

NCTAcronymPhaseStatusTitle
NCT03112603BATP3completedA Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Diffuse Large B-cell-lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03064867P1/P2active not recruitingVenetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ischemic Heart Disease (1)

NCTAcronymPhaseStatusTitle
NCT03072199RITA-MIP1/P2completedRituximab in Patients With Acute ST-elevation Myocardial Infarction Study

Non-hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03456466P1/P2unknownStudy of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

Cognitive Impairment (1)

NCTAcronymPhaseStatusTitle
NCT03530462N/AcompletedTo Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI

EBV-Related Post-Transplant Lymphoproliferative Disorder (1)

NCTAcronymPhaseStatusTitle
NCT02900976P2completedRituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

ANCA-Associated Vasculitis (1)

NCTAcronymPhaseStatusTitle
NCT02994927ADVOCATEP3completedA Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Metastatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03013218ALX148P1completedA Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Lung Disease, Interstitial (1)

NCTAcronymPhaseStatusTitle
NCT02990286EvER-ILDP3completedEvaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases

Eosinophilic Granulomatosis With Polyangiitis (EGPA) (1)

NCTAcronymPhaseStatusTitle
NCT02807103REOVASP3completedRituximab in Eosinophilic Granulomatosis With Polyangiitis

Generalized Myasthenia Gravis (1)

NCTAcronymPhaseStatusTitle
NCT02950155RinomaxP3completedA Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis

Diffuse Large B-cells Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02955823P2completedA Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Renal Insufficiency, Chronic (1)

NCTAcronymPhaseStatusTitle
NCT02966717CKDP2unknownRituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)

B-cell Lymphoma Recurrent (1)

NCTAcronymPhaseStatusTitle
NCT02843061P1/P2completedCombination of Rituximab and NK Immunotherapy for B Lymphoma

Waldenström Macroglobulinemia (1)

NCTAcronymPhaseStatusTitle
NCT02844322BDH-WM01P4completedThe Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia

Arthritis, Rheumatoid (1)

NCTAcronymPhaseStatusTitle
NCT02792699RAP3completedStudy to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Granulomatous and Lymphocytic Interstitial Lung Disease (1)

NCTAcronymPhaseStatusTitle
NCT02789397P2withdrawnTreatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency

Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02670616P2completedStudy of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Immunoglobulin G Subclass 4 Related Disease (1)

NCTAcronymPhaseStatusTitle
NCT02705638TIGR2P1completedTreatment of IgG4-Related Disease With Revlimid and Rituximab

Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02600897FLP1/P2completedA Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Follicular Low Grade Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02501473P1/P2terminatedStudy of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)

Hemophilia A With Inhibitor (1)

NCTAcronymPhaseStatusTitle
NCT03598725HA-LD-ITIP4unknownLow-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China

Granulomatosis With Polyangiitis (Wegener's Granulomatosis) (1)

NCTAcronymPhaseStatusTitle
NCT02626845RENTGPAP4terminatedRituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

Diffuse Large B-Cell Lymphoma, Lymphoma Follicular (1)

NCTAcronymPhaseStatusTitle
NCT02596971CHOPP1/P2completedA Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Off-Label Use (1)

NCTAcronymPhaseStatusTitle
NCT02654379N/AcompletedObservational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe

Contiguous Stage II Adult Lymphoblastic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02293109P1completedCarfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Multiple Sclerosis, Chronic Progressive (1)

NCTAcronymPhaseStatusTitle
NCT02545959EFFRITEP2completedIntrathecal Rituximab in Progressive Multiple Sclerosis

Composite Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02541565P1completedPembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic (1)

NCTAcronymPhaseStatusTitle
NCT02594384LAM-002A/NHLP1completedA Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Diffuse Large B-cell Lymphoma Refractory (1)

NCTAcronymPhaseStatusTitle
NCT02594163P2terminatedStudy of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Adult Burkitt Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02481310P1/P2unknownCombination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Myelodysplastic Syndromes (1)

NCTAcronymPhaseStatusTitle
NCT02356159P1/P2completedStudy of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Lymphoma,Non-Hodgkin (1)

NCTAcronymPhaseStatusTitle
NCT02367040CHRONOS-3P3completedCopanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Cryoglobulinemia (1)

NCTAcronymPhaseStatusTitle
NCT02556866ESBAMP2terminatedRituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis

Wegener's Granulomatosis or Microscopic Polyangiitis (1)

NCTAcronymPhaseStatusTitle
NCT02115997P4completedA Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis

Hematologic Disorders (1)

NCTAcronymPhaseStatusTitle
NCT02484053Early P1completedRapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders

Blastoid Variant Mantle Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02427620P2active not recruitingIbrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Pemphigus Vulgaris (1)

NCTAcronymPhaseStatusTitle
NCT02383589MMFP3completedA Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

Systemic Lupus Erythematosus, Lupus Nephritis (1)

NCTAcronymPhaseStatusTitle
NCT01773616RITUXILUPP3terminatedTrial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis

Relapsed/Refractory Mantle Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02460276PHILEMONP2completedA Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Refractory Diffuse Large B Cell Lymphoma (DLBCL) (1)

NCTAcronymPhaseStatusTitle
NCT02348216ZUMA-1P1/P2completedStudy Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02384954P1/P2terminatedQUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

ANCA-associated Vasculitides (1)

NCTAcronymPhaseStatusTitle
NCT02433522MAINRITSAN3P3completedComparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab

Hematologic Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT02367196P1completedA Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Chronic Lymphocyte Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02232386LLC1114P2completedPhase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia

ANCA-associated Vasculitis (1)

NCTAcronymPhaseStatusTitle
NCT02222155P2completedClinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Posttransplant Lymphoproliferative Disorder (1)

NCTAcronymPhaseStatusTitle
NCT02042391PTLD-2P2completedRisk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy

Frequent Relapsing Nephrotic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT02390362RAMPP3terminatedRandomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome

Lung Transplant (1)

NCTAcronymPhaseStatusTitle
NCT02266888P2completedB Cell Induction in Pediatric Lung Transplantation

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas (1)

NCTAcronymPhaseStatusTitle
NCT02086175P2completedA Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Transplants and Implants (1)

NCTAcronymPhaseStatusTitle
NCT02442648P1unknownB-Cell Targeted Carfilzomib Desensitization

CD20+ Follicular Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02391545CONTEMPOP1/P2terminatedA Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) (1)

NCTAcronymPhaseStatusTitle
NCT02315326BTKP1/P2completedBruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Fibrillary Glomerulonephritis (1)

NCTAcronymPhaseStatusTitle
NCT02197767P2completedPilot Study of Rituximab to Treat Fibrillary Glomerulonephritis

Primary Progressive Multiple Sclerosis (1)

NCTAcronymPhaseStatusTitle
NCT02253264P1completedA Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients

Acute Bilineal Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02135874P2completedClofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Lung Diseases, Interstitial (1)

NCTAcronymPhaseStatusTitle
NCT02251964RITUX-IPP2/P3completedRituximab in Interstitial Pneumonitis

Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME) (1)

NCTAcronymPhaseStatusTitle
NCT02229942RituxMEP3completedB-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.

Non-Hodgkin Lymphoma (NHL) (1)

NCTAcronymPhaseStatusTitle
NCT02265731P1/P2completedStudy Evaluating Venetoclax in Subjects With Hematological Malignancies

Macular Degeneration (1)

NCTAcronymPhaseStatusTitle
NCT02332941RituximabP1completedTreatment -Resistant Neovascular Age-Related Macular Degeneration

Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease (1)

NCTAcronymPhaseStatusTitle
NCT02228512P1/P2withdrawnStudy of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Advanced Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT02205333MEDI6469P1/P2terminatedA Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion (1)

NCTAcronymPhaseStatusTitle
NCT02044822P2terminatedEfficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02059239P1/P2completedBendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Myasthenia Gravis (1)

NCTAcronymPhaseStatusTitle
NCT02110706P2completedBeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

Recurrent Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02160015P1active not recruitingLenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Pulmonary Alveolar Proteinosis (PAP) (1)

NCTAcronymPhaseStatusTitle
NCT01842386P1completedRituximab for Anti-cytokine Autoantibody-Associated Diseases

Primary Central Nervous System Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01973062P2terminatedYttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma

Anemia (1)

NCTAcronymPhaseStatusTitle
NCT02048813P3active not recruitingIbrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

MEMBRANOUS NEPHROPATHY (1)

NCTAcronymPhaseStatusTitle
NCT01955187STARMENP3completedSequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy

Acute Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02043587P2terminatedChemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Ambulatory IPF (1)

NCTAcronymPhaseStatusTitle
NCT01969409ART-IPFP2completedAutoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis

Mature B-Cell Leukemia Burkitt Type (1)

NCTAcronymPhaseStatusTitle
NCT05049473BLP2unknownTreatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

MALT Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01808599P2active not recruitingPhase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Advanced Cancers (1)

NCTAcronymPhaseStatusTitle
NCT01983969P1/P2completedAza-SAHA-GBM With AutoSCT for Refractory Lymphoma

Primary Focal Segmental Glomerulosclerosis (1)

NCTAcronymPhaseStatusTitle
NCT01573533P2completedA Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

Follicular Lymphoma (FL/Indolent NHL) (1)

NCTAcronymPhaseStatusTitle
NCT01994382P1/P2completedPhase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Prostate Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01804712Early P1completedRituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

Head and Neck Squamous Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04361409P1completedRituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Non Hodgkin Lymphoma (NHL) (1)

NCTAcronymPhaseStatusTitle
NCT01829958N/Aactive not recruitingComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

Opsoclonus Myoclonus Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT01868269P3completedOpsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT01700946P2completedTherapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Refractory Non Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01811368P2unknownZevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Waldenstrom's Macroglobulinaemia (1)

NCTAcronymPhaseStatusTitle
NCT01592981R2WP2completedRandomised Trial in Waldenstrom's Macroglobulinaemia

Leukemia Lymphocytic Chronic B-Cell (1)

NCTAcronymPhaseStatusTitle
NCT01744626P1completedSafety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01724021P3completedA Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Recurrent/Refractory CNS (1)

NCTAcronymPhaseStatusTitle
NCT01542918P1completedLenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

Fatigue (1)

NCTAcronymPhaseStatusTitle
NCT02376335RITPBCP2completedB-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis

Hematopoietic Cell Transplantation Recipient (1)

NCTAcronymPhaseStatusTitle
NCT01701986P1/P2completedGemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Diffuse Large B Cell Lymphoma CD20 Positive (1)

NCTAcronymPhaseStatusTitle
NCT01659099GAINEDP3terminatedGA In NEwly Diagnosed Diffuse Large B Cell Lymphoma

CD20+, B-cell Lymphomas (1)

NCTAcronymPhaseStatusTitle
NCT01665768P2completedMaintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

Steroid Resistant Nephrotic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT01716442RTX2012P2/P3unknownRituximab Trial for Pediatric Nephrotic Syndrome

Heart Transplantation (1)

NCTAcronymPhaseStatusTitle
NCT01556347P2terminatedMulti-Drug Desensitization Protocol for Heart Transplant Candidates

Small Lymphocytic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01682616P1completedA Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Blood And Marrow Transplantation (1)

NCTAcronymPhaseStatusTitle
NCT01471067P1completedCord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Relapsed or Refractory Diffuse Large B Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01676558DLBCLP2unknownA Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01678417P2unknown131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma

Crohn's Disease (1)

NCTAcronymPhaseStatusTitle
NCT00692939P1/P2recruitingAutologous Stem Cell Transplantation for Crohn's Disease

Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) (1)

NCTAcronymPhaseStatusTitle
NCT01611259P2completedRituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue

Refractory/Relapsed Indolent Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01429025P1completedRituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Retroperitoneal Fibrosis (1)

NCTAcronymPhaseStatusTitle
NCT01584388P1/P2completedRituximab in IgG4-RD: A Phase 1-2 Trial

Primary Mediastinal Large B Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01516567P2completedIntergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

FSGS (1)

NCTAcronymPhaseStatusTitle
NCT01164098P3terminatedRituximab to Prevent Recurrence of Proteinuria

Recurrent IgA Nephropathy (1)

NCTAcronymPhaseStatusTitle
NCT02571842P4unknownRituximab in Recurrent IgA Nephropathy

Acute Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT01509300P1/P2unknownHLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors

Ophthalmopathy, Thyroid-Associated (1)

NCTAcronymPhaseStatusTitle
NCT02378298RTXP4completedRituximab (RTX) Therapy in Patients With Active TAO

Non-Hodgkin's Lymphomas (1)

NCTAcronymPhaseStatusTitle
NCT01567475(RAD001-R)P1completedThe Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01514344IRISP2completedIntralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01429610RADICALP2unknownRituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia

Post-transplant Lymphoproliferative Disease (1)

NCTAcronymPhaseStatusTitle
NCT01058239P2completedBortezomib Plus Rituximab for EBV+ PTLD

Low-grade B Cell Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01718691P2completedEfficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

CD20+ Aggressive B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01478542OPTIMAL>60P3completedOPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Post-Transplant Lymphoproliferative Disorder (1)

NCTAcronymPhaseStatusTitle
NCT01434472P2terminatedHigh-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Indolent Cutaneous B Cell Lymphomas (1)

NCTAcronymPhaseStatusTitle
NCT02867553RADIO-LYMPHP3unknownMultiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions

Relapsed or Refractory Marginal Zone B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01678404P2unknown131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Chemotherapeutic Agent Toxicity (1)

NCTAcronymPhaseStatusTitle
NCT01399372P2completedRituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Cardiac Allograft Vasculopathy (1)

NCTAcronymPhaseStatusTitle
NCT01278745P2terminatedPrevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Follicular Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01701232P3completedSafety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma

KSHV Inflammatory Cytokine Syndrome (KICS) (1)

NCTAcronymPhaseStatusTitle
NCT01419561KICSP2recruitingNatural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

Large B Cell Diffuse Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01448096P2completedStudy in Patients With Primary Breast Diffuse Large B-cell Lymphoma

Aplastic Anemia (1)

NCTAcronymPhaseStatusTitle
NCT01408342N/AwithdrawnAlemtuzumab and Rituximab in Aplastic Anemia

Adult B Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT01326702P1/P2completedVeliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Renal Transplant Recipients (1)

NCTAcronymPhaseStatusTitle
NCT01318915RESTARRTEarly P1terminatedResearch Study of ATG and Rituximab in Renal Transplantation

Recurrent Follicular Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01381692P1/P2completedBortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Lymphoma, Diffuse Large-Cell B-cell (1)

NCTAcronymPhaseStatusTitle
NCT01415765P1/P2withdrawnMLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Systemic Sclerosis-Associated PAH (1)

NCTAcronymPhaseStatusTitle
NCT01086540P2completedRituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

B-cell Chronic Lymphocytic Leukemia CLL (1)

NCTAcronymPhaseStatusTitle
NCT01370772P2completedIntensified Rituimab Prephase Before FCR in Untreated B-CLL

B-cell Small Lymphocytic Lymphoma Recurrent (1)

NCTAcronymPhaseStatusTitle
NCT01317901P1completedA Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Renal Insufficiency (1)

NCTAcronymPhaseStatusTitle
NCT01312064P4terminatedDe Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction

Chronic Graft-versus-host Disease (1)

NCTAcronymPhaseStatusTitle
NCT01161628GVHDP2completedRituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)

IPF (1)

NCTAcronymPhaseStatusTitle
NCT01266317P1/P2completedCombined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations

Warm Autoimmune Hemolytic Anemia (1)

NCTAcronymPhaseStatusTitle
NCT01181154RAHIAP3completedRituximab in Auto-Immune Hemolytic Anemia

Non Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01316523P2terminatedLenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Childhood Idiopathic Nephrotic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT01268033NEPHRUTIXP2/P3completedEfficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood

Function of Renal Transplant (1)

NCTAcronymPhaseStatusTitle
NCT01095172ReMINDP4unknownRituxiMab INDuction in Renal Transplantation

Ann Arbor Stage II Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00972478P1/P2active not recruitingVorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT01209130P1completedA Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Indolent or Intermediate Grade B-cell Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT01206777P2completedFeasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

AIDS-Related Plasmablastic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01193842P1/P2completedVorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

Adult Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00992446P2completedBortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Lymphoma, Large B-cell, Diffuse (1)

NCTAcronymPhaseStatusTitle
NCT01181999P2unknownRituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma

DMARD Resistant Rheumatoid Arthritis (1)

NCTAcronymPhaseStatusTitle
NCT01593332P4completedLow Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis

Type 1 Diabetes (1)

NCTAcronymPhaseStatusTitle
NCT01280682P4completedImmune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes

B-cell Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT00983619P1/P2completedA Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

Autoimmune Disease (1)

NCTAcronymPhaseStatusTitle
NCT01086631P1completedRituximab for Autoimmune Retinopathy

Accelerated Phase Chronic Myelogenous Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT01044745P2terminatedRituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Progressive Multiple Sclerosis (1)

NCTAcronymPhaseStatusTitle
NCT01719159ITT-PMSP2completedIntrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis

Anaplastic Large Cell Lymphoma, ALK-Negative (1)

NCTAcronymPhaseStatusTitle
NCT01035463P1/P2completedLenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

Blood Stem Cell Transplant Failure (1)

NCTAcronymPhaseStatusTitle
NCT01010217P2completedMismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) (1)

NCTAcronymPhaseStatusTitle
NCT00931918P2completedStudy to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Devic's Disease (1)

NCTAcronymPhaseStatusTitle
NCT00787722P1/P2completedHematopoietic Stem Cell Transplant in Devic's Disease

Large B-cell Diffuse Lymphoma of Testis (1)

NCTAcronymPhaseStatusTitle
NCT00945724IELSG30P2completedSafety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis

Active Chronic Graft Versus Host Disease (1)

NCTAcronymPhaseStatusTitle
NCT01001780PCRP2withdrawnPentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease

Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line. (1)

NCTAcronymPhaseStatusTitle
NCT01127841RBP2unknownTrial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (1)

NCTAcronymPhaseStatusTitle
NCT05063513ASTILP2/P3withdrawnAutologous Stem Cell Transplantation: International Lupus Trial

Pemphigus Disease (1)

NCTAcronymPhaseStatusTitle
NCT00784589Rituximab 3P3completedComparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus

Sarcoidosis (1)

NCTAcronymPhaseStatusTitle
NCT00855205RIPSP2completedRituximab for Pulmonary Sarcoidosis

CD20-Positive Lymphoid Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT00788684P1completedSafety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis) (1)

NCTAcronymPhaseStatusTitle
NCT00936546P2completedA Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy

MALT LYMPHOMA (1)

NCTAcronymPhaseStatusTitle
NCT01015248MALTP2completedTrial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

HLA Sensitization (1)

NCTAcronymPhaseStatusTitle
NCT00908583P4completedDesensitization in Kidney Transplantation

Advanced Refractory Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT00892827P2unknownCombined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia

Indolent Non Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01830478RP2unknownLenalidomide Plus Rituximab (R) in Non Follicular NHL

Epstein Barr Virus Associated Non Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01964755P2terminatedChemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

Follicular Lymphomas (1)

NCTAcronymPhaseStatusTitle
NCT00877214MAINTAINP3active not recruitingSignificance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

Leukemia, Lymphocytic, Acute (1)

NCTAcronymPhaseStatusTitle
NCT00905034MOADP2completedMethotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

High Risk Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00994643P2completedSafety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

Autoimmune Hemolytic Disease (Cold Type) (Warm Type) (1)

NCTAcronymPhaseStatusTitle
NCT01345708P2completedA Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia

T-Cell Peripheral Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01445535P1completedPhase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Wegener Granulomatosis (1)

NCTAcronymPhaseStatusTitle
NCT00748644MAINRITSANP3completedEfficacy Study of Two Treatments in the Remission of Vasculitis

Graft Rejection (1)

NCTAcronymPhaseStatusTitle
NCT00771875P2completedRandomized Trial for Mixed Acute Rejection

No Hodgkin B Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00849355CVP2unknownCiclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (1)

NCTAcronymPhaseStatusTitle
NCT00711828P2completedRituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

Hodgkins Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00515554P3completedHD18 for Advanced Stages in Hodgkins Lymphoma

Lymphoma of Mucosa-Associated Lymphoid Tissue (1)

NCTAcronymPhaseStatusTitle
NCT00656812MALTP2completedRituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

Thyroid-associated Ophthalmopathy (1)

NCTAcronymPhaseStatusTitle
NCT00595335P2/P3completedTrial of Rituximab for Graves' Ophthalmopathy

Lymphoma, Malignant (1)

NCTAcronymPhaseStatusTitle
NCT00509184MIRP2completedRituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma

Sjogren's Disease (1)

NCTAcronymPhaseStatusTitle
NCT00740948TEARSP2/P3completedTolerance and Efficacy of Rituximab in Sjogren's Disease

Classic Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00654732P2completedCombination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

Focal Segmental Glomerulosclerosis (FSGS) (1)

NCTAcronymPhaseStatusTitle
NCT00550342P2withdrawnRituximab Treatment of Focal Segmental Glomerulosclerosis

Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00617929P2terminatedAntithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT00609869P2completedLenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

Metastatic Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT01032122P1terminatedRituximab in Metastatic Melanoma

Chronic B-Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT00558181LT-CLL-001P2completedHigh-dose Methylprednisolone and Rituximab in High Risk B-CLL

Churg-Strauss Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT00424749P2terminatedRituxan in Churg Strauss Syndrome With Renal Involvement

Steroid-Refractory Chronic GVHD (1)

NCTAcronymPhaseStatusTitle
NCT00472225P2unknownStudy of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Richter's Transformation (1)

NCTAcronymPhaseStatusTitle
NCT00472849P1/P2completedOxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Kidney Insufficiency (1)

NCTAcronymPhaseStatusTitle
NCT00476515P1withdrawnRituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor

Ankylosing Spondylitis (1)

NCTAcronymPhaseStatusTitle
NCT00432653P2/P3unknownOpen Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis

Scleritis (1)

NCTAcronymPhaseStatusTitle
NCT00415506P1/P2completedRituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation

Primary Sjögren's Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT00426543P2completedEffect of B-cell Depletion in Patients With Primary Sjögren's Syndrome

Primary Biliary Cirrhosis (1)

NCTAcronymPhaseStatusTitle
NCT00364819P1/P2completedInitial Study of Rituximab to Treat Primary Biliary Cirrhosis

Pulmonary Alveolar Proteinosis (1)

NCTAcronymPhaseStatusTitle
NCT00552461PAPP2completedProspective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

Nonneoplastic Condition (1)

NCTAcronymPhaseStatusTitle
NCT00486421Early P1completedRituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

Graves' Dysthyroid Ophthalmopathy (1)

NCTAcronymPhaseStatusTitle
NCT00424151P1/P2completedRituximab Treatment of Graves' Dysthyroid Ophthalmopathy

Psoriatic Arthritis (1)

NCTAcronymPhaseStatusTitle
NCT00509678P1completedRituxan With or Without Methotrexate in Psoriatic Arthritis

Early and Severe Systemic Sclerosis (1)

NCTAcronymPhaseStatusTitle
NCT00379431P2completedA Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab

Waldenstroms Macroglobulinemia (1)

NCTAcronymPhaseStatusTitle
NCT00832234BDR-WMP2completedBortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia

AIDS-Related-Primary Central Nervous System Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00267865P2completedChemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

Non Hodgkin's Follicular Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01830465P2completedVELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

Refractory Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT00366418P1completedLower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia

Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD) (1)

NCTAcronymPhaseStatusTitle
NCT00346684RIPLP2completedRituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

Hemophilia A (1)

NCTAcronymPhaseStatusTitle
NCT00331006RICHP2completedRituximab to Treat Severe Hemophilia A

Leukemia, Lymphocytic (1)

NCTAcronymPhaseStatusTitle
NCT00327678ALLP3completedTreatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults

Behcet's Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT00664599P2completedRituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

Polyneuropathy (1)

NCTAcronymPhaseStatusTitle
NCT00259974P3completedRIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy

Leukemia, Lymphocytic, Chronic (1)

NCTAcronymPhaseStatusTitle
NCT00290407CLLP2terminatedRituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)

Thrombotic Thrombocytopenic Purpura (TTP) (1)

NCTAcronymPhaseStatusTitle
NCT00937131TTPP2completedThe Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)

AIDS-related Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00310128P2withdrawnCombination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Ocular Cicatricial Pemphigoid (1)

NCTAcronymPhaseStatusTitle
NCT00584935P1/P2completedClinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

Urticaria (1)

NCTAcronymPhaseStatusTitle
NCT00216762P1/P2terminatedSafety Study of Rituximab (Rituxan®) in Chronic Urticaria

Non-Hodgkin's Lymphoma (CD20+) (1)

NCTAcronymPhaseStatusTitle
NCT00280878P2completedRituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

Chronic Rejection (1)

NCTAcronymPhaseStatusTitle
NCT00261547P1/P2withdrawnRituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients

Dermatitis, Atopic (1)

NCTAcronymPhaseStatusTitle
NCT00267826N/AcompletedImmunopharmacological Effects of Rituximab in Atopic Dermatitis

Untreated T-cell Angioimmunoblastic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00169156P2completedA Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Glomerulonephritis, Membranoproliferative (1)

NCTAcronymPhaseStatusTitle
NCT00275613P1completedPilot Study of Rituximab for Membranoproliferative Glomerulonephritis

Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00288067P1/P2terminatedFenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Relapsed or Refractory Chronic Lymphoproliferative Disorders (1)

NCTAcronymPhaseStatusTitle
NCT01224769N/AcompletedBendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

Anemia, Aplastic (1)

NCTAcronymPhaseStatusTitle
NCT00229619P2completedRituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02486952N/AcompletedMabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma

Leukemia, Mast-Cell (1)

NCTAcronymPhaseStatusTitle
NCT00186628P2completedPhase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Opsoclonus-myoclonus Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT00244361P1/P2completedEffectiveness of Rituximab in Pediatric OMS Patients.

Immunocytoma/Morbus Waldenström (1)

NCTAcronymPhaseStatusTitle
NCT00927797PERLLP2unknownInterventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)

Precancerous Condition (1)

NCTAcronymPhaseStatusTitle
NCT00588822P2terminatedRituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

Vasculitis (1)

NCTAcronymPhaseStatusTitle
NCT00104299RAVEP2/P3completedRituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

Chronic Focal Encephalitis (1)

NCTAcronymPhaseStatusTitle
NCT00259805P1completedA Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis

Relapsed or Refractory Mantle Cell Lymphoma (MCL) (1)

NCTAcronymPhaseStatusTitle
NCT00656084P2completedPh2 Gem/Nov/Rituxan Rel/Ref MantleCell

Stiff Person Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT00091897P2completedRituximab to Treat Stiff Person Syndrome

Lymphoma, High-Grade (1)

NCTAcronymPhaseStatusTitle
NCT00385125P2unknownTreatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Hairy Cell Leukemia (HCL) (1)

NCTAcronymPhaseStatusTitle
NCT02157181P2completedTreatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab

Childhood Burkitt Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00057811P2completedRituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Untreated CD20-positive Large B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00169143P2completedStudy of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

Ulcerative Colitis (1)

NCTAcronymPhaseStatusTitle
NCT00261118P2/P3completedRituximab in Active Ulcerative Colitis

Follicular T-NHL Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01560117P2completedCombination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma

Diffuse Large-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00140595P3completedACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1

B-cell Childhood Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT00058461P2terminatedCombination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Refractory Aggressive Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01538641GROCP2completedPhase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

Graves´ Disease (1)

NCTAcronymPhaseStatusTitle
NCT00150111P1/P2completedRituximab in the Treatment of Graves' Disease

HIV Infections (1)

NCTAcronymPhaseStatusTitle
NCT00127569P2terminatedRituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

Primary Gastric Diffuse-Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00204659CHOPP2completedPhase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma (NHL) (1)

NCTAcronymPhaseStatusTitle
NCT00129090P3completedMega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma

AIDS-related Diffuse Large Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00049036P2completedCombination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Elderly Patients (>65 Years) (1)

NCTAcronymPhaseStatusTitle
NCT01148446ANZINTER3P3completedR-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL

Cutaneous B-cell Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00054639P2completedOblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Lymphoma, Mucosa-Associated Lymphoid Tissue (1)

NCTAcronymPhaseStatusTitle
NCT00210353P3completedRandomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Post-transplantation Lymphoproliferative Disorder (1)

NCTAcronymPhaseStatusTitle
NCT01458548PTLDP2terminatedSequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)

Polyneuropathies (1)

NCTAcronymPhaseStatusTitle
NCT00050245P2completedRituximab to Treat Neuropathy With Anti-MAG Antibodies

Aggressive Non-Hodgkin's Lymphoma in the Elderly. (1)

NCTAcronymPhaseStatusTitle
NCT00244127P2unknownOpen Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.

B-Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT00201721P2completedPentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia

CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT01933711P3unknownRituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma

AIDS-related Peripheral/Systemic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00036855P1terminatedRadiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Post-transplant Lymphoproliferative Disease (PTLD) (1)

NCTAcronymPhaseStatusTitle
NCT01088724FCD-RP4completedFludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)

Hepatitis C (1)

NCTAcronymPhaseStatusTitle
NCT00029107P2completedRituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis

Relapsed Non-Hodgkin-Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02099292Mz-135P2completedRituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma

Lymphoma, AIDS-related (1)

NCTAcronymPhaseStatusTitle
NCT00006436P2completedEPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

CD20-Positive Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00169169P3terminatedEfficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

Breast Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT00001805P2completedA Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT00168740P3completedTreatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Systemic Scleroderma (1)

NCTAcronymPhaseStatusTitle
NCT01047072P2withdrawnLow-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

Rituximab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
RITUX4NCT05898308P4recruitingPemphigus133
ITPNCT04518475P4recruitingPrimary Immune Thrombocytopenia (ITP)224
BEST-NMOSDNCT07010302P4not yet recruitingNMOSD540PMID 36007339
RESTORENCT06015750P4withdrawnHypophosphatasia0
PREP-ANCANCT07451847P4not yet recruitingANCA Associated Vasculitis (AAV)70
REPLYNCT04989491P4recruitingEpstein-Barr Virus Infections120
MINUTENCT06031233P4recruitingOncology776
GLUREDLUPNCT05207358P4recruitingLupus Nephritis30PMID 33572385
ARRIANCT06611696P4recruitingANCA Associated Vasculitis (AAV)160PMID 35110332
RITUXERANCT06003283P4recruitingRheumatoid Arthritis134PMID 39407334
BRRPJSNCT06410833P4recruitingSjogren's Syndrome15
RADARNCT06906549P4recruitingRheumatoid Arthritis (RA)260
RITANCT04525729P4completedIgA Nephropathy116PMID 38299639
BDH-WM01NCT02844322P4completedWaldenström Macroglobulinemia35PMID 38205507
ReMINDNCT01095172P4unknownFunction of Renal Transplant100
MAINTANCAVASNCT02749292P4terminatedAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis115PMID 38123922
LoVASNCT02198248P4unknownAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis140PMID 33164993
HA-LD-ITINCT03598725P4unknownHemophilia A With Inhibitor55PMID 40286913
BDH-MCL01NCT02858804P4completedMantle Cell Lymphoma55
RESCUENCT04256252P4completedNeuromyelitis Optica Spectrum Disorder108
RTXNCT02378298P4completedOphthalmopathy, Thyroid-Associated38
SCOUTNCT02169219P4completedGranulomatosis With Polyangiitis20
RENTGPANCT02626845P4terminatedGranulomatosis With Polyangiitis (Wegener's Granulomatosis)3PMID 22627727
RituxiCAN-C4NCT00476164P4completedKidney Transplantation62PMID 32117242
SWITCHNCT01295151P4completedRheumatoid Arthritis122PMID 32859608
ORBITNCT01021735P4completedRheumatoid Arthritis302PMID 27197690
SEWORRANCT01765374P4completedRheumatoid Arthritis30PMID 36377584
ROCNCT01000441P4completedRheumatoid Arthritis300PMID 27654603
RATE-RANCT01382940P4completedRheumatoid Arthritis351
PARISNCT02731560P4completedRheumatoid Arthritis74
RESONARNCT01117129P4terminatedRheumatoid Arthritis2
FCD-RNCT01088724P4completedPost-transplant Lymphoproliferative Disease (PTLD)4
PK-rituximabNCT00820469P4completedRenal Transplant20PMID 23432476
RFCNCT01124526P4completedNon Hodgkin Lymphoma75
EPCORE™FL-2NCT06191744P3recruitingFollicular Lymphoma (FL)1,095
VRNCT05947851P3recruitingLeukemia, Lymphocytic, Chronic, B-Cell735
CITADEL-310NCT04849715P3withdrawnMantle Cell Lymphoma0
MorningLyteNCT06284122P3recruitingFollicular Lymphoma790
FLNCT04796922P3withdrawnFollicular Lymphoma ( FL)0
MK-2140NCT06717347P3recruitingDiffuse Large B-Cell Lymphoma1,046
REFINENCT07509840P3recruitingAutoimmune Prematur Ovarian Insuffience40
CELESTIAL-RRCLLNCT06943872P3recruitingChronic Lymphocytic Leukemia630
iRITUXNCT06341205P3recruitingMembranous Nephropathy120PMID 40180405
MANGROVENCT04002297P3active not recruitingMantle Cell Lymphoma; Non-Hodgkin Lymphoma510PMID 32985902
ZUMA-23NCT05605899P3active not recruitingHigh-risk Large B-cell Lymphoma (LBCL)300
LEDANCT05888493P3active not recruitingFollicular Lymphoma (FL)109
Breakfree-SScNCT07335562P3recruitingSystemic Sclerosis92
ZUMA-22NCT05371093P3active not recruitingRelapsed/Refractory Follicular Lymphoma231
DESIRE MSNCT07189325P3not yet recruitingRelapsing-Remitting Multiple Sclerosis (RRMS)250
GOLSEEK-4NCT06911502P3recruitingFollicular Lymphoma400
MAHOGANYNCT05100862P3recruitingRelapsed/Refractory Follicular Lymphoma780
TRIONCT05758831P3recruitingMultiple Sclerosis386
IDARNCT05545384P3recruitingAcute Demyelinating Syndrome86
CaDAnCe-302NCT06846671P3recruitingCLL250
IGNITENCT07104032P3recruitingRelapsed/Refractory Primary Central Nervous System Lymphoma132
TAI-SHAN6NCT07139873P3recruitingChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma250
EPCORE DLBCL-2NCT05578976P3active not recruitingDiffuse Large B-Cell Lymphoma900
EPCORE FL-1NCT05409066P3active not recruitingFollicular Lymphoma (FL)549PMID 41371238
CelestimoNCT04712097P3active not recruitingRelapsed or Refractory Follicular Lymphoma478
CaDAnCe-303NCT06970743P3recruitingChronic Lymphocytic Leukemia150
GOLSEEK-1NCT06356129P3active not recruitingLarge B-cell Lymphoma850
OLYMPIA-1NCT06091254P3recruitingFollicular Lymphoma (FL)822
OLYMPIA-3NCT06091865P3recruitingDiffuse Large B-cell Lymphoma (DLBCL)904
OLYMPIA-2NCT06097364P3active not recruitingFollicular Lymphoma (FL)733
IMCOMGNCT06342544P3recruitingOcular Myasthenia Gravis128
DanNORMSNCT04688788P3active not recruitingRelapsing Remitting Multiple Sclerosis600
RITZNCT05735834P3active not recruitingSplenic Marginal Zone Lymphoma122
OLYMPIA-4NCT06230224P3active not recruitingB-Cell Non-Hodgkin Lymphoma (B-NHL)216
SATELITENCT04871191P3recruitingGranulomatosis With Polyangiitis42PMID 27338776
SYMPHONY-1NCT04224493P3active not recruitingRelapsed/Refractory Follicular Lymphoma599PMID 40896460
SAFE-LOWNCT06983821P3recruitingGranulomatosis With Polyangiitis36
OLYMPIA-5NCT06149286P3recruitingRelapsed/Refractory Follicular Lymphoma470
EVER-ILD 3NCT06549231P3recruitingInterstitial Lung Disease With Systemic Sclerosis102
THERAMAGNCT05136976P3recruitingAnti-MAG Neuropathy90
HO170DLBCLNCT06220032P3recruitingDLBCL - Diffuse Large B Cell Lymphoma324PMID 39875951
OptiMATeNCT04931368P3active not recruitingPrimary Central Nervous System Lymphoma331
ReCIXNCT06714838P3recruitingCIDP100
APG-2575NCT06319456P3recruitingCLL/SLL344
InMINDNCT04680052P3active not recruitingFollicular Lymphoma654PMID 41360064
LOTIS 5NCT04384484P3active not recruitingRelapsed Diffuse Large B-Cell Lymphoma440
EPCORE DLBCL-4NCT06508658P3active not recruitingDiffuse Large B-Cell Lymphoma379
GLOBRYTENCT06084936P3recruitingLymphoma182
REDUCE-PMR-2NCT05533164P3active not recruitingPolymyalgia Rheumatica174PMID 39400109
PRIMENCT05914155P3recruitingGlomerulonephritis, Membranous88PMID 40100934
RITUX-PLUS 2NCT05338190P3recruitingPrimary Immune Thrombocytopenia (ITP)132
frontMINDNCT04824092P3active not recruitingDiffuse Large B-cell Lymphoma899PMID 40993016
BRUIN CLL-313NCT05023980P3active not recruitingChronic Lymphocytic Leukemia309PMID 41363773
BRUIN CLL-322NCT04965493P3active not recruitingChronic Lymphocytic Leukemia600
SEQUOIANCT03336333P3active not recruitingChronic Lymphocytic Leukemia590PMID 33054121
B-NHL 2013NCT03206671P3active not recruitingMature B-cell Non-Hodgkin Lymphoma650
Noisy RebelsNCT05834855P3recruitingMultiple Sclerosis200
BRUIN CLL-321NCT04666038P3active not recruitingChronic Lymphocytic Leukemia238PMID 40479620
RITUX-MMPNCT03295383P3active not recruitingSevere Forms of Mucous Membrane Pemphigoid92
SUNMONCT05171647P3active not recruitingNon-Hodgkin Lymphoma208PMID 41037766
ESCALADENCT04529772P3active not recruitingDiffuse Large B-Cell Lymphoma611
ECHELON-3NCT04404283P3active not recruitingDiffuse Large B-cell Lymphoma239PMID 34780623
TIM-DePisTNCT05946486P3not yet recruitingMental Disorder174
STORMNCT05734794P3recruitingNephrotic Syndrome in Children80PMID 32872709
EvER-ILD2NCT05596786P3recruitingLung Diseases126PMID 39693827
POLARIXNCT03274492P3completedDiffuse Large B-Cell Lymphoma1,000PMID 35726803
RIGANCT05329090P3completedIgA Vasculitis75
REDUCE-PMR-1NCT05533125P3completedPolymyalgia Rheumatica114
OVERLORD-MSNCT04578639P3active not recruitingRelapsing Remitting Multiple Sclerosis214
REFINENCT05868837P3recruitingMyasthenia Gravis, Generalized40
DEBNCT04231448P3completedDiffuse Large B-cell Lymphoma423PMID 42018318
RIDOSE-MSNCT03979456P3unknownMultiple Sclerosis, Relapsing-Remitting200
ENDURRANCE-1NCT03942887P3unknownANCA Associated Vasculitis100PMID 36130755
CRISTALLONCT04285567P3completedChronic Lymphocytic Leukemia (CLL)166
MAINTAINNCT00877214P3active not recruitingFollicular Lymphomas1,272
POLARGONCT04182204P3completedDiffuse Large B-Cell Lymphoma270
CHRONOS-3NCT02367040P3completedLymphoma,Non-Hodgkin458PMID 33848462
MAINRITSEGNCT03164473P3completedEosinophilic Granulomatosis With Polyangiitis98
MAGNIFYNCT01996865P3completedLymphoma, Non-Hodgkin503PMID 30919940
NOR-MSNCT04121403P3completedRelapsing Multiple Sclerosis267
ILyADNCT03078855P3completedFollicular Lymphoma211PMID 39677358
RELEVANCENCT01650701P3completedFollicular Lymphoma1,030PMID 35947804
RELEVANCENCT01476787P3completedFollicular Lymphoma1,030PMID 24122387
GAIANCT02950051P3completedChronic Lymphocytic Leukemia926PMID 38821083
OPTIMAL>60NCT01478542P3completedCD20+ Aggressive B-Cell Lymphoma1,152PMID 33928400
RITURNS IINCT03899103P3completedSteroid-Dependent Nephrotic Syndrome100PMID 36456193
CIDPRITNCT06325943P3completedPolyradiculoneuropathy, Chronic Inflammatory Demyelinating37PMID 39658326
CHRONOS-4NCT02626455P3terminatedLymphoma, Non-Hodgkin551PMID 39058951
RITUXGOPRONCT03920722P3completedMicroscopic Polyangiitis (MPA)8PMID 24161361
MABRIDGENCT04680962P3withdrawnRheumatoid Arthritis0
SELENENCT01974440P3completedLymphoma403PMID 37722354
PACIFICONCT01303887P3completedFollicular Lymphoma680
BLOCAGE-01NCT02313389P3unknownPrimary Central Nervous System Lymphoma428PMID 38366824
ME-401NCT04745832P3terminatedFollicular Lymphoma (FL)82
FLINTERNCT03976102P3completedFollicular Lymphoma317PMID 40421128
TAR:GET-1NCT03994783P3terminatedKidney Transplant Rejection3
BATNCT03112603P3completedGraft-versus-host Disease (GVHD)330PMID 40561385
MURANONCT02005471P3completedChronic Lymphocytic Leukemia389PMID 35605176
ROBUSTNCT02285062P3completedLymphoma, Large B-Cell, Diffuse570PMID 33621109
RinomaxNCT02950155P3completedGeneralized Myasthenia Gravis47PMID 36121672
AUGMENTNCT01938001P3completedLymphoma, Non-Hodgkin358PMID 30897038
RIFUND-MSNCT02746744P3completedMultiple Sclerosis, Relapsing-Remitting200PMID 35841908
RO5072759NCT01332968P3completedNon-Hodgkin's Lymphoma1,401PMID 30309758
SLENCT03312907P3completedSystemic Lupus Erythematosus292PMID 30898822
SCNCT02406092P3completedNon-Hodgkin Lymphoma139
FLIRTNCT02303119P3completedFollicular Lymphoma221PMID 37071836
BRiFNCT02423837P3unknownFollicular Lymphoma200
CREHANCT01808911P3completedAcquired Haemophilia110PMID 38555718
DLBCLNCT03777085P3unknownDiffuse Large B-cell Lymphoma230
REOVASNCT02807103P3completedEosinophilic Granulomatosis With Polyangiitis (EGPA)107PMID 40720835
EvER-ILDNCT02990286P3completedLung Disease, Interstitial122PMID 37230499
RI-CYCLONCT03018535P3unknownGlomerulonephritis, Membranous76PMID 33649098
LYRITUXNCT02304354P3completedRheumatoid Arthritis70PMID 23918413
Javelin DLBCLNCT02951156P3terminatedDiffuse Large B-Cell Lymphoma29PMID 34687398
RITAZAREMNCT01697267P3completedAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis188PMID 36958796
ADVOCATENCT02994927P3completedANCA-Associated Vasculitis331PMID 35167187
MMFNCT02383589P3completedPemphigus Vulgaris135PMID 34097368
JASMINENCT02747043P3completedLymphoma, Non-Hodgkin256PMID 33044684
STARMENNCT01955187P3completedMEMBRANOUS NEPHROPATHY86PMID 34778952
TugelaNCT01569295P3completedChronic Lymphocytic Leukemia416PMID 31729982
DLBCLNCT01889069P3completedLymphoma159
LTFURITUX3NCT03790293P3completedAutoimmune Diseases80PMID 28342637
RADIO-LYMPHNCT02867553P3unknownIndolent Cutaneous B Cell Lymphomas36
(R-HAD)NCT01449344P3unknownMantle Cell Lymphoma128PMID 38678093
MCLelderlyNCT00209209P3unknownLymphoma, Mantle-Cell570PMID 22873532
RANCT02792699P3completedArthritis, Rheumatoid311PMID 32627420
PIX-RNCT01321541P3completedDiffuse Large B-cell Lymphoma312PMID 31879945
MAINRITSAN3NCT02433522P3completedANCA-associated Vasculitides97PMID 32479166
MabCuteNCT01461928P3completedNon-Hodgkin's Lymphoma692PMID 24720836
MADILYMNCT02617485P3completedDiffuse Large B-Cell Lymphoma143
GOYANCT01287741P3terminatedDiffuse Large B-Cell Lymphoma1,418PMID 38498084
ASSIST_FLNCT01419665P3completedFollicular Lymphoma629PMID 28712941
RITUXILUPNCT01773616P3terminatedSystemic Lupus Erythematosus, Lupus Nephritis24
GAINEDNCT01659099P3terminatedDiffuse Large B Cell Lymphoma CD20 Positive671PMID 33211799
RituxMENCT02229942P3completedChronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME)151PMID 30934066
SCNCT01200758P3completedNon-Hodgkin's Lymphoma410PMID 24521993
FNDNCT00577993P3completedLymphoma210
CLL11NCT02053610P3completedLymphocytic Leukemia, Chronic787PMID 29255066
CLL11NCT01998880P3completedLymphocytic Leukemia, Chronic787
CLL11NCT01010061P3completedLymphocytic Leukemia, Chronic787PMID 33131249
ITPNCT00909077P3completedIdiopathic Thrombocytopenic Purpura155
LLC2007SANCT00645606P3completedLeukemia542PMID 29275118
PLRG4NCT00801281P3completedFollicular Lymphoma250
DYNAMO + RNCT02204982P3terminatedFollicular Lymphoma13
RAMPNCT02390362P3terminatedFrequent Relapsing Nephrotic Syndrome3
Rituximab 3NCT00784589P3completedPemphigus Disease90PMID 32186656
HOMERNCT01200589P3terminatedNon-Hodgkin's Lymphoma438PMID 32810220
BRAVURANCT02576275P3withdrawnIndolent Non-Hodgkin's Lymphoma0
ASSIST-RTNCT02514772P3completedRheumatoid Arthritis107PMID 30295429
SPINOZANCT02366663P3terminatedRecurrent Diffuse Large B-Cell Lymphoma3
GEMRITUXNCT01508468P3completedIdiopathic Membranous Nephropathy80PMID 31340979
RIACTNCT01117662P3terminatedAcute Rejection13PMID 23101480
YosemiteNCT01732913P3terminatedIndolent Non-Hodgkin's Lymphomas295
BridalveilNCT01732926P3terminatedIndolent Non-Hodgkin's Lymphomas475
MAINRITSAN 2NCT01731561P3completedGranulomatosis With Polyangiitis166PMID 29695500
RAHIANCT01181154P3completedWarm Autoimmune Hemolytic Anemia32
RITULUPNCT01765842P3terminatedLupus Nephritis9
CLLNCT00718549P3completedLymphocytic Leukemia, Chronic128
BIORANCT01759030P3completedRheumatoid Arthritis181
ORCHARRDNCT01014208P3completedLymphoma, Large-Cell, Diffuse447
PETNCT01510184P3terminatedDiffuse Large B-cell Lymphoma79
CLLNCT01539512P3completedChronic Lymphocytic Leukemia220PMID 32599655
ALLNCT00327678P3completedLeukemia, Lymphocytic1,080PMID 24166518
IDEC-C2B8NCT00064116P3completedLymphoma824PMID 16648042
ITPNCT01506414P3completedPurpura91
ITPNCT01734057P3withdrawnPurpura0PMID 19005182
DLCL04NCT00499018P3unknownDiffuse Large B-Cell Lymphoma399PMID 28668386
IMAGENCT00299104P3completedRheumatoid Arthritis755PMID 20937671
SERENENCT00299130P3completedRheumatoid Arthritis511PMID 20488885
MAINRITSANNCT00748644P3completedWegener Granulomatosis117PMID 27049404
SCORENCT00578305P3completedRheumatoid Arthritis185PMID 25355728
DMARDNCT00503425P3completedRheumatoid Arthritis215
RANCT00422383P3completedRheumatoid Arthritis378PMID 20463186
SUNDIALNCT00443651P3completedRheumatoid Arthritis578PMID 23547218
LUNARNCT00282347P3completedLupus Nephritis144PMID 26867033
SuivirituxNCT01299857P3completedPemphigus22
NHLNCT01073163P3completedNon-Hodgkin's Lymphoma54
CLLNCT00090051P3completedChronic Lymphocytic Leukemia552PMID 23525797
BRNCT00877006P3completedNon-Hodgkin's Lymphoma447PMID 24591201
VOYAGERNCT00381810P3terminatedLupus Erythematosus, Systemic31
CLL-8NCT00281918P3completedLeukemia817PMID 24916506
NHLNCT01144364P3completedNon-Hodgkin's Lymphoma234PMID 23960180
RATENCT00719472P3completedNon-Hodgkin's Lymphoma451
NEMONCT00981838P3completedNephrotic Syndrome24PMID 24480824
NHLNCT00562965P3terminatedLymphoma, Follicular29
NHLNCT00088530P3completedLymphoma, Non-Hodgkin140PMID 22652183
NHLNCT00363636P3terminatedLymphoma, Non-Hodgkin's340
STARNCT00799773P3terminatedThrombotic Thrombocytopenic Purpura3
NHLNCT00384150P3terminatedLymphoma, Non-Hodgkin's16
RESETNCT01272908P3completedRheumatoid Arthritis120
ITPNCT00770562P3completedIdiopathic Thrombocytopenic Purpura103PMID 20130241
SUNRISENCT00266227P3completedRheumatoid Arthritis559
ANZINTER3NCT01148446P3completedElderly Patients (>65 Years)226PMID 29975624
BRAZANNCT06854003P2recruitingMantle Cell Lymphoma60
MT2023-20NCT06412497P2recruitingSevere Aplastic Anemia60
VIWA-1NCT05099471P2recruitingWaldenstrom Macroglobulinemia80PMID 37348018
IMCL-2023NCT07285590P2recruitingMantle Cell Lymphoma (MCL)50
PreTregNCT06688331P2recruitingPresymptomatic Diabetes Type 1 (Stage 1)150
PIONEER-MZLNCT06390956P2recruitingMarginal Zone Lymphoma23
MK-2140NCT06890884P2recruitingLymphoma, Large B-Cell, Diffuse594
SCNCT05283720P2recruitingNon-Hodgkin Lymphoma496
ZBR in WMNCT07259122P2not yet recruitingWaldenström Macroglobulinemia (WM)43
REFRACTNCT05848765P2recruitingRelapsed Follicular Lymphoma284PMID 38528445
HM2023-43NCT06792825P2recruitingFollicular Lymphoma65
HiHatNCT07517185P2not yet recruitingRelapsing-remitting Multiple Sclerosis60
EPOCH-RNCT07097363P2recruitingB-Cell Non-Hodgkin Lymphoma18
FIL_RICCONCT06835530P2recruitingDiffuse Large B Cell Non-Hodgkin Lymphoma47
CORALNCT06788964P2recruitingRelapsed or Refractory Large B-cell Lymphoma29
BRAWMNCT04624906P2active not recruitingWaldenstrom Macroglobulinemia63
REBOOTNCT03949855P2recruitingMembranous Nephropathy58PMID 33311560
GUIDANCE-10NCT07594899P2not yet recruitingLarge B-Cell Lymphoma (LBCL)178
Si-RiNCT06742502P2recruitingPrimary Mediastinal Diffuse Large B-cell Lymphoma30
ZR-MTXNCT06973811P2not yet recruitingPrimary Intraocular Lymphoma47
FLOURISHNCT07550855P2not yet recruitingFollicular Lymphoma (FL)52
MZLNCT06504940P2recruitingMarginal Zone Lymphoma69
PRIME-PCNSLNCT07350850P2recruitingPCNSL77
waveLINE-007NCT05406401P2active not recruitingLymphoma, Large B-Cell, Diffuse (DLBCL)60
ACRUENCT05952024P2recruitingDiffuse Large B-Cell Lymphoma80
TN25NCT03929601P2active not recruitingType 1 Diabetes Mellitus74PMID 39735417
FIL_COLUMNNCT05249959P2recruitingRelapsed Mantle Cell Lymphoma49
GATE1NCT06522386P2active not recruitingMantle Cell Lymphoma50
KICSNCT01419561P2recruitingKSHV Inflammatory Cytokine Syndrome (KICS)140PMID 40763275
ZillionNCT07405255P2not yet recruitingCentral Nervous System Lymphoma19
SOUND-MCLNCT07029737P2recruitingMantle-cell Lymphoma55
CARAMELNCT05004064P2recruitingMantle Cell Lymphoma48
Ra-P-OCDNCT04323566P2enrolling by invitationObsessive-Compulsive Disorder40PMID 27037228
ITPNCT07234019P2recruitingImmune Thrombocytopenia160
GOLSEEK-2NCT06425302P2active not recruitingLymphoma, Follicular90
Lemon-CNCT04627753P2recruitingPrimary CNS Lymphoma30
ZEBRANCT05635162P2recruitingMantle Cell Lymphoma50
TrAVeRseNCT05951959P2active not recruitingMantle Cell Lymphoma (MCL)108
MALTNCT06647732P2recruitingMucosa-associated Lymphoid Tissue Lymphoma (MALT)42
RR FLNCT04989621P2recruitingFollicular Lymphoma32
DA-EPOCHNCT06738368P2recruitingB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative30
EpLCARTNCT06414148P2recruitingRelapsed/Refractory Large B-cell Lymphoma40
PTLDNCT06954805P2recruitingLymphoma30
WMNCT07231952P2recruitingWaldenstrom Macroglobulinemia40
ITPNCT07362238P2recruitingImmune Thrombocytopenia122
R-Pola-GloNCT05798156P2active not recruitingLymphoma, Large B-Cell, Diffuse125
VALUABLENCT04758975P2recruitingChronic Lymphocytic Leukemia (CLL)55
ZEBRANCT06561347P2recruitingWaldenstrom Macroglobulinemia56
ITPNCT07297563P2recruitingImmune Thrombocytopenia160
DLBCLNCT07001540P2recruitingDiffuse Large B-Cell Lymphoma130
HCLNCT06561360P2recruitingHairy Cell Leukemia86
CLSGMCLPOLANCT04913103P2not yet recruitingLymphoma, Mantle-Cell21
PACIFICNCT04745949P2recruitingAnn Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma31
RENAL-F02NCT06047171P2recruitingGlomerulonephritis Rapidly Progressive80
MALIBUNCT03697512P2active not recruitingMarginal Zone Lymphoma175PMID 40550489
TOP-FLORNCT05788081P2active not recruitingFollicular Lymphoma Stage II40
STELLARNCT03899337P2recruitingRichter Syndrome105PMID 33206936
MTR²NCT05583071P2recruitingNon-Hodgkin Lymphoma20
SINAPPS2NCT03194815P2active not recruitingPsychosis70PMID 31174586
ITPNCT07362199P2recruitingImmune Thrombocytopenia20
PRNCT06263491P2recruitingMantle Cell Lymphoma50
HCTNCT05736419P2recruitingSickle Cell Disease24
ALTAMIRANCT05214183P2active not recruitingMCL81
iFCRNCT02251548P2active not recruitingChronic Lymphocytic Leukemia85PMID 38163317
RCT-RITSNCT05622201P2active not recruitingSchizophrenia Spectrum and Other Psychotic Disorders123PMID 37872497
P+R-ICENCT05221645P2active not recruitingDiffuse Large B Cell Lymphoma65
SAR445088NCT05156710P2active not recruitingTransplant Rejection48PMID 35332298
RNCT04980222P2active not recruitingLymphoma46PMID 41979332
PRONCT06530511P2recruitingDiffuse Large B Cell Lymphoma30
SScNCT03630211P2recruitingSystemic Sclerosis8
IANMDARNCT03274375P2recruitingAnti-NMDAR Encephalitis20
BallondorNCT03697356P2recruitingWaldenström's Macroglobulinemia54
CLL-SLLNCT01446133P2active not recruitingLeukemia120PMID 31076409
RMONCT05549284P2unknownPrimary Central Nervous System Lymphoma36
PORNCT05390749P2unknownPrimary Central Nervous System Lymphoma50
OVERALLNCT04920968P2recruitingCD20-positive Acute Lymphoblastic Leukemia124
PCNSLNCT04129710P2unknownRecurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)120
BV mini CHPNCT02734771P2active not recruitingDiffuse Large B-Cell Lymphoma24
ZBRNCT05914662P2recruitingWaldenstrom Macroglobulinemia42PMID 32698195
CZ-WM01NCT05979948P2unknownWaldenström's Macroglobulinemia60
ZR2NCT04460248P2active not recruitingDiffuse Large B Cell Lymphoma40PMID 40829156
PIMOCNCT03651518P2completedInflammatory Disease32
ZRNCT05504603P2unknownUntreated Mantle Cell Lymphoma20
AGRAF-2NCT05682196P2suspendedRheumatic Heart Disease in Children234
ZR2-CHOPNCT05200312P2unknownNon Hodgkin Lymphoma36PMID 41136989
PCRNCT05115409P2unknownRelapsed or Refractory DLBCL27
CNSNCT01011920P2completedCentral Nervous System Lymphoma227PMID 27132696
FIORELLANCT03495960P2completedPrimary Central Nervous System Lymphoma72
ZFCR/ZBRNCT05287984P2unknownChronic Lymphocytic Leukemia63PMID 31208944
PMMNNCT03804359P2completedIdiopathic Membranous Nephropathy68PMID 25457107
VEGANCT05564052P2completedLymphoma, Mantle-Cell36
PrE0405NCT03834688P2completedMantle Cell Lymphoma33
RelyageNCT04113226P2completedChemotherapy1
CLL1818NCT03804372P2terminatedLarge-B-cell Diffuse Lymphoma5PMID 33559286
LLC1114NCT02232386P2completedChronic Lymphocyte Leukemia156PMID 35913400
PembroWMNCT03630042P2completedWaldenstrom Macroglobulinemia17
BLNCT05049473P2unknownMature B-Cell Leukemia Burkitt Type100PMID 37560813
LOTIS-9NCT05144009P2terminatedDiffuse Large B-cell Lymphoma41
COMBIVASNCT03967925P2unknownANCA Associated Vasculitis31PMID 36906660
BIOVASNCT05168475P2terminatedGiant Cell Arteritis22
RIFIREINSNCT03970577P2unknownMinimal Change Nephrotic Syndrome (MCNS)148PMID 41563842
RTXvsMMFNCT04585152P2unknownNephrotic Syndrome Steroid-Dependent160PMID 34845071
IELSG30NCT00945724P2completedLarge B-cell Diffuse Lymphoma of Testis54PMID 38181782
PTISNCT05293509P2withdrawnStem Cell Transplantation0
PTLDNCT02753062P2unknownDiffuse Large B Cell Lymphoma22
LEGENDNCT02060656P2unknownDiffuse Large B-Cell Lymphoma92
C-R-HDMTXNCT04516655P2unknownCentral Nervous System Lymphoma51PMID 30008379
VeRitAsNCT03455517P2completedChronic Myeloid Leukemia77PMID 36632738
R2DLBCL80NCT04622579P2unknownDiffuse Large B Cell Lymphoma20
CORALNCT05209308P2withdrawnCLL0
WMNCT04062448P2completedWaldenstrom Macroglobulinemia16
ZUMA-14NCT04002401P2completedRefractory Large B-cell Lymphoma27PMID 41492094
RTXFIRPedINSNCT04783675P2completedSteroid-Sensitive Nephrotic Syndrome44
RIPPLENCT04246359P2unknownLymphoma, B-Cell52
PKNCT04660799P2completedLymphoma, Large B-Cell, Diffuse50PMID 39773004
CLLNCT01199575P2completedChronic Lymphocytic Leukemia30
PTLD-2NCT02042391P2completedPosttransplant Lymphoproliferative Disorder60PMID 35974101
MG4101NCT03578198P2terminatedCD20-positive Non-Hodgkin Lymphoma12
RITS-PS-2019NCT03983018P2completedSchizophrenia Spectrum and Other Psychotic Disorders9PMID 39350952
INCANCT01679119P2completedDiffuse Large B Cell Lymphoma129
SYMPHONY-2NCT04762160P2terminatedFollicular Lymphoma5
LYTPETNCT00324467P2unknownLymphoma, Non-Hodgkin150PMID 15266320
PNEUMOVASNCT03069703P2completedInvasive Pneumococcal Infection96PMID 23851398
ARGONCT03422523P2terminatedDiffuse Large B Cell Lymphoma53
CKDNCT02966717P2unknownRenal Insufficiency, Chronic116
DA-EPOCH-RNCT01030900P2completedHodgkin Lymphoma50
ICFEr-RITU2NCT03332888P2unknownHeart Failure With Reduced Ejection Fraction10PMID 30918029
REBOOTNCT01859819P2completedDiffuse Large Cell Lymphoma45PMID 33941850
FCRNCT01723839P2completedChronic Lymphocytic Leukemia (CLL)21PMID 16357183
RECIPENCT03864185P2completedChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)25PMID 32234705
Fol-BRITeNCT01234766P2completedLymphoma, Follicular39
Lymvac-2NCT02677155P2completedFollicular Lymphoma10
R-FNDNCT00290511P2completedLymphoma49
OAMLNCT01427114P2completedLymphoma33PMID 28978139
ThRiLNCT01125176P2completedChronic Lymphocytic Leukemia15
versusNCT04189588P2completedOncology Patients Receiving Chemotherapy34PMID 34555839
ART-IPFNCT01969409P2completedAmbulatory IPF58
R2WNCT01592981P2completedWaldenstrom's Macroglobulinaemia60
FIL_BRBNCT02371148P2completedWaldenstrom's Macroglobulinemia38
CLLNCT00759798P2completedChronic Lymphocytic Leukemia289PMID 24705492
ROOTSNCT03054259P2unknownSystemic Lupus Erythematosus Arthritis30
MAN2NCT02267915P2unknownMantle-cell Lymphoma36
TORCHNCT02752204P2completedDiffuse Large B-Cell Lymphoma36
R2NCT01939327P2completedNon-Hodgkin Lymphoma34
PHILEMONNCT02460276P2completedRelapsed/Refractory Mantle Cell Lymphoma50PMID 29396091
ICORGNCT00812669P2completedLeukemia52PMID 28925785
BRNCT02433795P2completedMarginal Zone B-cell Lymphoma27
IRISNCT01514344P2completedOcular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma20PMID 32182364
EFFRITENCT02545959P2completedMultiple Sclerosis, Chronic Progressive10PMID 24417802
CLLNCT02481297P2completedLeukemia7
SCTNCT01490723P2completedLeukemia20
CALIBRATENCT02260934P2completedLupus Nephritis43PMID 32755035
RADICALNCT01429610P2unknownPrecursor Cell Lymphoblastic Leukemia-Lymphoma78PMID 37334511
CyBeR-LymphNCT02758925P2unknownDiffuse Large B Cell Lymphoma78PMID 23753028
SYNBIoSeNCT02284984P2completedLupus Erythematosus, Systemic16PMID 29636274
WMNCT01813227P2completedWaldenstrom Macroglobulinemia7
ESHAPNCT00732498P2completedLymphoma28
CLLNCT00899431P2terminatedChronic Lymphocytic Leukemia39
VCRNCT00980395P2completedLymphoma24PMID 29056470
B-R-ENDANCT01686321P2completedAggressive Lymphoma68
STORMNCT01653067P2unknownDiffuse Large B-Cell Lymphoma88PMID 23799873
ESBAMNCT02556866P2terminatedCryoglobulinemia14
SGN-CD19ANCT02855359P2terminatedDiffuse, Large B-Cell, Lymphoma24
SGN-CD19ANCT02592876P2terminatedLymphoma, B-cell81
ALLNCT01134575P2completedAcute Lymphoblastic Leukemia90PMID 38551807
GDC-0199NCT02187861P2completedFollicular Lymphoma163PMID 32785666
Hi-CHOPNCT03485118P2completedDiffuse Large B-cell Lymphoma137
REVRINCT01956695P2completedLymphoma45PMID 30698644
BRIEFNCT01313611P2terminatedFollicular Lymphoma62PMID 30117149
G-CSFNCT01097057P2completedNon-Hodgkin Lymphoma20
ZAR2007NCT00662948P2completedLymphoma149PMID 34459702
CLLNCT00254410P2completedChronic Lymphocytic Leukemia30
FIL-RBAC500NCT01662050P2completedMantle Cell Lymphoma57PMID 27927586
DLBCLNCT01676558P2unknownRelapsed or Refractory Diffuse Large B Cell Lymphoma24
S-BRNCT02623920P2withdrawnDiffuse Large B Cell Lymphoma0
DLBCLNCT01925612P2terminatedLymphoma, B-cell87
R2-BNCT01737177P2completedMantle Cell Lymphoma42
GM-CSFNCT00940342P2completedLeukemia130
CAD5NCT02689986P2completedCold Agglutinin Disease43PMID 28533306
LBH589NCT01238692P2completedDiffuse Large B Cell Lymphoma42PMID 27166360
FRESCONCT02605694P2withdrawnLymphoma0
RITPBCNCT02376335P2completedFatigue71PMID 29790196
CaRDNCT01470196P2completedWaldenstrom's Macroglobulinemia31PMID 24859363
PrE0401NCT01889797P2terminatedIndolent Non-Hodgkin's Lymphoma32PMID 20194898
DLBCLNCT02531308P2terminatedDiffuse Large B-Cell Lymphoma5
NKNCT01181258P2completedNon-Hodgkin Lymphoma16PMID 29218366
DLBCLNCT01453205P2completedDiffuse Large B-Cell Lymphoma187
ITT-PMSNCT01719159P2completedProgressive Multiple Sclerosis23PMID 27536708
R-CHOPNCT00450385P2terminatedLymphoma57
CLLNCT00545714P2completedLeukemia, Lymphocytic, Chronic, B-Cell86PMID 30890600
CNSNCT02113007P2terminatedPrimary Central Nervous System Lymphoma2
BMRNCT00901927P2terminatedFollicular Lymphoma14
CLLNCT01466153P2completedChronic Lymphocytic Leukemia (CLL)183
RBNCT01127841P2unknownFollicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.60
FIZZNCT01493479P2completedFollicular Lymphoma76PMID 24297953
WMNCT00422799P2completedWaldenstrom's Macroglobulinemia63PMID 20142586
MZLNCT01213095P2completedLymphoma48PMID 31619290
ManteauRiBVDNCT00740415P2completedLymphoma39
CLLNCT02420938P2withdrawnLeukemia0
GVHDNCT01161628P2completedChronic Graft-versus-host Disease25PMID 10929168
PTLD-1/3NCT00590447P2completedPTLD152PMID 27992268
LLCRlowdozNCT01521689P2unknownChronic Lymphocytic Leukemia35
HYDRICNCT01625741P2terminatedChronic Lymphocytic Leukemia6
GATEWAYIINCT01569451P2completedMultiple Sclerosis53PMID 30635477
RGemOxNCT01562977P2completedAggressive Lymphoma82
MOADNCT00905034P2completedLeukemia, Lymphocytic, Acute37
SCTNCT01279616P2terminatedSickle Cell Disease8
FLE09NCT01523860P2completedFollicular Lymphoma76PMID 33476434
FRAIL-06NCT00911183P2completedLymphoma67
GM-CSFNCT00381004P2completedChronic Lymphocytic Leukemia60
CLLNCT02533401P2completedLymphocytic Leukemia, Chronic34
Lymvac-1NCT01926639P2completedFollicular Lymphoma14PMID 25293773
RNCT01830478P2unknownIndolent Non Hodgkin Lymphoma44
CLLNCT00448019P2completedChronic Lymphocytic Leukemia64PMID 25043749
CLLNCT01754870P2withdrawnChronic Lymphocytic Leukemia (CLL)0
B-ALLNCT01290120P2completedBurkitt Lymphoma182PMID 23753030
THRiL for WMNCT01779167P2terminatedWaldenstrom Macroglobulinemia4
R-GVHDNCT01135641P2completedGraft Versus Host Disease25PMID 28864814
Mz-135NCT02099292P2completedRelapsed Non-Hodgkin-Lymphoma103
NAVIGATENCT01423539P2withdrawnDiffuse Large B-Cell Lymphoma0
ZBEAM2NCT00689169P2completedLymphoma, Large Cell, Diffuse75PMID 25072780
MALTNCT01015248P2completedMALT LYMPHOMA60PMID 27029228
904NCT00831597P2completedDiffuse Large B-Cell Lymphoma61PMID 23955074
PTTrituxNCT00907751P2completedThrombotic Thrombocytopenic Purpura12PMID 27643485
Pento & tBUNCT00496340P2completedHematologic Malignancies42
BDR-WMNCT00832234P2completedWaldenstroms Macroglobulinemia59
MIRNCT00509184P2completedLymphoma, Malignant85PMID 31723798
RO5072759NCT00576758P2completedNon-Hodgkin's Lymphoma175PMID 26282650
RITAPSNCT00537290P2completedAntiphospholipid Syndrome19PMID 23124321
RIPSNCT00855205P2completedSarcoidosis10PMID 24488568
RANCT02093026P2completedRheumatoid Arthritis465
R-GEMOXNCT00169195P2completedDiffuse Large Cell Lymphoma49PMID 10907954
CMC-544NCT00867087P2completedLymphoma, B-Cell64
CLLNCT02013817P2completedLymphocytic Leukemia, Chronic43
CLLNCT01087151P2completedChronic Lymphocytic Leukemia118
R-BACNCT00992134P2completedLymphoma, Mantle-Cell41PMID 23401442
Z-BEAM LDGGBNCT00646750P2completedNon-Hodgkin's Lymphoma31
R-CHOPNCT00504491P2withdrawnChronic Lymphocytic Leukaemia0
R-COMPNCT01009970P2unknownDiffuse Large B-Cell Lymphoma50
SIERRANCT00282308P2completedRheumatoid Arthritis103PMID 20039397
FRNCT00860457P2completedChronic Lymphocytic Leukemia22
NHL-14NCT00575406P2completedDiffuse Large B-Cell Lymphoma94
RICHNCT00331006P2completedHemophilia A23
PERLLNCT00927797P2unknownImmunocytoma/Morbus Waldenström185
DLBCLNCT00968331P2terminatedDiffuse Large B-cell Lymphoma25
FORCENCT00774462P2completedMyositis30PMID 26539981
PAPNCT00552461P2completedPulmonary Alveolar Proteinosis10PMID 21478218
PTLDNCT01458548P2terminatedPost-transplantation Lymphoproliferative Disorder70PMID 22173060
PRIMAINNCT00989352P2unknownPrimary Non Hodgkin Lymphoma of the Central Nervous System56PMID 27843136
MALTNCT00656812P2completedLymphoma of Mucosa-Associated Lymphoid Tissue40
CLLNCT00628238P2unknownChronic Lymphocytic Leukemia80PMID 16750498
ITPNCT00372892P2completedPurpura, Thrombocytopenic, Idiopathic60PMID 22223819
CLLNCT00309881P2completedChronic Lymphocytic Leukemia75PMID 25196783
PCRNCT01001780P2withdrawnActive Chronic Graft Versus Host Disease0
LYM-2023NCT00509379P2completedLymphoma48
VRCDNCT00413959P2terminatedLymphoma, Non-Hodgkin12
CFARNCT01082939P2completedChronic Lymphocytic Leukemia80
DLBCLNCT00568815P2completedLymphoma31
CVNCT00849355P2unknownNo Hodgkin B Lymphoma44
NKNCT00536978P2completedLymphoma22
August IIINCT00664521P2completedRheumatoid Arthritis27PMID 26137975
DMNCT00106184P2completedMyositis200PMID 23124935
CLLNCT00758693P2withdrawnChronic Lymphocytic Leukemia0
TTPNCT00937131P2completedThrombotic Thrombocytopenic Purpura (TTP)40PMID 21636861
RANCT00422942P2terminatedRheumatoid Arthritis3
VERTICALNCT00636792P2completedFollicular Lymphoma73
CLLNCT00290407P2terminatedLeukemia, Lymphocytic, Chronic2
LT-CLL-001NCT00558181P2completedChronic B-Lymphocytic Leukemia29
TN05NCT00279305P2completedType 1 Diabetes Mellitus87PMID 19940299
BVRNCT00547534P2completedNon-Hodgkin's Lymphoma31PMID 21239695
GX15-070MSNCT00427856P2completedLymphoma, Follicular7
PREMIERNCT00308087P2terminatedLymphoma, Follicular75
NHLNCT00444912P2completedNon-Hodgkin Lymphoma30
GM-CSFNCT00896519P2unknownLymphoma30
RUMBANCT00243412P2completedRheumatoid Arthritis42
DLBCLNCT01054781P2completedDiffuse Large B-cell Lymphoma (DLBCL)91PMID 36996864
RAPTURENCT00371904P2unknownKidney Transplantation192
MMFNCT00446251P2completedKidney Failure, Chronic14PMID 11549905
GROCNCT01538641P2completedRefractory Aggressive Non-Hodgkin's Lymphoma43
S0629NCT00723658P2withdrawnLymphoma0
CHOPNCT00204659P2completedPrimary Gastric Diffuse-Large B-Cell Lymphoma30
NHLNCT00076349P2completedNon-Hodgkin's Lymphoma66
R-ESHAPNCT00367497P2terminatedLymphoma, Non-Hodgkin5
CLLNCT00086203P2completedChronic Lymphocytic Leukemia0
IL-2NCT00250861P2terminatedNon-Hodgkin's Lymphoma110
Rituximab GVHDNCT00578591P2withdrawnGraft vs Host Disease0
BORIDNCT00261612P2unknownLymphoma, Mantle-Cell16PMID 21486866
DLBCLNCT00556127P2completedDiffuse Large B-Cell Lymphoma94
RIPLNCT00346684P2completedLymphocyte Predominant Hodgkin´s Lymphoma (LPHD)0PMID 31636342
NHLNCT00333008P2unknownDiffuse Large B Cell Lymphoma27
LISTNCT00230035P2withdrawnSystemic Lupus Erythematosus0PMID 12428232
SLENCT00293072P2completedSystemic Lupus Erythematosus20
IL-2NCT00100737P2terminatedNon-Hodgkin Lymphoma300
CHOPNCT00126243P2terminatedAIDS Related Lymphoma60

Terminated and withdrawn Rituximab trials (374)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

All Rituximab trials (2053)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT04196413DIPGGD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)P1recruiting97Stanford UniversityJun 2020
NCT06973096CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial RadiotherapyP1recruiting9University of PennsylvaniaJul 2025
NCT06986382Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn DiseaseP1/P2not yet recruiting14Stanford UniversityJul 2025
NCT06854003BRAZANBRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaP2recruiting60Christine RyanApr 2025
NCT05934097FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaP1withdrawn0Fate TherapeuticsDec 2022
NCT05976763Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaP3recruiting421Alliance for Clinical Trials in OncologyOct 2023
NCT06191744EPCORE™FL-2Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaP3recruiting1,095GenmabFeb 2024
NCT07220187Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID TrialP3not yet recruiting102SWOG Cancer Research NetworkAug 2026
NCT06412497MT2023-20MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.P2recruiting60Masonic Cancer Center, University of MinnesotaJun 2024
NCT05947851VRA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).P3recruiting735Merck Sharp & Dohme LLCAug 2023
NCT05508009Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same DonorP1/P2recruiting12Alice BertainaJan 2023
NCT04849715CITADEL-310A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell LymphomaP3withdrawn0Incyte CorporationMar 2022
NCT04669171SIDNEYA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin LymphomaP1/P2recruiting80EnteromeJul 2021
NCT06284122MorningLyteStudy of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5P3recruiting790The Lymphoma Academic Research OrganisationJun 2024
NCT03361852Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular LymphomaP1active not recruiting20Dana-Farber Cancer InstituteMar 2022
NCT03418038Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaP2recruiting80Mayo ClinicMar 2018
NCT07520006Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesP1/P2not yet recruiting150Nurix Therapeutics, Inc.May 2026
NCT05991388Glo-BNHLA Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaP2/P3recruiting210University of BirminghamMay 2024
NCT05867030Parsaclisib in Patients With Relapsed or Refractory Follicular LymphomaP1withdrawn0Innovent Biologics (Suzhou) Co. Ltd.Jul 2023
NCT05099471VIWA-1Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaP2recruiting80Christian BuskeMar 2025
NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasP1/P2recruiting48University of California, San DiegoFeb 2026
NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaP2recruiting50Sun Yat-sen UniversityApr 2025
NCT06824701TARZANTazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin LymphomaP1suspended24University of UtahSep 2025
NCT07285590IMCL-2023Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell LymphomaP2recruiting50Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaSep 2025
NCT06688331PreTregTreatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 AntibodyP2recruiting150PolTREG S.A.Mar 2025
NCT06390956PIONEER-MZLPirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)P2recruiting23University of UtahFeb 2025
NCT06890884MK-2140A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)P2recruiting594Merck Sharp & Dohme LLCApr 2025
NCT05533775iMATRIX GLOA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaP1/P2recruiting65Hoffmann-La RocheNov 2022
NCT05283720SCA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaP2recruiting496GenmabJun 2022
NCT06644183IOA-244Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)P1/P2recruiting64Jennifer R. Brown, MD, PhDMar 2025
NCT06006117Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaP3recruiting260The Lymphoma Academic Research OrganisationSep 2023
NCT06655896Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisP2recruiting96Novartis PharmaceuticalsOct 2024
NCT04796922FLTo Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)P3withdrawn0Incyte CorporationDec 2022
NCT07137481Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological MalignanciesP2not yet recruiting70M.D. Anderson Cancer CenterFeb 2027
NCT06839053Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell LymphomaP2recruiting30Fred Hutchinson Cancer CenterJun 2025
NCT07259122ZBR in WMA Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström MacroglobulinemiaP2not yet recruiting43Institute of Hematology & Blood Diseases Hospital, ChinaDec 2025
NCT06363994A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLP3recruiting476InnoCare Pharma Inc.May 2024
NCT05389423Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasP1recruiting25National Cancer Institute (NCI)Jun 2023
NCT06040320RPolatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)P1/P2recruiting12Washington University School of MedicineOct 2023
NCT05898308RITUX4Comparison of a Personalized Maintenance Therapy With the Standard Treatment in PemphigusP4recruiting133University Hospital, RouenDec 2024
NCT07294677CAVALRYCApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLP1/P2recruiting104University of ChicagoMar 2026
NCT06337318Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaP3recruiting600National Cancer Institute (NCI)Oct 2024
NCT06717347MK-2140A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)P3recruiting1,046Merck Sharp & Dohme LLCJan 2025
NCT07509840REFINEImmunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian InsufficiencyP3recruiting40Angelica Lindén HirschbergFeb 2026
NCT06943872CELESTIAL-RRCLLA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)P3recruiting630BeOne MedicinesJun 2025
NCT06247540Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaP2withdrawn0Northwestern UniversityMar 2024
NCT04231877Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell LymphomaP1recruiting56University of WashingtonOct 2020
NCT05848765REFRACTRelapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyP2recruiting284University of BirminghamSep 2023
NCT06313996A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular LymphomaP3withdrawn0Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyMar 2024
NCT06205290A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesP3withdrawn0Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyJan 2024
NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaP2recruiting33Gottfried von Keudell, MD PhDFeb 2026
NCT06341205iRITUXPersonalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)P3recruiting120Centre Hospitalier Universitaire de NiceFeb 2025
NCT04002297MANGROVEA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationP3active not recruiting510BeOne MedicinesAug 2019
NCT01415752Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell LymphomaP2active not recruiting373Eastern Cooperative Oncology GroupAug 2012
NCT06792825HM2023-43HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLP2recruiting65Masonic Cancer Center, University of MinnesotaAug 2025
NCT07573436PLUTOLoncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)P1/P2not yet recruiting23University of UtahJun 2026
NCT07208981Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLP2recruiting169The First Affiliated Hospital with Nanjing Medical UniversityAug 2025
NCT05453500Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic LeukemiaP2active not recruiting32University of WashingtonMar 2023
NCT07299331Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone LymphomaN/Anot yet recruiting50Zhengzhou UniversityJan 2026
NCT07415980Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCLP1/P2not yet recruiting68Sun Yat-sen UniversityApr 2026
NCT05605899ZUMA-23Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell LymphomaP3active not recruiting300Kite, A Gilead CompanyFeb 2023
NCT04002947Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaP2recruiting132National Cancer Institute (NCI)Aug 2019
NCT05624554A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)P3active not recruiting300Merck Sharp & Dohme LLCMar 2023
NCT05888493LEDAA Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular LymphomaP3active not recruiting109Novartis PharmaceuticalsOct 2023
NCT02339922Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaP2active not recruiting33University of WashingtonMay 2016
NCT07517185HiHatThe HIt HArd and hiT Early in Multiple Sclerosis TrialP2not yet recruiting60Uppsala UniversityApr 2026
NCT06682169Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host DiseaseP3recruiting182Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Nov 2024
NCT06664411Pola-ZR2P in Previously Untreated DLBCLP2recruiting80Navy General Hospital, BeijingSep 2024
NCT05900401Delayed Tolerance Through Mixed ChimerismP1/P2active not recruiting20Massachusetts General HospitalOct 2023
NCT06607549SOLARLoncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)P1recruiting12University of UtahMar 2025
NCT05735717MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesP2recruiting70Masonic Cancer Center, University of MinnesotaMay 2023
NCT07257055Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 StudyP2recruiting30M.D. Anderson Cancer CenterApr 2026
NCT07335562Breakfree-SScA Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisP3recruiting92Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyAug 2026
NCT05371093ZUMA-22Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaP3active not recruiting231Kite, A Gilead CompanySep 2022
NCT06047080An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaP3active not recruiting1,130Hoffmann-La RocheSep 2023
NCT07255963Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCLP2recruiting29The First Affiliated Hospital of Soochow UniversityNov 2025
NCT07189325DESIRE MSA Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple SclerosisP3not yet recruiting250University Hospital, MontpellierSep 2025
NCT04518475ITPEltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in AdultsP4recruiting224Institute of Hematology & Blood Diseases Hospital, ChinaAug 2020
NCT06905509Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell LymphomaP2recruiting25Joseph TuscanoJul 2025
NCT04998669Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular LymphomaP2recruiting100Juan P. Alderuccio, MDFeb 2022
NCT06911502GOLSEEK-4A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)P3recruiting400CelgeneJul 2025
NCT06045247Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell LymphomaP2recruiting40M.D. Anderson Cancer CenterJan 2024
NCT05058404Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular LymphomaP3active not recruiting605Fondazione Italiana Linfomi - ETSDec 2021
NCT04318678CATCHAMLCD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)P1recruiting108St. Jude Children's Research HospitalJul 2020
NCT06364423Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for LeukemiasP1/P2recruiting132National Cancer Institute (NCI)Sep 2024
NCT07233720Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphomarecruiting30Henan Cancer HospitalNov 2025
NCT05100862MAHOGANYA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaP3recruiting780BeOne MedicinesMar 2022
NCT04843904SAVESafe Accelerated Venetoclax Escalation in CLLP1active not recruiting40Dana-Farber Cancer InstituteApr 2021
NCT07010302BEST-NMOSDRituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDP4not yet recruiting540Massachusetts General HospitalMay 2026
NCT07097363EPOCH-REpcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaP2recruiting18University of WashingtonDec 2025
NCT05758831TRIORItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.P3recruiting386Rennes University HospitalJun 2023
NCT05545384IDARImmediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical TrialP3recruiting86Assistance Publique - Hôpitaux de ParisApr 2025
NCT06730542Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS LymphomaP1recruiting20Juan P. Alderuccio, MDApr 2025
NCT06835530FIL_RICCOA Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)P2recruiting47Fondazione Italiana Linfomi - ETSApr 2025
NCT01661881Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell LymphomaP2active not recruiting23Christine RyanAug 2012
NCT07578077Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaP1/P2not yet recruiting58City of Hope Medical CenterDec 2026
NCT06788964CORALLoncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)P2recruiting29University of UtahAug 2025
NCT04624906BRAWMBendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaP2active not recruiting63Sunnybrook Health Sciences CentreMar 2021
NCT06336395Ma-Spore ALL 2020 StudyP2recruiting500National University Hospital, SingaporeMar 2020
NCT04061512RAINBOWRituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaP2/P3recruiting148University College, LondonFeb 2020
NCT06015750RESTOREMitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for HypophosphatasiaP4withdrawn0Alexion Pharmaceuticals, Inc.Jul 2026
NCT06965114Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaP1/P2recruiting84National Cancer Institute (NCI)May 2026
NCT06563596Epco, Zanu, Ritux for R/R FL or MZLP2recruiting45Reid Merryman, MDJan 2025
NCT03949855REBOOTBelimumab With Rituximab for Primary Membranous NephropathyP2recruiting58National Institute of Allergy and Infectious Diseases (NIAID)Mar 2020
NCT07226843A Study of LY4584180 in Adult Participants With Previously Treated Blood CancersP1recruiting460Eli Lilly and CompanyApr 2026
NCT07451847PREP-ANCAComparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.P4not yet recruiting70Assistance Publique - Hôpitaux de ParisFeb 2026
NCT05783609Epcoritamab and Rituximab for First-line Follicular LymphomaP2recruiting100Reid Merryman, MDJun 2023
NCT06082102Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaP3recruiting324Beijing InnoCare Pharma Tech Co., Ltd.Dec 2023
NCT06846671CaDAnCe-302A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsP3recruiting250BeOne MedicinesApr 2025
NCT00923013Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell LeukemiaP2active not recruiting175National Cancer Institute (NCI)Oct 2008
NCT07448324Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLP2recruiting50The First Affiliated Hospital with Nanjing Medical UniversityApr 2025
NCT07104032IGNITEIGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)P3recruiting132Ono Pharmaceutical Co., Ltd.Jun 2026
NCT07594899GUIDANCE-10AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLP2not yet recruiting178Ruijin HospitalMay 2026
NCT07410520PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.P2recruiting50The First Affiliated Hospital with Nanjing Medical UniversityFeb 2026
NCT07418190Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaP2recruiting33The First Affiliated Hospital with Nanjing Medical UniversityFeb 2026
NCT07051915The Holistic StudyP3not yet recruiting220Ostfold Hospital TrustSep 2025
NCT07139873TAI-SHAN6A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)P3recruiting250Dizal PharmaceuticalsSep 2025
NCT06521255Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaP3recruiting244Beijing InnoCare Pharma Tech Co., Ltd.May 2024
NCT06251180Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaP1recruiting112Guangzhou Lupeng Pharmaceutical Company LTD.Apr 2024
NCT06190301RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT LymphomaN/Arecruiting108Zhongshan Ophthalmic Center, Sun Yat-sen UniversityDec 2023
NCT06119685IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersP1/P2recruiting128Indapta Therapeutics, INC.Oct 2023
NCT05645718Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaP2recruiting27M.D. Anderson Cancer CenterJul 2023
NCT05578976EPCORE DLBCL-2A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)P3active not recruiting900GenmabFeb 2023
NCT06134284Clinical Study of OR for Second-line Treatment of Refractory MZLP4recruiting39Lixia ShengJan 2023
NCT05409066EPCORE FL-1Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular LymphomaP3active not recruiting549GenmabSep 2022
NCT04712097CelestimoA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaP3active not recruiting478Hoffmann-La RocheOct 2021
NCT04745728Different Immunosuppressive Treatment in iMNP3recruiting200Peking Union Medical College HospitalApr 2021
NCT02682641Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCLP2active not recruiting50Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaMay 2016
NCT02405676BNHL-2015BNHL-2015 for Children or Adolescents in ChinaP2/P3active not recruiting200Children's Cancer Group, ChinaJan 2015
NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLP2recruiting50Ou Bai, MD/PHDApr 2026
NCT07389356Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCLN/Anot yet recruiting70The First Affiliated Hospital with Nanjing Medical UniversityFeb 2026
NCT06742502Si-RiSintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBLP2recruiting30Sun Yat-sen UniversityNov 2024
NCT07034508A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1P2not yet recruiting134Institute of Hematology & Blood Diseases Hospital, ChinaJun 2025
NCT06946407Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System LymphomaN/Arecruiting41FengYan JinDec 2022
NCT04989491REPLYEvaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney AllograftP4recruiting120University Hospital, Strasbourg, FranceDec 2021
NCT06970743CaDAnCe-303A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsP3recruiting150BeOne MedicinesMay 2025
NCT06356129GOLSEEK-1Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaP3active not recruiting850CelgeneJun 2024
NCT06091254OLYMPIA-1A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaP3recruiting822Regeneron PharmaceuticalsDec 2023
NCT06973811ZR-MTXZR-MTX for PIOL Phase II TrialP2not yet recruiting47Peking Union Medical College HospitalMay 2025
NCT07124936A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell LymphomaP1/P2recruiting97Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Jul 2025
NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaP2recruiting43City of Hope Medical CenterApr 2026
NCT07550855FLOURISHSonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular LymphomaP2not yet recruiting52Sun Yat-sen UniversitySep 2026
NCT07608731Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS LymphomasP1not yet recruiting18Allison WinterJun 2026
NCT05800366A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaP2recruiting41Jennifer Crombie, MDApr 2023
NCT06091865OLYMPIA-3A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaP3recruiting904Regeneron PharmaceuticalsDec 2023
NCT07022223Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone LymphomaP2recruiting51Second Affiliated Hospital, School of Medicine, Zhejiang UniversityMar 2025
NCT06554561A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System LymphomaP1/P2recruiting43Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAug 2024
NCT06522555The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaP3recruiting100Ruijin HospitalJul 2024
NCT07588698Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin LymphomaP2not yet recruiting20Mwanasha Merrill, MDJul 2026
NCT07185373Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSLP2/P3not yet recruiting215Huashan HospitalOct 2025
NCT06097364OLYMPIA-2A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular LymphomaP3active not recruiting733Regeneron PharmaceuticalsNov 2023
NCT06504940MZLOptimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)P2recruiting69First Affiliated Hospital of Zhejiang UniversityJun 2024
NCT07562022A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaP3not yet recruiting93Sinocelltech Ltd.May 2026
NCT07350850PRIME-PCNSLA Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSLP2recruiting77Tongji HospitalDec 2025
NCT06342544IMCOMGImmediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.P3recruiting128Fondation Ophtalmologique Adolphe de RothschildApr 2025
NCT06792253Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaP3recruiting416BeBetter Med IncJan 2025
NCT06564038Soundtrack-EA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesP1/P2recruiting408AstraZenecaJan 2025
NCT04688788DanNORMSNon-inferiority Study of Ocrelizumab and Rituximab in Active Multiple SclerosisP3active not recruiting600Rigshospitalet, DenmarkApr 2021
NCT05864742Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaP2active not recruiting40Peter MacCallum Cancer Centre, AustraliaSep 2023
NCT05735834RITZComparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL PatientsP3active not recruiting122International Extranodal Lymphoma Study Group (IELSG)May 2024
NCT05303792Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic LymphomaP2active not recruiting68Alliance for Clinical Trials in OncologyJun 2023
NCT06230224OLYMPIA-4A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaP3active not recruiting216Regeneron PharmaceuticalsFeb 2024
NCT06942507BRZ-WMZanubrutinib Combined With BR in the First-line Treatment of Waldenström's MacroglobulinemiaN/Anot yet recruiting104Peking Union Medical College HospitalMay 2025
NCT05406401waveLINE-007A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)P2active not recruiting60Merck Sharp & Dohme LLCJul 2022
NCT05952024ACRUEStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLP2recruiting80AstraZenecaJul 2024
NCT04882163CC-220Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaP1/P2withdrawn0CelgeneOct 2021
NCT06516978A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLP2not yet recruiting528The First Affiliated Hospital with Nanjing Medical UniversityOct 2024
NCT06188676Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBLP3recruiting100National Research Center for Hematology, RussiaApr 2022
NCT04871191SATELITEStudy of Salvage Therapy to Treat Patients With Granulomatosis With PolyangiitisP3recruiting42Assistance Publique - Hôpitaux de ParisJun 2025
NCT06350318Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasP2recruiting43H. Lee Moffitt Cancer Center and Research InstituteApr 2024
NCT03929601TN25Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 DiabetesP2active not recruiting74National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Oct 2023
NCT05249959FIL_COLUMNConsolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.P2recruiting49Fondazione Italiana Linfomi - ETSMar 2022
NCT03414502Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseP3recruiting400University of NebraskaDec 2007
NCT06918431Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaP2recruiting53City of Hope Medical CenterOct 2025
NCT07029139A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous NephropathyP2not yet recruiting156Shanghai JMT-Bio Inc.Jun 2025
NCT04224493SYMPHONY-1A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.P3active not recruiting599Epizyme, Inc.Jun 2020
NCT07187960Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular LymphomaP3not yet recruiting228Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Nov 2025
NCT06983821SAFE-LOWSafe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)P3recruiting36Ottawa Hospital Research InstituteNov 2025
NCT06522386GATE1GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaP2active not recruiting50M.D. Anderson Cancer CenterJan 2025
NCT06149286OLYMPIA-5A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaP3recruiting470Regeneron PharmaceuticalsDec 2023
NCT06549231EVER-ILD 3Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic SclerosisP3recruiting102University Hospital, ToursJan 2025
NCT03579875Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersP2recruiting48Masonic Cancer Center, University of MinnesotaNov 2018
NCT07477366Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaP2not yet recruiting20ImmunityBio, Inc.Apr 2026
NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaP2recruiting150Guangzhou Lupeng Pharmaceutical Company LTD.Nov 2025
NCT07247383Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaP2active not recruiting39Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySep 2025
NCT07002099Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II StudyP2recruiting26Second Affiliated Hospital of Soochow UniversityJun 2025
NCT06803693Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLP2recruiting152Ruijin HospitalApr 2025
NCT06581562IRIS-RD-01Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.P1recruiting30IRIS Research and Development, LLCMay 2024
NCT05998642Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaP2recruiting30Canadian Cancer Trials GroupFeb 2024
NCT06031233MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieP4recruiting776IsalaSep 2023
NCT05136976THERAMAGRituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good RespondersP3recruiting90Centre Hospitalier Universitaire de Saint EtienneJun 2023
NCT05207358GLUREDLUPMinimizing Glucocorticoid Administration in Patients With Proliferative Lupus NephritisP4recruiting30Institutul Clinic FundeniMar 2022
NCT04784052Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing BriquilimabP1/P2recruiting18Porteus, Matthew, MDDec 2021
NCT04856137DLBLA Phase I/II Study of Diffuse Large B-cell LymphomaP1/P2not yet recruiting74National Health Research Institutes, TaiwanMay 2021
NCT03500731Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureP1/P2recruiting8Paul SzabolcsApr 2018
NCT01419561KICSNatural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)P2recruiting140National Cancer Institute (NCI)Sep 2011
NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLP2recruiting58Tianjin Medical University Cancer Institute and HospitalJan 2026
NCT07405255ZillionZillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS LymphomaP2not yet recruiting19Ruijin HospitalJan 2026
NCT02180711Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaP1/P2active not recruiting113Acerta Pharma BVDec 2014
NCT07029737SOUND-MCLA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainP2recruiting55AstraZenecaSep 2025
NCT06220032HO170DLBCLPrevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaP3recruiting324Stichting Hemato-Oncologie voor Volwassenen NederlandAug 2024
NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaP2recruiting65Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNov 2025
NCT05004064CARAMELAcalabrutinib and Rituximab in Previously Untreated Mantle Cell LymphomaP2recruiting48University College, LondonNov 2023
NCT04323566Ra-P-OCDRituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System InvolvementP2enrolling by invitation40Uppsala University HospitalMay 2022
NCT04884035CC-220Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaP1recruiting224CelgeneSep 2021
NCT07601607Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaP1/P2not yet recruiting51Sun Yat-sen UniversityMay 2026
NCT07234019ITPRituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)P2recruiting160Institute of Hematology & Blood Diseases Hospital, ChinaJan 2026
NCT04931368OptiMATeOptiMATe: De-escalated Induction Treatment in Primary CNS LymphomaP3active not recruiting331Klinikum StuttgartJun 2021
NCT06425302GOLSEEK-2A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaP2active not recruiting90CelgeneAug 2024
NCT04627753Lemon-CStudy of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.P2recruiting30Kim, Seok JinNov 2020
NCT06714838ReCIXRituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating PolyneuropathyP3recruiting100Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)Oct 2024
NCT05635162ZEBRAZanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell LymphomaP2recruiting50University College, LondonMay 2024
NCT05951959TrAVeRseA Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaP2active not recruiting108AstraZenecaDec 2023
NCT06090539A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasP1/P2recruiting308Bristol-Myers SquibbDec 2023
NCT05065554ACALA-R In Predominantly Demyelinating IgM Mediated NeuropathyP2active not recruiting12Shayna Sarosiek, MDNov 2021
NCT06611696ARRIAAvacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisP4recruiting160Chiba UniversityNov 2024
NCT06647732MALTZanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)P2recruiting42Sun Yat-sen UniversityOct 2024
NCT01808599Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT LymphomaP2active not recruiting112International Extranodal Lymphoma Study Group (IELSG)Dec 2013
NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseP2recruiting25Ruijin HospitalSep 2025
NCT07269639Go-Pro-DLBCLGolcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell LymphomaP1/P2not yet recruiting20Seoul National University HospitalJan 2026
NCT07169565Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström MacroglobulinemiaP1not yet recruiting21Institute of Hematology & Blood Diseases Hospital, ChinaSep 2025
NCT06554600A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaP2recruiting36Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAug 2024
NCT06541665Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSLP1active not recruiting20Ono Pharmaceutical Co., Ltd.May 2024
NCT06319456APG-2575A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.P3recruiting344Ascentage Pharma Group Inc.Apr 2024
NCT04989621RR FLOrelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)P2recruiting32Sun Yat-sen UniversityAug 2021
NCT04496037MOT-AMRMechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplantnot yet recruiting170Imperial College LondonSep 2020
NCT04680052InMINDA Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.P3active not recruiting654Incyte CorporationApr 2021
NCT04626791Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell LymphomaP2recruiting45Academic and Community Cancer Research UnitedAug 2021
NCT07614282Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemiaP1not yet recruiting28Jennifer AmengualJul 2026
NCT07224100Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaP2recruiting33University of WashingtonMar 2026
NCT06738368DA-EPOCHEtoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaP2recruiting30University of WashingtonMay 2026
NCT07073833The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin LymphomaP1recruiting40Imbioray (Hangzhou) Biomedicine Co., Ltd.Jul 2025
NCT07199296Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentP2recruiting45Ruijin HospitalJul 2025
NCT07432022A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin LymphomaP1/P2not yet recruiting115Shanghai EpimAb Biotherapeutics Co., Ltd.Mar 2026
NCT05018520The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low RiskP3recruiting640Ruijin HospitalSep 2021
NCT04384484LOTIS 5Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaP3active not recruiting440ADC Therapeutics S.A.Sep 2020
NCT06414148EpLCARTMRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell LymphomaP2recruiting40Peter MacCallum Cancer Centre, AustraliaMay 2024
NCT03863184Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCLP2active not recruiting37Weill Medical College of Cornell UniversityOct 2019
NCT04323956Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell LymphomaP1active not recruiting50Mayo ClinicJun 2020
NCT07583810Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone LymphomaP2not yet recruiting35City of Hope Medical CenterDec 2026
NCT06468943Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLP2enrolling by invitation20The First Affiliated Hospital of Soochow UniversityJul 2023
NCT01810588Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord TransplantationP2active not recruiting270Weill Medical College of Cornell UniversityOct 2012
NCT06954805PTLDDefining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)P2recruiting30Jennifer AmengualApr 2025
NCT07231952WMA Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)P2recruiting40Memorial Sloan Kettering Cancer CenterNov 2025
NCT03984448Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasP2/P3active not recruiting363National Cancer Institute (NCI)Oct 2019
NCT07362238ITPDaratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)P2recruiting122Institute of Hematology & Blood Diseases Hospital, ChinaMar 2026
NCT06508658EPCORE DLBCL-4A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaP3active not recruiting379GenmabAug 2024
NCT07041268Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of RituximabP2recruiting116Pirogov Russian National Research Medical UniversityApr 2024
NCT06084936GLOBRYTEA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaP3recruiting182Hoffmann-La RocheOct 2023
NCT04840602Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaP2recruiting92National Cancer Institute (NCI)Jan 2022
NCT06557330MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin LymphomaP2not yet recruiting24Fox Chase Cancer CenterJun 2025
NCT05025800ALX148ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaP1/P2active not recruiting47M.D. Anderson Cancer CenterOct 2021
NCT05929716An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaP2withdrawn0M.D. Anderson Cancer CenterSep 2023
NCT04404088Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaP2active not recruiting60M.D. Anderson Cancer CenterJul 2020
NCT06530004Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Childrenrecruiting50The First Affiliated Hospital of Xiamen UniversityMar 2020
NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisP3recruiting300Staidson (Beijing) Biopharmaceuticals Co., LtdNov 2025
NCT04623541EPCORE™ CLL-1Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeP1/P2active not recruiting194GenmabNov 2020
NCT05798156R-Pola-GloRituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOPP2active not recruiting125Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestMar 2023
NCT06832267RMTTRituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCLN/Arecruiting44Zhejiang Cancer HospitalFeb 2025
NCT03930953A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)P1/P2active not recruiting438CelgeneMay 2019
NCT05600686Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaP2recruiting24Joseph TuscanoMay 2023
NCT06929624A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaP3recruiting280Suzhou Suncadia Biopharmaceuticals Co., Ltd.Apr 2025
NCT06765317A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell LymphomaP2recruiting42Memorial Sloan Kettering Cancer CenterJan 2025
NCT05533164REDUCE-PMR-2Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR RelapseP3active not recruiting174Sint MaartenskliniekFeb 2023
NCT05615974A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant TumorsP1/P2recruiting139LaNova Medicines LimitedJan 2023
NCT03952637A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisP1/P2recruiting54National Human Genome Research Institute (NHGRI)Aug 2019
NCT07225439NHLRituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)P1not yet recruiting15Paolo Caimi, MDDec 2025
NCT06676631NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus NephritisP1recruiting18Guangdong Provincial People's HospitalFeb 2025
NCT06441097Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLP2not yet recruiting152Ruijin HospitalDec 2024
NCT06756308A Study of Enasidenib in People With T-Cell LymphomaP2recruiting25Memorial Sloan Kettering Cancer CenterDec 2024
NCT06046248Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-DiseaseP2recruiting25Northside Hospital, Inc.Jan 2024
NCT06003283RITUXERATapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid ArthritisP4recruiting134Universitaire Ziekenhuizen KU LeuvenJan 2024
NCT05786768OBIRINSEfficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic SyndromeP2/P3recruiting88Assistance Publique - Hôpitaux de ParisOct 2023
NCT05914155PRIMEClinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic SyndromeP3recruiting88Shoichi Maruyama MD PhDJun 2023
NCT05786040Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderP2recruiting28Timothy VoorheesMar 2023
NCT05600660Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System LymphomaP2recruiting28Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAug 2022
NCT05279300A Study of CS5001 in Patients With Advanced Solid Tumors and LymphomasP1recruiting480CStone PharmaceuticalsMar 2022
NCT03474744Copanlisib and Rituximab in Marginal Zone Lymphoma PatientsP2active not recruiting36Christian BuskeDec 2019
NCT00692939Autologous Stem Cell Transplantation for Crohn's DiseaseP1/P2recruiting20Paul SzabolcsJun 2012
NCT00977977Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyP2recruiting30National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Dec 2010
NCT01059786Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaP2active not recruiting69National Cancer Institute (NCI)Jul 2010
NCT06704555Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular LymphomaP2recruiting20Tianjin Medical University Cancer Institute and HospitalDec 2024
NCT06254560Rituximab for Serious Aplastic Anemia With Platelet Transfusion RefractorinessP2recruiting20Institute of Hematology & Blood Diseases Hospital, ChinaFeb 2023
NCT04758975VALUABLEVenetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)P2recruiting55Paolo GhiaSep 2022
NCT01371630Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic LeukemiaP1/P2recruiting276M.D. Anderson Cancer CenterAug 2011
NCT06700798Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II TrialP2recruiting90Fei LiDec 2024
NCT04872790Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute LeukemiaP1active not recruiting20OHSU Knight Cancer InstituteSep 2022
NCT06561347ZEBRAZanubrutinib, Bendamustine, Rituximab Prev. Untreated WMP2recruiting56Massachusetts General HospitalDec 2024
NCT02203526TEDDI-RPhase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS LymphomaP1active not recruiting68National Cancer Institute (NCI)Aug 2014
NCT07297563ITPAnti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)P2recruiting160Institute of Hematology & Blood Diseases Hospital, ChinaJan 2026
NCT03684980LTA Pilot Study of Glucarpidase in Patients With Central Nervous System LymphomaEarly P1active not recruiting58Memorial Sloan Kettering Cancer CenterNov 2018
NCT07001540DLBCLEvaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous TransplantationP2recruiting130Fudan UniversityMay 2025
NCT05338190RITUX-PLUS 2Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune ThrombocytopeniaP3recruiting132Assistance Publique - Hôpitaux de ParisNov 2022
NCT06136351A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell LymphomaP2recruiting23Ruijin HospitalNov 2023
NCT04824092frontMINDTafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsP3active not recruiting899Incyte CorporationMay 2021
NCT06952413Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)P2recruiting30National Center of Neurology and Psychiatry, JapanApr 2025
NCT05023980BRUIN CLL-313A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)P3active not recruiting309Loxo Oncology, Inc.Sep 2021
NCT04965493BRUIN CLL-322A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)P3active not recruiting600Loxo Oncology, Inc.Sep 2021
NCT03336333SEQUOIAA Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLP3active not recruiting590BeiGeneOct 2017
NCT01424982Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaP2active not recruiting88M.D. Anderson Cancer CenterOct 2011
NCT06351527Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell MalignanciesP1recruiting78InnoCare Pharma Inc.Apr 2024
NCT06176729Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL PatientsP2recruiting30Yan Zhang, MDOct 2023
NCT05270057LONCALoncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid MalignanciesP1active not recruiting11Medical College of WisconsinJan 2023
NCT06064344RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT LymphomaN/Anot yet recruiting108Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOct 2023
NCT02911142EPOCH-R2Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell LymphomaP1/P2active not recruiting17National Cancer Institute (NCI)Jul 2017
NCT02970318A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLP3active not recruiting310Acerta Pharma BVFeb 2017
NCT07138898Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyP2not yet recruiting80NYU Langone HealthSep 2025
NCT05683171A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaP1/P2recruiting60M.D. Anderson Cancer CenterMay 2023
NCT04679012Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's TransformationP2recruiting20Weill Medical College of Cornell UniversitySep 2021
NCT04663347EPCORE™ NHL-2Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)P1/P2active not recruiting543GenmabNov 2020
NCT04542824EPCORE™ NHL-3Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)P1/P2active not recruiting78GenmabAug 2020
NCT05139017MK-2140A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)P2/P3recruiting290Merck Sharp & Dohme LLCJan 2022
NCT06561360HCLA Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)P2recruiting86Memorial Sloan Kettering Cancer CenterSep 2024
NCT03571321Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic LeukemiaP1recruiting15University of ChicagoMay 2019
NCT07444710Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaP1not yet recruiting16National Cancer Institute (NCI)Aug 2026
NCT07270835Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaP4recruiting40The First Affiliated Hospital of Soochow UniversityNov 2025
NCT06265220AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusP1active not recruiting51Artiva Biotherapeutics, Inc.Apr 2024
NCT04913103CLSGMCLPOLAStudy of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCLP2not yet recruiting21Czech Lymphoma Study GroupSep 2021
NCT03150693Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaP3recruiting310Alliance for Clinical Trials in OncologySep 2017
NCT04745949PACIFICPACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyP2recruiting31M.D. Anderson Cancer CenterMay 2021
NCT03653338SCDT-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasP1/P2recruiting5Paul SzabolcsAug 2018
NCT03136146Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaP2recruiting42M.D. Anderson Cancer CenterAug 2017
NCT07206823Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune ThrombocytopeniaN/Arecruiting30The First Affiliated Hospital of Soochow UniversitySep 2025
NCT07071246Rituximab for the Treatment of New-onset AChR-Myasthenia GravisN/Aactive not recruiting30Tang-Du HospitalAug 2022
NCT04022239Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell TransplantP1/P2recruiting25M.D. Anderson Cancer CenterMar 2020
NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaP1/P2recruiting108Institute of Hematology & Blood Diseases Hospital, ChinaMay 2024
NCT06573645A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCLP3not yet recruiting428Xia YiAug 2024
NCT06496308Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentP3recruiting78Ruijin HospitalJul 2024
NCT05455697Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaP1/P2recruiting35University of WashingtonJan 2023
NCT07057778Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITPP2not yet recruiting120Peking University People's HospitalJul 2025
NCT05482542Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple SclerosisN/Awithdrawn0Scripps HealthJan 2023
NCT06475495COMPAREComparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid ArthritisP1/P2active not recruiting13Charite University, Berlin, GermanyDec 2024
NCT06475235Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLP1recruiting15Dana-Farber Cancer InstituteOct 2024
NCT06362967The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCTP2recruiting30Anhui Provincial HospitalMay 2024
NCT06047171RENAL-F02Rescue of Nephrons With ALE.F02 (RENAL-F02)P2recruiting80Alentis Therapeutics AGSep 2023
NCT04974216Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or OlderP2active not recruiting71The Lymphoma Academic Research OrganisationDec 2021
NCT04540380Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGHP1active not recruiting20Massachusetts General HospitalSep 2021
NCT03321643Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell LymphomaP1active not recruiting24National Cancer Institute (NCI)Sep 2018
NCT03206671B-NHL 2013Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and AdolescentsP3active not recruiting650University Hospital MuensterAug 2017
NCT02427620Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell LymphomaP2active not recruiting131M.D. Anderson Cancer CenterJun 2015
NCT00412594Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaP2recruiting150M.D. Anderson Cancer CenterJun 2004
NCT03523975Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaP1/P2recruiting28City of Hope Medical CenterDec 2018
NCT06478472ORProspective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local TherapyN/Arecruiting36The First Affiliated Hospital of Xiamen UniversityJun 2024
NCT03697512MALIBUMALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone LymphomasP2active not recruiting175International Extranodal Lymphoma Study Group (IELSG)Sep 2019
NCT06471738Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaP2recruiting30Chinese PLA General HospitalJul 2024
NCT05788081TOP-FLORTreatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.P2active not recruiting40Olivia Newton-John Cancer Research InstituteAug 2023
NCT03758989A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell LymphomaP2recruiting40University of RochesterMay 2019
NCT06489808Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCLP2recruiting89Institute of Hematology & Blood Diseases Hospital, ChinaMay 2024
NCT05834855Noisy RebelsNon-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MSP3recruiting200Amsterdam UMC, location VUmcApr 2023
NCT05551936A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular LymphomaP1/P2active not recruiting42Vaishalee KenkreJan 2023
NCT04666038BRUIN CLL-321Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)P3active not recruiting238Loxo Oncology, Inc.Mar 2021
NCT03899337STELLARA Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeP2recruiting105University of BirminghamJul 2019
NCT02727803Personalized NK Cell Therapy in CBTP2recruiting100M.D. Anderson Cancer CenterMay 2016
NCT04458610Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2active not recruiting60M.D. Anderson Cancer CenterMay 2020
NCT05868395Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell LymphomaP2recruiting16Medical University of ViennaJan 2024
NCT01473628Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular LymphomaP1/P2active not recruiting81M.D. Anderson Cancer CenterMay 2013
NCT04974996LOTIS-8A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)P1withdrawn0ADC Therapeutics S.A.Feb 2022
NCT05583071MTR²Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLP2recruiting20University of CologneAug 2024
NCT04447716An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentP1active not recruiting4Thomas Jefferson UniversityOct 2020
NCT03194815SINAPPS2IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2P2active not recruiting70University of CambridgeNov 2017
NCT01829958Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase TherapyN/Aactive not recruiting201Memorial Sloan Kettering Cancer CenterApr 2013
NCT07081022JS203 Combination Regimens in B-Cell Non-Hodgkin's LymphomaP2recruiting180Shanghai Junshi Bioscience Co., Ltd.Aug 2025
NCT04609046Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaP1recruiting47National Cancer Institute (NCI)May 2021
NCT07362199ITPAnti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)P2recruiting20Institute of Hematology & Blood Diseases Hospital, ChinaMar 2026
NCT05495464A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaEarly P1active not recruiting22M.D. Anderson Cancer CenterNov 2022
NCT03295383RITUX-MMPRandomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane PemphigoidP3active not recruiting92University Hospital, RouenJul 2019
NCT03710772Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaP2active not recruiting51M.D. Anderson Cancer CenterMay 2019
NCT04212013A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone LymphomaP3active not recruiting23Memorial Sloan Kettering Cancer CenterDec 2019
NCT05618925Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaP1recruiting20ImmunityBio, Inc.Aug 2025
NCT00972478Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaP1/P2active not recruiting83National Cancer Institute (NCI)Nov 2010
NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyP2recruiting41Mayo ClinicApr 2025
NCT01695941Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaP1active not recruiting24National Cancer Institute (NCI)Aug 2012
NCT06921044A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCLP2not yet recruiting33Xiaohui HeApr 2025
NCT06263491PRPhase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsP2recruiting50M.D. Anderson Cancer CenterMay 2024
NCT04799275Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaP2/P3active not recruiting422National Cancer Institute (NCI)May 2021
NCT06981988YY-20394A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHLP1/P2not yet recruiting80Jiangsu HengRui Medicine Co., Ltd.Jun 2025
NCT05171647SUNMOA Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaP3active not recruiting208Hoffmann-La RocheApr 2022
NCT03943901Split-Dose R-CHOP for Older Adults With DLBCLP2active not recruiting27University of Wisconsin, MadisonFeb 2021
NCT03620903Efficacy of First Line B-RI for Treatment Naive Waldenström's MacroglobulinemiaP2active not recruiting53Christian BuskeSep 2019
NCT03147612Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaP2active not recruiting22M.D. Anderson Cancer CenterFeb 2018
NCT02003222Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic LeukemiaP3active not recruiting488National Cancer Institute (NCI)May 2014
NCT01318317Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin LymphomaP1/P2active not recruiting8City of Hope Medical CenterSep 2011
NCT04529772ESCALADEA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)P3active not recruiting611Acerta Pharma BVOct 2020
NCT02972840A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLP3active not recruiting635Acerta Pharma BVApr 2017
NCT05736419HCTA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)P2recruiting24Memorial Sloan Kettering Cancer CenterFeb 2023
NCT05214183ALTAMIRAAcalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell LymphomaP2active not recruiting81Nordic Lymphoma GroupDec 2021
NCT03267433Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionP3active not recruiting689ECOG-ACRIN Cancer Research GroupNov 2017
NCT02251548iFCRA Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaP2active not recruiting85Dana-Farber Cancer InstituteOct 2014
NCT04978584Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyP2active not recruiting62M.D. Anderson Cancer CenterMar 2022
NCT06572618Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell LymphomaP2recruiting27City of Hope Medical CenterJan 2025
NCT04421560Pembrolizumab, Ibrutinib and Rituximab in PCNSLP1/P2recruiting37Dana-Farber Cancer InstituteAug 2020
NCT04075292Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaP3active not recruiting155AstraZenecaJan 2020
NCT03789240Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular LymphomaP2active not recruiting33National Cancer Institute (NCI)Aug 2019
NCT05514015Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous NephropathyP4recruiting78First Affiliated Hospital, Sun Yat-Sen UniversityMar 2024
NCT06301399Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety StudyP2recruiting20Tianjin Medical University Cancer Institute and HospitalMar 2024
NCT06410833BRRPJSBelimumab After Rituximab in Resistant Primary Juvenile SSP4recruiting15Peking Union Medical College HospitalMar 2024
NCT06209619CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaP1recruiting18Nathan DenlingerJan 2024
NCT05698147Selinexor in Combination With MTX+Ritu to Treat R/R CNSLP1/P2recruiting30Tong Chen, MDAug 2023
NCT05622201RCT-RITSA Randomized Controlled Trial With Rituximab for Psychotic Disorder in AdultsP2active not recruiting123Region Örebro CountyMar 2023
NCT05221645P+R-ICEPembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell LymphomaP2active not recruiting65University of SouthamptonJun 2022
NCT05280626First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOPP2not yet recruiting100Innovent Biologics (Suzhou) Co. Ltd.Mar 2022
NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaP3active not recruiting244National Cancer Institute (NCI)Oct 2021
NCT04624958Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCLP2active not recruiting42Sun Yat-sen UniversityDec 2020
NCT04375228Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)P2active not recruiting8Columbia UniversitySep 2020
NCT04442022R-GDPA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaP2/P3active not recruiting501Karyopharm Therapeutics IncSep 2020
NCT04161248Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaEarly P1active not recruiting40Canadian Cancer Trials GroupSep 2020
NCT04404283ECHELON-3Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLP3active not recruiting239Seagen, a wholly owned subsidiary of PfizerAug 2020
NCT04432714Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC RearrangementP1/P2recruiting81The First Affiliated Hospital with Nanjing Medical UniversityJun 2020
NCT04216524Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmP2recruiting40M.D. Anderson Cancer CenterMay 2020
NCT04115631A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaP2active not recruiting360ECOG-ACRIN Cancer Research GroupDec 2019
NCT03749018Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's LymphomaP2active not recruiting30David Bond, MDJan 2019
NCT03467867A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLLP2active not recruiting25Georgetown UniversityApr 2018
NCT02436707Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaP2active not recruiting129Canadian Cancer Trials GroupOct 2015
NCT01856192Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell LymphomaP2active not recruiting349National Cancer Institute (NCI)Aug 2013
NCT06388941Iptacopan in Patients With ANCA Associated VasculitisP2active not recruiting84Novartis PharmaceuticalsAug 2024
NCT05506410A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphomarecruiting100Zhengzhou UniversityAug 2022
NCT05850546Rituximab in the First Episode of Paediatric Nephrotic SyndromeP3not yet recruiting138Children's Hospital of Fudan UniversityMar 2025
NCT05946486TIM-DePisTEvaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.P3not yet recruiting174University Hospital, BordeauxOct 2023
NCT04850495Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell LymphomaP1suspended38Yazeed SawalhaNov 2021
NCT01959698Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell LymphomaP1active not recruiting29Roswell Park Cancer InstituteApr 2014
NCT05057468Second-line Treatment of Primary Autoimmune Hemolytic AnemiaP3recruiting30Assiut UniversityOct 2021
NCT03352765A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly PatientsP1active not recruiting28Memorial Sloan Kettering Cancer CenterNov 2017
NCT02877303Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaP2recruiting80M.D. Anderson Cancer CenterNov 2016
NCT05886036Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialP2recruiting70National Cancer Institute (NCI)Jan 2024
NCT06086197A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLP2recruiting41Zhejiang Cancer HospitalOct 2023
NCT05581030ALLCalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)P1recruiting7H. Lee Moffitt Cancer Center and Research InstituteMay 2023
NCT05728658The Study of ICP-248 in Patients With Mature B-cell MalignanciesP1recruiting191Beijing InnoCare Pharma Tech Co., Ltd.Mar 2023
NCT05156710SAR445088BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)P2active not recruiting48SanofiJun 2022
NCT02048813Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP3active not recruiting529National Cancer Institute (NCI)Mar 2014
NCT00092222Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityP2active not recruiting75National Cancer Institute (NCI)Oct 2004
NCT06599307The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple SclerosisP2recruiting46Cairo UniversityAug 2024
NCT04980222RA Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell LymphomaP2active not recruiting46Hoffmann-La RocheMar 2022
NCT03571568A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLP1/P2recruiting140BioInvent International ABMay 2018
NCT02337985Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin LymphomaP1active not recruiting10City of Hope Medical CenterNov 2015
NCT06832228Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody (PPR) in Third or Later Line Therapy of DLBCLN/Arecruiting30Zhejiang Cancer HospitalSep 2024
NCT01479842Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaP1active not recruiting48Kami Maddocks, MDMar 2014
NCT04765111Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaP2active not recruiting53M.D. Anderson Cancer CenterJun 2021
NCT02160015Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by SurgeryP1active not recruiting12National Cancer Institute (NCI)May 2014
NCT06530511PROPolatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCLP2recruiting30Affiliated Hospital of Nantong UniversityAug 2024
NCT05990985The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.N/Anot yet recruiting20The First Hospital of Jilin UniversitySep 2023
NCT05690191Chidamide in Patients With Recurrent and Refractory Diffuse Large benrolling by invitation169Second Affiliated Hospital of Soochow UniversityJun 2021
NCT03630211SScAutologous Stem Cell Transplantation in Patients With Systemic SclerosisP2recruiting8Paul SzabolcsJul 2018
NCT06906549RADAREvaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid ArthritisP4recruiting260University Hospital, Strasbourg, FranceJul 2025
NCT06977711DLBCLLoncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)P1recruiting10The University of Texas Health Science Center at San AntonioJun 2025
NCT04594798A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCLP2active not recruiting39University of RochesterSep 2021
NCT02446236Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell LymphomaP1active not recruiting27Hackensack Meridian HealthJun 2015
NCT02158091A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLP1/P2active not recruiting32Dana-Farber Cancer InstituteJun 2014
NCT01880567Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaP2active not recruiting113M.D. Anderson Cancer CenterJul 2013
NCT05734794STORMStudy of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled TrialP3recruiting80The Children's Hospital of Zhejiang University School of MedicineFeb 2023
NCT04981912Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL PatientsP1active not recruiting4University of California, San DiegoSep 2021
NCT04479267Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated LymphomaP2active not recruiting8Barbara Ann Karmanos Cancer InstituteAug 2020
NCT05596786EvER-ILD2Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized TrialP3recruiting126University Hospital, ToursJan 2023
NCT03220022Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasP1active not recruiting46National Cancer Institute (NCI)Mar 2018
NCT05809180Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsN/Arecruiting35The First Affiliated Hospital of Soochow UniversityJan 2023
NCT05843968Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic SyndromeP2recruiting46Children's Hospital of Chongqing Medical UniversityJan 2023
NCT04665765Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaP2active not recruiting41City of Hope Medical CenterJan 2021
NCT02790515Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior TransplantationP2active not recruiting170St. Jude Children's Research HospitalJul 2016
NCT05457556Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic SyndromeP3active not recruiting435Children's Oncology GroupMar 2023
NCT03274375IANMDARImmunoadsorption Therapy in Managing NMDAR Antibodies EncephalitisP2recruiting20Assistance Publique - Hôpitaux de ParisJun 2021
NCT04416451A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone LymphomaP2active not recruiting6Memorial Sloan Kettering Cancer CenterMay 2021
NCT04400994IVIG With Rituximab vs Rituximab as First Line Treatment of PemphigusP2active not recruiting20The University of Hong KongJun 2020
NCT03805932TMMoxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell LeukemiaP1active not recruiting18National Cancer Institute (NCI)Oct 2019
NCT03844061Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic SclerosisP2recruiting30Hospital for Special Surgery, New YorkJul 2019
NCT03719131Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab TherapyP2active not recruiting15Emory UniversityJun 2019
NCT03697356BallondorR-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's MacroglobulinemiaP2recruiting54Kosin University Gospel HospitalMar 2019
NCT02007044Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaP2active not recruiting66M.D. Anderson Cancer CenterDec 2013
NCT01446133CLL-SLLCombination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)P2active not recruiting120M.D. Anderson Cancer CenterDec 2011
NCT00492050Bortezomib and Rituximab for Patients With Waldenstrom's MacroglobulinemiaP2active not recruiting46M.D. Anderson Cancer CenterAug 2006
NCT04585893Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in MalawiP2active not recruiting15UNC Lineberger Comprehensive Cancer CenterJun 2021
NCT01886872Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic LeukemiaP3active not recruiting547National Cancer Institute (NCI)Jan 2014
NCT01829568Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular LymphomaP1active not recruiting33National Cancer Institute (NCI)Jun 2013
NCT05351346Genotype-guided Treatment in DLBCLP3unknown1,100Ruijin HospitalJun 2022
NCT05737628First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228P1active not recruiting17Byondis B.V.Mar 2024
NCT05425654RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSLP2unknown30National Research Center for Hematology, RussiaMay 2021
NCT05549284RMOOrelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)P2unknown36Affiliated Hospital to Academy of Military Medical SciencesJun 2022
NCT03808610Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic LeukemiaP1/P2terminated53M.D. Anderson Cancer CenterApr 2019
NCT06683885A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell LymphomaP1/P2recruiting80Mingzhi ZhangNov 2024
NCT05926427Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System InvolvementP2unknown25Ruijin HospitalAug 2023
NCT03274492POLARIXA Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell LymphomaP3completed1,000Hoffmann-La RocheNov 2017
NCT02889523Epi-RCHOPStudy of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by ChemiotherapyP1/P2active not recruiting214The Lymphoma Academic Research OrganisationOct 2016
NCT02446457Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell LymphomaP2active not recruiting53M.D. Anderson Cancer CenterJul 2015
NCT05390749PORSequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSLP2unknown50Peking Union Medical College HospitalApr 2022
NCT05388123Low Dose Vemurafenib and Rituximab in Hairy Cell LeukemiaP2completed15Scripps HealthMar 2022
NCT05828147Anti-CD20 Antibodies for Treatment of SLE-PAHP4unknown50Chinese SLE Treatment And Research GroupMay 2023
NCT04433156VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaP2completed26Henan Cancer HospitalApr 2020
NCT05696613A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous NephropathyP3unknown148Cerium Pharmaceuticals, Inc.Mar 2023
NCT03349346RICEIdelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsP1withdrawn0Gilead SciencesJun 2019
NCT05186558Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCLP2unknown54The First Affiliated Hospital with Nanjing Medical UniversityMay 2022
NCT02315326BTKBruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)P1/P2completed93Memorial Sloan Kettering Cancer CenterDec 2014
NCT03609593Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaP2completed42Nicole LamannaNov 2018
NCT03703167Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)P1completed25Memorial Sloan Kettering Cancer CenterJan 2019
NCT05329090RIGAEvaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA VasculitisP3completed75Hopital FochMar 2022
NCT04737889Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System LymphomaP2recruiting30Henan Cancer HospitalJan 2021
NCT00584935Clinical Trial Evaluating Rituximab in Ocular Cicatricial PemphigoidP1/P2completed3University of Alabama at BirminghamJan 2006
NCT05940064Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell LymphomaP2unknown30Peng LiuJul 2023
NCT05896007Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCTP2unknown29Ruijin HospitalJul 2023
NCT06201507BV-AVD-R Treatment Children Hodgkin's LymphomaP2unknown44Beijing Children's HospitalOct 2022
NCT05422066Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell LymphomaP2recruiting50Li ZhimingJul 2022
NCT04920968OVERALLObinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"P2recruiting124Maria Sklodowska-Curie National Research Institute of OncologyOct 2021
NCT04938297Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS LymphomaP2unknown100Henan Cancer HospitalMay 2021
NCT04688151RADRituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.P1active not recruiting22National Health Research Institutes, TaiwanFeb 2021
NCT04607772RRStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2withdrawn0Karyopharm Therapeutics IncNov 2020
NCT04494503Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLP1/P2recruiting123Ascentage Pharma Group Inc.Aug 2020
NCT04129710PCNSLA Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)P2unknown120Second Affiliated Hospital, School of Medicine, Zhejiang UniversityJan 2020
NCT02900976Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative DisorderP2completed18Children's Oncology GroupMar 2017
NCT02734771BV mini CHPA Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)P2active not recruiting24Patrick ReaganJun 2016
NCT03501459Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic SyndromeP3unknown100National University Health System, SingaporeJun 2008
NCT00006721S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's LymphomaP3completed571SWOG Cancer Research NetworkMar 2001
NCT05940051Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell LymphomaP2unknown35Peng LiuJul 2023
NCT05644210Telitacicept Followed With Rituximab Therapy on APS Secondary to SLEunknown80Qilu Hospital of Shandong UniversityOct 2022
NCT04481815Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaP2unknown240Second Affiliated Hospital, School of Medicine, Zhejiang UniversityOct 2020
NCT04058470Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell LymphomaP1/P2unknown140Huiqiang HuangApr 2020
NCT05179733The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 YearsP3unknown280Ruijin HospitalMar 2022
NCT04668365Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell LymphomaP2suspended59Henan Cancer HospitalDec 2020
NCT03740529A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLP1/P2completed803Loxo Oncology, Inc.Mar 2019
NCT02628405R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell LymphomaP1/P2active not recruiting30Academic and Community Cancer Research UnitedMay 2016
NCT05914662ZBRZanubrutinib Plus BR in Newly Diagnosed Symptomatic WMP2recruiting42Institute of Hematology & Blood Diseases Hospital, ChinaFeb 2023
NCT05052528Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaP1unknown36Mehrdad Abedi, MDSep 2021
NCT06078696CD2 SCDSiplizumab for Sickle Cell Disease TransplantP1/P2terminated1Columbia UniversitySep 2023
NCT05979948CZ-WM01A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's MacroglobulinemiaP2unknown60Shanghai Changzheng HospitalAug 2023
NCT05290090ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCLP2unknown31Zhejiang Cancer HospitalOct 2021
NCT04460248ZR2Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)P2active not recruiting40Ruijin HospitalAug 2020
NCT03505762Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy TreatmentP2active not recruiting80Wake Forest University Health SciencesJul 2018
NCT03829566ATTENDAutologous Transplant To End NMO Spectrum DisorderP2/P3withdrawn0Northwestern UniversityNov 2019
NCT03651518PIMOCPersonalized Therapies in Inflammatory Complex DiseaseP2completed32Assistance Publique - Hôpitaux de ParisOct 2020
NCT06164327Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaP1unknown75BeBetter Med IncDec 2023
NCT03259503Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell TransplantP1completed50M.D. Anderson Cancer CenterSep 2019
NCT05575973Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell LymphomaP2unknown55Jianfeng ZhouOct 2022
NCT05533125REDUCE-PMR-1Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently DiagnosedP3completed114Sint MaartenskliniekFeb 2023
NCT02296918Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLP1completed69Acerta Pharma BVDec 2014
NCT05364424A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaP1completed43Hoffmann-La RocheNov 2022
NCT03746223Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal LymphomaP2unknown42Peking Union Medical College HospitalNov 2018
NCT03856216Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell TransplantationP2terminated15M.D. Anderson Cancer CenterOct 2019
NCT04673617AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaP1/P2completed45Artiva Biotherapeutics, Inc.Mar 2021
NCT05498220Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell LymphomaP2terminated5UNC Lineberger Comprehensive Cancer CenterFeb 2023
NCT04835870Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLP2unknown78The First Affiliated Hospital of Soochow UniversityApr 2021
NCT04480450Rituximab in Chronic Inflammatory Demyelinating PolyneuropathyP2withdrawn0University of Kansas Medical CenterJul 2025
NCT06245707the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous NephropathyN/Aunknown2Beijing Friendship HospitalOct 2023
NCT05036577ORMD2021A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSLP1active not recruiting15Huashan HospitalOct 2021
NCT04578639OVERLORD-MSOcrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS DiseaseP3active not recruiting214Haukeland University HospitalNov 2020
NCT07200583PAIA-HaploProtein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patientscompleted50Ting YANGMay 2025
NCT05494593A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)P4withdrawn0TakedaFeb 2023
NCT05887726Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk FactorsP2unknown30Liaoning Cancer Hospital & InstituteAug 2023
NCT05868837REFINERituximab EfFicacy IN MyasthEnia Gravis (REFINE)P3recruiting40Fondazione Policlinico Universitario Agostino Gemelli IRCCSFeb 2022
NCT04914741COALITIONA Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)P1/P2active not recruiting80Peter MacCallum Cancer Centre, AustraliaJun 2021
NCT05504603ZRZanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell LymphomaP2unknown20The First Affiliated Hospital of Soochow UniversityJul 2020
NCT03671018BTCT4465AA Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin LymphomaP1/P2active not recruiting422Hoffmann-La RocheSep 2018
NCT03013218ALX148A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)P1completed174ALX Oncology Inc.Feb 2017
NCT04994626Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior TherapiesP2unknown20Chinese Academy of Medical SciencesOct 2021
NCT05950334FT522-101FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)P1completed20Fate TherapeuticsNov 2023
NCT06068829Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disordersunknown80Feng JinzhouOct 2023
NCT05923879Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphomaunknown30Ruijin HospitalJun 2023
NCT05428670The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.P2unknown150First Affiliated Hospital of Wenzhou Medical UniversityJun 2022
NCT04578613ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLP3unknown218Beijing InnoCare Pharma Tech Co., Ltd.Jan 2021
NCT03569995[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS LymphomaP2unknown35Won Seog KimNov 2018
NCT04231448DEBPhase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCLP3completed423Chipscreen Biosciences, Ltd.May 2020
NCT03704714Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaP1/P2suspended30Northwestern UniversityNov 2018
NCT02947347Study of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaP3completed445Pharmacyclics LLC.Jan 2017
NCT03979456RIDOSE-MSRItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MSP3unknown200Karolinska InstitutetJul 2018
NCT00878254Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell LymphomaP2completed25University of MiamiMar 2009
NCT06175338Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid ArthritisP1active not recruiting208Mabscale, LLCJun 2023
NCT05201248SCA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin LymphomaP1/P2active not recruiting49GenmabMar 2022
NCT04214626R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell LymphomaP2completed60Henan Cancer HospitalJan 2020
NCT03623373Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaP2completed13Washington University School of MedicineNov 2018
NCT04047797Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaP2terminated3M.D. Anderson Cancer CenterAug 2019
NCT04899570Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell LymphomaP2unknown20Peking Union Medical College HospitalApr 2021
NCT03942887ENDURRANCE-1Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated VasculitisP3unknown100Leiden University Medical CenterMay 2019
NCT02356159Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationP1/P2completed34National Cancer Institute (NCI)Sep 2015
NCT04285567CRISTALLOA Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 MutationP3completed166Hoffmann-La RocheMay 2020
NCT06790420RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Studycompleted2,703PfizerJan 2025
NCT05704400Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic SyndromeP2unknown20Istituto Giannina GasliniMar 2023
NCT01085617UKALL14Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemiacompleted0University College, LondonDec 2010
NCT03763643PRI-VENT FSGSPRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-TransplantEarly P1completed21University of MinnesotaJul 2019
NCT00788684Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersP1completed29AbbVieJul 2009
NCT05682196AGRAF-2Rituximab in Patients With Acute Rheumatic FeverP2suspended234African Academy of Methodology and StatisticsJan 2023
NCT05200312ZR2-CHOPA Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaP2unknown36The First Affiliated Hospital with Nanjing Medical UniversityFeb 2022
NCT07035561Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity PneumonitisP2completed30Shereen Medhat Mohammed Elsayed NassarJun 2023
NCT01865110R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCLP3completed623The Lymphoma Academic Research OrganisationNov 2013
NCT01868269Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)P3completed102Institut CurieApr 2013
NCT03366272NIVEAUNivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma PatientsP2/P3completed348Universität des SaarlandesDec 2017
NCT04464798A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory LymphomasP1terminated62CelgeneNov 2020
NCT05784987R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaN/Aunknown60The First Affiliated Hospital with Nanjing Medical UniversityApr 2023
NCT05498259Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCLP2unknown46The First Affiliated Hospital of Soochow UniversityJul 2022
NCT05821192Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.N/Aunknown34Ou Bai, MD/PHDMar 2023
NCT05115409PCRAnti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)P2unknown27Sun Yat-sen UniversityJun 2022
NCT05265975SWATCHA Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHLP1/P2terminated54Antengene CorporationApr 2022
NCT05379647NKNatural Killer (NK) Cell Therapy for B-Cell MalignanciesP1unknown24Zhejiang UniversityNov 2021
NCT03010202The PROLONG Trial - Rituximab Maintenance Therapy in ITPP3unknown136Ostfold Hospital TrustDec 2016
NCT02881086Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentP3completed1,023Goethe UniversityAug 2016
NCT02752815Reduced Chemotherapy in Low Risk DLBCLP4unknown290Ruijin HospitalJun 2016
NCT00877214MAINTAINSignificance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasP3active not recruiting1,272Jurgen BarthApr 2009
NCT05078177Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple SclerosisP1unknown40St. Petersburg State Pavlov Medical UniversityDec 2020
NCT04743739Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMNP3terminated12Peking Union Medical College HospitalApr 2021
NCT03997968A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsP1/P2completed169Cyteir Therapeutics, Inc.Oct 2019
NCT01011920CNSTrial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) LymphomaP2completed227International Extranodal Lymphoma Study Group (IELSG)Nov 2009
NCT05586737Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian InsufficiencyP2completed15Angelica Lindén HirschbergApr 2019
NCT03495960FIORELLAStudy on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous SystemP2completed72International Extranodal Lymphoma Study Group (IELSG)Jun 2019
NCT04268277Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDYP2terminated22University of UlmMar 2022
NCT03467373CHOPA Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLP1completed111Hoffmann-La RocheMar 2018
NCT05527912A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP TherapyP2unknown45Sun Yat-sen UniversityFeb 2023
NCT03791827Multicenter Registry of Pediatric Lupus Nephritis in Chinaunknown1,200Xiqiang DangDec 2018
NCT05287984ZFCR/ZBRZanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLP2unknown63Institute of Hematology & Blood Diseases Hospital, ChinaMar 2022
NCT04182204POLARGOA Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaP3completed270Hoffmann-La RocheFeb 2020
NCT06186219Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous GoutP1completed2University of California, Los AngelesApr 2024
NCT02367040CHRONOS-3Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)P3completed458BayerAug 2015
NCT03524235Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLP1completed20Noah MerinJul 2018
NCT03804359PMMNPersonalized Medicine for Membranous NephropathyP2completed68Centre Hospitalier Universitaire de NiceJan 2020
NCT05073250IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.P2unknown40Chinese PLA General HospitalDec 2021
NCT02213913DA-EPOCH-RLenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell LymphomasP1/P2completed55University of ChicagoJul 2014
NCT00670358Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell LymphomaP1/P2completed138Mayo ClinicAug 2008
NCT03688451Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin LymphomaP2active not recruiting20Tahir LatifOct 2018
NCT05532111Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical TrialN/Aunknown60RenJi HospitalSep 2022
NCT04285268Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaP2withdrawn0Rutgers, The State University of New JerseyMay 2020
NCT05564052VEGAA Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell LymphomaP2completed36Janssen Research & Development, LLCDec 2022
NCT03164473MAINRITSEGMaintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.P3completed98Assistance Publique - Hôpitaux de ParisMar 2018
NCT03401853Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell LymphomaP2terminated18University of WashingtonMar 2018
NCT01996865MAGNIFYLenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.P3completed503CelgeneApr 2014
NCT03837873DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaP2unknown118Institute of Hematology & Blood Diseases Hospital, ChinaJan 2019
NCT05777369R-CMOP in Patients With Primary Diffuse Large B-cell LymphomaN/Aunknown30The First Affiliated Hospital with Nanjing Medical UniversityMar 2023
NCT04121403NOR-MSNorwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)P3completed267Oslo University HospitalOct 2019
NCT04120350REMLAR2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL:a Multicenter Phase Ib/II StutyP1/P2unknown47Peking Union Medical College HospitalAug 2019
NCT05679336Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous NephropathyN/Aunknown40St. Petersburg State Pavlov Medical UniversityMay 2018
NCT02632396Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in RemissionP1/P2unknown12Emory UniversityMar 2016
NCT05267054BGB-A1217Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or RituximabP1/P2completed53BeiGeneApr 2022
NCT03783403A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic CancersP1terminated206CelgeneMar 2019
NCT04899453Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRLP2unknown42Peking Union Medical College HospitalAug 2020
NCT05032183Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaP1/P2terminated4M.D. Anderson Cancer CenterFeb 2022
NCT04004819Rituximab for HTLV-1-associated MyelopathyP2unknown100First Affiliated Hospital of Fujian Medical UniversityAug 2019
NCT02481310Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaP1/P2unknown38Northwestern UniversityOct 2015
NCT03834688PrE0405Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of AgeP2completed33PrECOG, LLC.Jan 2020
NCT03078855ILyADA Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's LymphomaP3completed211Jonathan FriedbergSep 2017
NCT03440567Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell LymphomaP1completed16City of Hope Medical CenterApr 2018
NCT01776840A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell LymphomaP3completed523Janssen Research & Development, LLCMay 2013
NCT02763319B-MINDA Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)P2/P3completed453Incyte CorporationNov 2016
NCT03576547Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaP1/P2terminated9M.D. Anderson Cancer CenterJun 2018
NCT01701986Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaP1/P2completed64M.D. Anderson Cancer CenterOct 2012
NCT04113226RelyageAssessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell LymphomaP2completed1Centre Hospitalier Universitaire, AmiensNov 2021
NCT05398224R-MTX-zanbrutinib in Secondary CNS LymphomaP2unknown45Peking UniversityFeb 2021
NCT00001337Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's LymphomaP2completed348National Cancer Institute (NCI)May 1993
NCT03804372CLL1818The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideP2terminated5Gruppo Italiano Malattie EMatologiche dell'AdultoJul 2020
NCT04790903RA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)P1terminated50Hoffmann-La RocheJul 2021
NCT05376319PR3-AAV Resilient Remission or PRRRP2terminated6Mayo ClinicJun 2023
NCT03919175Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone LymphomaP2terminated18Massachusetts General HospitalSep 2019
NCT05392257Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical TrialP2unknown20Qingdao Central HospitalMay 2022
NCT01788020Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's MacroglobulinemiaP3completed202University of UlmNov 2013
NCT01650701RELEVANCEA Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular LymphomaP3completed1,030The Lymphoma Academic Research OrganisationFeb 2012
NCT01476787RELEVANCECombined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaP3completed1,030CelgeneDec 2011
NCT02232386LLC1114Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic LeukemiaP2completed156Gruppo Italiano Malattie EMatologiche dell'AdultoMar 2015
NCT00848328Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin LymphomaP2terminated30University of California, DavisAug 2008
NCT01316523Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's LymphomaP2terminated30University of California, DavisDec 2010
NCT05861297Immune Thrombocytopenia Management in AdultsP4unknown467Nahda UniversityMay 2020
NCT05384743Rituximab Monotherapy for EBV-HLH and CAEBVP3unknown30Beijing Friendship HospitalFeb 2022
NCT04083066Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System LymphomaP4unknown20Mingzhi ZhangSep 2019
NCT04525729RITARituximab and RASi in Patients with IgANP4completed116Nan Chen,MDJul 2020
NCT04659044Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaP2terminated3Academic and Community Cancer Research UnitedApr 2021
NCT02953509Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaP1/P2terminated178Gilead SciencesNov 2016
NCT02329080New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System InvolvementP2completed79International Extranodal Lymphoma Study Group (IELSG)Dec 2014
NCT03615105Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsP2terminated9Memorial Sloan Kettering Cancer CenterJul 2018
NCT02950051GAIAStandard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationP3completed926German CLL Study GroupDec 2016
NCT03630042PembroWMInvestigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's MacroglobulinaemiaP2completed17University College, LondonSep 2019
NCT03742258Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell LymphomaP1completed12Northwestern UniversityMar 2019
NCT05049473BLTreatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.P2unknown100PETHEMA FoundationJan 2014
NCT05144009LOTIS-9A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)P2terminated41ADC Therapeutics S.A.Jun 2022
NCT03295240The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell LymphomaEarly P1completed10Memorial Sloan Kettering Cancer CenterSep 2017
NCT01478542OPTIMAL>60OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal VincristineP3completed1,152Universität des SaarlandesNov 2011
NCT00006436EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV InfectionP2completed68National Cancer Institute (NCI)Jan 2001
NCT05667909Prognostic Model of Rituximab in the Treatment of MNunknown50Qianfoshan HospitalJun 2023
NCT04138875A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)P2withdrawn0Yale UniversityJan 2022
NCT07049172Rituximab and Targeted Nursing for Pediatric Nephrotic SyndromeN/Acompleted91Wuhan Children's HospitalJan 2021
NCT02382575Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic SyndromeP4unknown120Nilratan Sircar Medical CollegeMar 2015
NCT01811368Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaP2unknown20Joseph TuscanoMar 2013
NCT01359592S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell LymphomaP2completed159SWOG Cancer Research NetworkSep 2011
NCT04842487R2-CHOP in Untreated DEL-DLBCL:An Open-lable,Multicenter,Phase II StudyP2unknown80Sun Yat-sen UniversityApr 2021
NCT04181489Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOSP2unknown55The First Affiliated Hospital with Nanjing Medical UniversityJan 2019
NCT03899103RITURNS IICompare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic SyndromeP3completed100Nilratan Sircar Medical CollegeMay 2019
NCT04021992GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCLP2unknown48Sun Yat-sen UniversityJul 2019
NCT00577278A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and MelphalanP2completed41City of Hope Medical CenterOct 2007
NCT02031419Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaP1terminated174CelgeneDec 2013
NCT05782933Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous NephropathyN/Aunknown2Beijing Friendship HospitalAug 2022
NCT04933617Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell LymphomasP1terminated8National Cancer Institute (NCI)Mar 2022
NCT04555811FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHLP1completed7Masonic Cancer Center, University of MinnesotaSep 2020
NCT06325943CIDPRITRituximab in Chronic Inflammatory Demyelinating PolyradiculoneuropathyP3completed37Istituto Clinico HumanitasApr 2019
NCT03967925COMBIVASRituximab and Belimumab Combination Therapy in PR3 VasculitisP2unknown31Rachel JonesFeb 2019
NCT05168475BIOVASBiologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated VasculitisP2terminated22Cambridge University Hospitals NHS Foundation TrustJul 2021
NCT03970577RIFIREINSRItuximab From the FIRst Episode of Idiopathic Nephrotic SyndromeP2unknown148Assistance Publique - Hôpitaux de ParisJul 2020
NCT03492125A Study Of The Selective PKC-β Inhibitor MS- 553P1/P2terminated60MingSight Pharmaceuticals, IncMay 2018
NCT04128176Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous PemphigoidP3withdrawn0University of California, DavisMar 2017
NCT04431635Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaP1terminated6University of Michigan Rogel Cancer CenterJun 2020
NCT02626455CHRONOS-4Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)P3terminated551BayerJan 2016
NCT02320292Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular LymphomaP3terminated20Mayo ClinicFeb 2015
NCT04752163DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaP1/P2terminated17M.D. Anderson Cancer CenterMar 2021
NCT04023071FT516 in Subjects With Advanced Hematologic MalignanciesP1terminated72Fate TherapeuticsOct 2019
NCT05076097A Study of OLR in First-line Treatment of Mantle Cell LymphomaP2unknown29Tianjin Medical University Cancer Institute and HospitalSep 2021
NCT04519710HepB20Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal AntibodiesN/Acompleted60Centre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaSep 2020
NCT05553496Assessment of Rituximab Therapeutic Response Versus Conventional TreatmentP2/P3unknown40Ain Shams UniversitySep 2022
NCT05824390A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA NephropathyP4unknown116XIEJINGYUANJun 2020
NCT04585152RTXvsMMFRituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.P2unknown160Istituto Giannina GasliniOct 2020
NCT03736616Acalabrutinib Plus RICE for Relapsed/Refractory DLBCLP2unknown47Swedish Medical CenterAug 2019
NCT05877040A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune TherapyP2unknown20Istituto Clinico HumanitasJun 2019
NCT02957019DLBCLA Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)P1/P2terminated6Philogen S.p.A.Jul 2013
NCT04245722FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesP1terminated98Fate TherapeuticsMar 2020
NCT00945724IELSG30Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of TestisP2completed54International Extranodal Lymphoma Study Group (IELSG)Sep 2009
NCT05293509PTISPharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic DisordersP2withdrawn0M.D. Anderson Cancer CenterMar 2022
NCT00112931Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaP3completed462University College, LondonSep 2004
NCT03920722RITUXGOPROEfficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic PolyangiitisP3completed8Assistance Publique - Hôpitaux de ParisOct 2020
NCT02753062PTLDBendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell LymphomaP2unknown22Asan Medical CenterAug 2015
NCT02060656LEGENDPhase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)P2unknown92Royal Marsden NHS Foundation TrustSep 2013
NCT04516655C-R-HDMTXA Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma PatientsP2unknown51Fudan UniversitySep 2020
NCT05245916IBI397 or Combination Therapies in Patients With Advanced MalignanciesP1withdrawn0Innovent Biologics (Suzhou) Co. Ltd.Apr 2022
NCT02728531Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell LymphomaP1completed18Washington University School of MedicineApr 2016
NCT02532257Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaP2completed48M.D. Anderson Cancer CenterApr 2016
NCT03064867Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell LymphomaP1/P2active not recruiting65Molly GalloglyJun 2017
NCT03121677Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular LymphomaP1terminated4Washington University School of MedicineOct 2018
NCT04680962MABRIDGEMabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid ArthritisP3withdrawn0Mabion SAAug 2023
NCT03636503Rituximab + Immunotherapy in Follicular LymphomaP1terminated24Dana-Farber Cancer InstituteOct 2018
NCT01472562Lenalidomide Plus Rituxan for Untreated Mantle Cell LymphomaP2completed38Weill Medical College of Cornell UniversityJul 2011
NCT02348216ZUMA-1Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaP1/P2completed307Kite, A Gilead CompanyApr 2015
NCT03864419Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaP1terminated18Fred Hutchinson Cancer CenterOct 2019
NCT02451111Rituximab With or Without Ibrutinib for Patients With Advanced Follicular LymphomaP2terminated190Swiss Cancer InstituteNov 2015
NCT04127747Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus ErythematosusP4unknown110Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAug 2020
NCT02073097Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell LymphomaP1/P2completed48Case Comprehensive Cancer CenterJan 2015
NCT01664910CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid MalignanciesP1/P2completed27M.D. Anderson Cancer CenterOct 2012
NCT01974440SELENEA Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin LymphomaP3completed403Janssen Research & Development, LLCJan 2014
NCT00863369Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin LymphomaP1/P2completed33City of Hope Medical CenterJun 2005
NCT04156828Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaP1terminated12University of WashingtonMar 2020
NCT05963048Rituxmab Versus IL-6 in Treating ILDP2/P3completed60Assiut UniversityDec 2021
NCT04025593Biomarker Guided Treatment in DLBCLP2unknown128Ruijin HospitalJul 2019
NCT02844322BDH-WM01The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström MacroglobulinemiaP4completed35Institute of Hematology & Blood Diseases Hospital, ChinaMay 2016
NCT03788291Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaP2completed39University of RochesterMar 2019
NCT04517435ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell LymphomaP1/P2terminated13Deepa JagadeeshApr 2021
NCT03003546Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 TrialP1completed9Mayo ClinicApr 2019
NCT03455517VeRitAsActivity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaP2completed77Gruppo Italiano Malattie EMatologiche dell'AdultoOct 2018
NCT01303887PACIFICOA Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly PatientsP3completed680University of LiverpoolOct 2009
NCT02313389BLOCAGE-01Maintenance Treatment Versus Observation in Elderly Patients With PCNS LymphomaP3unknown428Assistance Publique - Hôpitaux de ParisSep 2015
NCT01027000Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2completed68Alliance for Clinical Trials in OncologyFeb 2010
NCT04074330A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin LymphomaP1/P2terminated38TakedaOct 2019
NCT04136756NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaP1completed30Nektar TherapeuticsOct 2019
NCT00602459Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic LeukemiaP2completed418National Cancer Institute (NCI)Jan 2008
NCT05324917Population Pharmacokinetic-pharmacodynamic Study of Rituximab in Children With Blood Diseasesunknown20The Affiliated Hospital of Qingdao UniversityApr 2022
NCT04622579R2DLBCL80Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 YearsP2unknown20Guangdong Provincial People's HospitalOct 2020
NCT02594384LAM-002A/NHLA Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's LymphomaP1completed62OrphAI TherapeuticsOct 2015
NCT02914938A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaP1terminated97MEI Pharma, Inc.Oct 2016
NCT04045028PKA Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaP1terminated41Genentech, Inc.Jul 2019
NCT04745832ME-401Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)P3terminated82MEI Pharma, Inc.Aug 2021
NCT05209308CORALRituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLLP2withdrawn0MEI Pharma, Inc.Nov 2022
NCT04022005Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCLP2completed54Sun Yat-sen UniversityJun 2019
NCT04062448WMA Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)P2completed16Janssen Pharmaceutical K.K.Sep 2019
NCT03976102FLINTERCompare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular LymphomaP3completed317Dr. Reddy's Laboratories LimitedMay 2019
NCT02135874Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute LeukemiaP2completed16M.D. Anderson Cancer CenterOct 2014
NCT02199184Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaP2completed14M.D. Anderson Cancer CenterJan 2015
NCT04224571CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in ChildrenP2completed208Chinese University of Hong KongSep 2018
NCT02960646Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesP1completed11M.D. Anderson Cancer CenterJan 2017
NCT04507477Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot TrialP1/P2unknown10University Health Network, TorontoJul 2020
NCT05659407PREDICTBAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritisunknown60University of CagliariJul 2020
NCT00293475Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaP1/P2unknown81OHSU Knight Cancer InstituteOct 2005
NCT04002401ZUMA-14Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaP2completed27Kite, A Gilead CompanyNov 2019
NCT01307605Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular LymphomaP2terminated154Swiss Cancer InstituteFeb 2011
NCT04154787Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous NephropathyP2terminated37Novartis PharmaceuticalsNov 2019
NCT04783675RTXFIRPedINSEfficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic SyndromeP2completed44Children's Hospital of Fudan UniversityApr 2021
NCT04246359RIPPLERituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell LymphomaP2unknown52Huiqiang HuangJan 2020
NCT05057481Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus ErythematosusP3unknown30Assiut UniversitySep 2021
NCT03934814Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and LymphomaP1completed98I-Mab Biopharma US LimitedApr 2019
NCT03994783TAR:GET-1Transplant Antibody-Mediated Rejection: Guiding Effective TreatmentsP3terminated3Imperial College LondonJul 2019
NCT05191225Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid StudyP4unknown48Laida Cuevas PalomaresSep 2021
NCT04425824Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell LymphomaP2unknown20Chinese Academy of Medical SciencesJun 2020
NCT04319601AITLRituximab Combined With Chidamide and Lenalidomide for r/r AITLN/Aunknown26Zhejiang Cancer HospitalMar 2020
NCT02398240Brentuximab for Newly Diagnosed Hodgkin DiseaseP2completed40Mitchell CairoMay 2015
NCT00790413Haploidentical Stem Cell Transplantation in NeuroblastomaEarly P1unknown15Lund University HospitalAug 2005
NCT04235036Ibrutinib and Rituxan for Chronic GVHDP2terminated15Northside Hospital, Inc.Dec 2019
NCT04337827Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative DisorderP2terminated6Deepa JagadeeshSep 2020
NCT03112603BATA Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)P3completed330Incyte CorporationJun 2017
NCT04776850Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe HemoglobinopathiesEarly P1withdrawn0M.D. Anderson Cancer CenterDec 2020
NCT02955823A Phase II Study of the FIL on Elderly Frail Patients With DLBCLP2completed68Fondazione Italiana Linfomi - ETSSep 2016
NCT02663518TTI-621A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsP1terminated249PfizerJan 2016
NCT01516567Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab EvaluationP2completed47Gustave Roussy, Cancer Campus, Grand ParisApr 2012
NCT01516580Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk PatientsP3completed482Gustave Roussy, Cancer Campus, Grand ParisDec 2011
NCT04934579Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System LymphomaP2completed17Second Affiliated Hospital, School of Medicine, Zhejiang UniversityJan 2020
NCT04588194Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaP2unknown12David Gomez AlmaguerNov 2020
NCT04640818Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapyunknown45Claudio GobbiDec 2020
NCT01095172ReMINDRituxiMab INDuction in Renal TransplantationP4unknown100Guy's and St Thomas' NHS Foundation TrustNov 2010
NCT01796171LYMRIT-37-01A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin LymphomaP1/P2completed191Nordic NanovectorDec 2012
NCT02636322Smart Start: A Phase II Study of Rituximab, Lenalidomide, and IbrutinibP2completed60M.D. Anderson Cancer CenterMar 2016
NCT04660799PKA Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)P2completed50Hoffmann-La RocheFeb 2021
NCT03432741Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerP1terminated17Mayo ClinicMar 2018
NCT04531865Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab TreatmentP3withdrawn0Children's Hospital of Fudan UniversityJan 2021
NCT03096782Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaP2completed6M.D. Anderson Cancer CenterOct 2017
NCT02733042FUSION NHL 001A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic LeukemiaP1/P2completed106CelgeneMay 2016
NCT04542629Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in ChildrenP4unknown140Assiut UniversityOct 2020
NCT00493467Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent LymphomasP2completed31M.D. Anderson Cancer CenterJun 2006
NCT00114738EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell LymphomaP2completed53National Cancer Institute (NCI)Jun 2005
NCT02611323FLA Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2completed133Hoffmann-La RocheMar 2016
NCT02005471MURANOA Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)P3completed389Hoffmann-La RocheMar 2014
NCT02285062ROBUSTEfficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell LymphomaP3completed570CelgeneFeb 2015
NCT01199575CLLPhase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)P2completed30University of California, San DiegoAug 2010
NCT02042391PTLD-2Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and ImmunochemotherapyP2completed60Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbHFeb 2015
NCT03384277Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With RituximabP4completed66Institute of Hematology & Blood Diseases Hospital, ChinaDec 2017
NCT05332587Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia GravisP3unknown50First Affiliated Hospital, Sun Yat-Sen UniversityAug 2020
NCT01754857Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLLP2completed36University of Wisconsin, MadisonNov 2013
NCT03424122CITADEL-112INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)P1completed50Incyte CorporationJul 2018
NCT01682616A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaP1completed49AbbVieJul 2012
NCT02115997A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic PolyangitisP4completed30Hoffmann-La RocheJul 2015
NCT02898259Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell LymphomaP1/P2terminated19Brian HillFeb 2017
NCT03949062Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLP2unknown30Ruijin HospitalMar 2019
NCT04361279A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCLP3completed421Shanghai Institute Of Biological ProductsJul 2019
NCT01399372Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System LymphomaP2completed91Radiation Therapy Oncology GroupSep 2011
NCT01193842Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell LymphomasP1/P2completed107National Cancer Institute (NCI)Oct 2010
NCT04033276IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific AntibodiesP4completed50Seoul National University HospitalJan 2019
NCT03023046Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaP2completed54University of WashingtonFeb 2017
NCT03003520A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell LymphomaP2completed46CelgeneFeb 2017
NCT02043587Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic LymphomaP2terminated31University of California, San DiegoJan 2014
NCT03578198MG4101Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)P2terminated12Seoul National University HospitalNov 2018
NCT04502706Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin LymphomaP1terminated9Gilead SciencesNov 2020
NCT03983031RITS-PO-2019Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)P1completed11Region Örebro CountyAug 2019
NCT03983018RITS-PS-2019Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)P2completed9Region Örebro CountyAug 2019
NCT03193866COMBAT-MSCOMparison Between All immunoTherapies for Multiple Sclerosis.completed3,526Karolinska InstitutetJun 2017
NCT01679119INCATreatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing ChemotherapyP2completed129University College, LondonOct 2013
NCT04762160SYMPHONY-2SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular LymphomaP2terminated5Epizyme, Inc.Dec 2020
NCT04189952Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaP2terminated2University of MiamiSep 2020
NCT00667329Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and RituximabP1completed14M.D. Anderson Cancer CenterJul 1999
NCT04236141A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).P3terminated42Hoffmann-La RocheJul 2020
NCT02950155RinomaxA Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia GravisP3completed47Fredrik PiehlOct 2016
NCT02749292MAINTANCAVASMaintenance of ANCA Vasculitis Remission by Intermittent Rituximab DosingP4terminated115Massachusetts General HospitalJun 2016
NCT01938001AUGMENTRituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)P3completed358CelgeneNov 2013
NCT03298698Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic SyndromeP3unknown40Radboud University Medical CenterAug 2018
NCT01145495Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaP2completed66National Cancer Institute (NCI)Jun 2010
NCT05762003CPECzech Pharmaco-epidemiological Study on Disease Modifying Drugscompleted17,478IMPULS Endowment FundJan 2019
NCT02871869Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell LymphomaP2/P3unknown316Xinjiang Medical UniversitySep 2016
NCT00324467LYTPETTailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid TreatmentP2unknown150British Columbia Cancer AgencyAug 2006
NCT03169790NHLQUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLP1/P2withdrawn0ImmunityBio, Inc.Dec 2017
NCT02600897FLA Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2completed114Hoffmann-La RocheMar 2016
NCT01619761NK Cells in Cord Blood TransplantationP1unknown13M.D. Anderson Cancer CenterMay 2013
NCT03069703PNEUMOVASInnovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab TherapyP2completed96Assistance Publique - Hôpitaux de ParisFeb 2018
NCT03422523ARGOAtezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose TherapyP2terminated53University Hospital Southampton NHS Foundation TrustMay 2018
NCT00118209Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's LymphomaP3completed524Alliance for Clinical Trials in OncologyMay 2005
NCT03036904V+DA-EPOCH-RStudy of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell LymphomasP1completed31Weill Medical College of Cornell UniversityFeb 2017
NCT02966717CKDRituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)P2unknown116Zhujiang HospitalAug 2016
NCT04220008Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaP2withdrawn0M.D. Anderson Cancer CenterOct 2021
NCT02257567DCDS4501AA Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell LymphomaP1/P2completed331Hoffmann-La RocheOct 2014
NCT02471911KPT-330+RICEKPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell LymphomaP1completed22Weill Medical College of Cornell UniversityDec 2015
NCT04572620Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.unknown30Federal Research Institute of Pediatric Hematology, Oncology and ImmunologySep 2020
NCT02442648B-Cell Targeted Carfilzomib DesensitizationP1unknown32E. Steve WoodleDec 2014
NCT02741388SELINDAA Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDPP1completed39The Lymphoma Academic Research OrganisationOct 2016
NCT03689894Ibrutinib Plus Rituximab for cGVHD Following Allo-SCTP1/P2terminated2Dartmouth-Hitchcock Medical CenterApr 2019
NCT02652468TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed LymphomaN/Acompleted11University of Wisconsin, MadisonMar 2016
NCT01381692Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaP1/P2completed9National Cancer Institute (NCI)Jul 2011
NCT02746744RIFUND-MSRItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.P3completed200Anders SvenningssonMay 2016
NCT00075946Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's LymphomaP3completed545Eastern Cooperative Oncology GroupJan 2004
NCT04419389R/RAPR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)P1/P2terminated1Aprea TherapeuticsMar 2021
NCT03019640Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaP2completed22M.D. Anderson Cancer CenterOct 2017
NCT01030900DA-EPOCH-RPhase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin LymphomasP2completed50National Cancer Institute (NCI)Oct 2009
NCT02314403Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)P1completed2Massachusetts General HospitalFeb 2015
NCT02538926Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaP2withdrawn0University of WashingtonJul 2018
NCT01332968RO5072759A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)P3completed1,401Hoffmann-La RocheJul 2011
NCT01700946Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and LymphomaP2completed80St. Jude Children's Research HospitalApr 2013
NCT03332888ICFEr-RITU2Safety of HMA-CD20 in Patients With HFrEFP2unknown10Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec SaludJan 2021
NCT03312907SLEA Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVEP3completed292GlaxoSmithKlineMar 2018
NCT03232307Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaP2withdrawn0M.D. Anderson Cancer CenterJul 2019
NCT02961816Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed LymphomaP2withdrawn0M.D. Anderson Cancer CenterJun 2017
NCT02406092SCSafety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3AP3completed139Hoffmann-La RocheOct 2015
NCT02198248LoVASLow-dose Glucocorticoid Vasculitis Induction StudyP4unknown140Chiba UniversityOct 2014
NCT01859819REBOOTTreatment for Advanced B-Cell LymphomaP2completed45New York Medical CollegeJan 2013
NCT00317096FCM Versus R-FCM Followed by R-Maintenance or Observation OnlyP3unknown319Ludwig-Maximilians - University of MunichNov 1998
NCT02303119FLIRTFollicular Lymphoma IV/SC Rituximab Therapy (FLIRT)P3completed221The Lymphoma Academic Research OrganisationFeb 2015
NCT02564744Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHLP2completed100Debiopharm International SAJun 2016
NCT03161054Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell LymphomasP2completed21Fondazione Italiana Linfomi - ETSSep 2017
NCT02703272A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaP3terminated72Janssen Research & Development, LLCJul 2016
NCT01723839FCRPhase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus LenalidomideP2completed21Hackensack Meridian HealthFeb 2012
NCT03864185RECIPEThe Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 AutoantibodiesP2completed25Nagoya UniversityMar 2019
NCT03518112Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic LeukemiaP2terminated6M.D. Anderson Cancer CenterApr 2018
NCT04074187A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)P2/P3completed21SanofiOct 2019
NCT01842386Rituximab for Anti-cytokine Autoantibody-Associated DiseasesP1completed7National Institute of Allergy and Infectious Diseases (NIAID)Apr 2014
NCT03072199RITA-MIRituximab in Patients With Acute ST-elevation Myocardial Infarction StudyP1/P2completed24Papworth Hospital NHS Foundation TrustJun 2017
NCT03892421Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin LymphomaP1/P2completed22La Raza Medical CenterApr 2018
NCT02423837BRiFBendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular LymphomaP3unknown200National Research Center for Hematology, RussiaDec 2013
NCT01644253Phase 1b Safety and Efficacy Study of TRU-016P1terminated87Aptevo TherapeuticsSep 2012
NCT02018861CITADEL-101A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)P1/P2completed88Incyte CorporationSep 2016
NCT01234766Fol-BRITeBendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular LymphomaP2completed39Dartmouth-Hitchcock Medical CenterOct 2010
NCT03527147PRISMPlatform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)P1completed30Acerta Pharma BVJun 2018
NCT02187133Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaP1completed10University of California, San FranciscoMay 2015
NCT01412879S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell LymphomaP2completed53SWOG Cancer Research NetworkNov 2011
NCT04155840Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2terminated1University of WashingtonJan 2020
NCT02265731Study Evaluating Venetoclax in Subjects With Hematological MalignanciesP1/P2completed38AbbVieSep 2014
NCT00712582Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell LymphomaP2completed96Memorial Sloan Kettering Cancer CenterJul 2008
NCT03443570Rituximab Combining Bortezomib Versus Rituximab in Management of ITPP3unknown200Shandong UniversityMar 2018
NCT03304288The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune ThrombocytopeniaP2unknown168Peking University People's HospitalOct 2017
NCT02677155Lymvac-2Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular LymphomaP2completed10Oslo University HospitalJan 2016
NCT00290511R-FNDRituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular LymphomaP2completed49M.D. Anderson Cancer CenterJun 2004
NCT02086175A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin LymphomaP2completed25Dana-Farber Cancer InstituteDec 2014
NCT04279938A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCLP1withdrawn0Royal Marsden NHS Foundation TrustSep 2018
NCT03018626R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCLP3unknown402Nanfang Hospital, Southern Medical UniversityJul 2017
NCT01862926RECITALRituximab Versus Cyclophosphamide in Connective Tissue Disease-ILDP2/P3completed104Royal Brompton & Harefield NHS Foundation TrustNov 2014
NCT02128061Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+P3completed250The Lymphoma Academic Research OrganisationAug 2014
NCT02420717Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaP2terminated11M.D. Anderson Cancer CenterJul 2015
NCT02692248Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCTP2completed64Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaApr 2016
NCT01808911CREHAOutcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)P3completed110University Hospital, RouenMay 2012
NCT00599170Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaP2completed52University of Southern CaliforniaJan 2008
NCT01427114OAMLR-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)P2completed33Konkuk University Medical CenterJul 2011
NCT02767674Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell LymphomaP3unknown258The First Affiliated Hospital with Nanjing Medical UniversityMay 2016
NCT02853370Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone LymphomaP2completed78International Extranodal Lymphoma Study Group (IELSG)Jul 2012
NCT03777085DLBCLStudy of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)P3unknown230Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Jan 2019
NCT01125176ThRiLAlternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLLP2completed15Weill Medical College of Cornell UniversityMar 2012
NCT02367196A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic CancersP1completed60CelgeneMar 2015
NCT04189588versusPhase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V DiphenhydramineP2completed34TerSera Therapeutics LLCMar 2020
NCT02077166Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaP1/P2completed138Pharmacyclics LLC.Mar 2014
NCT03283202CC-122Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk FactorsP1completed35CelgeneOct 2017
NCT01994382Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLP1/P2completed260Alexion Pharmaceuticals, Inc.Aug 2013
NCT02384954QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabP1/P2terminated43Altor BioScienceApr 2015
NCT03598725HA-LD-ITILow-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in ChinaP4unknown55Beijing Children's HospitalJan 2016
NCT01969409ART-IPFAutoantibody Reduction Therapy in Patients With Idiopathic Pulmonary FibrosisP2completed58University of Alabama at BirminghamJan 2014
NCT00783367Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell LymphomasP2completed50Abramson Cancer Center at Penn MedicineJul 2008
NCT02257242BRiMVincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell LymphomaP1completed11Brown UniversityMay 2017
NCT01319981Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic LeukemiaP2completed31M.D. Anderson Cancer CenterMar 2013
NCT03136497A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaP1terminated10Hackensack Meridian HealthSep 2017
NCT01267812Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell TransplantationP2completed23City of Hope Medical CenterOct 2011
NCT02951728DR-CHOPDecitabine Plus R-CHOP in Diffuse Large B-cell LymphomaP1/P2unknown58Ruijin HospitalOct 2016
NCT02670616Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell LymphomaP2completed24Samsung Medical CenterMay 2016
NCT03778619MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell OriginP1/P2unknown9GC Cell CorporationNov 2018
NCT03545035LLC178Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Studycompleted104Gruppo Italiano Malattie EMatologiche dell'AdultoFeb 2019
NCT00477412Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell LymphomaP1/P2completed107M.D. Anderson Cancer CenterApr 2007
NCT01445535Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasP1completed15National Cancer Institute (NCI)Jan 2009
NCT02807103REOVASRituximab in Eosinophilic Granulomatosis With PolyangiitisP3completed107Assistance Publique - Hôpitaux de ParisDec 2016
NCT01742988CUDC-907Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With LymphomaP1completed106Curis, Inc.Dec 2012
NCT02423915GVHDFucosylated T Cells for Graft Versus Host Disease (GVHD) PreventionP1completed5M.D. Anderson Cancer CenterJul 2015
NCT03189836Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell LymphomaP1terminated26Cogent Biosciences, Inc.Oct 2017
NCT04402580Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic SyndromeP2terminated30Istituto Giannina GasliniJul 2019
NCT01665768Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in LymphomaP2completed56Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSep 2012
NCT01439750VELCADEBortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)P1unknown13Milton S. Hershey Medical CenterMay 2012
NCT03520920BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)P2completed41BeiGeneJan 2018
NCT01671904CLLA Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)P1completed84Genentech, Inc.Jan 2014
NCT01804712Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical ProstatectomyEarly P1completed8Christopher KaneJul 2013
NCT01592981R2WRandomised Trial in Waldenstrom's MacroglobulinaemiaP2completed60University College, LondonJan 2013
NCT02525172Immune Modulation Therapy for Pompe DiseaseP4unknown8National Taiwan University HospitalAug 2015
NCT00515554HD18 for Advanced Stages in Hodgkins LymphomaP3completed1,500University of CologneMay 2008
NCT02954406A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaP1terminated43Millennium Pharmaceuticals, Inc.Mar 2017
NCT02371148FIL_BRBFase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia'sP2completed38Fondazione Italiana Linfomi - ETSJun 2014
NCT00759798CLLIdentifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)P2completed289M.D. Anderson Cancer CenterAug 2008
NCT01594229BRA Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaP1completed60AbbVieMay 2012
NCT00695786Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin LymphomaP2completed156M.D. Anderson Cancer CenterJun 2008
NCT02858804BDH-MCL01EDOCH Alternating With DHAP for New Diagnosed Younger MCLP4completed55Institute of Hematology & Blood Diseases Hospital, ChinaJan 2016
NCT04256252RESCUERituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)P4completed108Tang-Du HospitalApr 2014
NCT01780454Renal Allograft Tolerance Through Mixed ChimerismP1/P2completed2Massachusetts General HospitalMar 2013
NCT02631538Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's SyndromeP2completed86GlaxoSmithKlineFeb 2016
NCT02059239Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory LymphomaP1/P2completed34Weill Medical College of Cornell UniversityJun 2014
NCT02428751R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell LymphomaP3unknown216Wenqi JiangSep 2015
NCT02596971CHOPA Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2completed91Hoffmann-La RocheDec 2015
NCT01434472High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaP2terminated20Fred Hutchinson Cancer CenterNov 2011
NCT03135262FLA Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2terminated29Hoffmann-La RocheJun 2017
NCT03700229Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia AP2unknown22Peking Union Medical College HospitalOct 2018
NCT03488225Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic LeukemiaP2terminated4M.D. Anderson Cancer CenterMar 2018
NCT02933320BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or LeukaemiaP1/P2completed14Cancer Research UKOct 2016
NCT00591630Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell TransplantationP2completed30M.D. Anderson Cancer CenterNov 2007
NCT03054259ROOTSRituximab Objective Outcome Measures Trial in SLEP2unknown30University of LeedsSep 2017
NCT02267915MAN2Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCTP2unknown36Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaMar 2015
NCT02990286EvER-ILDEvaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung DiseasesP3completed122University Hospital, ToursJan 2017
NCT01554514Low Dose Rituximab in Thrombotic Thrombocytopenic PurpuraP2completed19Washington University School of MedicineAug 2012
NCT02776813Study of ACTR087 in Subjects With Relapsed or Refractory B-cell LymphomaP1completed34Cogent Biosciences, Inc.Aug 2016
NCT02752204TORCHAn Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell LymphomaP2completed36University of BirminghamOct 2015
NCT02378298RTXRituximab (RTX) Therapy in Patients With Active TAOP4completed38Göteborg UniversityDec 2011
NCT01939327R2Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's LymphomaP2completed34Institut Paoli-CalmettesSep 2013
NCT02343536CC-486A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaP1completed59CelgeneApr 2015
NCT03259529BeGeRNSafety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCLP1/P2completed30St. Petersburg State Pavlov Medical UniversityMar 2017
NCT03795571R2-GODLenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCLP1unknown12The First Affiliated Hospital with Nanjing Medical UniversityJan 2019
NCT03372837Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell LymphomaP3completed40SymBio PharmaceuticalsJan 2018
NCT03180723Effect of Rituximab in Treatment of Membranoproliferative GlomerulonephritisP3unknown30Assiut UniversityJul 2017
NCT02772822A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL PatientsP3unknown330Sinocelltech Ltd.Jun 2016
NCT02460276PHILEMONA Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaP2completed50Lund University HospitalApr 2015
NCT03018535RI-CYCLORituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous NephropathyP3unknown76Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaJan 2012
NCT02867566A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma PatientsP3completed420Innovent Biologics (Suzhou) Co. Ltd.Aug 2016
NCT02304354LYRITUXRelationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)P3completed70University Hospital, ToursMar 2015
NCT01086540Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)P2completed57National Institute of Allergy and Infectious Diseases (NIAID)Jun 2011
NCT02951156Javelin DLBCLAvelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)P3terminated29PfizerDec 2016
NCT01216683Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular LymphomaP2completed289ECOG-ACRIN Cancer Research GroupFeb 2011
NCT02400437Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's MacroglobulinemiaP2completed26Dana-Farber Cancer InstituteApr 2015
NCT03507348Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant CandidatesN/Aterminated8University Hospital, GrenobleJul 2018
NCT01697267RITAZAREMRituximab Vasculitis Maintenance StudyP3completed188Cambridge University Hospitals NHS Foundation TrustApr 2013
NCT00812669ICORGCLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7P2completed52Cancer Trials IrelandAug 2008
NCT00058422Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell LymphomaP2completed65Memorial Sloan Kettering Cancer CenterFeb 2003
NCT03154385RITUX PLUSEfficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune ThrombocytopeniaN/Acompleted15Assistance Publique - Hôpitaux de ParisMar 2017
NCT02165397Ibrutinib With Rituximab in Adults With Waldenström's MacroglobulinemiaP3completed181Pharmacyclics LLC.Jul 2014
NCT04274257DesiReSA Study of the Efficacy and Safety of Rituximab in Participants With Systemic SclerosisP2/P3completed56Tokyo UniversityDec 2017
NCT02994927ADVOCATEA Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated VasculitisP3completed331AmgenMar 2017
NCT03980379Pharmacokinetics, Efficacy and Safety of the 304 InjectionP1unknown60Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Dec 2018
NCT02433795BRBendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)P2completed27Seoul National University HospitalMay 2015
NCT01514344IRISIntralesional Rituximab for the Treatment of Conjunctival Indolent LymphomaP2completed20Andres J. M. FerreriDec 2011
NCT02383589MMFA Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)P3completed135Hoffmann-La RocheMay 2015
NCT00992446Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaP2completed27Fred Hutchinson Cancer CenterSep 2010
NCT03225924ENTOStudy of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by ChemiotherapyP1/P2terminated25The Lymphoma Academic Research OrganisationJul 2017
NCT02945215IBI301A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma PatientsP1completed181Innovent Biologics (Suzhou) Co. Ltd.Dec 2016
NCT03593902CASTCardiac Safe Transplants for Systemic SclerosisP2/P3terminated9Northwestern UniversityMay 2018
NCT02729896FLA Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2completed36Hoffmann-La RocheNov 2016
NCT03579927CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell LymphomaP1/P2withdrawn0M.D. Anderson Cancer CenterOct 2019
NCT00267865Chemotherapy and HAART to Treat AIDS-related Primary Brain LymphomaP2completed12National Cancer Institute (NCI)Sep 2006
NCT02545959EFFRITEIntrathecal Rituximab in Progressive Multiple SclerosisP2completed10Centre Hospitalier de PAUNov 2015
NCT00770224S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaP2completed87SWOG Cancer Research NetworkApr 2009
NCT02481297CLLLirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsP2completed7M.D. Anderson Cancer CenterJun 2015
NCT02501473Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)P1/P2terminated52Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Feb 2016
NCT01118234Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)P3completed256Arbeitsgemeinschaft medikamentoese TumortherapieDec 2009
NCT00383994Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell TransplantationP1completed6M.D. Anderson Cancer CenterSep 2006
NCT02453087A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaP1completed66Hoffmann-La RocheAug 2015
NCT01448096Study in Patients With Primary Breast Diffuse Large B-cell LymphomaP2completed33Chonbuk National University HospitalAug 2011
NCT02280525NKCord Blood Natural Killer (NK) Cells in Leukemia/LymphomaP1completed8M.D. Anderson Cancer CenterMar 2015
NCT03255096A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6P1completed39Hoffmann-La RocheAug 2017
NCT02843061Combination of Rituximab and NK Immunotherapy for B LymphomaP1/P2completed30Fuda Cancer Hospital, GuangzhouJul 2016
NCT01429025Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin LymphomaP1completed26Alliance for Clinical Trials in OncologyMay 2012
NCT02266888B Cell Induction in Pediatric Lung TransplantationP2completed45National Institute of Allergy and Infectious Diseases (NIAID)Jan 2015
NCT02141451ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCLP1/P2completed30Masonic Cancer Center, University of MinnesotaMay 2014
NCT01576588Rituximab in Pretreated Elderly or Unfit B-CLL PatientsP2completed25Prof. Dr. Med. Laimonas GriskeviciusOct 2011
NCT02747043JASMINEStudy to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to RituximabP3completed256AmgenMay 2016
NCT02055820NHLA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCLP1/P2completed267Hoffmann-La RocheNov 2013
NCT01955187STARMENSequential Therapy With Tacrolimus and Rituximab in Primary Membranous NephropathyP3completed86Hospital Universitario 12 de OctubreJan 2014
NCT01136395Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal TransplantationP2completed85University of GiessenJan 2010
NCT01569295TugelaStudy Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )P3completed416Gilead SciencesJun 2012
NCT03188198Risk Adapted Therapy in Diffuse Large B Cell LymphomaP2unknown60Mansoura UniversityJun 2016
NCT02394119Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic SyndromeP2completed140Istituto Giannina GasliniJun 2015
NCT01889069DLBCLA Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)P3completed159Hoffmann-La RocheJul 2013
NCT00880815Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell TransplantP1completed60M.D. Anderson Cancer CenterFeb 2009
NCT03003039A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaP1completed85Nanjing Yoko Biomedical Co., Ltd.Jun 2017
NCT02624986FLA Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) ParticipantsP1/P2terminated25Hoffmann-La RocheDec 2015
NCT02705638TIGR2Treatment of IgG4-Related Disease With Revlimid and RituximabP1completed6Mayo ClinicApr 2016
NCT02753647Chidamide Plus R-CHOP in Elderly DLBCLP2unknown49Ruijin HospitalApr 2016
NCT01490723SCTZevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)P2completed20M.D. Anderson Cancer CenterJan 2013
NCT03790293LTFURITUX3Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" TrialP3completed80University Hospital, RouenNov 2018
NCT03558750Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaP1terminated6Vanderbilt-Ingram Cancer CenterJun 2018
NCT02049541Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaP1completed18Kami Maddocks, MDJul 2014
NCT02589145Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeP1/P2terminated8M.D. Anderson Cancer CenterJun 2016
NCT01855750A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaP3completed838Janssen Research & Development, LLCSep 2013
NCT00992030R-ABVD vs ABVD-RT in Early Stage Hodgkin's LymphomaP3terminated112Fondazione MichelangeloSep 2009
NCT00274924Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's LymphomaP2completed100Eastern Cooperative Oncology GroupSep 2006
NCT03582098RETRO-idelClinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Irelandcompleted112Gilead SciencesSep 2018
NCT00983619A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell MalignanciesP1/P2completed136MedImmune LLCApr 2010
NCT03670888A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma PatientsP1terminated1JHL Biotech, Inc.Nov 2018
NCT02980042Safety of Switching From Rituximab to Ocrelizumab in MS PatientsP3completed200University of Colorado, DenverJan 2017
NCT03315923Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsP2/P3completed84Isfahan University of Medical SciencesDec 2017
NCT01307267A Study Of PF-05082566 As A Single Agent And In Combination With RituximabP1completed190PfizerJun 2011
NCT01253460Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)P2terminated18M.D. Anderson Cancer CenterAug 2011
NCT02260934CALIBRATERituximab and Belimumab for Lupus NephritisP2completed43National Institute of Allergy and Infectious Diseases (NIAID)Jul 2015
NCT01691898ROMULUSA Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)P1/P2completed231Genentech, Inc.Sep 2012
NCT02867553RADIO-LYMPHMultiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent LesionsP3unknown36CHU de ReimsOct 2011
NCT01611090A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP3completed578Janssen Research & Development, LLCSep 2012
NCT01429610RADICALRituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic LeukemiaP2unknown78Asan Medical CenterNov 2011
NCT02971982PCD Versus RCD for the Treatment of Patients With Waldenstrom's MacroglobulinemiaP1/P2unknown40The First Affiliated Hospital of Soochow UniversityOct 2016
NCT02758925CyBeR-LymphCyBeR Association in Relapsed/Refractory DLBCLP2unknown78University Hospital, CaenJun 2016
NCT02757196Treatment of ITP With Rituximab and / or AccutaneP2unknown112Peking University People's HospitalMay 2016
NCT02315118Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell MalignanciesP1/P2unknown18National University Hospital, SingaporeDec 2014
NCT02381899Observational Study in CLL Patients Receiving BRcompleted83Czech CLL Study GroupSep 2014
NCT01805037Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasP1/P2terminated20Northwestern UniversityMar 2013
NCT01280682Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 DiabetesP4completed120Yang TaoJul 2010
NCT01449344(R-HAD)Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCLP3unknown128Prof. Dr. M. Dreyling (co-chairman)May 2009
NCT00520130Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune SystemP1/P2completed92National Cancer Institute (NCI)Oct 2007
NCT00209209MCLelderlyInduction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCLP3unknown570European Mantle Cell Lymphoma NetworkJan 2004
NCT00078949Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaP3completed849NCIC Clinical Trials GroupAug 2003
NCT01933711Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell LymphomaP3unknown328University Hospital HeidelbergJul 2002
NCT03269552Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone LymphomaP2terminated4University of WashingtonDec 2017
NCT01992653A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's LymphomaP1/P2completed85Genentech, Inc.Nov 2013
NCT02541565Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular LymphomaP1completed30University of WashingtonNov 2015
NCT00787722Hematopoietic Stem Cell Transplant in Devic's DiseaseP1/P2completed13Northwestern UniversityOct 2009
NCT01573533A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGSP2completed9Mayo ClinicOct 2013
NCT02284984SYNBIoSeSynergetic B-cell Immodulation in SLEP2completed16Leiden University Medical CenterMar 2014
NCT01813227WMA Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531P2completed7Hackensack Meridian HealthApr 2013
NCT00732498ESHAPRituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHLP2completed28University of ArizonaMay 2006
NCT02792699RAStudy to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to RituximabP3completed311AmgenMay 2016
NCT00899431CLLNonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)P2terminated39M.D. Anderson Cancer CenterMay 2009
NCT01729104Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell LymphomaP1terminated18M.D. Anderson Cancer CenterApr 2013
NCT02779283Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaP1completed7OHSU Knight Cancer InstituteJan 2016
NCT01321541PIX-RComparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantP3completed312CTI BioPharmaApr 2011
NCT00654732Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin LymphomaP2completed58M.D. Anderson Cancer CenterMar 2008
NCT02500251Belimumab Impacting Transplant EligibilityP1/P2completed11E. Steve WoodleJun 2015
NCT01848132Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.P2completed121Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOct 2013
NCT00278421Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's LymphomaP3completed592German High-Grade Non-Hodgkin's Lymphoma Study GroupNov 2005
NCT00115700Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular LymphomaP3completed150Trans Tasman Radiation Oncology GroupFeb 2000
NCT02433522MAINRITSAN3Comparison Between a Long Term and a Conventional Maintenance Treatment With RituximabP3completed97Assistance Publique - Hôpitaux de ParisMar 2015
NCT00980395VCRBortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaP2completed24University of ArizonaJul 2009
NCT01520519Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma PatientsP2completed40M.D. Anderson Cancer CenterFeb 2012
NCT01686321B-R-ENDARituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell LymphomaP2completed68University of GöttingenJul 2012
NCT01653067STORMSTORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell LymphomaP2unknown88Mathias Witzens-HarigSep 2012
NCT01035463Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin LymphomaP1/P2completed74University of NebraskaNov 2009
NCT03456466Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's LymphomaP1/P2unknown122Chia Tai Tianqing Pharmaceutical Group Co., Ltd.May 2017
NCT01964755Chemotherapy for Relapsed Epstein Barr Virus Associated LymphomaP2terminated6University of MiamiApr 2009
NCT00439556Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell TransplantP2completed40M.D. Anderson Cancer CenterFeb 2007
NCT01461928MabCuteA Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous RituximabP3completed692Hoffmann-La RocheDec 2011
NCT02787239Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCLP3completed407Shanghai Henlius BiotechOct 2015
NCT02556866ESBAMRituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia VasculitisP2terminated14Assistance Publique - Hôpitaux de ParisJul 2015
NCT02110706BeatMG: Phase II Trial of Rituximab In Myasthenia GravisP2completed52Yale UniversityMay 2014
NCT02855359SGN-CD19ADenintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaP2terminated24Seagen Inc.Aug 2016
NCT01750697A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic PolyangiitisP2completed25Hoffmann-La RocheMay 2013
NCT00477815Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple MyelomaP1completed30Mayo ClinicMay 2005
NCT00074282Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLLP2completed102Eastern Cooperative Oncology GroupApr 2005
NCT02592876SGN-CD19ATreatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaP2terminated81Seagen Inc.Oct 2015
NCT01134575ALLCMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)P2completed90M.D. Anderson Cancer CenterJun 2010
NCT00711828Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell LymphomaP2completed21Mayo ClinicAug 2008
NCT01197560DLBCLStudy of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)P2/P3completed111CelgeneSep 2010
NCT01622439VALFRIDValproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell LymphomaP1/P2completed50Lund University HospitalJun 2012
NCT01729806Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaP1completed32National Cancer Institute (NCI)Nov 2012
NCT00104858Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2completed66Fred Hutchinson Cancer CenterDec 2004
NCT02624492To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCLP2completed21Boehringer IngelheimJan 2016
NCT02187861GDC-0199A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)P2completed163Hoffmann-La RocheDec 2014
NCT00295932Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's LymphomaP1/P2completed79Memorial Sloan Kettering Cancer CenterDec 2005
NCT02789397Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable ImmunodeficiencyP2withdrawn0Medical College of WisconsinMay 2016
NCT03530462To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRIcompleted22First Affiliated Hospital of Zhejiang UniversityApr 2017
NCT02251964RITUX-IPRituximab in Interstitial PneumonitisP2/P3completed20Human AdamsSep 2014
NCT00278408Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's LymphomaP3completed700German High-Grade Non-Hodgkin's Lymphoma Study GroupJan 2006
NCT02617485MADILYMMabionCD20 Compared to MabThera in Lymphoma PatientsP3completed143Mabion SADec 2015
NCT01400685Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLP1completed34Massachusetts General HospitalDec 2012
NCT01287741GOYAA Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)P3terminated1,418Hoffmann-La RocheJul 2011
NCT00769522FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic LeukemiaP3completed564German CLL Study GroupOct 2008
NCT01419665ASSIST_FLGP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)P3completed629SandozDec 2011
NCT03485118Hi-CHOPRHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell LymphomaP2completed137Zhejiang Hisun Pharmaceutical Co. Ltd.May 2016
NCT02293109Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or LymphomaP1completed10Mehrdad Abedi, MDDec 2015
NCT01956695REVRIEfficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System LymphomaP2completed45Institut CurieSep 2013
NCT01773616RITUXILUPTrial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus NephritisP3terminated24Imperial College LondonApr 2015
NCT01659099GAINEDGA In NEwly Diagnosed Diffuse Large B Cell LymphomaP3terminated671The Lymphoma Academic Research OrganisationSep 2012
NCT02792491Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and OverP2unknown57Pusan National University HospitalAug 2012
NCT01313611BRIEFBRIEF Bendamustine and Rituximab In Elderly FollicularP2terminated62The Lymphoma Academic Research OrganisationFeb 2011
NCT01446900R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic LymphomaP2terminated25European Institute of OncologyJan 2011
NCT01097057G-CSFRituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem CellsP2completed20Fred Hutchinson Cancer CenterNov 2010
NCT00227695Rituximab in Treating Patients With Follicular Non-Hodgkin's LymphomaP3completed270Swiss Cancer InstituteJun 2004
NCT00490529Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCLP2completed59Ronald LevyAug 2009
NCT02229942RituxMEB-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.P3completed151Haukeland University HospitalSep 2014
NCT01980654Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaP2completed80Pharmacyclics LLC.Dec 2013
NCT01058239Bortezomib Plus Rituximab for EBV+ PTLDP2completed7Massachusetts General HospitalNov 2011
NCT01684865An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphomacompleted22Hoffmann-La RocheOct 2012
NCT01983969Aza-SAHA-GBM With AutoSCT for Refractory LymphomaP1/P2completed61M.D. Anderson Cancer CenterNov 2013
NCT01292603A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic LeukemiaP1completed240Hoffmann-La RocheApr 2011
NCT01686165Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHLP2completed5University of ArizonaAug 2012
NCT02169219SCOUTPilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated VasculitisP4completed20Massachusetts General HospitalJun 2014
NCT02468791MabionCD20® Compared to MabThera® in Patients With Rheumatoid ArthritisP3completed709Mabion SAMay 2013
NCT01200758SCA Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's LymphomaP3completed410Hoffmann-La RocheFeb 2011
NCT01451879Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapiescompleted11University of FloridaOct 2008
NCT00129090Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's LymphomaP3completed450German High-Grade Non-Hodgkin's Lymphoma Study GroupMar 2003
NCT00662948ZAR2007ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)P2completed149PETHEMA FoundationDec 2008
NCT01044745Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic CancerP2terminated20University of NebraskaDec 2009
NCT01010217Mismatched Transplantation Using High-dose Post-transplant CyclophosphamideP2completed176M.D. Anderson Cancer CenterNov 2009
NCT01180036MENTORMEmbranous Nephropathy Trial Of RituximabP2/P3completed130Mayo ClinicNov 2011
NCT02594163Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell LymphomaP2terminated25Seagen Inc.Oct 2015
NCT02834286Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaP2unknown15Hospital Universitario Dr. Jose E. GonzalezMar 2015
NCT01670084Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous LeukemiaP2withdrawn0Mayo ClinicDec 2012
NCT00376961S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell LymphomaP2completed68SWOG Cancer Research NetworkAug 2006
NCT02654379Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europecompleted1,408Hoffmann-La RocheDec 2015
NCT00254410CLLFCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 YearsP2completed30M.D. Anderson Cancer CenterMar 2005
NCT00602836Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2completed45Mayo ClinicFeb 2008
NCT01662050FIL-RBAC500Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCLP2completed57Fondazione Italiana Linfomi - ETSMar 2012
NCT01078142BERTTemsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell LymphomaP1/P2completed39Georg Hess, MDFeb 2010
NCT02253264A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis PatientsP1completed8Johns Hopkins UniversityNov 2014
NCT01334502Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell LymphomaP1completed26Alliance for Clinical Trials in OncologyMar 2012
NCT00963534LENA-BERITLenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.P1/P2completed51Lund University HospitalSep 2009
NCT01318915RESTARRTResearch Study of ATG and Rituximab in Renal TransplantationEarly P1terminated10National Institute of Allergy and Infectious Diseases (NIAID)Jul 2011
NCT00577993FNDFludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma PatientsP3completed210M.D. Anderson Cancer CenterMar 1998
NCT02053610CLL11CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)P3completed787Hoffmann-La RocheDec 2009
NCT01998880CLL11CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)P3completed787Hoffmann-La RocheDec 2009
NCT01010061CLL11CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)P3completed787Hoffmann-La RocheDec 2009
NCT00074490Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph CancersP2terminated442National Cancer Institute (NCI)Jan 2004
NCT01973387A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/LymphomaP3completed160Janssen Research & Development, LLCOct 2013
NCT00290498Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or YoungerP2completed67M.D. Anderson Cancer CenterAug 2005
NCT02200848CLLPhase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)P1terminated5Georgetown UniversityApr 2014
NCT00909077ITPThe Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)P3completed155Copenhagen University Hospital at HerlevAug 2004
NCT03151044R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCLP3unknown408FENG Ji-fengJul 2016
NCT02626845RENTGPARituximab for the Otolaryngologic Manifestations of Granulomatosis With PolyangiitisP4terminated3Hospital for Special Surgery, New YorkDec 2015
NCT01900496Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin LymphomaP1terminated6Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJun 2014
NCT05063513ASTILAutologous Stem Cell Transplantation: International Lupus TrialP2/P3withdrawn0European Society for Blood and Marrow TransplantationJul 2009
NCT00645606LLC2007SARituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic LeukemiaP3completed542University Hospital, ToursDec 2007
NCT00004179Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaP3completed475European Organisation for Research and Treatment of Cancer - EORTCMay 1999
NCT02194374CLLAutologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)P1withdrawn0M.D. Anderson Cancer CenterJan 2015
NCT01676558DLBCLA Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)P2unknown24Korea Cancer Center HospitalJun 2012
NCT01678417131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell LymphomaP2unknown29Korea Cancer Center HospitalJun 2012
NCT00801281PLRG4First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.P3completed250Polish Lymphoma Research GroupFeb 2007
NCT02419469Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaP2terminated1M.D. Anderson Cancer CenterNov 2015
NCT00722137Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell LymphomaP3completed487Millennium Pharmaceuticals, Inc.May 2008
NCT00787969Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell LymphomaP1completed74Alliance for Clinical Trials in OncologyApr 2009
NCT00720876Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin LymphomaP2completed30City of Hope Medical CenterJul 2008
NCT02391545CONTEMPOA Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)P1/P2terminated55SecuraBioDec 2014
NCT02623920S-BRBrentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaP2withdrawn0University of ArizonaDec 2015
NCT02219737Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaP1completed26National Cancer Institute (NCI)Sep 2014
NCT01925612DLBCLStudy of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)P2terminated87Seagen Inc.Aug 2013
NCT02197767Pilot Study of Rituximab to Treat Fibrillary GlomerulonephritisP2completed11Mayo ClinicNov 2014
NCT00476164RituxiCAN-C4Study of Rituximab to Treat Chronic Renal Transplant RejectionP4completed62King's College LondonJan 2007
NCT01613599An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitiscompleted100Genentech, Inc.Jun 2012
NCT01471067Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesP1completed33M.D. Anderson Cancer CenterJul 2012
NCT01812005Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaP2terminated14Ohio State University Comprehensive Cancer CenterMay 2013
NCT01987505MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for LymphomaP3completed140Hoffmann-La RocheNov 2013
NCT01263704A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic LeukemiaP2completed42Hoffmann-La RocheJul 2011
NCT02204982DYNAMO + RStudy of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular LymphomaP3terminated13SecuraBioSep 2014
NCT01096992FBRFludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)P1/P2completed51M.D. Anderson Cancer CenterApr 2010
NCT00764517Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's LymphomaP2completed57OHSU Knight Cancer InstituteAug 2008
NCT00553943Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at DiagnosisP2completed60Lymphoma Study AssociationJul 2007
NCT00481832Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's LymphomaP2terminated50Stanford UniversityJan 2007
NCT00695409Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin LymphomaP2completed122City of Hope Medical CenterMar 2008
NCT01596127Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous SystemP1/P2terminated4M.D. Anderson Cancer CenterJan 2013
NCT00022971Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic LeukemiaP1terminated35National Cancer Institute (NCI)Aug 2001
NCT00921414Mantel Cell Lymphoma Efficacy of Rituximab MaintenanceP3completed299French Innovative Leukemia OrganisationSep 2008
NCT00667615DLBCLTrial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2completed30Memorial Sloan Kettering Cancer CenterApr 2008
NCT00841945Treatment of Aggressive Localized LymphomaP3terminated334French Innovative Leukemia OrganisationApr 2005
NCT01491841BRPIIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's LymphomaP1completed33Anne Beaven, MDNov 2011
NCT01737177R2-BBendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCLP2completed42Fondazione Italiana Linfomi - ETSJul 2012
NCT02491398LLC1315Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemiacompleted494Gruppo Italiano Malattie EMatologiche dell'AdultoFeb 2016
NCT02484053Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic DisordersEarly P1completed20Baylor College of MedicineJun 2015
NCT04361409Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaP1completed10China Medical University HospitalMay 2013
NCT01701232Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's LymphomaP3completed174BiocadSep 2011
NCT01279902Abbreviated R-CHOP in Completely Excised Stage I or II DLBCLP2unknown32Asan Medical CenterAug 2010
NCT02390362RAMPRandomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic SyndromeP3terminated3Nationwide Children's HospitalJan 2015
NCT00940342GM-CSFRituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic LeukemiaP2completed130M.D. Anderson Cancer CenterOct 2004
NCT03002038Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD PatientsP2/P3completed86Isfahan University of Medical SciencesSep 2015
NCT04494438Rituximab for Idiopathic Nephrotic SyndromeP3completed30Istituto Giannina GasliniJul 2013
NCT02689986CAD5Bendamustine and Rituximab Combination Therapy for Cold Agglutinin DiseaseP2completed43Helse FonnaJan 2013
NCT01760226DA-EPOCH-RDose Adjusted EPOCH-R, to Treat Mature B Cell MalignanciesEarly P1completed4Baylor College of MedicineJan 2013
NCT02571842Rituximab in Recurrent IgA NephropathyP4unknown30Chulalongkorn UniversityJan 2012
NCT01238692LBH589A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)P2completed42Sarit AssoulineNov 2010
NCT03258866The Study of Different Dose Rituximab in the Treatment of ITPP4completed62Shandong UniversityJan 2010
NCT00784589Rituximab 3Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With PemphigusP3completed90University Hospital, RouenJul 2009
NCT00869323Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisordersP2terminated3Masonic Cancer Center, University of MinnesotaMar 2009
NCT00824135Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic MalignanciesP1completed34St. Jude Children's Research HospitalJan 2009
NCT00140582Primary Rituximab and MaintenanceP3completed1,217Lymphoma Study AssociationDec 2004
NCT00068250Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System LymphomaP1/P2completed60Radiation Therapy Oncology GroupJul 2003
NCT01682044Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone LymphomaP2completed20Roswell Park Cancer InstituteApr 2007
NCT01200589HOMERSingle Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing TherapyP3terminated438Novartis PharmaceuticalsOct 2010
NCT02649504Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune ThrombocytopeniaP3withdrawn0Weill Medical College of Cornell UniversityDec 2016
NCT02605694FRESCODuvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)P2withdrawn0SecuraBioDec 2015
NCT02576275BRAVURAA Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)P3withdrawn0SecuraBioDec 2015
NCT00633594Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaP1/P2completed39SCRI Development Innovations, LLCJun 2008
NCT00536341CLLFludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)P1/P2completed64SCRI Development Innovations, LLCJan 2008
NCT00411086Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell LymphomaP2completed60M.D. Anderson Cancer CenterNov 2006
NCT00816595Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2completed68Mayo ClinicFeb 2009
NCT01832922BR in Patients With CLL With Comorbidities and/or Renal DysfunctionP1completed8Dartmouth-Hitchcock Medical CenterApr 2013
NCT00577629Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins LymphomaP2completed39Duke UniversityJun 2005
NCT02281279Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaP1/P2withdrawn0Mayo ClinicOct 2016
NCT02514772ASSIST-RTGP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®P3completed107SandozJul 2015
NCT02366663SPINOZABEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCLP3terminated3City of Hope Medical CenterJan 2015
NCT01164098Rituximab to Prevent Recurrence of ProteinuriaP3terminated30George W. BurkeFeb 2012
NCT01810926T&B Depletion Non MalignantP2unknown130Franco LocatelliSep 2011
NCT00918723Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP1/P2completed40Fred Hutchinson Cancer CenterJun 2009
NCT00498316Cord Blood Expansion on Mesenchymal Stem CellsP1completed98M.D. Anderson Cancer CenterJul 2007
NCT00425802Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaP2completed61Memorial Sloan Kettering Cancer CenterNov 2006
NCT01397825MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- VincristineP1/P2completed45Millennium Pharmaceuticals, Inc.Aug 2011
NCT02438982Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic SyndromeP3completed120Nilratan Sircar Medical CollegeMay 2015
NCT02376335RITPBCB-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary CirrhosisP2completed71Newcastle-upon-Tyne Hospitals NHS TrustOct 2012
NCT01470196CaRDCarfilzomib, Rituximab and Dexamethasone in Waldenstrom's MacroglobulinemiaP2completed31Dana-Farber Cancer InstituteOct 2011
NCT01678404131I-rituximab for Relapsed or Refractory Marginal Zone B-cell LymphomaP2unknown28Korea Cancer Center HospitalOct 2011
NCT01649856A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell LymphomaP3completed572Hoffmann-La RocheAug 2012
NCT01889797PrE0401Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's LymphomaP2terminated32PrECOG, LLC.Dec 2013
NCT01775631Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins LymphomaP1completed47Bristol-Myers SquibbMar 2013
NCT01508468GEMRITUXEvaluate Rituximab Treatment for Idiopathic Membranous NephropathyP3completed80Assistance Publique - Hôpitaux de ParisJan 2012
NCT01234467Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell LymphomaP2completed23UNC Lineberger Comprehensive Cancer CenterMar 2011
NCT01542918Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular LymphomaP1completed14James RubensteinDec 2012
NCT01117662RIACTEfficacy of Rituximab in Acute Cellular Rejection in Renal Transplant PatientsP3terminated13Hannover Medical SchoolMay 2012
NCT02531308DLBCLMetformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)P2terminated5Rush University Medical CenterJul 2015
NCT01181258NKPenostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid MalignanciesP2completed16Masonic Cancer Center, University of MinnesotaAug 2010
NCT01029730Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade LymphomaP2completed55SCRI Development Innovations, LLCMar 2010
NCT01133158R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical TrialP2completed61Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaJul 2009
NCT02222155Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated VasculitisP2completed42AmgenFeb 2015
NCT01453205DLBCLA Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)P2completed187MedImmune LLCFeb 2012
NCT01871675Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic MalignanciesP1completed48SCRI Development Innovations, LLCMay 2013
NCT01524068A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis ExacerbationsP2withdrawn0University of PittsburghSep 2012
NCT01203930A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLLP2terminated105Gilead SciencesOct 2010
NCT01719159ITT-PMSIntrathecal Therapy With Monoclonal Antibodies in Progressive Multiple SclerosisP2completed23Anders SvenningssonNov 2009
NCT00513747Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic LeukemiaP3terminated84Alliance for Clinical Trials in OncologyJan 2008
NCT01980888Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic LeukemiaP3terminated311Gilead SciencesFeb 2014
NCT02735876A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaP3withdrawn0Acerta Pharma BVMay 2016
NCT01556347Multi-Drug Desensitization Protocol for Heart Transplant CandidatesP2terminated2Providence Health & ServicesJul 2012
NCT00450385R-CHOPGenes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)P2terminated57University of MiamiApr 2007
NCT00545714CLLA Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)P2completed86Hoffmann-La RocheNov 2007
NCT01732913YosemiteEfficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasP3terminated295Gilead SciencesJan 2013
NCT02044822Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p DeletionP2terminated102Gilead SciencesAug 2014
NCT01732926BridalveilEfficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasP3terminated475Gilead SciencesJan 2013
NCT01271010A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic StatusP4terminated89Hoffmann-La RocheJun 2011
NCT02258529Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaP2terminated10Gilead SciencesSep 2015
NCT01156922B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue SyndromeP2terminated8Haukeland University HospitalJun 2010
NCT00987493Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell LymphomaP1/P2completed49Swiss Cancer InstituteSep 2009
NCT00119392Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaP2completed42Fred Hutchinson Cancer CenterJun 2004
NCT01748084RECOVERRituximab in Systemic SclerosisP2/P3completed22Assistance Publique - Hôpitaux de ParisApr 2013
NCT02205333MEDI6469A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal AntibodiesP1/P2terminated48MedImmune LLCAug 2014
NCT01731561MAINRITSAN 2Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated VasculitisP3completed166Assistance Publique - Hôpitaux de ParisNov 2012
NCT02259348Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior TransplantationP2terminated12St. Jude Children's Research HospitalOct 2014
NCT01562990Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second RelapseP1/P2completed11The Lymphoma Academic Research OrganisationDec 2012
NCT01370772Intensified Rituimab Prephase Before FCR in Untreated B-CLLP2completed140French Innovative Leukemia OrganisationMay 2011
NCT01078974Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's MacroglobulinemiaP1terminated7Steven P. Treon, MD, PhDMay 2010
NCT01283386A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic StatusP4terminated26Hoffmann-La RocheApr 2011
NCT01643928REFLECTIONS B328-04Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)N/Acompleted185PfizerAug 2012
NCT02113007CNSStudy of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) LymphomaP2terminated2SCRI Development Innovations, LLCJul 2014
NCT01719692ITPLow-dose Rituximab Regimens in Chinese Adult Patients With Immune ThrombocytopeniaN/Acompleted100Institute of Hematology & Blood Diseases Hospital, ChinaOct 2012
NCT01990144Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FILP2unknown49Fondazione Italiana Linfomi - ETSNov 2011
NCT01004991Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell LymphomaP1/P2completed14Weill Medical College of Cornell UniversityJan 2010
NCT00784927Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin LymphomaP2completed36Mayo ClinicNov 2008
NCT00294632MCLLenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell LymphomaP1/P2completed54M.D. Anderson Cancer CenterFeb 2006
NCT00594815RTCombined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System LymphomaN/Acompleted52Memorial Sloan Kettering Cancer CenterAug 2002
NCT00210353Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT LymphomaP3completed454International Extranodal Lymphoma Study Group (IELSG)Jan 2003
NCT02137681A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)P3withdrawn0Shandong UniversityMay 2014
NCT00901927BMRBendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular LymphomaP2terminated14M.D. Anderson Cancer CenterMay 2009
NCT00544219PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneN/Acompleted156Swiss Cancer InstituteSep 2007
NCT00541034Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic LeukemiaP2completed49Memorial Sloan Kettering Cancer CenterMay 2005
NCT01466153CLLA Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)P2completed183MedImmune LLCFeb 2012
NCT01181154RAHIARituximab in Auto-Immune Hemolytic AnemiaP3completed32Assistance Publique - Hôpitaux de ParisMar 2011
NCT02532192A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell LymphomaP1withdrawn0M.D. Anderson Cancer CenterDec 2015
NCT02456207A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaP2unknown80Sinocelltech Ltd.May 2015
NCT02417129BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular LymphomaP3terminated2Boehringer IngelheimApr 2015
NCT01744626Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaP1completed40Celgene CorporationDec 2012
NCT01765842RITULUPComparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus NephropathyP3terminated9Fundación Pública Andaluza Progreso y SaludNov 2012
NCT01598558Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CTN/Awithdrawn0Sanjiv Sam GambhirJan 2012
NCT01567475(RAD001-R)The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's LymphomasP1completed21The Lymphoma Academic Research OrganisationDec 2011
NCT01309997Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host DiseaseP2completed72Lee, StephanieMar 2011
NCT01212094Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)P1/P2terminated44National Institute of Neurological Disorders and Stroke (NINDS)Sep 2010
NCT01127841RBTrial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First LineP2unknown60Grupo Oncológico para el Tratamiento y el Estudio de los LinfomasJul 2009
NCT00107380S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaP2completed86SWOG Cancer Research NetworkNov 2005
NCT02408042Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)P1/P2withdrawn0Western Regional Medical CenterApr 2015
NCT01609023CaLLypsoA Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemiacompleted67Hoffmann-La RocheApr 2012
NCT01295151SWITCHSWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.P4completed122Julia BrownAug 2011
NCT00634179A Phase I/II Trial of VR-CHOP in Lymphoma PatientsP1/P2completed37Emory UniversityFeb 2008
NCT01046006Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's MacroglobulinemiaP2completed59Meletios A. DimopoulosMar 2007
NCT00290667Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell LymphomaP2completed586German High-Grade Non-Hodgkin's Lymphoma Study GroupFeb 2004
NCT01493479FIZZPhase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular LymphomaP2completed76The Christie NHS Foundation TrustJun 2007
NCT01278745Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac TransplantationP2terminated362National Institute of Allergy and Infectious Diseases (NIAID)Sep 2011
NCT00617929Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell TransplantP2terminated12Masonic Cancer Center, University of MinnesotaJan 2008
NCT00669877Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/LymphomaP2completed56M.D. Anderson Cancer CenterAug 2002
NCT00422799WMCombination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)P2completed63Dana-Farber Cancer InstituteAug 2006
NCT01613027An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritiscompleted135Hoffmann-La RocheFeb 2012
NCT01421173SCTVorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid MalignanciesP1completed78M.D. Anderson Cancer CenterAug 2011
NCT01213095MZLRituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)P2completed48Dong-A University HospitalSep 2010
NCT00498368Rituximab in Progressive Immunoglobulin A (IgA) NephropathyP4completed34Mayo ClinicFeb 2009
NCT00718549CLLA Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)P3completed128Hoffmann-La RocheJul 2009
NCT02584920A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell LymphomaP1/P2completed87Shanghai Henlius BiotechOct 2014
NCT01022021PBSCPeripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With BendamustineEarly P1completed17University of Kansas Medical CenterJan 2010
NCT00931918Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma PatientsP2completed206Millennium Pharmaceuticals, Inc.Oct 2009
NCT00895661High Dose Rituximab for Initial Treatment of Indolent B-Cell LymphomasP2completed40Massachusetts General HospitalJul 2009
NCT00609869Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After RituximabP2completed29H. Lee Moffitt Cancer Center and Research InstituteOct 2007
NCT00740415ManteauRiBVDRituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell LymphomaP2completed39French Innovative Leukemia OrganisationJun 2007
NCT00238238Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to RituximabP2completed97Alliance for Clinical Trials in OncologyMar 2006
NCT02420938CLLUrelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsP2withdrawn0M.D. Anderson Cancer CenterJul 2015
NCT01759030BIORAStudy of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid ArthritisP3completed181BiocadDec 2012
NCT01161628GVHDRituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)P2completed25Northside Hospital, Inc.Apr 2011
NCT01266317Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis ExacerbationsP1/P2completed9Michael DonahoeMar 2011
NCT00856245Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular LymphomaP2completed21University of Kansas Medical CenterFeb 2009
NCT00335140Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System LymphomaP2terminated26Eastern Cooperative Oncology GroupAug 2007
NCT00590447PTLD-1/3Risk Stratified Sequential Treatment for CD20-positive PTLDP2completed152Charite University, Berlin, GermanyDec 2006
NCT00450801R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell LymphomaP2completed22University of MiamiApr 2004
NCT02332941RituximabTreatment -Resistant Neovascular Age-Related Macular DegenerationP1completed5Washington University School of MedicineAug 2014
NCT01973062Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin LymphomaP2terminated1Case Comprehensive Cancer CenterMar 2014
NCT01974518Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe PemphigusP3unknown20Uprety ShraddhaNov 2013
NCT01521689LLCRlowdozTolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation TreatmentP2unknown35Institut Paoli-CalmettesDec 2011
NCT01421667A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin LymphomaP2completed176Seagen Inc.Aug 2011
NCT01558167CLL2PA Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaP1/P2completed22German CLL Study GroupFeb 2011
NCT01269385Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic LeukemiaP1/P2completed22Mayo ClinicJan 2011
NCT01165112TRECBendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin LymphomaP1/P2completed48University of WashingtonSep 2010
NCT01178086CLLA Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)completed681Hoffmann-La RocheFeb 2010
NCT01007292A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior TreatmentP2completed43Astellas Pharma IncNov 2009
NCT00565331Rituximab for Prevention of Rejection After Renal TransplantationP2/P3completed280Radboud University Medical CenterDec 2007
NCT00772655Zevalin® First Line in Follicular LymphomaP2unknown60Charite University, Berlin, GermanyOct 2007
NCT00275054Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaP3completed825German CLL Study GroupOct 2005
NCT00096044Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaP2completed45Roswell Park Cancer InstituteMar 2004
NCT00994643Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's LymphomaP2completed11Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityFeb 2009
NCT00936546A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and EfficacyP2completed3University Hospital, GhentJun 2009
NCT01625741HYDRICPhase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction ImmunochemotherapyP2terminated6Cliniques universitaires Saint-Luc- Université Catholique de LouvainJul 2012
NCT01569451GATEWAYIIComparison of Rituximab Induction Therapy Followed by Glatiramer AcetateP2completed53University of Colorado, DenverFeb 2012
NCT01549886Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's LymphomaP2terminated5Spectrum Pharmaceuticals, IncNov 2011
NCT00581776Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell LymphomaP2completed30University of Wisconsin, MadisonMay 2005
NCT00641095MCLPIIIPhase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell LymphomaP2/P3completed370University College, LondonDec 2006
NCT02228512Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated LymphomasP1/P2withdrawn0National Cancer Institute (NCI)Aug 2014
NCT01326702Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsP1/P2completed43National Cancer Institute (NCI)Jul 2011
NCT01562977RGemOxStudy to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCLP2completed82Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaApr 2011
NCT01021735ORBITOptimal Management of Rheumatoid Arthritis Patients Requiring Biologic TherapyP4completed302University of GlasgowApr 2010
NCT00904722Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular LymphomaP2completed32M.D. Anderson Cancer CenterJan 2010
NCT00974233Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLLP2completed34University of Wisconsin, MadisonOct 2009
NCT00301821Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaP2completed107Alliance for Clinical Trials in OncologyJan 2006
NCT02983097R²-DHAPTherapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPP1/P2terminated34Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHNov 2010
NCT01088048Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic LeukemiaP1completed241Gilead SciencesMar 2010
NCT01013961Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic LeukemiaP2terminated31ECOG-ACRIN Cancer Research GroupApr 2011
NCT01373229CLLLenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)P1completed21David Rizzieri, MDJan 2012
NCT01209130A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's LymphomaP1completed91Genentech, Inc.Oct 2010
NCT00110149Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's LymphomaP2terminated12Beth Israel Deaconess Medical CenterMay 2004
NCT00867529Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell LymphomaP2completed63Fred Hutchinson Cancer CenterFeb 2009
NCT00080886Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's LymphomaP2completed68University of NebraskaMay 2002
NCT02168907CPI-613CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaP1terminated1Wake Forest University Health SciencesDec 2014
NCT01611259Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid TissueP2completed50Arbeitsgemeinschaft medikamentoese TumortherapieMay 2012
NCT01244958Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid ArthritisP3completed156Frank BehrensAug 2010
NCT00905034MOADMethotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) SalvageP2completed37M.D. Anderson Cancer CenterMar 2009
NCT00453102Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone LymphomaP2completed18University of MiamiFeb 2006
NCT02371096Comparative Pharmacokinetic Trial of RGB-03 and MabTheraP1unknown0Gedeon Richter Plc.
NCT01724021A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3aP3completed743Hoffmann-La RocheDec 2012
NCT01584388Rituximab in IgG4-RD: A Phase 1-2 TrialP1/P2completed30Massachusetts General HospitalApr 2012
NCT01641952An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agentcompleted505Hoffmann-La RocheOct 2011
NCT01279616SCTA Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell DiseaseP2terminated8Nationwide Children's HospitalSep 2010
NCT01173679Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLLP2terminated10Massachusetts General HospitalJul 2010
NCT01523860FLE09Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular LymphomaP2completed76Fondazione Italiana Linfomi - ETSJun 2009
NCT00070018S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's LymphomaP2completed46SWOG Cancer Research NetworkFeb 2004
NCT00637832Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin LymphomaP2terminated1University of SouthamptonApr 2008
NCT00911183FRAIL-06Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II TrialP2completed67Institut BergoniéDec 2008
NCT01592292An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapycompleted90Hoffmann-La RocheNov 2011
NCT00798785Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic PatientsP1/P2unknown50Universitair Ziekenhuis BrusselOct 2006
NCT00381004GM-CSFFCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic LeukemiaP2completed60M.D. Anderson Cancer CenterSep 2006
NCT02533401CLLA Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)P2completed34Hoffmann-La RocheFeb 2006
NCT00209222Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCLP3unknown360European Mantle Cell Lymphoma NetworkJul 2004
NCT00794820Fludarabine, Cyclophosphamide, and Rituximab - High Dose FrontlineP2completed66M.D. Anderson Cancer CenterDec 2003
NCT00562328Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic LeukemiaP2completed33Mayo ClinicJan 2008
NCT01226849SGH652Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell LymphomaP1completed6Singapore General HospitalNov 2010
NCT01014208ORCHARRDOfatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell LymphomaP3completed447GlaxoSmithKlineMar 2010
NCT00801632Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant RejectionP2completed5National Institute of Allergy and Infectious Diseases (NIAID)Dec 2008
NCT00765245Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin LymphomaP2completed44Vanderbilt-Ingram Cancer CenterOct 2008
NCT00598169Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin LymphomaP1completed23AIDS Malignancy ConsortiumNov 2007
NCT00438880Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin LymphomaP1/P2completed38Mayo ClinicOct 2004
NCT01290549A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins LymphomaP1completed95Genentech, Inc.Mar 2011
NCT01873443Long-Term Efficacy and Safety of CT-P10 in Patients With RAP1completed87CelltrionMay 2013
NCT01765374SEWORRAStudy of Sonographic Efficacy of Rituximab in Rheumatoid ArthritisP4completed30University Hospital, RouenFeb 2011
NCT01071798An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritiscompleted1,653Hoffmann-La RocheJan 2010
NCT01926639Lymvac-1Phase II Cancer Vaccine Trial for Patients With Follicular LymphomaP2completed14Oslo University HospitalOct 2009
NCT01830478RLenalidomide Plus Rituximab (R) in Non Follicular NHLP2unknown44Gruppo Italiano Studio LinfomiApr 2009
NCT00448019CLLFCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)P2completed64M.D. Anderson Cancer CenterFeb 2007
NCT00350545A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host DiseaseN/Acompleted37Stanford UniversityAug 2006
NCT00369681Phase 2 Study of Rituximab-ABVD in Classical Hodgkin LymphomaP2completed51Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMay 2006
NCT00039130Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's LeukemiaP2completed105Alliance for Clinical Trials in OncologyMay 2002
NCT01510184PETStudy of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyP3terminated79Spectrum Pharmaceuticals, IncApr 2012
NCT00369707Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHLP2completed42Northwestern UniversityAug 2006
NCT01470456Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell LymphomaP2completed50SanofiNov 2011
NCT01181999Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell LymphomaP2unknown50Chonnam National University HospitalAug 2010
NCT00101010Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell LymphomaP2completed80M.D. Anderson Cancer CenterSep 2005
NCT00098774Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS LymphomaP2completed47Alliance for Clinical Trials in OncologyOct 2004
NCT01754870CLLPhase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)P2withdrawn0University of Wisconsin, MadisonNov 2013
NCT02040116Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune DiseasesP4completed19Wake Forest University Health SciencesFeb 2013
NCT01282476Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaP2terminated18Massachusetts General HospitalJun 2011
NCT01144403A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.P2terminated8Hoffmann-La RocheJun 2010
NCT01125293Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaP1/P2terminated46Dana-Farber Cancer InstituteApr 2010
NCT00759603Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic LeukemiaP2completed60M.D. Anderson Cancer CenterSep 2008
NCT00553501Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaP2completed60Alliance for Clinical Trials in OncologyMar 2008
NCT00720135Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaP1completed9City of Hope Medical CenterJan 2008
NCT00057811Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or LymphomaP2completed97Children's Oncology GroupJun 2004
NCT01086631Rituximab for Autoimmune RetinopathyP1completed5National Eye Institute (NEI)Jan 2010
NCT01670812Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic LeukemiaP3unknown100The First Affiliated Hospital with Nanjing Medical UniversityJan 2012
NCT01525836rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITPP3completed123Shandong UniversityMay 2011
NCT02536664Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participantscompleted505Hoffmann-La RocheSep 2009
NCT00198978German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaP4completed377Goethe UniversityJan 2003
NCT01290120B-ALLChemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin LymphomaP2completed182Northern Italy Leukemia GroupNov 2002
NCT00299494NHLStudy Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)P1/P2completed119PfizerMay 2006
NCT01497275Zevalin and Velcade in Relapsed/Refractory Mantle Cell LymphomaP2terminated5Duke UniversityFeb 2012
NCT01268033NEPHRUTIXEfficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During ChildhoodP2/P3completed26University Hospital, LimogesDec 2010
NCT00891839Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell LymphomaP2completed45CephalonJun 2009
NCT00669318Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2completed41Mayo ClinicJul 2008
NCT00546377Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell CancerP1/P2completed50Memorial Sloan Kettering Cancer CenterJul 2005
NCT00250718Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic ApproachP2terminated17New Mexico Cancer Research AllianceOct 2004
NCT02472756REFLECT 2A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphomacompleted41Hoffmann-La RocheSep 2008
NCT02136511Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemiaapproved for marketing0Gilead Sciences
NCT01779167THRiL for WMThalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom MacroglobulinemiaP2terminated4Weill Medical College of Cornell UniversityJun 2012
NCT01539512CLLA Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)P3completed220Gilead SciencesApr 2012
NCT01390441MK-8808-002A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)P1terminated100Merck Sharp & Dohme LLCJul 2011
NCT00809341R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's LymphomaP2terminated27Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJan 2009
NCT00691015Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantP2completed48Barbara Ann Karmanos Cancer InstituteMay 2008
NCT00387959Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's LymphomaP2completed17Memorial Sloan Kettering Cancer CenterJul 2006
NCT00327678ALLTreatment of Acute Lymphoblastic Leukemia (ALL) in Younger AdultsP3completed1,080Assistance Publique - Hôpitaux de ParisMay 2006
NCT00005089S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's LymphomaP2completed71SWOG Cancer Research NetworkApr 2000
NCT01509300HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid TumorsP1/P2unknown10Asan Medical CenterJan 2012
NCT01135641R-GVHDStudy of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)P2completed25Nantes University HospitalJun 2010
NCT01055496Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's LymphomaP1completed103PfizerMar 2010
NCT01056510A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)P4completed357Hoffmann-La RocheMar 2010
NCT00958256Study of Bortezomib in Combination With Cyclophosphamide and RituximabP2completed22M.D. Anderson Cancer CenterAug 2009
NCT00344149Rituximab as Second Line Treatment for ITPP3completed112Ostfold Hospital TrustJun 2006
NCT02099292Mz-135Rituximab and DexaBEAM as Salvage Therapy for Relapsed LymphomaP2completed103Georg Hess, MDMay 2001
NCT01232556A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyP3terminated338PfizerApr 2011
NCT01534884Triad RADemonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid ArthritisP1completed154CelltrionFeb 2012
NCT01423539NAVIGATEA Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)P2withdrawn0Genentech, Inc.Oct 2011
NCT01369849Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP1/P2completed15National Cancer Institute (NCI)Sep 2011
NCT01332994A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid ArthritisP3completed519Hoffmann-La RocheMar 2011
NCT01224093MABERYCAn Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)completed219Hoffmann-La RocheOct 2010
NCT01156909B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue SyndromeP2completed29Haukeland University HospitalOct 2010
NCT02699892RITAMStudy to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritiscompleted130Hoffmann-La RocheOct 2007
NCT01408342Alemtuzumab and Rituximab in Aplastic AnemiaN/Awithdrawn0Hospital Universitario Dr. Jose E. GonzalezJul 2011
NCT00689169ZBEAM2Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell LymphomaP2completed75Lymphoma Study AssociationAug 2007
NCT00330252Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLLP1completed29Dana-Farber Cancer InstituteMay 2006
NCT00064116IDEC-C2B8Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's LymphomaP3completed824NCIC Clinical Trials GroupMay 2001
NCT01415765MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell LymphomaP1/P2withdrawn0National Cancer Institute (NCI)Jul 2011
NCT01506414ITPRecombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)P3completed91Ming HouJun 2009
NCT01015248MALTTrial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) LymphomaP2completed60Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaMay 2009
NCT00388193Rituximab Combined With Chemotherapy in Burkitt's LymphomaP2completed20PETHEMA FoundationAug 2006
NCT00119730Chemotherapy Followed by Zevalin for Relapsed Mantle Cell LymphomaP2completed30Dana-Farber Cancer InstituteFeb 2005
NCT00066469Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ TransplantationP2completed55Children's Oncology GroupApr 2004
NCT01716442RTX2012Rituximab Trial for Pediatric Nephrotic SyndromeP2/P3unknown88Seoul National University Childrens HospitalAug 2012
NCT01718691Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell LymphomaP2completed70SymBio PharmaceuticalsNov 2011
NCT02461290Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1completed99Hoffmann-La RocheApr 2008
NCT00401817Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell LymphomaP2completed11Weill Medical College of Cornell UniversityNov 2007
NCT00072514Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesP2completed55Fred Hutchinson Cancer CenterAug 2003
NCT01650727P07974A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)P1completed5Merck Sharp & Dohme LLCOct 2012
NCT01734057ITPRecombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)P3withdrawn0Shandong UniversityJul 2012
NCT01186458Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin LymphomaP2terminated4Hoosier Cancer Research NetworkOct 2010
NCT00004031SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's LymphomaP3completed397SWOG Cancer Research NetworkJul 1997
NCT00076752Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus ErythematosusP2completed9National Cancer Institute (NCI)Jan 2004
NCT01205737A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma SubjectsP1completed186Teva Branded Pharmaceutical Products R&D, Inc.Sep 2010
NCT01185262LLC-LENAR-08Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic LeukemiaP1completed25MD Anderson International Spain SAApr 2009
NCT00831597904Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaP2completed61PharmatechNov 2008
NCT00595335Trial of Rituximab for Graves' OphthalmopathyP2/P3completed25Rebecca BahnApr 2008
NCT00510887Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular LymphomaP2terminated14Duke UniversityJan 2007
NCT00499018DLCL04Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell LymphomaP3unknown399Fondazione Italiana Linfomi - ETSJan 2006
NCT01939730Rituximab + GM-CSF in Patients With Follicular B-Cell LymphomaP2completed42M.D. Anderson Cancer CenterAug 1999
NCT01403740EHEMTurkish Acquired Haemophilia Registryunknown250Turkish Society of HematologySep 2011
NCT00907751PTTrituxRituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic PurpuraP2completed12Assistance Publique - Hôpitaux de ParisMay 2010
NCT00496340Pento & tBUPhase II Trial of Pentostatin and Targeted BusulfanP2completed42H. Lee Moffitt Cancer Center and Research InstituteJul 2007
NCT00647049Freiburg ZNS-NHL StudyP2unknown78University Hospital FreiburgJan 2007
NCT00133991Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or LeukemiaP2completed23Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJul 2005
NCT02569996A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular LymphomaP3completed124Hoffmann-La RocheJul 2005
NCT00117975Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaP2completed62Alliance for Clinical Trials in OncologyJun 2005
NCT01000441ROCRotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid ArthritisP4completed300University Hospital, Strasbourg, FranceDec 2009
NCT01831505Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy AgentsP1completed4Presage BiosciencesNov 2012
NCT00930514A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular LymphomaP1completed281Hoffmann-La RocheSep 2009
NCT00564512Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMPP3completed178French Innovative Leukemia OrganisationNov 2007
NCT00521014GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin LymphomaP2completed14Memorial Sloan Kettering Cancer CenterOct 2007
NCT00392834Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's LymphomaP2completed34AIDS Malignancy ConsortiumSep 2006
NCT00299104IMAGEA Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid ArthritisP3completed755Genentech, Inc.Jan 2006
NCT00288067Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaP1/P2terminated32National Cancer Institute (NCI)Oct 2005
NCT00299130SERENEA Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid ArthritisP3completed511Genentech, Inc.Oct 2005
NCT00671658Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic LeukemiaP2completed220M.D. Anderson Cancer CenterNov 2002
NCT00946023Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and RituximabP2terminated135Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJul 2009
NCT00372905Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular LymphomaP1/P2terminated18Northwestern UniversityJul 2007
NCT01317901A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent LymphomaP1completed12Aptevo TherapeuticsMay 2011
NCT01116232Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationP2terminated4Barbara Ann Karmanos Cancer InstituteAug 2010
NCT00748644MAINRITSANEfficacy Study of Two Treatments in the Remission of VasculitisP3completed117Assistance Publique - Hôpitaux de ParisOct 2008
NCT00433537Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell LymphomaP2completed77National Cancer Institute (NCI)May 2007
NCT00832234BDR-WMBortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms MacroglobulinemiaP2completed59European Myeloma Network B.V.Sep 2006
NCT00268983Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins LymphomaP3completed14GlaxoSmithKlineOct 2004
NCT02097745A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa TherapiesP3completed341Hoffmann-La RocheJun 2004
NCT00578305SCOREA Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to MethotrexateP3completed185Hoffmann-La RocheNov 2007
NCT00392691Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous TreatmentP1completed20Swiss Cancer InstituteOct 2006
NCT00397800Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's LymphomaP1/P2unknown12Technical University of MunichJun 2005
NCT00561379Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-RituximabN/Acompleted350Nantes University HospitalApr 2005
NCT00505895FM 140 vs FM100 Study in Patients With Multiple MyelomaP2completed52M.D. Anderson Cancer CenterJan 2002
NCT00503425DMARDA Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.P3completed215Hoffmann-La RocheJun 2005
NCT01482754Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin LymphomaN/Acompleted30National University Hospital, SingaporeMay 2012
NCT01206777Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell MalignanciesP2completed52Ohio State University Comprehensive Cancer CenterOct 2010
NCT00509184MIRRituximab and Involved Field Radiotherapy in Early Stage Follicular LymphomaP2completed85Klaus Herfarth, MDMar 2008
NCT02316613OLYMPEProspective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)completed260Hoffmann-La RocheFeb 2007
NCT00005589Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaP3completed460EBMT Solid Tumors Working PartyOct 1999
NCT00151320Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHLP1/P2completed76Weill Medical College of Cornell UniversityJan 2004
NCT00701129An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe DiseaseP4completed4Genzyme, a Sanofi CompanyOct 2009
NCT00845832A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to MethotrexateP2terminated24Hoffmann-La RocheMar 2009
NCT00771875Randomized Trial for Mixed Acute RejectionP2completed30University of CincinnatiSep 2008
NCT00576758RO5072759GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's LymphomaP2completed175Hoffmann-La RocheJan 2008
NCT00221325A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain LymphomaP1completed14University of California, San FranciscoApr 2007
NCT00422383RAA Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)P3completed378Hoffmann-La RocheFeb 2006
NCT00400478A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13P3completed683Arbeitsgemeinschaft medikamentoese TumortherapieJan 2006
NCT00193492A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's LymphomaP2completed60SCRI Development Innovations, LLCSep 2005
NCT00355199Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.P3completed246Gruppo Italiano Terapie Innovative nei LinfomiMay 2005
NCT00582166Ibritumomab Tiuxetan (Zevalin)+ Rituximab MaintenanceP2terminated18University of Wisconsin, MadisonJan 2005
NCT01662102Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)P3terminated1Spectrum Pharmaceuticals, IncDec 2012
NCT01534949Triad-DLBCLProvide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence TrialP1terminated1CelltrionFeb 2012
NCT00443651SUNDIALA Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid ArthritisP3completed578Genentech, Inc.Jan 2007
NCT01107951Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITPP2completed21Hospital Universitario Dr. Jose E. GonzalezApr 2010
NCT00740948TEARSTolerance and Efficacy of Rituximab in Sjogren's DiseaseP2/P3completed122University Hospital, BrestMar 2008
NCT00537290RITAPSA Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid SyndromeP2completed19Hospital for Special Surgery, New YorkSep 2007
NCT00451178A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP OnlyP2completed101Eli Lilly and CompanyMay 2007
NCT00282347LUNARA Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus NephritisP3completed144Genentech, Inc.Jan 2006
NCT00134082Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin LymphomaP1/P2completed31Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNov 2005
NCT02157181Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus RituximabP2completed89Jurgen BarthJun 2004
NCT00280241Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic LeukemiaP2completed65University of PittsburghJun 2004
NCT00858117A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLLP2completed30Northwestern UniversitySep 2005
NCT00738374A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.P2completed97Hoffmann-La RocheNov 2008
NCT01382940RATE-RAA Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid ArthritisP4completed351Hoffmann-La RocheJul 2011
NCT01358253Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic LeukemiaP4completed100Ruijin HospitalDec 2010
NCT02731560PARISRituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)P4completed74Prof. Abid Z. FarooqiJan 2010
NCT00855205RIPSRituximab for Pulmonary SarcoidosisP2completed10University of CincinnatiJul 2009
NCT00807196Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin LymphomaP1/P2unknown20Maisonneuve-Rosemont HospitalSep 2008
NCT00543114Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLLP1terminated9Dana-Farber Cancer InstituteOct 2007
NCT00307125Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA AlloantibodiesP2completed757National Institute of Allergy and Infectious Diseases (NIAID)Mar 2006
NCT00244985Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaP1/P2completed42Roswell Park Cancer InstituteSep 2005
NCT02093026RAExtension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)P2completed465Hoffmann-La RocheAug 2002
NCT00901069Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory LymphomaP1completed12Shams ShakilMay 2009
NCT00908583Desensitization in Kidney TransplantationP4completed44University of CincinnatiMay 2009
NCT00425932Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid ArthritisP2completed60Gaylis, Norman B., M.D.Feb 2007
NCT00436280Chemotherapy for Participants With LymphomaP2completed68Eli Lilly and CompanyFeb 2007
NCT00169156A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic LymphomaP2completed27Lymphoma Study AssociationDec 2005
NCT00169195R-GEMOXRituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell LymphomaP2completed49Lymphoma Study AssociationApr 2003
NCT01230788RituximabRituximab for Patients With Relapsed Acute Lymphoblastic LeukemiaN/Aterminated1Emory UniversitySep 2010
NCT00867087CMC-544Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's LymphomaP2completed64PfizerJun 2009
NCT00881387Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to TreatmentP2withdrawn0University of MiamiFeb 2009
NCT00736450Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaEarly P1terminated37University of NebraskaJul 2008
NCT00410982Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid MalignanciesP1completed145M.D. Anderson Cancer CenterDec 2006
NCT00248534Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's LymphomaP2terminated16Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSep 2005
NCT02013817CLLCHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to ChemotherapyP2completed43Hoffmann-La RocheOct 2005
NCT01040871Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaP2completed164Millennium Pharmaceuticals, Inc.Jan 2010
NCT00379587Rituximab for Prevention of Chronic GVHDP1/P2completed65Dana-Farber Cancer InstituteSep 2006
NCT00060346Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's MacroglobulinemiaP2terminated16Eastern Cooperative Oncology GroupOct 2004
NCT00577161Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHLP3withdrawn0CTI BioPharmaSep 2007
NCT00387023Radioimmunotherapy With 90Y Zevalin for Orbital LymphomaN/Acompleted12M.D. Anderson Cancer CenterFeb 2004
NCT01381705Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphomacompleted259ECOG-ACRIN Cancer Research GroupFeb 2012
NCT01299857SuivirituxLong-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by RituximabP3completed22University Hospital, RouenJun 2011
NCT01087151CLLA Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)P2completed118Genentech, Inc.Aug 2010
NCT01073163NHLStudy to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)P3completed54CephalonFeb 2010
NCT01338103Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via CylexN/Aunknown10Rabin Medical CenterJan 2010
NCT00992134R-BACImmunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell LymphomaP2completed41St. Bortolo HospitalJun 2009
NCT00646750Z-BEAM LDGGBTransplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse LymphomP2completed31Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaJan 2008
NCT00504491R-CHOPR-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic LeukemiaP2withdrawn0CABYCJul 2007
NCT00472056Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid MalignanciesP2completed93M.D. Anderson Cancer CenterMar 2005
NCT00954005R-GOStudy With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent LymphomaP1/P2terminated56German Low Grade Lymphoma Study GroupJan 2003
NCT00574730CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's LymphomaN/Acompleted27University of NebraskaMay 2001
NCT01419795Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantP2terminated3Fred Hutchinson Cancer CenterMay 2012
NCT01009970R-COMPStudy With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's LymphomaP2unknown50Fondazione Italiana Linfomi - ETSMay 2010
NCT00636155EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2terminated20David RizzieriFeb 2008
NCT00090051CLLFCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed PatientsP3completed552Hoffmann-La RocheJul 2003
NCT00282308SIERRAA Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background MethotrexateP2completed103Genentech, Inc.Jan 2006
NCT01000610A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateP4completed18Hoffmann-La RocheMar 2008
NCT01312064De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab InductionP4terminated2National Taiwan University HospitalApr 2011
NCT00949988BMS-CA180105A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic LeukemiaP1/P2terminated3University of California, San DiegoMay 2009
NCT01144754Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRTterminated1Stanford UniversityFeb 2009
NCT00532129A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.P2completed100Hoffmann-La RocheNov 2007
NCT01300793V-RICEStudy of Standard-Dose Rituximab, Ifosfamide, Carboplatin and EtoposideP1terminated6University of California, San FranciscoMay 2007
NCT00405340Rituximab in the Treatment of Idiopathic Membranous NephropathyEarly P1completed20Mayo ClinicOct 2006
NCT00299182Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's LymphomaP1/P2completed50M.D. Anderson Cancer CenterMar 2006
NCT00144807ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell LymphomaP2completed128Lymphoma Study AssociationDec 2003
NCT00140660ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell LymphomaP3terminated223Lymphoma Study AssociationDec 2003
NCT01045928Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaP1terminated5Case Comprehensive Cancer CenterJan 2010
NCT00877006BRStudy of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT StudyP3completed447Teva Branded Pharmaceutical Products R&D, Inc.Apr 2009
NCT00963703Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid ArthritisN/Acompleted15University of ManitobaDec 2007
NCT00818961Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic CancerP2terminated36Northside Hospital, Inc.May 2005
NCT00109967CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaP2completed71National Cancer Institute (NCI)May 2005
NCT00201877Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's LymphomaP2completed25Ohio State University Comprehensive Cancer CenterDec 2004
NCT00504504Rituximab and ABVD for Hodgkin's PatientsP2completed85M.D. Anderson Cancer CenterMar 2001
NCT00860457FRLenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)P2completed22Georgetown UniversityFeb 2008
NCT00472849Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and LeukemiasP1/P2completed92M.D. Anderson Cancer CenterMay 2007
NCT00381810VOYAGERA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus ErythematosusP3terminated31Genentech, Inc.Jun 2006
NCT00726700Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin LymphomaP2completed109Universität des SaarlandesMay 2004
NCT00416819Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS LymphomaN/Acompleted10University of California, San FranciscoSep 2003
NCT01539174Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell LymphomaP2withdrawn0Fox Chase Cancer Center
NCT00504751Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCLP2completed15Weill Medical College of Cornell UniversityMay 2007
NCT01042509LowARCombination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host DiseaseN/Acompleted15Hospital Universitario Dr. Jose E. GonzalezOct 2009
NCT00960713RITAIThe RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorderscompleted35University Hospital, ToulouseJun 2009
NCT00738829Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLLP1/P2completed45Arbeitsgemeinschaft medikamentoese TumortherapieOct 2008
NCT00575406NHL-14Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell LymphomaP2completed94Arbeitsgemeinschaft medikamentoese TumortherapieDec 2007
NCT00331006RICHRituximab to Treat Severe Hemophilia AP2completed23Carelon ResearchJun 2006
NCT00927797PERLLInterventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)P2unknown185Heidelberg UniversityFeb 2005
NCT00117156Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's LymphomaP2completed26Dana-Farber Cancer InstituteDec 2003
NCT01406782DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402completed200Eastern Cooperative Oncology GroupDec 2011
NCT00428142Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's LymphomaP2completed95NCIC Clinical Trials GroupMay 2007
NCT00073957Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's LymphomaP2completed25Beth Israel Deaconess Medical CenterDec 2003
NCT01075477An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)completed151Hoffmann-La RocheSep 2009
NCT00968331DLBCLStudy of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)P2terminated25University of BolognaMar 2009
NCT00774462FORCERituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia GravisP2completed30Assistance Publique - Hôpitaux de ParisJan 2008
NCT00552461PAPProspective Trial of Rituximab for Primary Pulmonary Alveolar ProteinosisP2completed10East Carolina UniversityJan 2007
NCT00048737Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid MalignanciesP1/P2completed70M.D. Anderson Cancer CenterOct 2002
NCT00869999Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaP2completed26Massachusetts General HospitalMay 2009
NCT00486759A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell LymphomaP3terminated787Hoffmann-La RocheJul 2007
NCT00515138RICEA Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell TransplantEarly P1terminated7University of California, San FranciscoMay 2007
NCT01126541SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa TherapyP3completed224Hoffmann-La RocheSep 2006
NCT00436904Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic LeukemiaP2completed30Mayo ClinicDec 2004
NCT00001586Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression AnalysisP2completed105National Cancer Institute (NCI)Sep 1997
NCT01277172TRENDTREatment of degeNerative and Neoplastic Diseases With RituximabP2/P3unknown54Probiomed S.A. de C.V.Oct 2010
NCT01593332Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid ArthritisP4completed44Mashhad University of Medical SciencesJul 2010
NCT01118845Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell LymphomaP2completed63SymBio PharmaceuticalsApr 2010
NCT00850499Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With RituximabP2terminated12Millennium Pharmaceuticals, Inc.Sep 2009
NCT00334438Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's LymphomaP1completed12UNC Lineberger Comprehensive Cancer CenterJul 2006
NCT00281918CLL-8Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic LeukemiaP3completed817Hoffmann-La RocheJul 2003
NCT01458548PTLDSequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)P2terminated70Charite University, Berlin, GermanyDec 2002
NCT00972101Infusion of Expanded Cord Blood T CellsP1withdrawn0M.D. Anderson Cancer CenterSep 2009
NCT00989352PRIMAINMethotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-LymphomaP2unknown56University Hospital FreiburgSep 2009
NCT00851552Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentP2terminated9Roswell Park Cancer InstituteJan 2009
NCT00656812MALTRituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) LymphomaP2completed40Arbeitsgemeinschaft medikamentoese TumortherapieMay 2008
NCT00651755Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma PatientsN/Acompleted23M.D. Anderson Cancer CenterMar 2008
NCT00389818Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's LymphomaP2completed43AIDS Malignancy ConsortiumJan 2007
NCT00468442B-Lymphocyte Immunotherapy in Islet TransplantationP2terminated2National Institute of Allergy and Infectious Diseases (NIAID)Nov 2006
NCT00254163Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia PatientsP3completed184US Oncology ResearchDec 2003
NCT00208975Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and RituximabP2terminated15Emory UniversityJul 2002
NCT00502840A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.P3completed193Hoffmann-La RocheJul 2007
NCT01066598A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)P2terminated1University Health Network, TorontoMay 2010
NCT01350232Treatment of Sickle Cell Anemia With Stem Cell TransplantN/Aterminated2Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversitySep 2009
NCT00475423A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.P2completed122Hoffmann-La RocheMay 2007
NCT00244855Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin LymphomaP2completed32Fred Hutchinson Cancer CenterMay 2004
NCT00986947Desensitization of Highly Sensitized Deceased Donor Renal Transplantation CandidatesP2terminated20Johns Hopkins UniversitySep 2009
NCT00628238CLLMulti-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)P2unknown80Chronic Lymphocytic Leukemia Research ConsortiumFeb 2008
NCT00656656Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for PemphigusP2completed23University of LuebeckJan 2008
NCT00455897CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's LymphomaP2terminated3Massachusetts General HospitalDec 2006
NCT00298272Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid ArthritisP2terminated54BiogenMay 2006
NCT00971763Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaP2completed62University College, LondonMar 2006
NCT00525603CFAR Study in Patients With Chronic Lymphocytic LeukemiaP2completed60M.D. Anderson Cancer CenterJun 2005
NCT00278161Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's LymphomaP2completed94Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJan 2005
NCT00074438Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid ArthritisP2completed465Genentech, Inc.Jun 2003
NCT01609010A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) LymphomaP3completed313Hoffmann-La RocheOct 2002
NCT01144364NHLA Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)P3completed234Hoffmann-La RocheJan 2004
NCT01072240An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemiacompleted92Hoffmann-La RocheSep 2009
NCT00578565Rituximab in Rheumatoid Arthritis Lung DiseaseP3completed10Eric MattesonMay 2007
NCT00372892ITPPilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)P2completed60Hamilton Health Sciences CorporationSep 2006
NCT00126191Intensive Chemotherapy and Rituximab in the Treatment of Burkitt LymphomaP2terminated10Dana-Farber Cancer InstituteJul 2005
NCT00041132S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell LymphomaP2completed56SWOG Cancer Research NetworkSep 2002
NCT00719472RATEA Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)P3completed451Genentech, Inc.Jul 2008
NCT01032122Rituximab in Metastatic MelanomaP1terminated9Medical University of ViennaOct 2007
NCT00529503A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCLP2terminated151Seagen Inc.Sep 2007
NCT01830465VELCADE® Plus Rituximab in Non Hodgkin's Follicular LymphomaP2completed45Gruppo Italiano Studio LinfomiAug 2006
NCT00029107Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic VasculitisP2completed47National Institute of Allergy and Infectious Diseases (NIAID)Dec 2001
NCT00430352MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.P4completed545Hoffmann-La RocheSep 2006
NCT00472420A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.P2completed48Hoffmann-La RocheJun 2007
NCT00981838NEMORituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)P3completed24Mario Negri Institute for Pharmacological ResearchApr 2009
NCT00562965NHLStudy Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)P3terminated29PfizerNov 2007
NCT00785330Allo-hNHL (FluBuCy)P2completed84Institut fuer anwendungsorientierte Forschung und klinische Studien GmbHApr 2004
NCT00983944Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell LymphomaP2withdrawn0Ohio State University Comprehensive Cancer CenterSep 2009
NCT00151281Phase II Study of RT-PEPC in Relapsed Mantle Cell LymphomaP2completed25Weill Medical College of Cornell UniversityNov 2004
NCT00715208Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular LymphomaP2completed55Millennium Pharmaceuticals, Inc.Sep 2008
NCT00460109Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's LymphomaP2completed24Alliance for Clinical Trials in OncologyApr 2008
NCT00415506Rituximab in the Treatment of Scleritis and Non-Infectious Orbital InflammationP1/P2completed20Oregon Health and Science UniversityJan 2007
NCT00493454Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent LymphomasP2terminated6M.D. Anderson Cancer CenterApr 2006
NCT00274989Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic LeukemiaP2completed195German CLL Study GroupNov 2005
NCT00337246Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaP2completed56Cancer Research UKJul 2005
NCT00088881Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's LymphomaP2terminated62National Cancer Institute (NCI)Dec 2004
NCT00309881CLLCombination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)P2completed75German CLL Study GroupApr 2003
NCT01307592Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin LymphomaP2unknown70Auxilio Mutuo Cancer CenterFeb 2011
NCT00772668Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZLN/Aterminated3University of MiamiSep 2009
NCT00588822Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined SignificanceP2terminated21Mayo ClinicJan 2005
NCT00098670Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic LeukemiaP2completed102National Cancer Institute (NCI)Oct 2004
NCT01001780PCRPentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host DiseaseP2withdrawn0University of RochesterAug 2009
NCT01345708A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic AnemiaP2completed23Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoJan 2009
NCT00531089Rituximab in Patients With Relapsed or Refractory TTP-HUSP2unknown60Hamilton Health Sciences CorporationDec 2007
NCT00509379LYM-2023Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent LymphomaP2completed48Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieSep 2006
NCT00413959VRCDVELCADE,Rituximab,Cyclophosphamide and DecadronP2terminated12Oncology Specialists, S.C.Aug 2006
NCT02486952MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphomacompleted154Hoffmann-La RocheAug 2005
NCT00452374Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLLP1/P2completed48M.D. Anderson Cancer CenterNov 2004
NCT01082939CFARCyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)P2completed80M.D. Anderson Cancer CenterDec 2002
NCT00007852Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's LymphomaP2completed44University of NebraskaSep 2000
NCT00892827Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic LeukemiaP2unknown10Wolfson Medical CenterApr 2009
NCT00771602Alemtuzumab + Rituximab Consolidation in CLLP2terminated1M.D. Anderson Cancer CenterAug 2008
NCT00568815DLBCLRituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)P2completed31Fudan UniversityApr 2007
NCT00186628Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHDP2completed36Stanford UniversityJun 2005
NCT00121199Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell LymphomaP2completed73National Cancer Institute (NCI)Jun 2005
NCT00695097The Effect of Rituximab on the Development of Anti-Donor AntibodiesN/Acompleted18University of California, San FranciscoAug 2004
NCT00080925T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesP1completed20National Institutes of Health Clinical Center (CC)Feb 2004
NCT00501748Safety and Tolerability of Rituximab in Neuromyelitis OpticaP1completed20University of California, San FranciscoJan 2004
NCT01456351Bendamustine Plus Rituximab Versus Fludarabine Plus RituximabP3completed230University of GiessenSep 2003
NCT00849355CVCiclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) RiskP2unknown44Asociacion Doctor Peset Para el Estudio de la HematologíaAug 2008
NCT00576433A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.P4completed60Hoffmann-La RocheDec 2007
NCT00556699A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's LymphomaP1completed22Genentech, Inc.Dec 2007
NCT00934648A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to MethotrexateP4completed15Hoffmann-La RocheOct 2007
NCT00536978NKNatural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid MalignanciesP2completed22M.D. Anderson Cancer CenterSep 2007
NCT02079532A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF InhibitorP3completed302Hoffmann-La RocheNov 2006
NCT00427557Cellular Therapy With Cord Blood CellsP2completed31M.D. Anderson Cancer CenterOct 2006
NCT00136396Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host DiseaseP1/P2completed30Dana-Farber Cancer InstituteJan 2004
NCT01238146Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaP1/P2withdrawn0National Cancer Institute (NCI)Oct 2010
NCT00664521August IIIAtacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)P2completed27Merck KGaA, Darmstadt, GermanyMar 2008
NCT00690560Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell LymphomaP2completed30Centre Antoine LacassagneMay 2007
NCT00072007Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLLP2completed43Swiss Cancer InstituteJun 2002
NCT00939328S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous TreatmentP2withdrawn0SWOG Cancer Research NetworkSep 2009
NCT00525876Non-Myeloablative Allogeneic Stem Cell TransplantationN/Acompleted49M.D. Anderson Cancer CenterJan 2005
NCT00078234Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic LeukemiaP1/P2completed25Genta IncorporatedNov 2003
NCT00038844Safety and Efficacy of Campath in Nonmyeloablative TransplantationN/Acompleted65M.D. Anderson Cancer CenterJun 2001
NCT01153971A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular LymphomasP2completed47Hoffmann-La RocheJul 2005
NCT00749112Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune CytopeniasP2/P3completed19Hospital Universitario Dr. Jose E. GonzalezAug 2008
NCT00426543Effect of B-cell Depletion in Patients With Primary Sjögren's SyndromeP2completed21University of CopenhagenJan 2007
NCT00106184DMRituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)P2completed200University of PittsburghMar 2006
NCT00385125Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHLP2unknown30University of MagdeburgAug 2004
NCT00052936Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaP3completed1,506German High-Grade Non-Hodgkin's Lymphoma Study GroupJan 2001
NCT01005979CR2A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)P1terminated6Emory UniversityJul 2010
NCT00758693CLLFrontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)P2withdrawn0University of KentuckyOct 2008
NCT00312845Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaP3completed676Millennium Pharmaceuticals, Inc.Mar 2006
NCT00088530NHLBBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)P3completed140CTI BioPharmaJul 2004
NCT01560117Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell LymphomaP2completed29Arbeitsgemeinschaft medikamentoese TumortherapieJan 2004
NCT00281983Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's MacroglobulinemiaP1/P2completed100German CLL Study GroupJun 2000
NCT00502853A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.P4completed10Hoffmann-La RocheOct 2007
NCT01117129RESONARA Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)P4terminated2Hoffmann-La RocheApr 2010
NCT00848692KTS-1-2008Drug Intervention in Chronic Fatigue SyndromeP2/P3completed30Haukeland University HospitalJun 2008
NCT00788606R-CHOP-B Bevacizumab for Diffuse Large B Cell LymphomaP2terminated7Royal Marsden NHS Foundation TrustMay 2008
NCT00937131TTPThe Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)P2completed40University College, LondonMar 2006
NCT00422942RAA Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)P2terminated3Hoffmann-La RocheJan 2006
NCT00229619Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan AnemiaP2completed11National Heart, Lung, and Blood Institute (NHLBI)Sep 2005
NCT00384553Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-LymphomaP1/P2unknown30University of MagdeburgJun 2004
NCT00072449Rituximab in Treating Patients With Refractory or Relapsed Primary CNS LymphomaP2terminated12Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMay 2004
NCT00199082Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in AdultsP4completed650Nicola GoekbugetJul 2002
NCT00003248Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic LeukemiaP2completed104Alliance for Clinical Trials in OncologyMar 1998
NCT00794638A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's LymphomaP1completed9SymBio PharmaceuticalsNov 2008
NCT00636792VERTICALA Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaP2completed73Millennium Pharmaceuticals, Inc.Feb 2008
NCT00482053Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCTP2terminated3Stanford UniversityOct 2006
NCT00373594Therapy for Chronic Cold Agglutinin DiseaseP2completed30University of BergenJun 2005
NCT00842595Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive LymphomasP2completed50French Innovative Leukemia OrganisationDec 2003
NCT01076556Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP1terminated9National Cancer Institute (NCI)Apr 2010
NCT00625729Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic LeukemiaP1/P2terminated6Masonic Cancer Center, University of MinnesotaJan 2008
NCT00363636NHLA Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)P3terminated340BiogenSep 2006
NCT01103388Rituximab Maintenance After Autologous TransplantationP3terminated4M.D. Anderson Cancer CenterAug 2003
NCT00012298Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaP1/P2terminated81National Cancer Institute (NCI)Apr 2001
NCT00135499R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell LymphomaP3terminated138Lymphoma Study AssociationOct 2001
NCT00504777A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.P4completed36Hoffmann-La RocheJul 2007
NCT00509678Rituxan With or Without Methotrexate in Psoriatic ArthritisP1completed6Swedish Medical CenterDec 2006
NCT00286325Rituximab in the Treatment of Patients With Bullous PemphigoidP1/P2completed8Duke UniversityMar 2005
NCT00588094Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHLP2completed20Memorial Sloan Kettering Cancer CenterOct 2003
NCT01088724FCD-RFludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)P4completed4A.O. Ospedale Papa Giovanni XXIIIFeb 2002
NCT00724971CMC-544Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And RituximabP1completed10PfizerJul 2008
NCT00500058A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18P1completed24GlaxoSmithKlineJul 2007
NCT00799773STAREvaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)P3terminated3Carelon ResearchApr 2009
NCT00655837Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCLP1completed33Seagen Inc.Apr 2008
NCT00193479Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's LymphomaP2completed51SCRI Development Innovations, LLCApr 2003
NCT00147121JCOG0203Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)P2/P3completed300Haruhiko FukudaSep 2002
NCT00038623Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell LymphomaP2completed35M.D. Anderson Cancer CenterApr 2002
NCT00820469PK-rituximabStudy of the Influence of Plasma Exchange on the Pharmacokinetics of RituximabP4completed20University Hospital, ToulouseSep 2008
NCT00384150NHLRetreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)P3terminated16BiogenNov 2007
NCT00039195Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With LymphomaP2completed98Memorial Sloan Kettering Cancer CenterNov 2006
NCT00259974RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal GammopathyP3completed60Assistance Publique - Hôpitaux de ParisApr 2006
NCT00290407CLLRituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)P2terminated2University of LouisvilleMar 2006
NCT00104299RAVERituximab for the Treatment of Wegener's Granulomatosis and Microscopic PolyangiitisP2/P3completed197National Institute of Allergy and Infectious Diseases (NIAID)Jan 2005
NCT00054639Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaP2completed48National Cancer Institute (NCI)Jan 2003
NCT01047072Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic SclerosisP2withdrawn0Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
NCT00147966Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)P2completed24University of California, San DiegoJun 2008
NCT00517049A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)P2completed49Genentech, Inc.Mar 2008
NCT00550342Rituximab Treatment of Focal Segmental GlomerulosclerosisP2withdrawn0National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Jan 2008
NCT00558181LT-CLL-001High-dose Methylprednisolone and Rituximab in High Risk B-CLLP2completed29Vilnius UniversitySep 2007
NCT00364819Initial Study of Rituximab to Treat Primary Biliary CirrhosisP1/P2completed6University of California, DavisJan 2007
NCT00556192Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus ErythematosusP2completed20Chinese University of Hong KongJun 2006
NCT01224769Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorderscompleted109Gruppo Italiano Studio LinfomiSep 2005
NCT00908986Open Label Pilot Trial of Rituximab in Lupus Membranous NephritisN/Awithdrawn0Northwell HealthDec 2008
NCT00473551Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid MalignanciesP1terminated4M.D. Anderson Cancer CenterMay 2007
NCT00432653Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing SpondylitisP2/P3unknown20Charite University, Berlin, GermanyMar 2007
NCT00279305TN05Rituximab in New Onset Type 1 DiabetesP2completed87National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Aug 2005
NCT00053027Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaP2completed30Alliance for Clinical Trials in OncologyFeb 2003
NCT00547534BVRPilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's LymphomaP2completed31University of RochesterOct 2007
NCT00424502A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.P4completed20Hoffmann-La RocheJan 2007
NCT00427791Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic LeukemiaP2completed23M.D. Anderson Cancer CenterJul 2005
NCT00261118Rituximab in Active Ulcerative ColitisP2/P3completed24Royal Liverpool University HospitalApr 2004
NCT00086775Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic LeukemiaP2completed0BayerJul 2003
NCT01702038Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLEP2withdrawn0National Institute of Allergy and Infectious Diseases (NIAID)Sep 2009
NCT00020943Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell LymphomaP2completed79Alliance for Clinical Trials in OncologyJun 2001
NCT00398372Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody TreatmentN/Acompleted500Stanford UniversityNov 2000
NCT00980304R Retreatment in 1st Relapsed DLBCLP2unknown0Shanghai Jiao Tong University School of Medicine
NCT03069248Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha InterferonP2completed36Sunnybrook Health Sciences CentreJun 2000
NCT00101829Anti-CD20 Antibody Therapy for Sjogren's SyndromeP1completed12National Institute of Allergy and Infectious Diseases (NIAID)Apr 2004
NCT00201682Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaP1/P2completed36John ByrdOct 2002
NCT00462345A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.P4completed40Hoffmann-La RocheJun 2007
NCT00424749Rituxan in Churg Strauss Syndrome With Renal InvolvementP2terminated4Fernando FervenzaJun 2007
NCT00427856GX15-070MSSafety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)P2completed7Gemin XMar 2007
NCT00396812RARituximab for the Treatment of Early Rheumatoid Arthritis (RA)P1/P2terminated4National Institute of Allergy and Infectious Diseases (NIAID)Nov 2006
NCT00143065Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2completed8Ohio State University Comprehensive Cancer CenterAug 2005
NCT00308087PREMIERComparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's LymphomaP2terminated75Genzyme, a Sanofi CompanyMay 2006
NCT00444912NHLThe Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)P2completed30Genzyme, a Sanofi CompanyFeb 2006
NCT00965289High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell LymphomaP2completed42Nantes University HospitalApr 2002
NCT00366418Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic LeukemiaP1completed4National Heart, Lung, and Blood Institute (NHLBI)Aug 2006
NCT00472225Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host DiseaseP2unknown42The Korean Society of Hematopoietic Stem Cell TransplantationMay 2007
NCT00476229Thymoglobulin and Total Lymphoid Irradiation for Hematologic MalignanciesN/Acompleted20M.D. Anderson Cancer CenterJun 2006
NCT00091897Rituximab to Treat Stiff Person SyndromeP2completed24National Institute of Neurological Disorders and Stroke (NINDS)Sep 2004
NCT00049036Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaP2completed106National Cancer Institute (NCI)Mar 2003
NCT00033423Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaP1terminated18University of Alabama at BirminghamAug 2001
NCT00003659Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic LeukemiaP2completed39Memorial Sloan Kettering Cancer CenterSep 1998
NCT00691652Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin LymphomaP1/P2terminated2OHSU Knight Cancer InstituteMay 2008
NCT00251277Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic PurpuraP1/P2withdrawn0Weill Medical College of Cornell UniversityNov 2005
NCT00032019Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaP2completed78Alliance for Clinical Trials in OncologyFeb 2002
NCT00269113A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's LymphomaP3completed360Hoffmann-La RocheSep 1998
NCT00896519GM-CSFGM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin LymphomaP2unknown30French Innovative Leukemia OrganisationMar 2009
NCT00893477GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaP2unknown60French Innovative Leukemia OrganisationMar 2009
NCT00517699A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.P2terminated5Hoffmann-La RocheSep 2007
NCT00424151Rituximab Treatment of Graves' Dysthyroid OphthalmopathyP1/P2completed12Silkiss, Rona Z., M.D., FACSDec 2006
NCT00275613Pilot Study of Rituximab for Membranoproliferative GlomerulonephritisP1completed10Mayo ClinicNov 2005
NCT00096460BMT CTN 0202Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)P2/P3terminated30Medical College of WisconsinAug 2004
NCT00199004Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and RituximabP4completed60Johann Wolfgang Goethe University HospitalApr 2004
NCT00619671A Pilot Trial of Rituxan in Refractory Myasthenia GravisP1/P2completed10University of VermontApr 2004
NCT00058292Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaP1completed44Northwestern UniversityApr 2000
NCT01272908RESETA Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)P3completed120Hoffmann-La RocheJul 2006
NCT00833534Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell TransplantP2withdrawn0Fred Hutchinson Cancer CenterFeb 2009
NCT00863187Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With RituximabN/Aunknown100Rambam Health Care CampusFeb 2009
NCT00567229Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple MyelomaP2terminated3Memorial Sloan Kettering Cancer CenterNov 2007
NCT00250926Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms MacroglobulinemiaP2completed23Dana-Farber Cancer InstituteOct 2005
NCT00243412RUMBAA Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving MethotrexateP2completed42Genentech, Inc.Aug 2005
NCT00053092Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell LymphomaP2completed82Institute of Cancer Research, United KingdomOct 2002
NCT00202930Use of Rituximab in Opsoclonus-Myoclonus in Children With NeuroblastomaP2terminated4Jean M. Tersak, M.D.Jul 2005
NCT00379431A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), RituximabP2completed9University Hospital, GhentNov 2006
NCT00829205Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentP1/P2withdrawn0Cancer Research UKJan 2009
NCT00845104Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To TreatmentP2withdrawn0Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumJan 2009
NCT01054781DLBCLIntensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)P2completed91Samsung Medical CenterJan 2009
NCT00371904RAPTURETrial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney RecipientsP2unknown192Hunter and New England HealthApr 2006
NCT00140595ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1P3completed380Lymphoma Study AssociationDec 2003
NCT00193440Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's LymphomaP2completed40SCRI Development Innovations, LLCApr 2002
NCT00648037EBVRituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCTN/Acompleted26Memorial Sloan Kettering Cancer CenterMar 2008
NCT00446251MMFEffects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal TransplantP2completed14University of WashingtonDec 2006
NCT00502996A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.P3completed246Hoffmann-La RocheFeb 2006
NCT00259805A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal EncephalitisP1completed10California Pacific Medical Center Research InstituteJan 2005
NCT01538641GROCPhase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive LymphomasP2completed43Auxilio Mutuo Cancer CenterOct 2003
NCT00285389Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 YearsP2completed39French Innovative Leukemia OrganisationFeb 2002
NCT00734773Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSLEarly P1withdrawn0Northwestern UniversityNov 2008
NCT00486421Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic PurpuraEarly P1completed22Mayo ClinicJan 2007
NCT00440388Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's LymphomaP2completed23Ascenta TherapeuticsOct 2006
NCT00363350Rituximab Treatment in Sjogren's SyndromeP1/P2completed30University Medical Center GroningenAug 2006
NCT00499343G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL PatientsP2completed84M.D. Anderson Cancer CenterJan 2004
NCT00137995R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell LymphomaP3completed481Lymphoma Study AssociationJun 2003
NCT00723658S0629S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom MacroglobulinemiaP2withdrawn0SWOG Cancer Research NetworkSep 2008
NCT00204659CHOPPhase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's LymphomaP2completed30University Hospital TuebingenMar 2003
NCT02622503A Study on Rheumatoid Arthritis Patients Treated With Rituximabcompleted81Hoffmann-La RocheApr 2008
NCT00087009Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell TransplantationP1terminated3Memorial Sloan Kettering Cancer CenterMay 2004
NCT00003820Rituximab in Treating Patients With Hodgkin's LymphomaP2completed39Ranjana AdvaniJan 1999
NCT00137969EXPLORERA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus ErythematosusP2/P3completed262Genentech, Inc.May 2005
NCT00770562ITPA Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)P3completed103Hoffmann-La RocheJul 2005
NCT00854321KuoRituxi1Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospitalcompleted49Kuopio University HospitalNov 2004
NCT01124526RFCEfficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) LymphomaP4completed75Asociacion Espanola de Hematologia y HemoterapiaSep 2004
NCT00555542An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid ArthritisP2completed10Chinese University of Hong KongJul 2006
NCT00361621Ph II CHOP+Velcade in Mediastinal LBCLP2terminated3Dana-Farber Cancer InstituteJul 2006
NCT00347971Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's LymphomaP1completed23ZymoGeneticsJun 2006
NCT00142168CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's MacroglobulinemiaP2terminated16Dana-Farber Cancer InstituteSep 2004
NCT00193466Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2completed40SCRI Development Innovations, LLCJan 2002
NCT00007865Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's LymphomaP2completed0University of NebraskaSep 2000
NCT00167791Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney TransplantN/Awithdrawn0University of Wisconsin, MadisonJul 2005
NCT00182650Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's LymphomaP1completed5City of Hope Medical CenterJun 2004
NCT00076349NHLSDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)P2completed66CephalonApr 2004
NCT00031642Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell TransplantationP1/P2completed26University of NebraskaJan 2002
NCT00176475Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseP1terminated2University of Medicine and Dentistry of New JerseyJan 2005
NCT00774202Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITPP2/P3completed17Weill Medical College of Cornell UniversityNov 2003
NCT00142116Thalidomide and Rituximab in Waldenstrom's MacroglobulinemiaP2completed25Steven P. Treon, MD, PhDMay 2003
NCT00005601Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaP2completed58Alliance for Clinical Trials in OncologyOct 2000
NCT00003849Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's DiseaseP2completed39Alliance for Clinical Trials in OncologyJul 1999
NCT01998893A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's LymphomaP2completed38Hoffmann-La RocheJan 1997
NCT00612612Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaP1terminated28National Cancer Institute (NCI)Jan 2008
NCT00664599Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's DiseaseP2completed20Tehran University of Medical SciencesApr 2006
NCT00656084Ph2 Gem/Nov/Rituxan Rel/Ref MantleCellP2completed16US Oncology ResearchDec 2004
NCT00601718Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaP1/P2completed29University of WashingtonDec 2007
NCT00244361Effectiveness of Rituximab in Pediatric OMS Patients.P1/P2completed25National Pediatric Neuroinflammation Organization, Inc.Jun 2005
NCT00261547Rituximab Treatment to Block HLA Antibodies in Renal Transplant RecipientsP1/P2withdrawn0Massachusetts General HospitalDec 2005
NCT00367497R-ESHAPSafety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's LymphomaP2terminated5Keio UniversityAug 2005
NCT00090038Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's LymphomaP4completed168BiogenOct 2003
NCT02006706A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD TherapyP3completed15Hoffmann-La RocheAug 2006
NCT00255593Safety and Efficacy Study of Rituximab in Renal TransplantationP1completed140Karolinska University HospitalNov 2005
NCT00040950Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaP1completed0Jonsson Comprehensive Cancer CenterMar 2002
NCT00012051Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaP3completed340Commissie Voor Klinisch Toegepast OnderzoekSep 2000
NCT00050245Rituximab to Treat Neuropathy With Anti-MAG AntibodiesP2completed30National Institute of Neurological Disorders and Stroke (NINDS)Nov 2002
NCT00476515Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living DonorP1withdrawn0Massachusetts General HospitalMar 2007
NCT00280878Rituximab in Combination With Outpatient Therapy for CD20+ LymphomaP2completed12Bayside HealthJan 2006
NCT00214266A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal TransplantationP2completed31University of Wisconsin, MadisonJan 2005
NCT00081861Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's LymphomaP2completed13M.D. Anderson Cancer CenterMar 2004
NCT00086203CLLStudy of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)P2completed0Point Therapeutics
NCT00238368Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow TransplantP2completed59Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsFeb 2004
NCT00258206Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple MyelomaP2completed21Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDec 2004
NCT00551239Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin LymphomaP3withdrawn0CTI BioPharmaAug 2007
NCT01902862An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular LymphomaP2terminated7Janssen-Cilag G.m.b.HFeb 2006
NCT00250861IL-2Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's LymphomaP2terminated110US Oncology ResearchOct 2005
NCT00697996Rituximab for Pediatric Renal Transplant RejectionP2/P3completed20Stanford UniversityJun 2005
NCT00071396Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid DisordersP2completed48M.D. Anderson Cancer CenterOct 2002
NCT00311129Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHLP2completed41Genzyme, a Sanofi CompanyDec 2005
NCT00003757Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine TherapyP2completed25Swiss Cancer InstituteFeb 1998
NCT00689845Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell LymphomaN/Aunknown120University Hospital Southampton NHS Foundation TrustJun 2007
NCT00578591Rituximab GVHDRituximab for GVHDP2withdrawn0Baylor College of MedicineJun 2007
NCT00307593RATTRAPRATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing VasculitidesN/Acompleted20Assistance Publique - Hôpitaux de ParisMay 2004
NCT00343447Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic LeukemiaP2withdrawn0Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAug 2006
NCT00216762Safety Study of Rituximab (Rituxan®) in Chronic UrticariaP1/P2terminated15Johns Hopkins UniversityJan 2006
NCT00642655IVIGRituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal TransplantationP1/P2completed20Cedars-Sinai Medical CenterSep 2005
NCT00060684Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's LymphomaP1completed30CTI BioPharmaDec 2001
NCT00579592Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal TransplanationN/Aterminated11University of Wisconsin, MadisonApr 2006
NCT00425217Rituximab in Membranous NephropathyP2/P3completed15Mayo ClinicAug 2004
NCT00062114Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's LymphomaP2completed84Alliance for Clinical Trials in OncologyApr 2004
NCT00242996Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell LymphomaP2completed44Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2004
NCT00416923Intrathecal Rituximab in Treating Patients With Recurrent CNS LymphomaP1completed10University of California, San FranciscoAug 2002
NCT00216164Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaP2terminated8Hoosier Cancer Research NetworkApr 2005
NCT00142155Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's MacroglobulinemiaN/Acompleted300Dana-Farber Cancer InstituteJan 2002
NCT00210379Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's LymphomaP2completed64International Extranodal Lymphoma Study Group (IELSG)Nov 2000
NCT00429065Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.unknown30Instituto Nacional de Cancerologia de MexicoJan 2007
NCT00261612BORIDBortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell LymphomaP2unknown16Medical University of ViennaJan 2005
NCT00169143Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell LymphomaP2completed60Lymphoma Study AssociationMay 2004
NCT00143871Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's LymphomaP2completed35University of Michigan Rogel Cancer CenterApr 2001
NCT00003716Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression TherapyP2completed25Stanford UniversityMar 1998
NCT00797810Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in AdultsP4unknown25University of BolognaDec 2006
NCT00267826Immunopharmacological Effects of Rituximab in Atopic DermatitisN/Acompleted6University of BernDec 2005
NCT00097188A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple SclerosisP2completed104Genentech, Inc.Dec 2004
NCT00169208Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's LymphomaP2completed50Lymphoma Study AssociationApr 2001
NCT00183989Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell LymphomaP2terminated30University of Southern CaliforniaAug 2000
NCT00006708S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaP3terminated7SWOG Cancer Research NetworkOct 2000
NCT00404157A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970gP3withdrawn0Genentech, Inc.
NCT00150111Rituximab in the Treatment of Graves' DiseaseP1/P2completed20Odense University HospitalJun 2003
NCT00281931Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic LeukemiaP2terminated21German CLL Study GroupSep 1999
NCT00120198Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma PatientsP2terminated50Geriatric Oncology ConsortiumMar 2005
NCT00201721Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic LeukemiaP2completed28Ohio State University Comprehensive Cancer CenterJul 2002
NCT00556127DLBCLRituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell LymphomaP2completed94Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieJun 2002
NCT00003150Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's LymphomaP3completed630Eastern Cooperative Oncology GroupDec 1997
NCT00393107Safety and Efficacy of Fludarabine and Cyclophosphamide + RituximabP2completed54Gruppo Italiano Studio LinfomiMar 2000
NCT00346684RIPLRituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)P2completed0University of CologneJul 2006
NCT00400764A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's LymphomasP1/P2terminated72Genentech, Inc.Jun 2006
NCT00070447Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaP2completed0National Cancer Institute (NCI)Nov 2003
NCT00333008NHLA Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.P2unknown27The Alvin and Lois Lapidus Cancer InstituteMay 2006
NCT00274794VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHLN/Acompleted55The Cleveland ClinicFeb 2000
NCT00324831GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaP3suspended480Favrille
NCT00301795Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaP2terminated52National Cancer Institute (NCI)Mar 2006
NCT00265915Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic LeukemiaP2terminated0Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJul 2005
NCT00055640Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's LymphomaP2completed9Case Comprehensive Cancer CenterOct 2002
NCT00301301GEM-PA Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)completed39Royal Marsden NHS Foundation Trust
NCT00310128Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's LymphomaP2withdrawn0AIDS Malignancy ConsortiumFeb 2006
NCT01392716A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's LymphomaP2completed48Hoffmann-La RocheOct 1997
NCT00266227SUNRISEA Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background MethotrexateP3completed559Genentech, Inc.Jan 2006
NCT00974792Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin LymphomaP2unknown150Cancer Research UKJan 2006
NCT00183976Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's LymphomasP2terminated15University of Southern CaliforniaApr 2005
NCT00169468Association of Velcade to R-CHOP in the Treatment of B Cell LymphomaP2completed48Lymphoma Study AssociationJan 2005
NCT00060671Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's LymphomaP3terminated800CTI BioPharmaJan 2005
NCT00127569Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on ChemotherapyP2terminated25French National Agency for Research on AIDS and Viral HepatitisMay 2003
NCT00036491Anti-CD20 in Systemic Lupus ErythematosusP1/P2completed24National Institute of Allergy and Infectious Diseases (NIAID)Jan 2001
NCT01713738ITPClinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)P1/P2completed36Neufeld, Ellis J, MD, PhDMay 2003
NCT00141700Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's LymphomaP2terminated30University of Michigan Rogel Cancer CenterMar 2003
NCT00049413Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic LymphomaP2completed0Hoag Memorial Hospital PresbyterianJun 2002
NCT00265928Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaP2terminated46University of Virginia
NCT00005592Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaP2completed23University of Alabama at BirminghamNov 1999
NCT00003658Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell CancersP2completed60Memorial Sloan Kettering Cancer CenterSep 1998
NCT00230035LISTLupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)P2withdrawn0National Institute of Allergy and Infectious Diseases (NIAID)Sep 2005
NCT00210340A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous MeningitisP1withdrawn0International Extranodal Lymphoma Study Group (IELSG)
NCT00072592An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard TherapiesP1completed10National Institute of Allergy and Infectious Diseases (NIAID)Oct 2003
NCT00193505Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell LymphomaP2completed40SCRI Development Innovations, LLCOct 2003
NCT00062296Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaP2completed5Fox Chase Cancer CenterMar 2003
NCT00169169Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell LymphomaP3terminated430Lymphoma Study AssociationOct 1999
NCT00004889Rituximab in Treating Patients With Waldenstrom's MacroglobulinemiaP2completed8Jonsson Comprehensive Cancer CenterDec 1999
NCT00293072SLEPilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and VasculitisP2completed20Cambridge University Hospitals NHS Foundation TrustMar 2002
NCT00001563EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated LymphomaP2completed39National Cancer Institute (NCI)Jan 1997
NCT0009848817-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaP1terminated30National Cancer Institute (NCI)Apr 2005
NCT01851551Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLP1/P2completed22Acrotech Biopharma Inc.Sep 2001
NCT00003963Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell TransplantationP2completed14Jonsson Comprehensive Cancer CenterMay 1999
NCT00100737IL-2Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)P2terminated300Chiron Corporation
NCT00082836Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS LymphomaN/Acompleted10Memorial Sloan Kettering Cancer CenterDec 2004
NCT00110006Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's LymphomaN/Awithdrawn0Case Comprehensive Cancer CenterDec 2004
NCT00136552Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor BurdenP3completed360Lymphoma Study AssociationMay 2000
NCT00180882LMBA02 Protocol for Patients With a Burkitt LymphomaP3unknown260Gustave Roussy, Cancer Campus, Grand ParisOct 2004
NCT00093769Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's LymphomaP2completed15Jonsson Comprehensive Cancer CenterAug 2004
NCT00258336Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's LymphomaP2unknown56FavrilleAug 2004
NCT02693210A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid ArthritisP2completed161Hoffmann-La RocheFeb 2001
NCT00089115Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaP3terminated0FavrilleJul 2004
NCT00087425Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaP2completed48National Institute on Aging (NIA)Jul 2004
NCT00180895Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALLP2terminated40Gustave Roussy, Cancer Campus, Grand ParisJun 2004
NCT00147953Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's LymphomaP2completed30University of CologneJun 2004
NCT00087529OLYMPUSA Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple SclerosisP2/P3completed439Genentech, Inc.Jun 2004
NCT00057447Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma PatientsP1/P2terminated24InterMuneMar 2003
NCT00059904Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's LymphomaP2completed0Memorial Sloan Kettering Cancer CenterJan 2003
NCT00086944Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaP1/P2completed25National Cancer Institute (NCI)May 2004
NCT00085696VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaP2completed66Millennium Pharmaceuticals, Inc.May 2004
NCT00078598A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's LymphomaP3unknown506Corixa CorporationApr 2004
NCT00003554Rituximab in Treating Patients With Multiple MyelomaP2completed0The Cleveland ClinicNov 1998
NCT01388959A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's LymphomaP2completed40Hoffmann-La RocheNov 1998
NCT00080847S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's LymphomaP2terminated160National Cancer Institute (NCI)Mar 2004
NCT00324779Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic LeukemiaP2completed79University Hospital ErlangenMar 2004
NCT00161564A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan AloneP2withdrawn0Weill Medical College of Cornell UniversityFeb 2004
NCT00005609Rituximab in Treating Patients With Waldenstrom's MacroglobulinemiaP2completed0Eastern Cooperative Oncology GroupApr 2000
NCT00079443FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's LymphomaP2terminated60National Cancer Institute (NCI)Jan 2004
NCT00058461Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaP2terminated82National Cancer Institute (NCI)Nov 2003
NCT00126243CHOPEfficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's LymphomaP2terminated60French National Agency for Research on AIDS and Viral HepatitisJan 1999
NCT00064246Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderP1/P2completed28National Cancer Institute (NCI)Jul 2003
NCT00068315Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaP1completed18National Cancer Institute (NCI)Jul 2003
NCT00070083Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaP1completed0British Columbia Cancer AgencyJul 2003
NCT00026351Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaP2completed0Pharmatech OncologyDec 2000
NCT00004260Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's LymphomaP1completed0Mayo ClinicOct 1999
NCT00069966Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First RelapseP2unknown0TheradexApr 2003
NCT00058227Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaP1completed37National Cancer Institute (NCI)Apr 2003
NCT00060294Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's MacroglobulinemiaP1terminated0Jonsson Comprehensive Cancer CenterApr 2003
NCT00052923Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell LymphomaP3completed427Eastern Cooperative Oncology GroupMar 2003
NCT00057343Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's LymphomaP3terminated400BiogenMar 2003
NCT00225212Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's LymphomaP2completed35Stanford UniversityNov 1997
NCT00004112Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaP3completed0University of NebraskaSep 1999
NCT01148446ANZINTER3R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCLP3completed226Fondazione Italiana Linfomi - ETSJan 2003
NCT00003397Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaP2completed25University of Maryland, BaltimoreSep 1998
NCT00005631Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell LymphomaP2completed0Memorial Sloan Kettering Cancer CenterNov 1999
NCT00244127Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.P2unknown75Zeneus PharmaOct 2002
NCT00045864Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.P2completed0Chiron Corporation
NCT00045877Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan TreatmentsP2/P3completed0Chiron Corporation
NCT00036855Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory LymphomaP1terminated36National Cancer Institute (NCI)Jun 2002
NCT00003356Rituximab Plus Interleukin-2 in Treating Patients With LymphomaP1/P2completed58University of RochesterNov 1997
NCT00003280Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell LymphomaP3completed240Swiss Cancer InstituteJan 1998
NCT00031902Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's LymphomaP1unknown0Lymphoma Trials OfficeOct 2001
NCT00026182Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's LymphomaP2completed99National Cancer Institute (NCI)Oct 2001
NCT00020800Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's MacroglobulinemiaP2completed7Jonsson Comprehensive Cancer CenterSep 2001
NCT00017381Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaEarly P1completed30National Cancer Institute (NCI)Apr 2001
NCT00028717Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaP3unknown400Commissie Voor Klinisch Toegepast OnderzoekFeb 2001
NCT00010192Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerP1completed30National Cancer Institute (NCI)Dec 2000
NCT00005652Phase II Study of Rituximab in Patients With Immune Thrombocytopenic PurpuraP2completed20University of Alabama at BirminghamDec 2000
NCT00028665Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's LymphomaP2completed37Case Comprehensive Cancer CenterJun 2000
NCT00001805A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by RituximabP2completed20National Cancer Institute (NCI)Mar 1999
NCT00435955Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular LymphomaP3unknown240Azienda Ospedaliera San Giovanni BattistaMar 2000
NCT00006669Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's LymphomaP2withdrawn0Medstar Health Research InstituteSep 1999
NCT00004039Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV LymphomaP2withdrawn0Hoag Memorial Hospital PresbyterianJun 1998
NCT00003663Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's LymphomaP2withdrawn0Hoag Memorial Hospital PresbyterianJun 1998
NCT00003605Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's LymphomaP2withdrawn0Hoag Memorial Hospital PresbyterianMay 1998
NCT00005959Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaP2unknown0AmgenDec 1999
NCT00004040Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After ChemotherapyP2withdrawn0Hoag Memorial Hospital PresbyterianJun 1998
NCT00003595Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's LymphomaP3completed120National Cancer Institute (NCI)Jan 1999
NCT00003204Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's LymphomaP3completed515National Cancer Institute (NCI)Mar 1998
NCT00168740Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)P3completed150BiogenApr 1995

Rituximab clinical trials: frequently asked questions

How many Rituximab clinical trials are there?
2053 Rituximab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 262 are actively recruiting participants. 987 are marked completed.
Are Rituximab clinical trials recruiting in 2026?
Yes — 262 Rituximab trials are actively recruiting in 2026, with 1419 U.S. sites across 50 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Rituximab being studied for?
Rituximab is being studied for Lymphoma, Chronic Lymphocytic Leukemia, Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma and 1520 more. The trials are grouped by indication on this page.
What phase is Rituximab in?
Rituximab clinical trials span 77 Phase 4, 367 Phase 3, 950 Phase 2, 246 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Rituximab clinical trials?
The lead sponsor across the most Rituximab trials is M.D. Anderson Cancer Center, with 625 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Rituximabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: